{"docstore/data": {"aa00e485-6a39-40ce-9cbc-92520f1f6570": {"__data__": {"id_": "aa00e485-6a39-40ce-9cbc-92520f1f6570", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Nov-2023  \nMcKesson Corp.   (MCK ) \nQ2 2024 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Nov-2023  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "033fafe1-146e-4889-91d5-095860852b9e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f44f1a3eefa1264ba7d69c0feeb412339cd766c510dabbc123b772ac666f1aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "969653cc-e42c-44dd-9e5b-25b022f5d422", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Nov-2023  \nMcKesson Corp.   (MCK ) \nQ2 2024 Earnings Call    ", "original_text": "(MCK ) \nQ2 2024 Earnings Call    "}, "hash": "01718861c15f074a9f9ac14e5cfe371bf31dc25ca0449abb19cb6edeefd73dce", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Nov-2023  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "969653cc-e42c-44dd-9e5b-25b022f5d422": {"__data__": {"id_": "969653cc-e42c-44dd-9e5b-25b022f5d422", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Nov-2023  \nMcKesson Corp.   (MCK ) \nQ2 2024 Earnings Call    ", "original_text": "(MCK ) \nQ2 2024 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "033fafe1-146e-4889-91d5-095860852b9e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f44f1a3eefa1264ba7d69c0feeb412339cd766c510dabbc123b772ac666f1aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa00e485-6a39-40ce-9cbc-92520f1f6570", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Nov-2023  \nMcKesson Corp.   (MCK ) \nQ2 2024 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Nov-2023  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ac5ea799f5e0cb30aa562697381ec4c53a75f3a5696f0064f021b428c482622", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96af4f32-e99d-4b4b-98bc-80bd2b3c1dd6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "fb3d6d1d519e9b18a28e08a7d8824e0ed2dfd6aa92f491eb6fd9713e6fc990ef", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call    ", "start_char_idx": 165, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96af4f32-e99d-4b4b-98bc-80bd2b3c1dd6": {"__data__": {"id_": "96af4f32-e99d-4b4b-98bc-80bd2b3c1dd6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "784f73bcf80e719df71d5faef7fed9313f4bf939da11ec7bda146e7771065688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "969653cc-e42c-44dd-9e5b-25b022f5d422", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Nov-2023  \nMcKesson Corp.   (MCK ) \nQ2 2024 Earnings Call    ", "original_text": "(MCK ) \nQ2 2024 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbefd3bde88137937c3247f1c92f8d5e6eb91f28a7567b0fe55ffe2df1c31818", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a220c07-4857-4eea-8522-dd3aa408cbb3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n"}, "hash": "07ddc77ab46ae9eb82b06a781bf17b0f9509d5ee252bc314b7535a8d52b4bff5", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a220c07-4857-4eea-8522-dd3aa408cbb3": {"__data__": {"id_": "8a220c07-4857-4eea-8522-dd3aa408cbb3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "784f73bcf80e719df71d5faef7fed9313f4bf939da11ec7bda146e7771065688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96af4f32-e99d-4b4b-98bc-80bd2b3c1dd6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77001f73b08355c525e008d442cf1368914eac86423e15bbcee58ace72dfbfcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "099e83b8-6dfb-44af-b97e-2e1319142825", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "50816cdb32224f2de5a39f94d8a279a7a68e2b481088815c2ac4b72e1c65b3ea", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "099e83b8-6dfb-44af-b97e-2e1319142825": {"__data__": {"id_": "099e83b8-6dfb-44af-b97e-2e1319142825", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "784f73bcf80e719df71d5faef7fed9313f4bf939da11ec7bda146e7771065688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a220c07-4857-4eea-8522-dd3aa408cbb3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d195e992027c4fa87d37dec4c8f08218da60ed97a42ed97ddc46f901ab4c00c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64e00170-b91d-4ad9-87dc-e3f9b8aa1d93", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n "}, "hash": "a9851f1f7c337b02b5befc5eb0e7f2feb8bcaf707993f8e4b9d9f5c7af5e452a", "class_name": "RelatedNodeInfo"}}, "text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 281, "end_char_idx": 353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64e00170-b91d-4ad9-87dc-e3f9b8aa1d93": {"__data__": {"id_": "64e00170-b91d-4ad9-87dc-e3f9b8aa1d93", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "784f73bcf80e719df71d5faef7fed9313f4bf939da11ec7bda146e7771065688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "099e83b8-6dfb-44af-b97e-2e1319142825", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "087b4917854da7185e24ee1ecc65a3afc5b17e12b2392ba006090ec7633dd4f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aacafba1-1a00-4b56-90cb-0e3ca421e1bd", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n"}, "hash": "b05bb3c83d97e77ba3d9198fbace9d1a36ffe694f0c008e160dfc6fb3ab61901", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "start_char_idx": 353, "end_char_idx": 443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aacafba1-1a00-4b56-90cb-0e3ca421e1bd": {"__data__": {"id_": "aacafba1-1a00-4b56-90cb-0e3ca421e1bd", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "784f73bcf80e719df71d5faef7fed9313f4bf939da11ec7bda146e7771065688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64e00170-b91d-4ad9-87dc-e3f9b8aa1d93", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1dcaae3c9f51ad7d5eec2475ed75378034112a3865ead6e2f56f71d65867d23c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be0832c2-7b64-4f6a-9832-be1fabddd096", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n"}, "hash": "ee9f0a6752b236ac408ccf05e2671f141c4eb003be107295201e51c090fe7af6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "start_char_idx": 443, "end_char_idx": 977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be0832c2-7b64-4f6a-9832-be1fabddd096": {"__data__": {"id_": "be0832c2-7b64-4f6a-9832-be1fabddd096", "embedding": null, "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "784f73bcf80e719df71d5faef7fed9313f4bf939da11ec7bda146e7771065688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aacafba1-1a00-4b56-90cb-0e3ca421e1bd", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2e3a60b6980a7af880065ce34a3076c37e0621e8be1f83d58bb2591f1400e94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb2df4f0-ce88-4f48-8afc-f97b6fa1f3f2", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "b06bb6eb0b4fe93324d0ceacc8375f6e398e98b837cee2a57a9f63fbfbdcab6e", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "start_char_idx": 977, "end_char_idx": 1085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb2df4f0-ce88-4f48-8afc-f97b6fa1f3f2": {"__data__": {"id_": "bb2df4f0-ce88-4f48-8afc-f97b6fa1f3f2", "embedding": null, "metadata": {"window": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "784f73bcf80e719df71d5faef7fed9313f4bf939da11ec7bda146e7771065688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be0832c2-7b64-4f6a-9832-be1fabddd096", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d99a23d823b6eb2183bfaf1a83894141f3eb0494f8dd058b4aed2c69bb25f8ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae85b463-057e-4d7b-b9a9-76198b013ee3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. "}, "hash": "be9eb539b6854f14c790021bfc2cbaa9346b8026315995090eb7568d7b5bbdfd", "class_name": "RelatedNodeInfo"}}, "text": "Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 1085, "end_char_idx": 1131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae85b463-057e-4d7b-b9a9-76198b013ee3": {"__data__": {"id_": "ae85b463-057e-4d7b-b9a9-76198b013ee3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "784f73bcf80e719df71d5faef7fed9313f4bf939da11ec7bda146e7771065688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb2df4f0-ce88-4f48-8afc-f97b6fa1f3f2", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf6566a130f1ea275581c5459d921cce30fc231f6c09a283418492e15cb2baf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd5d8aa2-1c97-4d3c-990e-a8c1a783af1c", "node_type": "1", "metadata": {"window": "Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  "}, "hash": "ed33b2811ad7e06c255231397dde018f546452bf8ddba1bb9185a54456121e77", "class_name": "RelatedNodeInfo"}}, "text": "Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 1131, "end_char_idx": 1182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd5d8aa2-1c97-4d3c-990e-a8c1a783af1c": {"__data__": {"id_": "cd5d8aa2-1c97-4d3c-990e-a8c1a783af1c", "embedding": null, "metadata": {"window": "Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "784f73bcf80e719df71d5faef7fed9313f4bf939da11ec7bda146e7771065688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae85b463-057e-4d7b-b9a9-76198b013ee3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, TD Cowen  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2cf68c5dd6063221f22145ee7d6418bde803a4409585f35c20e074ab951caf5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89607f5b-075d-4403-ace2-8c3ff01d6b67", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "McKesson Corp.  "}, "hash": "21bcd701a0abc08c301cb32162bb7c729de8e839e24789a08e1f3be5c3837ded", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "start_char_idx": 1182, "end_char_idx": 1297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89607f5b-075d-4403-ace2-8c3ff01d6b67": {"__data__": {"id_": "89607f5b-075d-4403-ace2-8c3ff01d6b67", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd5d8aa2-1c97-4d3c-990e-a8c1a783af1c", "node_type": "1", "metadata": {"window": "Kevin Caliendo  \nAnalyst, UBS Securities LLC  Daniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Allen Lutz  \nAnalyst, BofA Securities, Inc.  \n Erin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "original_text": "LLC  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n  ", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f49dc464463f84229bbb852a8a272f1d5451ae52753828448d19b18b54c7132", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bec546ab-b705-47b3-bb24-4e1c9e6bd82b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call. "}, "hash": "b8902801f2bb7784e0d2a2086f3c05cc6c59e55c21a2dea7810046587f19ecdd", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bec546ab-b705-47b3-bb24-4e1c9e6bd82b": {"__data__": {"id_": "bec546ab-b705-47b3-bb24-4e1c9e6bd82b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89607f5b-075d-4403-ace2-8c3ff01d6b67", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75fec6f8bf230710335b62fb4a901da0c09a1617eeae1626c0c8c87a2c4e0b6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f432ced-d0cd-4d49-852f-fd9d683ff06a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n"}, "hash": "b496b137fe203e78b6017042f573fe32702f6de8b3d973240218447de8d0ce80", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call. ", "start_char_idx": 16, "end_char_idx": 303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f432ced-d0cd-4d49-852f-fd9d683ff06a": {"__data__": {"id_": "3f432ced-d0cd-4d49-852f-fd9d683ff06a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bec546ab-b705-47b3-bb24-4e1c9e6bd82b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "939a6285f53838816b27e01a9b4cc7ba1683f981aa14bf650a5d51c2e7661cbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fe9932c-d76e-4660-9a36-a199064dcb15", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. "}, "hash": "6631af72c0b83fc039c3c2831b29b63bed5786d6bbf1d75088d2d63f8ce9bb82", "class_name": "RelatedNodeInfo"}}, "text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "start_char_idx": 303, "end_char_idx": 369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fe9932c-d76e-4660-9a36-a199064dcb15": {"__data__": {"id_": "8fe9932c-d76e-4660-9a36-a199064dcb15", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f432ced-d0cd-4d49-852f-fd9d683ff06a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96b564e7df66f06869e7e89d36c6dabb1eba43004b8627aa91eb1bd5926e1db9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcd4a6a1-d4ca-4eff-a32d-75d0e2d34a8c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall. ", "original_text": "Please go ahead.  \n "}, "hash": "5bafe90e88f3a6407c44ecba0c3026501417cb27a5af040a6b993f50be937485", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "start_char_idx": 369, "end_char_idx": 465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcd4a6a1-d4ca-4eff-a32d-75d0e2d34a8c": {"__data__": {"id_": "fcd4a6a1-d4ca-4eff-a32d-75d0e2d34a8c", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall. ", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fe9932c-d76e-4660-9a36-a199064dcb15", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c28013bbba15449b495a0076c03d90192cf118b6d606ae0131a9133fa5a1285", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5454c77-7f12-46a3-99b6-62e659afc5ee", "node_type": "1", "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n"}, "hash": "9761beca92c51831ef8dc4ead1f6fefeb8eb52e0b7c8dd4be4951a8625ba0ea0", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 465, "end_char_idx": 485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5454c77-7f12-46a3-99b6-62e659afc5ee": {"__data__": {"id_": "a5454c77-7f12-46a3-99b6-62e659afc5ee", "embedding": null, "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcd4a6a1-d4ca-4eff-a32d-75d0e2d34a8c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall. ", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61bb87ca0745a578bfd46c931100a70f2f84393e2d39789bb924689e8982580f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfe87f8e-2059-415e-9a4c-f049f1d598b9", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n", "original_text": "Thank you, operator. "}, "hash": "cba6dbbb376f994edc399579bac9ad6082266ad2fbbdf1abebb9db22524828fd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n", "start_char_idx": 485, "end_char_idx": 829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfe87f8e-2059-415e-9a4c-f049f1d598b9": {"__data__": {"id_": "dfe87f8e-2059-415e-9a4c-f049f1d598b9", "embedding": null, "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n", "original_text": "Thank you, operator. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5454c77-7f12-46a3-99b6-62e659afc5ee", "node_type": "1", "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c42f4a74fffa54429ddf6df413b06da3fb60427a23f9de6fc7e7ac4dd2e9f8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff8e79a4-1501-4f51-afc8-9773f8489b74", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall. "}, "hash": "6cae59856f510ed24518222148943d3f11cf0ef9cfd31f9ab3670e2acd948164", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, operator. ", "start_char_idx": 829, "end_char_idx": 850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff8e79a4-1501-4f51-afc8-9773f8489b74": {"__data__": {"id_": "ff8e79a4-1501-4f51-afc8-9773f8489b74", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfe87f8e-2059-415e-9a4c-f049f1d598b9", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n", "original_text": "Thank you, operator. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "002f3e21850c540db719fcb22ea94e10ca8140849307dd14f86928ee801bde0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4763077-f613-44b9-88ce-d8355a607c6d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n"}, "hash": "7e425d6c7d48eb9a7e2b2c71685b79779e63c2ad0d23cb12cc930f8e67d931c1", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall. ", "start_char_idx": 850, "end_char_idx": 944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4763077-f613-44b9-88ce-d8355a607c6d": {"__data__": {"id_": "f4763077-f613-44b9-88ce-d8355a607c6d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff8e79a4-1501-4f51-afc8-9773f8489b74", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2924035a59437736cab79edafb18409aa7aa0986ba618bbd77641abc552c9764", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7923f500-16fe-471c-a4b4-ac797127c5b2", "node_type": "1", "metadata": {"window": "Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides. ", "original_text": "Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n"}, "hash": "f34a937b8a271545577bfe880efbf561ec7ee26e2a3755abdd3af1179cdffcdc", "class_name": "RelatedNodeInfo"}}, "text": "Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "start_char_idx": 944, "end_char_idx": 1056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7923f500-16fe-471c-a4b4-ac797127c5b2": {"__data__": {"id_": "7923f500-16fe-471c-a4b4-ac797127c5b2", "embedding": null, "metadata": {"window": "Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides. ", "original_text": "Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4763077-f613-44b9-88ce-d8355a607c6d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f1ebb5d9e95b355d137256cf72e73e77d5ae488c510d685ff60a8d489ce6e85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "847c096e-6794-449e-bf55-f0058d047ca0", "node_type": "1", "metadata": {"window": "Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. "}, "hash": "1e45bce1fa028f8005c3ffed11ccc1a113e3686e185f4f2b9d13f108a251753a", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n", "start_char_idx": 1056, "end_char_idx": 1156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "847c096e-6794-449e-bf55-f0058d047ca0": {"__data__": {"id_": "847c096e-6794-449e-bf55-f0058d047ca0", "embedding": null, "metadata": {"window": "Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7923f500-16fe-471c-a4b4-ac797127c5b2", "node_type": "1", "metadata": {"window": "Thank you, operator.  Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides. ", "original_text": "Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c2debcd30170bf58f78eb4f279ba38418460584817feb001c381396e6cbfcdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec6d1691-3ac4-450f-87ea-6d601e20223c", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n"}, "hash": "d18b6e5e7ee2054c14eca66054fa737adae2a2b68922cca66ca3cc826c441d72", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "start_char_idx": 1156, "end_char_idx": 1283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec6d1691-3ac4-450f-87ea-6d601e20223c": {"__data__": {"id_": "ec6d1691-3ac4-450f-87ea-6d601e20223c", "embedding": null, "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "847c096e-6794-449e-bf55-f0058d047ca0", "node_type": "1", "metadata": {"window": "Good afternoon and welcome everyone  to McKesson's second quarter fiscal 2024 earnings \ncall.  Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "589c71446e598609323be3496520b67d26ff5ac5867a667df9e85138728ce541", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "677d71d5-b8ea-480c-9827-f328ec625dc8", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides. "}, "hash": "1d5fb69741b25e1d8681f572c4b60cc7e15dcab275617daca45e1b79d2c96690", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "start_char_idx": 1283, "end_char_idx": 1673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "677d71d5-b8ea-480c-9827-f328ec625dc8": {"__data__": {"id_": "677d71d5-b8ea-480c-9827-f328ec625dc8", "embedding": null, "metadata": {"window": "Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec6d1691-3ac4-450f-87ea-6d601e20223c", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dea5be9e7b4d25efde344e8b62e7faa92e644f004483748c8c82bbc574d152c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88eab0df-3c24-4cd8-a362-17e7f528365d", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody. ", "original_text": "The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n"}, "hash": "54d3eaf6b92eaec03ce4cdea226f4a11b52e7b3045a238d5ea8e04c1870b8dff", "class_name": "RelatedNodeInfo"}}, "text": "Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides. ", "start_char_idx": 1673, "end_char_idx": 1888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88eab0df-3c24-4cd8-a362-17e7f528365d": {"__data__": {"id_": "88eab0df-3c24-4cd8-a362-17e7f528365d", "embedding": null, "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody. ", "original_text": "The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "677d71d5-b8ea-480c-9827-f328ec625dc8", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we'll move to a question -and-answer ses sion.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e2e21b15095b67ecd97336187230b2ac9ef0b28efe570cfe0db3a2a0ae1272a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fac08a8-9767-422a-ae8e-e739307103f0", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today. ", "original_text": "With that, let me turn it over to Brian.  \n "}, "hash": "a1a0b1eb6b9d5c74f14519165ea7b03f73a57dcb73c37c4ec1887c512c7016fb", "class_name": "RelatedNodeInfo"}}, "text": "The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n", "start_char_idx": 1888, "end_char_idx": 1994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fac08a8-9767-422a-ae8e-e739307103f0": {"__data__": {"id_": "5fac08a8-9767-422a-ae8e-e739307103f0", "embedding": null, "metadata": {"window": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today. ", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88eab0df-3c24-4cd8-a362-17e7f528365d", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody. ", "original_text": "The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1776c2c8df0d9473fa0cf103a5319c747b8776618dcd5d2e3fe0d15cb14a07c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecb61339-b0ed-4981-83fc-8d8f24f3b1b2", "node_type": "1", "metadata": {"window": "Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "1575ac3957fc4d2b7dcc566d7b1656cd49a5696c5277ec1f402d3c86101029f4", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it over to Brian.  \n ", "start_char_idx": 1994, "end_char_idx": 2038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecb61339-b0ed-4981-83fc-8d8f24f3b1b2": {"__data__": {"id_": "ecb61339-b0ed-4981-83fc-8d8f24f3b1b2", "embedding": null, "metadata": {"window": "Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fac08a8-9767-422a-ae8e-e739307103f0", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at in vestor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk factors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today. ", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22eea024202c16e2da36dc8711203421e6203805d1e1eb652dc35e26350f830f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a63a54dc-7284-45a9-8108-73834e6ece33", "node_type": "1", "metadata": {"window": "The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion. ", "original_text": "Thank you, Rachel, and good afternoon, everybody. "}, "hash": "0f6fa0941b06ad0caccd63baf09b119379c6a7c876d168e609dbdbf1a2760a43", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 2038, "end_char_idx": 2383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a63a54dc-7284-45a9-8108-73834e6ece33": {"__data__": {"id_": "a63a54dc-7284-45a9-8108-73834e6ece33", "embedding": null, "metadata": {"window": "The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion. ", "original_text": "Thank you, Rachel, and good afternoon, everybody. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecb61339-b0ed-4981-83fc-8d8f24f3b1b2", "node_type": "1", "metadata": {"window": "Information about non -GAAP financial measures that we will discuss during this webcast, including reconciliation \nof those measures to GAAP results can be found in today's earnings release and presentation slides.  The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e314c0a19d8dd207b55e26025dd963634cc4bbe1ca1596266b6b2ca32e90385b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e4ad327-4a0c-4c4c-9eed-9a515569b0ed", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n", "original_text": "We appreciate you joining us on o ur call today. "}, "hash": "3f5008c559f4c9b7d861fd478e8383c37b84d4ab568062494f3e643f59b6f5f8", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Rachel, and good afternoon, everybody. ", "start_char_idx": 2383, "end_char_idx": 2433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e4ad327-4a0c-4c4c-9eed-9a515569b0ed": {"__data__": {"id_": "1e4ad327-4a0c-4c4c-9eed-9a515569b0ed", "embedding": null, "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n", "original_text": "We appreciate you joining us on o ur call today. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a63a54dc-7284-45a9-8108-73834e6ece33", "node_type": "1", "metadata": {"window": "The \npresentation slides also include a su mmary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion. ", "original_text": "Thank you, Rachel, and good afternoon, everybody. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01edeb63a7ce521491950dc90edb9f86f9b5b3f4bcce6ab2bfcc6a54a5994e1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10ac4c4d-637d-4e21-9cc3-c1de7d6a808c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n", "original_text": "We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n"}, "hash": "ef7e5abb031c42e72594d6b5fdf184347ae4ef0880d5c96311696c37ca318214", "class_name": "RelatedNodeInfo"}}, "text": "We appreciate you joining us on o ur call today. ", "start_char_idx": 2433, "end_char_idx": 2482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10ac4c4d-637d-4e21-9cc3-c1de7d6a808c": {"__data__": {"id_": "10ac4c4d-637d-4e21-9cc3-c1de7d6a808c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n", "original_text": "We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e4ad327-4a0c-4c4c-9eed-9a515569b0ed", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n", "original_text": "We appreciate you joining us on o ur call today. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a0d9197943c145fb909effa8df3d0611d303408808ba9b3423f87b85d6fb7d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38be99dd-9d12-414b-9be3-908b763e5cff", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare. ", "original_text": "In the  second quarter, revenues increased 10% to $77.2 billion. "}, "hash": "29705997a59ea03a9cee52010d989bda72196d7620debe8845213b681ec3d03f", "class_name": "RelatedNodeInfo"}}, "text": "We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n", "start_char_idx": 2482, "end_char_idx": 2722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38be99dd-9d12-414b-9be3-908b763e5cff": {"__data__": {"id_": "38be99dd-9d12-414b-9be3-908b763e5cff", "embedding": null, "metadata": {"window": "Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare. ", "original_text": "In the  second quarter, revenues increased 10% to $77.2 billion. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10ac4c4d-637d-4e21-9cc3-c1de7d6a808c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n", "original_text": "We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "901001246f545812c9cc3dbc23e1ca891840778442b01e79af0850ca06015536", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1382ce07-80e4-4cad-af5b-e523d92140ef", "node_type": "1", "metadata": {"window": "We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n", "original_text": "Adjusted earnings per diluted share were $6.23. \n"}, "hash": "c4d3f4ceb89301f537491de48cd81c64b4c341358f14dd3bfe61c13d8e9817b8", "class_name": "RelatedNodeInfo"}}, "text": "In the  second quarter, revenues increased 10% to $77.2 billion. ", "start_char_idx": 2722, "end_char_idx": 2787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1382ce07-80e4-4cad-af5b-e523d92140ef": {"__data__": {"id_": "1382ce07-80e4-4cad-af5b-e523d92140ef", "embedding": null, "metadata": {"window": "We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n", "original_text": "Adjusted earnings per diluted share were $6.23. \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38be99dd-9d12-414b-9be3-908b763e5cff", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and good afternoon, everybody.  We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare. ", "original_text": "In the  second quarter, revenues increased 10% to $77.2 billion. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9b36994ae3c5d764fea26de6dc1659e4b1e2616224df7c7e81129890fedac0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7761c5e1-47ef-4aed-b476-5e9e85e31188", "node_type": "1", "metadata": {"window": "We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting. ", "original_text": "When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n"}, "hash": "f2e5b93874b100bacfae18e7d3b6a6e6eb9f216f25f3797e71153ac6204df438", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted earnings per diluted share were $6.23. \n", "start_char_idx": 2787, "end_char_idx": 2836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7761c5e1-47ef-4aed-b476-5e9e85e31188": {"__data__": {"id_": "7761c5e1-47ef-4aed-b476-5e9e85e31188", "embedding": null, "metadata": {"window": "We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting. ", "original_text": "When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1382ce07-80e4-4cad-af5b-e523d92140ef", "node_type": "1", "metadata": {"window": "We appreciate you joining us on o ur call today.  We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n", "original_text": "Adjusted earnings per diluted share were $6.23. \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcf89bc27892e45a7fabfc2cd96dcb06beb16096d9015c4260954aa20b7a00f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91421e40-6fe8-445e-8eaa-e0004d0ac0fb", "node_type": "1", "metadata": {"window": "In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n", "original_text": "Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare. "}, "hash": "db5c176c6eba675c2abbd3d55034e6bf9b0ba02b936bde0bf39987f8e5a47887", "class_name": "RelatedNodeInfo"}}, "text": "When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n", "start_char_idx": 2836, "end_char_idx": 2941, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91421e40-6fe8-445e-8eaa-e0004d0ac0fb": {"__data__": {"id_": "91421e40-6fe8-445e-8eaa-e0004d0ac0fb", "embedding": null, "metadata": {"window": "In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n", "original_text": "Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7761c5e1-47ef-4aed-b476-5e9e85e31188", "node_type": "1", "metadata": {"window": "We're very \npleased to report another solid quarter in fiscal 2024 with adjusted results above expectations, demonstrating our \nability to consistently execute against company priorities and create sustained value for our shareholders.  \n \n In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting. ", "original_text": "When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "909658d7318249db510c5c55a3919a5657e2f9aa9b19f86aca55c41efcf9601d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ed3365b-9098-4934-b77c-067c6c9d55e2", "node_type": "1", "metadata": {"window": "Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings. ", "original_text": "Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n"}, "hash": "3eeba6ede759dfc6173896312545260aa917763bd4da6528ed6470cdc994566d", "class_name": "RelatedNodeInfo"}}, "text": "Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare. ", "start_char_idx": 2941, "end_char_idx": 3174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ed3365b-9098-4934-b77c-067c6c9d55e2": {"__data__": {"id_": "0ed3365b-9098-4934-b77c-067c6c9d55e2", "embedding": null, "metadata": {"window": "Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings. ", "original_text": "Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91421e40-6fe8-445e-8eaa-e0004d0ac0fb", "node_type": "1", "metadata": {"window": "In the  second quarter, revenues increased 10% to $77.2 billion.  Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n", "original_text": "Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0919c8268a85b4acea688e04dd0385321e522263fc5a2528f040694a4f371b61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d59c5b46-c33d-446b-b95c-710031414c5f", "node_type": "1", "metadata": {"window": "When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings.  We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "original_text": "Team McKesson continues to deliver on our mission of improving care in every setting. "}, "hash": "e722fbebc4aee4d9c1e609d4b5375a925f11c45f6b2aa1acffe5f3180cca571f", "class_name": "RelatedNodeInfo"}}, "text": "Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n", "start_char_idx": 3174, "end_char_idx": 3276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d59c5b46-c33d-446b-b95c-710031414c5f": {"__data__": {"id_": "d59c5b46-c33d-446b-b95c-710031414c5f", "embedding": null, "metadata": {"window": "When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings.  We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "original_text": "Team McKesson continues to deliver on our mission of improving care in every setting. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ed3365b-9098-4934-b77c-067c6c9d55e2", "node_type": "1", "metadata": {"window": "Adjusted earnings per diluted share were $6.23. \n When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings. ", "original_text": "Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6dbe53cfee9720ad469f857400f3659a7b62dfa33b837e15c3d49ed1ae6d9ec2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf5497d4-44cb-4b44-b46f-5a34b54e6fe6", "node_type": "1", "metadata": {"window": "Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings.  We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "original_text": "As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n"}, "hash": "2d0c652a6f621f9a47b3ae7daf71f25f6870f282dc58288fe3e1514893b7ee6f", "class_name": "RelatedNodeInfo"}}, "text": "Team McKesson continues to deliver on our mission of improving care in every setting. ", "start_char_idx": 3276, "end_char_idx": 3362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf5497d4-44cb-4b44-b46f-5a34b54e6fe6": {"__data__": {"id_": "bf5497d4-44cb-4b44-b46f-5a34b54e6fe6", "embedding": null, "metadata": {"window": "Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings.  We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "original_text": "As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d59c5b46-c33d-446b-b95c-710031414c5f", "node_type": "1", "metadata": {"window": "When excluding certain items, adjusted earnings per diluted share increased 14% from the prior year.  \n \n Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings.  We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "original_text": "Team McKesson continues to deliver on our mission of improving care in every setting. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0f72ff9e6c1e04cea07d8a0fcbde924805270869bd150ec4798a817e819b78f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43b8b382-5630-4fc0-ae99-644fc416b3a9", "node_type": "1", "metadata": {"window": "Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings.  We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "original_text": "Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings. "}, "hash": "84aaed8e9c612a4b9a9e8838434e7516b68649cceec20579e1f2f54c61d13258", "class_name": "RelatedNodeInfo"}}, "text": "As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n", "start_char_idx": 3362, "end_char_idx": 3564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43b8b382-5630-4fc0-ae99-644fc416b3a9": {"__data__": {"id_": "43b8b382-5630-4fc0-ae99-644fc416b3a9", "embedding": null, "metadata": {"window": "Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings.  We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "original_text": "Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf5497d4-44cb-4b44-b46f-5a34b54e6fe6", "node_type": "1", "metadata": {"window": "Our performance through the first half of the fi scal year combined with the continued momentum in advancing our \ncompany strategies gives us the confidence to raise our guidance for fiscal 2024 adjusted earnings per diluted \nshare.  Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings.  We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "original_text": "As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1eb42d6f9934961926e57f15e0ed52930e42e2ff70bb05a81534f97605c538c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be7f7286-4504-46be-9695-cb59e6de843c", "node_type": "1", "metadata": {"window": "Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings.  We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "original_text": "We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  "}, "hash": "d171c1658c9619ec43bb6abf2e1dfdff7778f24f425ef6e91558cb6bc9ae7765", "class_name": "RelatedNodeInfo"}}, "text": "Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings. ", "start_char_idx": 3564, "end_char_idx": 3718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be7f7286-4504-46be-9695-cb59e6de843c": {"__data__": {"id_": "be7f7286-4504-46be-9695-cb59e6de843c", "embedding": null, "metadata": {"window": "Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings.  We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "original_text": "We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bb3b76a1424ac760bc778682aa1e7a6231515cc96137824c300416fe857110", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43b8b382-5630-4fc0-ae99-644fc416b3a9", "node_type": "1", "metadata": {"window": "Our previous guidance range of $26.55 to $27.35 has been updated to a rang e of $26.80 to $27.40.  \n \n Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings.  We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "original_text": "Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings. ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b0f9f9d4aca0642226049b190253f539b464e520e056b3f2f63b206953169c2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f60a01d5-896a-421a-8842-4cf1dbeca723", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "f9d840916e1c591702a6154747a8c1593ecad871863a69bb8451d11bd2e7d414", "class_name": "RelatedNodeInfo"}}, "text": "We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "start_char_idx": 3718, "end_char_idx": 3827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f60a01d5-896a-421a-8842-4cf1dbeca723": {"__data__": {"id_": "f60a01d5-896a-421a-8842-4cf1dbeca723", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be7f7286-4504-46be-9695-cb59e6de843c", "node_type": "1", "metadata": {"window": "Team McKesson continues to deliver on our mission of improving care in every setting.  As a diversified \nhealthcare services company, we're making important progress in strengthening our portfolio of differentiated \nassets and bringing  more value to our customers and their patients.  \n \n Before I turn my attention to our company priorities and the second quarter results, I want to briefly discuss Rite \nAid's recent bankruptcy proceedings.  We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "original_text": "We have been supplying Rite Aid with the majority of their pharmaceutical \nproducts for more than 20 years.  ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "136e27ab935e6b2b6e1e8d7b4235ea1f25c80c0647ba96646464293cf2bfc4c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "049ab5e4-70bb-4bbd-86bf-8bd53b5718d6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products. "}, "hash": "67254111518f9e8f0530613e47ceaf75e19e614301182f8dc26ab4530618fbc8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "049ab5e4-70bb-4bbd-86bf-8bd53b5718d6": {"__data__": {"id_": "049ab5e4-70bb-4bbd-86bf-8bd53b5718d6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f60a01d5-896a-421a-8842-4cf1dbeca723", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b6f28e6b279796e55472489bef4135509781eb9c266be42f806878e59e74360", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3937c700-7f64-49e1-b4db-f959cf6a3e3e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n", "original_text": "We're closely monitoring developments. "}, "hash": "29e119b7d28f937aa955caaf73a88f47f15b49a982dbf63e1662f775042e37c4", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products. ", "start_char_idx": 16, "end_char_idx": 314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3937c700-7f64-49e1-b4db-f959cf6a3e3e": {"__data__": {"id_": "3937c700-7f64-49e1-b4db-f959cf6a3e3e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n", "original_text": "We're closely monitoring developments. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "049ab5e4-70bb-4bbd-86bf-8bd53b5718d6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca941b7cbc334e9ed0240bcb7562830adf258605a89977d270515fba36dcd27a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6093f32d-cc09-4fee-872e-976950b20214", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent. ", "original_text": "But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n"}, "hash": "4d981ea729c02700bcf6acbdce0807bc996bf111a07153798c19b88e32fe94ab", "class_name": "RelatedNodeInfo"}}, "text": "We're closely monitoring developments. ", "start_char_idx": 314, "end_char_idx": 353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6093f32d-cc09-4fee-872e-976950b20214": {"__data__": {"id_": "6093f32d-cc09-4fee-872e-976950b20214", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent. ", "original_text": "But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3937c700-7f64-49e1-b4db-f959cf6a3e3e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n", "original_text": "We're closely monitoring developments. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d0d302f00198645c19fb043bc6fd9178dfbdeb390d9c29eeccc46857cf7be25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a227b051-baa8-4084-b34c-7fdca65f94f8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized. ", "original_text": "Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson. "}, "hash": "2aea7860f645d3303386e5add4d4cf4c06a0b908a9f87ba08e3e012fcb59ecc2", "class_name": "RelatedNodeInfo"}}, "text": "But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n", "start_char_idx": 353, "end_char_idx": 527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a227b051-baa8-4084-b34c-7fdca65f94f8": {"__data__": {"id_": "a227b051-baa8-4084-b34c-7fdca65f94f8", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized. ", "original_text": "Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6093f32d-cc09-4fee-872e-976950b20214", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent. ", "original_text": "But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e872482e899ad2c99df64a8a9887b912dc5b65efb964ed242be62119a4b56874", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d0fe18e-7f02-4d14-8f52-6fbb108f3d58", "node_type": "1", "metadata": {"window": "We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women. ", "original_text": "Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n"}, "hash": "04c492d81af91c2d73eda67dfbd7f252c3a55a8de87ff13a0dfb160c1c651d83", "class_name": "RelatedNodeInfo"}}, "text": "Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson. ", "start_char_idx": 527, "end_char_idx": 704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d0fe18e-7f02-4d14-8f52-6fbb108f3d58": {"__data__": {"id_": "6d0fe18e-7f02-4d14-8f52-6fbb108f3d58", "embedding": null, "metadata": {"window": "We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women. ", "original_text": "Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a227b051-baa8-4084-b34c-7fdca65f94f8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized. ", "original_text": "Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7bdba47b0d3657cfe4d9242aff86413d737873e6e7acb72386f49bad176a76ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ff3631f-a09b-4cf5-9bf5-107d5793c8f3", "node_type": "1", "metadata": {"window": "But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n", "original_text": "We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent. "}, "hash": "07242f4af69d9fbb26c7f9255bd27071c22689d4115bde1f6549f9d4288c6e4f", "class_name": "RelatedNodeInfo"}}, "text": "Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n", "start_char_idx": 704, "end_char_idx": 958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ff3631f-a09b-4cf5-9bf5-107d5793c8f3": {"__data__": {"id_": "0ff3631f-a09b-4cf5-9bf5-107d5793c8f3", "embedding": null, "metadata": {"window": "But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n", "original_text": "We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d0fe18e-7f02-4d14-8f52-6fbb108f3d58", "node_type": "1", "metadata": {"window": "We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women. ", "original_text": "Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7722fc47fa3998040fae891115e0809b517d2919b84e186919ba4726e6e83fcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd947ace-bf49-4d25-ae64-74b7e48bc89a", "node_type": "1", "metadata": {"window": "Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other. ", "original_text": "Our efforts fostering a culture of belonging are well -recognized. "}, "hash": "eaa1da96175a8f12e9ea9ff0565283c0e4a17935e8679c078218144755162016", "class_name": "RelatedNodeInfo"}}, "text": "We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent. ", "start_char_idx": 958, "end_char_idx": 1080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd947ace-bf49-4d25-ae64-74b7e48bc89a": {"__data__": {"id_": "fd947ace-bf49-4d25-ae64-74b7e48bc89a", "embedding": null, "metadata": {"window": "Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other. ", "original_text": "Our efforts fostering a culture of belonging are well -recognized. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ff3631f-a09b-4cf5-9bf5-107d5793c8f3", "node_type": "1", "metadata": {"window": "But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n", "original_text": "We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c13d696205624abe2359dfa23b4ee01f4a8d7523d48eb3986f7447b48cda991", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e4857d1-f313-42d0-af3c-a3ab00bdac53", "node_type": "1", "metadata": {"window": "Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way. ", "original_text": "Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women. "}, "hash": "377f05539e94e7020229895d55d5d29b0c0dfbdd6aa265e549399711efc54e9b", "class_name": "RelatedNodeInfo"}}, "text": "Our efforts fostering a culture of belonging are well -recognized. ", "start_char_idx": 1080, "end_char_idx": 1147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e4857d1-f313-42d0-af3c-a3ab00bdac53": {"__data__": {"id_": "9e4857d1-f313-42d0-af3c-a3ab00bdac53", "embedding": null, "metadata": {"window": "Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way. ", "original_text": "Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd947ace-bf49-4d25-ae64-74b7e48bc89a", "node_type": "1", "metadata": {"window": "Now let me move on to our company priorities, and I want to start by recognizing our people, including the \ndiverse, ded icated, and talented team we've built here at McKesson.  Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other. ", "original_text": "Our efforts fostering a culture of belonging are well -recognized. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ccf6909b8ffaae137bb6a10338b594d3b5300317f7a77090823a4fe3adebb2fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d80afbde-ca1a-470e-8e41-53ef92b9fc1f", "node_type": "1", "metadata": {"window": "We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n", "original_text": "And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n"}, "hash": "198bb0621dace386b468a64aa2abf13b9bbf32e4f1c91080451f81516e1c10fb", "class_name": "RelatedNodeInfo"}}, "text": "Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women. ", "start_char_idx": 1147, "end_char_idx": 1243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d80afbde-ca1a-470e-8e41-53ef92b9fc1f": {"__data__": {"id_": "d80afbde-ca1a-470e-8e41-53ef92b9fc1f", "embedding": null, "metadata": {"window": "We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n", "original_text": "And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e4857d1-f313-42d0-af3c-a3ab00bdac53", "node_type": "1", "metadata": {"window": "Investing in people and culture is \nfoundational to our strategy, and we offer many engagement programs and initiatives to empower our employees \nand allow them to express new ideas to contribute their unique perspectives and to care for each other.  \n \n We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way. ", "original_text": "Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe20329ac34e00aa22670290f63f88c3d39c803b2096771239ff90b49de0a3ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fc11a11-64ab-4106-9964-47b069027fef", "node_type": "1", "metadata": {"window": "Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth. ", "original_text": "We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other. "}, "hash": "31cb5ccc74112d59e56015005807ff78ba2c0c9105366b9f56a14308aebdb7ed", "class_name": "RelatedNodeInfo"}}, "text": "And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n", "start_char_idx": 1243, "end_char_idx": 1395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fc11a11-64ab-4106-9964-47b069027fef": {"__data__": {"id_": "0fc11a11-64ab-4106-9964-47b069027fef", "embedding": null, "metadata": {"window": "Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth. ", "original_text": "We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d80afbde-ca1a-470e-8e41-53ef92b9fc1f", "node_type": "1", "metadata": {"window": "We firmly believe that we achieve our full potential when our culture is diverse, inclusive, and focused on best \ntalent.  Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n", "original_text": "And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e04f2376767aa3f8b1598a9dcedfe1335e170988861ada298062e506ba68f7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c6fbd94-7199-4dab-974e-46ba7d35c226", "node_type": "1", "metadata": {"window": "Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n", "original_text": "On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way. "}, "hash": "3fdaa5b207b922e1c6b97da9c90de3ef30f281846d30006631eeed1f66bc07bb", "class_name": "RelatedNodeInfo"}}, "text": "We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other. ", "start_char_idx": 1395, "end_char_idx": 1547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c6fbd94-7199-4dab-974e-46ba7d35c226": {"__data__": {"id_": "0c6fbd94-7199-4dab-974e-46ba7d35c226", "embedding": null, "metadata": {"window": "Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n", "original_text": "On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fc11a11-64ab-4106-9964-47b069027fef", "node_type": "1", "metadata": {"window": "Our efforts fostering a culture of belonging are well -recognized.  Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth. ", "original_text": "We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de8a47de9359406de8b4ca2fe87f09a77ce69b121c64528174a7d0cfa6580770", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "563e362a-50ec-4b1d-86b8-18ae3c373399", "node_type": "1", "metadata": {"window": "And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n", "original_text": "This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n"}, "hash": "493bba1800ff2db471bad7103603233b33ece5385079fddc8669ffb8d3632b2f", "class_name": "RelatedNodeInfo"}}, "text": "On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way. ", "start_char_idx": 1547, "end_char_idx": 1628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "563e362a-50ec-4b1d-86b8-18ae3c373399": {"__data__": {"id_": "563e362a-50ec-4b1d-86b8-18ae3c373399", "embedding": null, "metadata": {"window": "And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n", "original_text": "This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c6fbd94-7199-4dab-974e-46ba7d35c226", "node_type": "1", "metadata": {"window": "Recently, we were ho nored to be named \nby Forbes as one of America's Best Employers for Women.  And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n", "original_text": "On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce9dc8a2dfee76440544b97ed6940072cbb9bf487c5fde7631f3e1646ae05448", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14c2d3e6-a84b-485d-a3a2-4cc53c92f3a2", "node_type": "1", "metadata": {"window": "We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter. ", "original_text": "Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth. "}, "hash": "747c5a25cf4d68e69a619ab85bc8214c74be8804333a892b6ece2d4f53d22b76", "class_name": "RelatedNodeInfo"}}, "text": "This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n", "start_char_idx": 1628, "end_char_idx": 1837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14c2d3e6-a84b-485d-a3a2-4cc53c92f3a2": {"__data__": {"id_": "14c2d3e6-a84b-485d-a3a2-4cc53c92f3a2", "embedding": null, "metadata": {"window": "We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter. ", "original_text": "Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "563e362a-50ec-4b1d-86b8-18ae3c373399", "node_type": "1", "metadata": {"window": "And for the eighth consecutive year, we were named \nas one of the Best Places to Work for Disability Inclusion, earning a top ranking score of 100.  \n \n We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n", "original_text": "This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97b0f3230c0e8311830c9466d6f93c7cd78abd61e612ed89a619a46818e2b085", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9960734f-c167-4c11-b315-e9904d5853e5", "node_type": "1", "metadata": {"window": "On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines. ", "original_text": "In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n"}, "hash": "780b198e9cccfeb888a7ad9072f9305f263539fa6b7f6fe237c4811c2175a987", "class_name": "RelatedNodeInfo"}}, "text": "Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth. ", "start_char_idx": 1837, "end_char_idx": 1974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9960734f-c167-4c11-b315-e9904d5853e5": {"__data__": {"id_": "9960734f-c167-4c11-b315-e9904d5853e5", "embedding": null, "metadata": {"window": "On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines. ", "original_text": "In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14c2d3e6-a84b-485d-a3a2-4cc53c92f3a2", "node_type": "1", "metadata": {"window": "We appreciate all the hard work an d dedication from Team McKesson, and we recognize the importance of \nhelping, respecting, and caring for each other.  On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter. ", "original_text": "Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2edfd6565f07ca9722f6ac711b3019f7ae1c0ea6e9028303b6e3a6b13b3778c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61b8298d-e5cf-4e4f-8274-a45c0365643e", "node_type": "1", "metadata": {"window": "This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n", "original_text": "Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n"}, "hash": "acb3eda50fd297e51950fc42513b77bbe6655ff536bad2d3458a4f269b6f5465", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n", "start_char_idx": 1974, "end_char_idx": 2058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61b8298d-e5cf-4e4f-8274-a45c0365643e": {"__data__": {"id_": "61b8298d-e5cf-4e4f-8274-a45c0365643e", "embedding": null, "metadata": {"window": "This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n", "original_text": "Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9960734f-c167-4c11-b315-e9904d5853e5", "node_type": "1", "metadata": {"window": "On October 27, we celebrated our annual Wellness Day called \nYour Day, Your Way.  This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines. ", "original_text": "In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b0e84dafbf40eb84ea3cca6de4707e634fa8ce150e41e5bcf5b30a9c3b9b66da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2b666f4-9576-4bf8-a9ea-2cc6487dedae", "node_type": "1", "metadata": {"window": "Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels. ", "original_text": "In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter. "}, "hash": "95cff39e24a849ca61c746c9b827913a2e731cf63907037c9eddec624a6e41d6", "class_name": "RelatedNodeInfo"}}, "text": "Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n", "start_char_idx": 2058, "end_char_idx": 2227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2b666f4-9576-4bf8-a9ea-2cc6487dedae": {"__data__": {"id_": "e2b666f4-9576-4bf8-a9ea-2cc6487dedae", "embedding": null, "metadata": {"window": "Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels. ", "original_text": "In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61b8298d-e5cf-4e4f-8274-a45c0365643e", "node_type": "1", "metadata": {"window": "This is the third year that we've celebrated this tradition and shown appreciation for our \nemployees by providing them with an additional day off work to prioritize their personal health and well -being.  \n \n Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n", "original_text": "Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a8566c3ad3f8c9d93ef806e4bb3527e51484498a92acf639274a08a1ccf7fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16206b8a-d80c-4817-8803-6e52cc4c5e7a", "node_type": "1", "metadata": {"window": "In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner. ", "original_text": "And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines. "}, "hash": "6dcfda1b565e782f3b8854955bb3689eb01042060c1d0acc4681949c002fb01c", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter. ", "start_char_idx": 2227, "end_char_idx": 2412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16206b8a-d80c-4817-8803-6e52cc4c5e7a": {"__data__": {"id_": "16206b8a-d80c-4817-8803-6e52cc4c5e7a", "embedding": null, "metadata": {"window": "In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner. ", "original_text": "And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2b666f4-9576-4bf8-a9ea-2cc6487dedae", "node_type": "1", "metadata": {"window": "Let's take a minute to review the performance of the distribution business and the progress we've made driving \nsustainable core growth.  In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels. ", "original_text": "In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fe3aa535398d5a0d544f6a519754cda49b05b542b0f2c394c123ebf1e373463", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bda19614-1ccd-436c-8e1c-135ad9e85cd7", "node_type": "1", "metadata": {"window": "Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products. ", "original_text": "Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n"}, "hash": "2d820c3c05a032461e1e76a31ed9c0fe9d3cb7036d0bc3d3addc4c9ba4fd5e9e", "class_name": "RelatedNodeInfo"}}, "text": "And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines. ", "start_char_idx": 2412, "end_char_idx": 2543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bda19614-1ccd-436c-8e1c-135ad9e85cd7": {"__data__": {"id_": "bda19614-1ccd-436c-8e1c-135ad9e85cd7", "embedding": null, "metadata": {"window": "Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products. ", "original_text": "Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16206b8a-d80c-4817-8803-6e52cc4c5e7a", "node_type": "1", "metadata": {"window": "In the second quarter, we saw strong performance in the US Pharmaceutical segment. \n Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner. ", "original_text": "And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48f23a46e8e068b1d909f3af0c28b8066f3109f9ed11031cc79107f9e3af8a5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d887fe2-a841-43b8-959a-6d0d0ff70c6f", "node_type": "1", "metadata": {"window": "In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n", "original_text": "This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels. "}, "hash": "55e378a02b30a93fc33f63485f8458bb3bd54c7e1a5e37634550a4f72eaf2385", "class_name": "RelatedNodeInfo"}}, "text": "Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n", "start_char_idx": 2543, "end_char_idx": 2693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d887fe2-a841-43b8-959a-6d0d0ff70c6f": {"__data__": {"id_": "2d887fe2-a841-43b8-959a-6d0d0ff70c6f", "embedding": null, "metadata": {"window": "In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n", "original_text": "This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bda19614-1ccd-436c-8e1c-135ad9e85cd7", "node_type": "1", "metadata": {"window": "Over the past 10 quarters, the segment has consistently delivered double -digit revenue increases, demonstrating \nour ability to serve and grow with ou r customers.  \n \n In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products. ", "original_text": "Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c449abb87eed6d6dac7300be65139b0c10017f1fc0e2d8a6128c1592670a220c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d01099f-c09f-4bca-aec4-fffb60135758", "node_type": "1", "metadata": {"window": "And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies. ", "original_text": "We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner. "}, "hash": "6dedc1b1412e2c1b2e4f18697c4eac0d68dbd0f3ad965e9d79b1362363219c86", "class_name": "RelatedNodeInfo"}}, "text": "This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels. ", "start_char_idx": 2693, "end_char_idx": 2799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d01099f-c09f-4bca-aec4-fffb60135758": {"__data__": {"id_": "1d01099f-c09f-4bca-aec4-fffb60135758", "embedding": null, "metadata": {"window": "And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies. ", "original_text": "We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d887fe2-a841-43b8-959a-6d0d0ff70c6f", "node_type": "1", "metadata": {"window": "In the second quarter, we continued to observe solid prescription volume trends, particularly in the category of \nGLP-1 medications, which contributed to revenue growth in the quarter.  And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n", "original_text": "This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcb624ccc4340c8ea418363adda8f1e832a9c84ff4b6deff7d71a92827baa3e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edc9f716-693a-404c-8b6d-3afbe76ec5ab", "node_type": "1", "metadata": {"window": "Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices. ", "original_text": "As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products. "}, "hash": "09ac3075ba054bea7c20ecb2acd5b91ffa2057780ccfdcc858cf20fe327865fc", "class_name": "RelatedNodeInfo"}}, "text": "We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner. ", "start_char_idx": 2799, "end_char_idx": 2910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edc9f716-693a-404c-8b6d-3afbe76ec5ab": {"__data__": {"id_": "edc9f716-693a-404c-8b6d-3afbe76ec5ab", "embedding": null, "metadata": {"window": "Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices. ", "original_text": "As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d01099f-c09f-4bca-aec4-fffb60135758", "node_type": "1", "metadata": {"window": "And over the past three years, we were \nhonored to support the US government as the centralized distributor of COVID -19 vaccines.  Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies. ", "original_text": "We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f4383f3dbe52da0fe80bf7063180d2a040896bdb2f57b1465ff76bb64114ab4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "955271a0-d83b-4e65-a0c0-ccd5d1b25ce2", "node_type": "1", "metadata": {"window": "This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n", "original_text": "And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n"}, "hash": "0681ac93cd6c976c1ea65f82a5fad360ed3a0962d689d3a1d23cca9af9cab6d7", "class_name": "RelatedNodeInfo"}}, "text": "As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products. ", "start_char_idx": 2910, "end_char_idx": 3062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "955271a0-d83b-4e65-a0c0-ccd5d1b25ce2": {"__data__": {"id_": "955271a0-d83b-4e65-a0c0-ccd5d1b25ce2", "embedding": null, "metadata": {"window": "This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n", "original_text": "And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edc9f716-693a-404c-8b6d-3afbe76ec5ab", "node_type": "1", "metadata": {"window": "Our team \ndemonstrated incredible agility and dedication in standing up a fit -for-purpose operation distribute the vaccines \nacross the country.  \n \n This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices. ", "original_text": "As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4127ff335569a4a7e048870b3774966ea9976fdd5f1cf30668747beea1f14d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9e51b1f-9051-43fc-972e-fdf50ba193ee", "node_type": "1", "metadata": {"window": "We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business. ", "original_text": "In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies. "}, "hash": "1c58bdc75e78919a2a3f1db3e48b60cb748bf7a8dadc6260735e47feea128c58", "class_name": "RelatedNodeInfo"}}, "text": "And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n", "start_char_idx": 3062, "end_char_idx": 3204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9e51b1f-9051-43fc-972e-fdf50ba193ee": {"__data__": {"id_": "f9e51b1f-9051-43fc-972e-fdf50ba193ee", "embedding": null, "metadata": {"window": "We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business. ", "original_text": "In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "955271a0-d83b-4e65-a0c0-ccd5d1b25ce2", "node_type": "1", "metadata": {"window": "This past September, we started transitio ning the COVID -19 vaccine distribution to commercial channels.  We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n", "original_text": "And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20ad3c735fa9c98bac3d3fb866e405e99283bba9c4a952c14cc9e39d48739005", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0de9f81-6598-4a89-95fb-c8017b7a8dde", "node_type": "1", "metadata": {"window": "As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook. ", "original_text": "As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices. "}, "hash": "bc6228dd1f117d1d5c4954629ce868688df275486dbc6fdd3a42cbccf9ca9392", "class_name": "RelatedNodeInfo"}}, "text": "In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies. ", "start_char_idx": 3204, "end_char_idx": 3399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0de9f81-6598-4a89-95fb-c8017b7a8dde": {"__data__": {"id_": "d0de9f81-6598-4a89-95fb-c8017b7a8dde", "embedding": null, "metadata": {"window": "As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook. ", "original_text": "As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9e51b1f-9051-43fc-972e-fdf50ba193ee", "node_type": "1", "metadata": {"window": "We're \nworking closely with the manufacturers to bring vaccines to patients in an efficient and timely manner.  As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business. ", "original_text": "In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28c7b20dca7f10a405c7da1e2572efa169d304c989c570105086a468761bc65b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6c21810-dc96-45ef-a2f7-186ac5afb299", "node_type": "1", "metadata": {"window": "And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook.  However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "original_text": "We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n"}, "hash": "9e4ec18c78dc27920fbfc7d8f086b0670ab180deb25089bb984143ad8bf771b8", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices. ", "start_char_idx": 3399, "end_char_idx": 3548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6c21810-dc96-45ef-a2f7-186ac5afb299": {"__data__": {"id_": "b6c21810-dc96-45ef-a2f7-186ac5afb299", "embedding": null, "metadata": {"window": "And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook.  However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "original_text": "We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0de9f81-6598-4a89-95fb-c8017b7a8dde", "node_type": "1", "metadata": {"window": "As one of \nthe largest distributors of flu vaccines in the country, we have scaled c hannel reach and deep expertise in working \nwith vaccine products.  And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook. ", "original_text": "As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96dbfae3f1695316bcc302d6ed1e800014504c17d05d92950268aca70260d029", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f340c04-7de7-4c66-99b3-58f027ad8744", "node_type": "1", "metadata": {"window": "In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook.  However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "original_text": "We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business. "}, "hash": "4f423e67394c577a220b3ac6fd930734fca0fe047dbad7786b00f38cccc50b55", "class_name": "RelatedNodeInfo"}}, "text": "We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n", "start_char_idx": 3548, "end_char_idx": 3682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f340c04-7de7-4c66-99b3-58f027ad8744": {"__data__": {"id_": "5f340c04-7de7-4c66-99b3-58f027ad8744", "embedding": null, "metadata": {"window": "In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook.  However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "original_text": "We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6c21810-dc96-45ef-a2f7-186ac5afb299", "node_type": "1", "metadata": {"window": "And I'm pleased to say that through October 20, we have distributed nearly 8 million \nCOVID -19 vaccines through our commercial channels.  \n \n In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook.  However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "original_text": "We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0bafb03789691aae508b90753c9720c6fe90762ae0156d6509e102e1e75fae6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f4b40e3-8688-4fc9-a8c9-b58adfec6d94", "node_type": "1", "metadata": {"window": "As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook.  However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "original_text": "These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook. "}, "hash": "5d2eda762cdaeaed9c41e4aab8ce3ccc1b2b0e48c5333a9dec7d242508db1700", "class_name": "RelatedNodeInfo"}}, "text": "We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business. ", "start_char_idx": 3682, "end_char_idx": 3859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f4b40e3-8688-4fc9-a8c9-b58adfec6d94": {"__data__": {"id_": "8f4b40e3-8688-4fc9-a8c9-b58adfec6d94", "embedding": null, "metadata": {"window": "As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook.  However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "original_text": "These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f340c04-7de7-4c66-99b3-58f027ad8744", "node_type": "1", "metadata": {"window": "In the Medical -Surgical segment, we continued to supp ort our customers' evolving needs with a diversified \nportfolio of products and broad experience in Medical -Surgical and related supplies.  As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook.  However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "original_text": "We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1157fb0fad90c2fc49cfb96c54f0e0a279de4d99368c56924706a33e1ae391c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23021893-dc40-4706-b88a-e8ed613ef8ab", "node_type": "1", "metadata": {"window": "We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook.  However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "original_text": "However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  "}, "hash": "a42edd92f83928ae041986c5580471e59b03085cb1db56aa0fdcbe5d86630e60", "class_name": "RelatedNodeInfo"}}, "text": "These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook. ", "start_char_idx": 3859, "end_char_idx": 3966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23021893-dc40-4706-b88a-e8ed613ef8ab": {"__data__": {"id_": "23021893-dc40-4706-b88a-e8ed613ef8ab", "embedding": null, "metadata": {"window": "We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook.  However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "original_text": "However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c38e3124827a8997cadfa57e46ad220cfc27abd40ec95f94f69e1b635296c19a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f4b40e3-8688-4fc9-a8c9-b58adfec6d94", "node_type": "1", "metadata": {"window": "As a reminder, while we \nserve many alternate site providers, the biggest channel within the segment is primary care, i ncluding physician \noffices.  We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook.  However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "original_text": "These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook. ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7accdd837bed707844f2af6944b079a096782cc99bac4b865457dde9ea99d280", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d9a48a6-ce7d-43d4-8649-a81e859efe64", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "4dc40c1953f6ab3bd8d7b84ff9fae9bf99fdfb4c0f99d62a9db3154ad9e20074", "class_name": "RelatedNodeInfo"}}, "text": "However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "start_char_idx": 3966, "end_char_idx": 4110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d9a48a6-ce7d-43d4-8649-a81e859efe64": {"__data__": {"id_": "4d9a48a6-ce7d-43d4-8649-a81e859efe64", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23021893-dc40-4706-b88a-e8ed613ef8ab", "node_type": "1", "metadata": {"window": "We closely track market data, and during the second quarter we observed general market moderations in \nprimary care foot traffic.  \n \n We also saw a year -over-year decline in instances of respiratory illness and flu, which contribute d to lower illness \ntesting and patient visits in the primary care business.  These dynamics impacted the segment results in the \nsecond quarter and our full -year fiscal 2024 outlook.  However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "original_text": "However, we remain confident in the fundamentals of the \nbusiness and the st rength of our scaled assets within the Medical -Surgical segment.  ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00cea8d64b9cdd9d278008730bb873283e4491899cdebd9387f67cdba7f594ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1470b283-4a83-46d3-8542-8f43a11888f5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms. "}, "hash": "8cc1ebdbde35585191c57fd903104d03a28d72513fcf9173b540c0fa352c9af8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1470b283-4a83-46d3-8542-8f43a11888f5": {"__data__": {"id_": "1470b283-4a83-46d3-8542-8f43a11888f5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d9a48a6-ce7d-43d4-8649-a81e859efe64", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1878d1da20d58973bf5cb07af988d81545a457da85161308b85e4579b7756aea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccc2af5a-182a-4782-a8c6-ec38da3e0ecc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n", "original_text": "Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network. "}, "hash": "baf9f11cb9881192ab65f4ee6b4733c8078a505d5822f48fb0f6b4ea77b9be55", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms. ", "start_char_idx": 16, "end_char_idx": 272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccc2af5a-182a-4782-a8c6-ec38da3e0ecc": {"__data__": {"id_": "ccc2af5a-182a-4782-a8c6-ec38da3e0ecc", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n", "original_text": "Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1470b283-4a83-46d3-8542-8f43a11888f5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64b7841a80cdd206b0f396ea206beaab3b3cb92786a38885902432a3e5eee889", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97e735c9-0614-47f2-a25d-38e3e508cd1d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n", "original_text": "The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n"}, "hash": "b6fe72edb2400e71c236d415f278d6b9bb2a3c06bcf108d229c3eb05bdac5dda", "class_name": "RelatedNodeInfo"}}, "text": "Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network. ", "start_char_idx": 272, "end_char_idx": 416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97e735c9-0614-47f2-a25d-38e3e508cd1d": {"__data__": {"id_": "97e735c9-0614-47f2-a25d-38e3e508cd1d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n", "original_text": "The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccc2af5a-182a-4782-a8c6-ec38da3e0ecc", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n", "original_text": "Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15879800dd6e2dd5a32f4c35b6225dc258702ca4c988a530adcd49d149321f51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a695925-ddd8-4b65-a728-6555e526ec82", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report. ", "original_text": "As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed. "}, "hash": "d087298010462943db42ead5e361b2470f132b76aefd844d66be91a9dddb9e57", "class_name": "RelatedNodeInfo"}}, "text": "The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n", "start_char_idx": 416, "end_char_idx": 605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a695925-ddd8-4b65-a728-6555e526ec82": {"__data__": {"id_": "1a695925-ddd8-4b65-a728-6555e526ec82", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report. ", "original_text": "As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97e735c9-0614-47f2-a25d-38e3e508cd1d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n", "original_text": "The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab681acd4596dbd7ffd3a2b02328f7a08e5f32ac1bbea28d6136d8f4f14f1f4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7a5a808-47b6-43e9-ac7e-aeea1fec4955", "node_type": "1", "metadata": {"window": "Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n", "original_text": "Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n"}, "hash": "98f1a066fbe2a2717272de758e0ff368e901699d87cc46078810f2ffd22a7732", "class_name": "RelatedNodeInfo"}}, "text": "As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed. ", "start_char_idx": 605, "end_char_idx": 763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7a5a808-47b6-43e9-ac7e-aeea1fec4955": {"__data__": {"id_": "e7a5a808-47b6-43e9-ac7e-aeea1fec4955", "embedding": null, "metadata": {"window": "Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n", "original_text": "Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a695925-ddd8-4b65-a728-6555e526ec82", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report. ", "original_text": "As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab6a21d0733cad0da830185fa0e808f52d9890b53d8ae0696c20996df8d94a5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86d7bf56-226f-4a2d-9b2c-b75ddb75edf9", "node_type": "1", "metadata": {"window": "The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n", "original_text": "Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n"}, "hash": "99dc9d7fa111303c81fda8e0de33efd096f8055a847749868f03bc7e6c5542e2", "class_name": "RelatedNodeInfo"}}, "text": "Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n", "start_char_idx": 763, "end_char_idx": 929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86d7bf56-226f-4a2d-9b2c-b75ddb75edf9": {"__data__": {"id_": "86d7bf56-226f-4a2d-9b2c-b75ddb75edf9", "embedding": null, "metadata": {"window": "The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n", "original_text": "Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7a5a808-47b6-43e9-ac7e-aeea1fec4955", "node_type": "1", "metadata": {"window": "Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n", "original_text": "Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5327f7dc12142c100ae51bad472fb341ab2ed24f9d0ed872c50fb66195628720", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fc91e45-9bd7-4cfc-bd1e-739f157daa65", "node_type": "1", "metadata": {"window": "As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform. ", "original_text": "More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report. "}, "hash": "17f14a0c5c35adc822770692ce0c1e3a01d458b9fd1b6775b8f0ee50ddbc12dd", "class_name": "RelatedNodeInfo"}}, "text": "Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n", "start_char_idx": 929, "end_char_idx": 1102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fc91e45-9bd7-4cfc-bd1e-739f157daa65": {"__data__": {"id_": "5fc91e45-9bd7-4cfc-bd1e-739f157daa65", "embedding": null, "metadata": {"window": "As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform. ", "original_text": "More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86d7bf56-226f-4a2d-9b2c-b75ddb75edf9", "node_type": "1", "metadata": {"window": "The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n", "original_text": "Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6334a145e25d0fee6e58dbdb9e22b65a09fc6e41bdac10511a583b9713f2a868", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8bd62b7-d5af-4ef7-9103-26f962bb6f68", "node_type": "1", "metadata": {"window": "Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment. ", "original_text": "In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n"}, "hash": "b8e74bbfb8aa57fd88af747060c2ad761fde53088fb075a8a0cdfafc3e5da241", "class_name": "RelatedNodeInfo"}}, "text": "More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report. ", "start_char_idx": 1102, "end_char_idx": 1296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8bd62b7-d5af-4ef7-9103-26f962bb6f68": {"__data__": {"id_": "c8bd62b7-d5af-4ef7-9103-26f962bb6f68", "embedding": null, "metadata": {"window": "Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment. ", "original_text": "In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fc91e45-9bd7-4cfc-bd1e-739f157daa65", "node_type": "1", "metadata": {"window": "As an important element of the  integration, all of the new practices will be operating on the same Electronic \nHealth Record or EHR system we call iKnowMed.  Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform. ", "original_text": "More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a399976a335d17c117ba7f1989d242c6132af9b76218b471852dae642399c0ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d66f7f4-d9b6-4cd7-9cd5-f7d47c3c20f5", "node_type": "1", "metadata": {"window": "Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n", "original_text": "Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n"}, "hash": "354fdeb03c3c36e6d6d9884ae6de1465f526bf02287d2bcdab8cbb51faf436e6", "class_name": "RelatedNodeInfo"}}, "text": "In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n", "start_char_idx": 1296, "end_char_idx": 1432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d66f7f4-d9b6-4cd7-9cd5-f7d47c3c20f5": {"__data__": {"id_": "8d66f7f4-d9b6-4cd7-9cd5-f7d47c3c20f5", "embedding": null, "metadata": {"window": "Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n", "original_text": "Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8bd62b7-d5af-4ef7-9103-26f962bb6f68", "node_type": "1", "metadata": {"window": "Designed in close collaboration with oncologists, iKnowMed \nserves as an important link between the US oncology network and Ontada,  our data and insights business. \n Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment. ", "original_text": "In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d05d5ee8a6f980c439b14a7fd6a65036b96c2fce78c76db73a9189c56d77af81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20380a8e-2054-4f83-a7aa-efd6006ecbb3", "node_type": "1", "metadata": {"window": "More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications. ", "original_text": "Moving on to the biopharma services platform. "}, "hash": "bb35a6b1fe2bc91ffe5edbc23aa28731e51e3e55a71527453c13529adf944a6f", "class_name": "RelatedNodeInfo"}}, "text": "Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n", "start_char_idx": 1432, "end_char_idx": 1681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20380a8e-2054-4f83-a7aa-efd6006ecbb3": {"__data__": {"id_": "20380a8e-2054-4f83-a7aa-efd6006ecbb3", "embedding": null, "metadata": {"window": "More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications. ", "original_text": "Moving on to the biopharma services platform. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d66f7f4-d9b6-4cd7-9cd5-f7d47c3c20f5", "node_type": "1", "metadata": {"window": "Powered by the innovative technology from Ontada, iKnowMed creates powerful insights and provides \ncomprehensive point -of-care treatment decision support to providers.  \n \n More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n", "original_text": "Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6785ce5687cddf147cb56fc6dc04084d51c8818c1176e8ce1febee0c4d517174", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f00bc185-3c6a-49da-9ad2-db7905d52977", "node_type": "1", "metadata": {"window": "In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n", "original_text": "Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment. "}, "hash": "46258dd92cf2025342f605ec9c36b18bccd132276f266e3df13c7e99f7936cc0", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to the biopharma services platform. ", "start_char_idx": 1681, "end_char_idx": 1727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f00bc185-3c6a-49da-9ad2-db7905d52977": {"__data__": {"id_": "f00bc185-3c6a-49da-9ad2-db7905d52977", "embedding": null, "metadata": {"window": "In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n", "original_text": "Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20380a8e-2054-4f83-a7aa-efd6006ecbb3", "node_type": "1", "metadata": {"window": "More than 2,600 providers across the country use iKnowM ed as their EHR, and we are pleased to see iKnowMed \nbeing honored as a top -ranked medical oncology EHR in the 2023 Best in KLAS report.  In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications. ", "original_text": "Moving on to the biopharma services platform. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "708a6d4765bf20fb01dd5aaaee3d2171456a15a1cd7c00423db6263ebd23b687", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b79369f-5a99-496e-b105-0adc2695674d", "node_type": "1", "metadata": {"window": "Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications. ", "original_text": "The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n"}, "hash": "16701a6fff6210d46ef8e1525f128cb0b78d79f2c868302ca5202a34fe3d82f1", "class_name": "RelatedNodeInfo"}}, "text": "Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment. ", "start_char_idx": 1727, "end_char_idx": 1880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b79369f-5a99-496e-b105-0adc2695674d": {"__data__": {"id_": "9b79369f-5a99-496e-b105-0adc2695674d", "embedding": null, "metadata": {"window": "Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications. ", "original_text": "The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f00bc185-3c6a-49da-9ad2-db7905d52977", "node_type": "1", "metadata": {"window": "In addition to technology \nsolutions like iKnowMed, Ontada continues to advance its mission of transforming the fight aga inst cancer. \n Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n", "original_text": "Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "367e5af0e41434d1ae3c5e213a458f7c011c9d8986c45260df05f2f44355692c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac8014df-c485-4948-be17-3c27ef9d39a5", "node_type": "1", "metadata": {"window": "Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n", "original_text": "We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications. "}, "hash": "6a8c4a8461136950f74cc0e5dead8c03aae959e45379da8338d14dc8d83d0ded", "class_name": "RelatedNodeInfo"}}, "text": "The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n", "start_char_idx": 1880, "end_char_idx": 2035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac8014df-c485-4948-be17-3c27ef9d39a5": {"__data__": {"id_": "ac8014df-c485-4948-be17-3c27ef9d39a5", "embedding": null, "metadata": {"window": "Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n", "original_text": "We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b79369f-5a99-496e-b105-0adc2695674d", "node_type": "1", "metadata": {"window": "Recently, the US Food and Drug Administration awarded Ontada a contract to advance the use of real -world data \nin the US community oncology setting, which is a good opportunity to identify insights that will inform care and \nclinical research.  \n \n Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications. ", "original_text": "The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da8e5abd5cd546a1802dd4b3d4ed3ba9e8625216cc0bd5cb848e75ef83f04d66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e2d741d-bdc5-4f56-9740-87e6db1f01b8", "node_type": "1", "metadata": {"window": "Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications. ", "original_text": "We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n"}, "hash": "187acba2965ba305ec23e1dc5defb4f030ba21e44e46f19f6061135debcec807", "class_name": "RelatedNodeInfo"}}, "text": "We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications. ", "start_char_idx": 2035, "end_char_idx": 2168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e2d741d-bdc5-4f56-9740-87e6db1f01b8": {"__data__": {"id_": "9e2d741d-bdc5-4f56-9740-87e6db1f01b8", "embedding": null, "metadata": {"window": "Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications. ", "original_text": "We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac8014df-c485-4948-be17-3c27ef9d39a5", "node_type": "1", "metadata": {"window": "Moving on to the biopharma services platform.  Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n", "original_text": "We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6213d360de1e8614177cb2ef98b6c35a7f075a0ff5ec0cc299825ff576f3a373", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "096940a1-316e-4a56-9f62-a7e2ba68d1ac", "node_type": "1", "metadata": {"window": "The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n", "original_text": "In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications. "}, "hash": "0665d4f76ca77ae9f47d31ae7d74ef79ce95a50bcac1bdbde72091c9e2686a90", "class_name": "RelatedNodeInfo"}}, "text": "We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n", "start_char_idx": 2168, "end_char_idx": 2353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "096940a1-316e-4a56-9f62-a7e2ba68d1ac": {"__data__": {"id_": "096940a1-316e-4a56-9f62-a7e2ba68d1ac", "embedding": null, "metadata": {"window": "The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n", "original_text": "In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e2d741d-bdc5-4f56-9740-87e6db1f01b8", "node_type": "1", "metadata": {"window": "Through strategic acquisitions and investments, we've built a set of \nhighly differentiated assets within the Prescription Technology Solutions segment.  The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications. ", "original_text": "We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e100e5c5d82f60d3469c9b2c9f76d81517c8421f9576029ba356f71246e4044c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4de5c3c-a595-422f-b68a-980c7ae3741f", "node_type": "1", "metadata": {"window": "We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow. ", "original_text": "The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n"}, "hash": "cd6538b7f5cc8394424837b198b398418f06a84d5110fa8e35906d43952c8659", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications. ", "start_char_idx": 2353, "end_char_idx": 2624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4de5c3c-a595-422f-b68a-980c7ae3741f": {"__data__": {"id_": "e4de5c3c-a595-422f-b68a-980c7ae3741f", "embedding": null, "metadata": {"window": "We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow. ", "original_text": "The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "096940a1-316e-4a56-9f62-a7e2ba68d1ac", "node_type": "1", "metadata": {"window": "The combination of these \nassets creates a powerful and sca led network that includes multiple touch points throughout the patient treatment \njourney.  \n \n We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n", "original_text": "In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "789579a89f00ef522b24fbcad3ea4f23f4cdfc0c06a7bebc8c884ae023bc2627", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20353e6c-8fb6-4be1-99d1-a9e3ce7ab875", "node_type": "1", "metadata": {"window": "We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process. ", "original_text": "One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications. "}, "hash": "272ab52d4f0d66b608f1c9f6cfcefe87b49d809001c7e6344d3b6b38142dc86e", "class_name": "RelatedNodeInfo"}}, "text": "The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n", "start_char_idx": 2624, "end_char_idx": 2906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20353e6c-8fb6-4be1-99d1-a9e3ce7ab875": {"__data__": {"id_": "20353e6c-8fb6-4be1-99d1-a9e3ce7ab875", "embedding": null, "metadata": {"window": "We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process. ", "original_text": "One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4de5c3c-a595-422f-b68a-980c7ae3741f", "node_type": "1", "metadata": {"window": "We are connected to approximately 900,000 providers, enabling solutions that help move barriers to access \nprescription medications.  We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow. ", "original_text": "The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2088222d082ed201d6a804eaa37d131315f9e4e8d6f68a8052c0c8331742f2ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce023f55-612d-438e-90be-87e6d020e042", "node_type": "1", "metadata": {"window": "In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n", "original_text": "For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n"}, "hash": "043b43a216e154056abf65d641fe62183515f4a1f3b7964e21c9f8a3f4e2934c", "class_name": "RelatedNodeInfo"}}, "text": "One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications. ", "start_char_idx": 2906, "end_char_idx": 3074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce023f55-612d-438e-90be-87e6d020e042": {"__data__": {"id_": "ce023f55-612d-438e-90be-87e6d020e042", "embedding": null, "metadata": {"window": "In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n", "original_text": "For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20353e6c-8fb6-4be1-99d1-a9e3ce7ab875", "node_type": "1", "metadata": {"window": "We're also connected to over 50,0 00 pharmacies, helping patients afford their \nprescriptions through solutions like cash co -pay and digital coupons right at the pharmacy counter.  \n \n In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process. ", "original_text": "One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3358cec0e6852ccea08cf1770cb77a44cfd064b01ac284283126cc2a050a401b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ff8a047-26a7-41f8-bc0c-ff51b6c491f7", "node_type": "1", "metadata": {"window": "The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience. ", "original_text": "What we offer is an a utomated technology solution that is embedded within the provider's workflow. "}, "hash": "d3d5e6da13a051665954c789b20ea7636c228bc4231a979e2b40df7f63d83414", "class_name": "RelatedNodeInfo"}}, "text": "For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n", "start_char_idx": 3074, "end_char_idx": 3228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ff8a047-26a7-41f8-bc0c-ff51b6c491f7": {"__data__": {"id_": "8ff8a047-26a7-41f8-bc0c-ff51b6c491f7", "embedding": null, "metadata": {"window": "The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience. ", "original_text": "What we offer is an a utomated technology solution that is embedded within the provider's workflow. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce023f55-612d-438e-90be-87e6d020e042", "node_type": "1", "metadata": {"window": "In the second quarter, we were pleased with the strong performance in the segment with double -digit growth in \nboth revenue and adjusted operating profit, driven by growth in access solutions, including increased volumes in \nprior authorizations for GLP -1 medications.  The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n", "original_text": "For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa4ecc786f93a68fdcb86b6effbffbb3f584a3f36f9fc12bfafa1d71c3d2fb55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6f6325f-30e2-43a5-a417-608eff552b6b", "node_type": "1", "metadata": {"window": "One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination. ", "original_text": "Our \ntechnology solution introduces efficiency to the process. "}, "hash": "47207c044b61aaffeb578c7021f8d7ffe83459a1cb03413e0e5622f983dc6526", "class_name": "RelatedNodeInfo"}}, "text": "What we offer is an a utomated technology solution that is embedded within the provider's workflow. ", "start_char_idx": 3228, "end_char_idx": 3328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6f6325f-30e2-43a5-a417-608eff552b6b": {"__data__": {"id_": "c6f6325f-30e2-43a5-a417-608eff552b6b", "embedding": null, "metadata": {"window": "One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination. ", "original_text": "Our \ntechnology solution introduces efficiency to the process. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ff8a047-26a7-41f8-bc0c-ff51b6c491f7", "node_type": "1", "metadata": {"window": "The year -over-year comparison was also partially impacted by lower \nprior-year results, which, as we  called out in Q2 of our fiscal 2023, included higher operating expenses resulting \nfrom the timing of increased head count to support customer annual verification activities.  \n \n One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience. ", "original_text": "What we offer is an a utomated technology solution that is embedded within the provider's workflow. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06dfeb4f29a47b785e69225e0fec008fdce42982f91e82ba4cdbd830478ebdfb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "555dcf8e-535a-4c67-8d74-7e13c1cb3a86", "node_type": "1", "metadata": {"window": "For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process. ", "original_text": "More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n"}, "hash": "57e2f77446ca2561a5cca68434112125b3d93d8e56d3c03262ece5bc9ca77f37", "class_name": "RelatedNodeInfo"}}, "text": "Our \ntechnology solution introduces efficiency to the process. ", "start_char_idx": 3328, "end_char_idx": 3391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "555dcf8e-535a-4c67-8d74-7e13c1cb3a86": {"__data__": {"id_": "555dcf8e-535a-4c67-8d74-7e13c1cb3a86", "embedding": null, "metadata": {"window": "For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process. ", "original_text": "More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6f6325f-30e2-43a5-a417-608eff552b6b", "node_type": "1", "metadata": {"window": "One of the areas where we saw significant growth in the past two quarters is our  access solutions, including prior \nauthorizations for brands like GLP -1 medications.  For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination. ", "original_text": "Our \ntechnology solution introduces efficiency to the process. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ebe4d40421b4f1cb01dd16c6db1f2fc60db826fbbe35c91821eeb1e9cf18abe7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1668bbc-bfe2-4085-8466-2d852e0113ef", "node_type": "1", "metadata": {"window": "What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy. ", "original_text": "We continue to add new features and functionalities to improve the user experience. "}, "hash": "65b6668ed15413b91ef8f653b0a647f4f34d48e8b70865a675b0b62b9a341755", "class_name": "RelatedNodeInfo"}}, "text": "More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n", "start_char_idx": 3391, "end_char_idx": 3513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1668bbc-bfe2-4085-8466-2d852e0113ef": {"__data__": {"id_": "d1668bbc-bfe2-4085-8466-2d852e0113ef", "embedding": null, "metadata": {"window": "What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy. ", "original_text": "We continue to add new features and functionalities to improve the user experience. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "555dcf8e-535a-4c67-8d74-7e13c1cb3a86", "node_type": "1", "metadata": {"window": "For selected prescription drugs, patients are required to obtain \napproval from their health plan, which sometimes can be very manual and cumbersome.  \n \n What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process. ", "original_text": "More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3d15d5e51a64ae693c19b3f6a6e838425f6eaac2dc6217d5db9e41eabfdd121", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2363fe81-d246-4b6c-a9b2-4cd88aba6ee4", "node_type": "1", "metadata": {"window": "Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy.  It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "original_text": "The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination. "}, "hash": "49161fe2f750f4c36228fa9e23b443154fa7673d10023c8ef96bc3022d4b39d2", "class_name": "RelatedNodeInfo"}}, "text": "We continue to add new features and functionalities to improve the user experience. ", "start_char_idx": 3513, "end_char_idx": 3597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2363fe81-d246-4b6c-a9b2-4cd88aba6ee4": {"__data__": {"id_": "2363fe81-d246-4b6c-a9b2-4cd88aba6ee4", "embedding": null, "metadata": {"window": "Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy.  It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "original_text": "The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1668bbc-bfe2-4085-8466-2d852e0113ef", "node_type": "1", "metadata": {"window": "What we offer is an a utomated technology solution that is embedded within the provider's workflow.  Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy. ", "original_text": "We continue to add new features and functionalities to improve the user experience. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2feecc3a28c1ffd8af87edb8adb74818f833da0a925e1a3fa725561ad765d94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79449d2c-1e08-4a82-b4c9-329d750d3a1d", "node_type": "1", "metadata": {"window": "More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy.  It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "original_text": "Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process. "}, "hash": "c30456bf4b5a77c02e6b42db03fd88ff94fcacee8a559f2929126c9e42729b25", "class_name": "RelatedNodeInfo"}}, "text": "The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination. ", "start_char_idx": 3597, "end_char_idx": 3755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79449d2c-1e08-4a82-b4c9-329d750d3a1d": {"__data__": {"id_": "79449d2c-1e08-4a82-b4c9-329d750d3a1d", "embedding": null, "metadata": {"window": "More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy.  It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "original_text": "Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2363fe81-d246-4b6c-a9b2-4cd88aba6ee4", "node_type": "1", "metadata": {"window": "Our \ntechnology solution introduces efficiency to the process.  More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy.  It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "original_text": "The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09ffc4c977483d88660e309cad09727fcf13265f9fe65cf15120bdf7a21cadf9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "336599c8-478f-4ca0-a321-3857cec9d050", "node_type": "1", "metadata": {"window": "We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy.  It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "original_text": "Solutions like prior authorizations are great examples of the success of our \nbusiness strategy. "}, "hash": "9a995c0503ae4c393f449feff45df1e972271c2af297a2465efa33e45e517efa", "class_name": "RelatedNodeInfo"}}, "text": "Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process. ", "start_char_idx": 3755, "end_char_idx": 3888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "336599c8-478f-4ca0-a321-3857cec9d050": {"__data__": {"id_": "336599c8-478f-4ca0-a321-3857cec9d050", "embedding": null, "metadata": {"window": "We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy.  It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "original_text": "Solutions like prior authorizations are great examples of the success of our \nbusiness strategy. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79449d2c-1e08-4a82-b4c9-329d750d3a1d", "node_type": "1", "metadata": {"window": "More than 40% of our prior authorizations are approved \ninstantly and approximately 65% are approved within one hour.  \n \n We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy.  It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "original_text": "Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1dea0b516c689fffccf8df52bc14ec29a1be1d911d25ca3561f88807bf74090", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3dcff51-7b0f-489b-8996-440bfb94cfd8", "node_type": "1", "metadata": {"window": "The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy.  It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "original_text": "It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  "}, "hash": "2bf87d1eaa2879bbc49de6871cc32751ef41e66e0b6f7a34698c351757d30c12", "class_name": "RelatedNodeInfo"}}, "text": "Solutions like prior authorizations are great examples of the success of our \nbusiness strategy. ", "start_char_idx": 3888, "end_char_idx": 3985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3dcff51-7b0f-489b-8996-440bfb94cfd8": {"__data__": {"id_": "c3dcff51-7b0f-489b-8996-440bfb94cfd8", "embedding": null, "metadata": {"window": "The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy.  It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "original_text": "It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54d6dad8d081062be8ee559dac7f81a5f284c890220d3dfe07afd3f896a4d21b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "336599c8-478f-4ca0-a321-3857cec9d050", "node_type": "1", "metadata": {"window": "We continue to add new features and functionalities to improve the user experience.  The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy.  It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "original_text": "Solutions like prior authorizations are great examples of the success of our \nbusiness strategy. ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "faa4317e367e2b027d3b7b6cd9a3175751d245cc24a8f7b3ac16ad76dd9f89ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "069ff281-071f-4093-83b1-f71404037b2a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support. ", "original_text": "McKesson Corp.  "}, "hash": "a1902b0cfa6be43094be30d9255cdeb09627fcb9c90c9825620d22f0e4dc87b3", "class_name": "RelatedNodeInfo"}}, "text": "It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "start_char_idx": 3985, "end_char_idx": 4105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "069ff281-071f-4093-83b1-f71404037b2a": {"__data__": {"id_": "069ff281-071f-4093-83b1-f71404037b2a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3dcff51-7b0f-489b-8996-440bfb94cfd8", "node_type": "1", "metadata": {"window": "The latest feature introduced \nallows providers to share prior authorization outcomes directly with their patients when a health plan makes a \ndetermination.  Through improv ements like this, we help remove barriers and provide greater patient visibility to \nthe prior authorization process.  Solutions like prior authorizations are great examples of the success of our \nbusiness strategy.  It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "original_text": "It's also a reflection of our efforts to im prove medication access and, ultimately, advance health \noutcomes for all.  ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6866d8a641451c926b4f91f29703d7d2dc59a776039be4da6790ac604f1c5dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ced5154-0f9c-416b-bcc4-db24e1b2de88", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work. "}, "hash": "ca8af9d1d1a352caf48fcaea8c6ceceb1667020a4cf7ee6d1980a0979d6e27a5", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ced5154-0f9c-416b-bcc4-db24e1b2de88": {"__data__": {"id_": "9ced5154-0f9c-416b-bcc4-db24e1b2de88", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "069ff281-071f-4093-83b1-f71404037b2a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d060291f58f1f482fc544269dc7a0048604dc9f1f22617f4eecb8a4f8b8dc0d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "931d355b-630b-4b09-aa6d-1b343aaa2d5f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n", "original_text": "This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n"}, "hash": "38e383f72e71c4b5dde267b1c1128291a234e23d3dfa1cf4db6a29526ba22c0a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work. ", "start_char_idx": 16, "end_char_idx": 347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "931d355b-630b-4b09-aa6d-1b343aaa2d5f": {"__data__": {"id_": "931d355b-630b-4b09-aa6d-1b343aaa2d5f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n", "original_text": "This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ced5154-0f9c-416b-bcc4-db24e1b2de88", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a81aa597aac122c82922f8d12d61e1d85c07ffbb8c7150e14fe02cb805c88524", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3eff30c9-3341-43e5-a22d-c257747f6ea4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together. ", "original_text": "Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support. "}, "hash": "79a80fa2881773897cd307045cc1973a7338514062f1d0d0f546cb61fe6a992d", "class_name": "RelatedNodeInfo"}}, "text": "This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n", "start_char_idx": 347, "end_char_idx": 488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3eff30c9-3341-43e5-a22d-c257747f6ea4": {"__data__": {"id_": "3eff30c9-3341-43e5-a22d-c257747f6ea4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together. ", "original_text": "Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "931d355b-630b-4b09-aa6d-1b343aaa2d5f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n", "original_text": "This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d15295c41f2220cbb3a99da6a5bc87af21e1c6f6c6c6e36134fade2d3ce1bb2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "613a2b34-abc8-4874-b6a1-3d8a1c570030", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter. ", "original_text": "This year marked the 25th anniversary of the event. "}, "hash": "019cdd98793f95b4dc35e99a7fd9dac7ea06951f89bb0ec1505d00ee1cba6996", "class_name": "RelatedNodeInfo"}}, "text": "Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support. ", "start_char_idx": 488, "end_char_idx": 650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "613a2b34-abc8-4874-b6a1-3d8a1c570030": {"__data__": {"id_": "613a2b34-abc8-4874-b6a1-3d8a1c570030", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter. ", "original_text": "This year marked the 25th anniversary of the event. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3eff30c9-3341-43e5-a22d-c257747f6ea4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together. ", "original_text": "Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f50df10cf66282067ad4356106d1abab9013f0a713cb509263c0d28a700f7020", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46433335-5df7-4bdf-a9d2-7bd68af3d746", "node_type": "1", "metadata": {"window": "This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence. ", "original_text": "And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n"}, "hash": "84ac06916ef5999f25f438b5d6c0f70069346f9375b257c19a0afbbbbada2bd3", "class_name": "RelatedNodeInfo"}}, "text": "This year marked the 25th anniversary of the event. ", "start_char_idx": 650, "end_char_idx": 702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46433335-5df7-4bdf-a9d2-7bd68af3d746": {"__data__": {"id_": "46433335-5df7-4bdf-a9d2-7bd68af3d746", "embedding": null, "metadata": {"window": "This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence. ", "original_text": "And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "613a2b34-abc8-4874-b6a1-3d8a1c570030", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter. ", "original_text": "This year marked the 25th anniversary of the event. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0edfa31a2eb03248336a472b865337bba410683ba7f1ac1e8987e8bf6d5e8662", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e5ebcab-b21a-4263-88fd-cf1ac07f677a", "node_type": "1", "metadata": {"window": "Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting. ", "original_text": "So, let me pull everything together. "}, "hash": "afb5bf676875769cf347708850daba66388a77151d89aa34321b92cd5477bf61", "class_name": "RelatedNodeInfo"}}, "text": "And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n", "start_char_idx": 702, "end_char_idx": 846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e5ebcab-b21a-4263-88fd-cf1ac07f677a": {"__data__": {"id_": "7e5ebcab-b21a-4263-88fd-cf1ac07f677a", "embedding": null, "metadata": {"window": "Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting. ", "original_text": "So, let me pull everything together. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46433335-5df7-4bdf-a9d2-7bd68af3d746", "node_type": "1", "metadata": {"window": "This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence. ", "original_text": "And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d34e52f834df358c0eb4ddab7bf11d3dbcf12b02c9863f0f9e42c5791e3bf53b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "530660c8-5569-418f-8be0-e6e2888bb13d", "node_type": "1", "metadata": {"window": "This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n", "original_text": "McKesso n delivered a solid second quarter. "}, "hash": "ae362a1cbd87ff240ccef6fbd8bb2acfe7ea1b3b22db0a883b9c749702745280", "class_name": "RelatedNodeInfo"}}, "text": "So, let me pull everything together. ", "start_char_idx": 846, "end_char_idx": 883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "530660c8-5569-418f-8be0-e6e2888bb13d": {"__data__": {"id_": "530660c8-5569-418f-8be0-e6e2888bb13d", "embedding": null, "metadata": {"window": "This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n", "original_text": "McKesso n delivered a solid second quarter. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e5ebcab-b21a-4263-88fd-cf1ac07f677a", "node_type": "1", "metadata": {"window": "Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support.  This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting. ", "original_text": "So, let me pull everything together. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4253a829bb6000d836e0556ccaf704f95500558534c192bec588f3c86f4b123f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b404915-74ab-4889-84a0-8db1494685a6", "node_type": "1", "metadata": {"window": "And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n ", "original_text": "Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence. "}, "hash": "844954cc1a077849e186d893bf9f290090bf33dfdf90a5a34064845b64f3586f", "class_name": "RelatedNodeInfo"}}, "text": "McKesso n delivered a solid second quarter. ", "start_char_idx": 883, "end_char_idx": 927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b404915-74ab-4889-84a0-8db1494685a6": {"__data__": {"id_": "2b404915-74ab-4889-84a0-8db1494685a6", "embedding": null, "metadata": {"window": "And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n ", "original_text": "Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "530660c8-5569-418f-8be0-e6e2888bb13d", "node_type": "1", "metadata": {"window": "This year marked the 25th anniversary of the event.  And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n", "original_text": "McKesso n delivered a solid second quarter. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a53bc0bb1c4b63500e4f1dde66523a6813073b35884402e71dc31453b11b854", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f7b0960-eec5-4c99-9593-95e4458c2571", "node_type": "1", "metadata": {"window": "So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting. "}, "hash": "4e71363e51ae215c3d34debe02b5fa584a564101fe5d2716ab4450573a1326fe", "class_name": "RelatedNodeInfo"}}, "text": "Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence. ", "start_char_idx": 927, "end_char_idx": 1087, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f7b0960-eec5-4c99-9593-95e4458c2571": {"__data__": {"id_": "4f7b0960-eec5-4c99-9593-95e4458c2571", "embedding": null, "metadata": {"window": "So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b404915-74ab-4889-84a0-8db1494685a6", "node_type": "1", "metadata": {"window": "And we \nwill continue honoring this tradition and we'll work to find more ways to enhance the health of those who live in our \ncommunities.  \n \n So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n ", "original_text": "Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc5bf5a2909faa755208209f55e67636aae84bc3c5eaa7647b47fe56897b7cce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03c655c7-e996-4dc2-a7fe-4907031f7251", "node_type": "1", "metadata": {"window": "McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian. ", "original_text": "Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n"}, "hash": "779a2caf9351591aeba3573388b8cdd31d4b961ebb01a66f8165b2ee8a307e1f", "class_name": "RelatedNodeInfo"}}, "text": "Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting. ", "start_char_idx": 1087, "end_char_idx": 1211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03c655c7-e996-4dc2-a7fe-4907031f7251": {"__data__": {"id_": "03c655c7-e996-4dc2-a7fe-4907031f7251", "embedding": null, "metadata": {"window": "McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian. ", "original_text": "Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f7b0960-eec5-4c99-9593-95e4458c2571", "node_type": "1", "metadata": {"window": "So, let me pull everything together.  McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e28ecb4724af29deec0e5f7e50c1288c8ef9e54fb817b95e5b1baa66d2cb362d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97d369c4-efdb-45ea-af36-95318954212d", "node_type": "1", "metadata": {"window": "Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n", "original_text": "And with that, I'll turn it over to Britt for additional comments.  \n "}, "hash": "b381af31baebb7a123f4166c1a8a7bcb9b48bb22e853f207ee21ec8fe578d012", "class_name": "RelatedNodeInfo"}}, "text": "Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n", "start_char_idx": 1211, "end_char_idx": 1341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97d369c4-efdb-45ea-af36-95318954212d": {"__data__": {"id_": "97d369c4-efdb-45ea-af36-95318954212d", "embedding": null, "metadata": {"window": "Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n", "original_text": "And with that, I'll turn it over to Britt for additional comments.  \n ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03c655c7-e996-4dc2-a7fe-4907031f7251", "node_type": "1", "metadata": {"window": "McKesso n delivered a solid second quarter.  Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian. ", "original_text": "Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4ad56b63581890ff5a1158d474f5cb3d402826b722e4e5f281c5bdc97555161", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b906b1c7-11a5-4d11-9fb0-5a7a3aa7b548", "node_type": "1", "metadata": {"window": "Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n"}, "hash": "fea6b4080dc8948a2edbcea588582c22b64e568ec9d6e2a66db59d92a11740f2", "class_name": "RelatedNodeInfo"}}, "text": "And with that, I'll turn it over to Britt for additional comments.  \n ", "start_char_idx": 1341, "end_char_idx": 1411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b906b1c7-11a5-4d11-9fb0-5a7a3aa7b548": {"__data__": {"id_": "b906b1c7-11a5-4d11-9fb0-5a7a3aa7b548", "embedding": null, "metadata": {"window": "Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97d369c4-efdb-45ea-af36-95318954212d", "node_type": "1", "metadata": {"window": "Thanks to the contribution and \ndedication of over 50,000 McKesson employees, we continue to execute against our company priorities with \nfocus and excellence.  Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n", "original_text": "And with that, I'll turn it over to Britt for additional comments.  \n ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6378653b1337eb621c63f19adb1cd2a0452a73f43db96695778aa3ada76862e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cd29bd1-1811-48e5-b899-317519a39ce4", "node_type": "1", "metadata": {"window": "Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n", "original_text": "Thank you, Brian. "}, "hash": "d43fca369aa0b14ce4e314f92a794293f792f843fab43e2fa991ab3aa56262ce", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "start_char_idx": 1411, "end_char_idx": 1772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cd29bd1-1811-48e5-b899-317519a39ce4": {"__data__": {"id_": "6cd29bd1-1811-48e5-b899-317519a39ce4", "embedding": null, "metadata": {"window": "Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n", "original_text": "Thank you, Brian. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b906b1c7-11a5-4d11-9fb0-5a7a3aa7b548", "node_type": "1", "metadata": {"window": "Leveraging our differentiated services and solutions, we're we ll positioned to continue to \nimprove care in every setting.  Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d3eb0a322624fdb156b01855010a176e96752d17c7321b2d0a20f4fbd35a00f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e65a7921-c951-4ffd-9585-d58d2bbcba40", "node_type": "1", "metadata": {"window": "And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n", "original_text": "We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n"}, "hash": "43acdfc631d00f802e6dce0151a986e3948a62def9f5e9f310d2b27a720d53a3", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Brian. ", "start_char_idx": 1772, "end_char_idx": 1790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e65a7921-c951-4ffd-9585-d58d2bbcba40": {"__data__": {"id_": "e65a7921-c951-4ffd-9585-d58d2bbcba40", "embedding": null, "metadata": {"window": "And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n", "original_text": "We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cd29bd1-1811-48e5-b899-317519a39ce4", "node_type": "1", "metadata": {"window": "Looking ahead, we're confident in our ability to drive continued growth and strategic \nadvancement in fiscal 2024 and beyond.  \n \n And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n", "original_text": "Thank you, Brian. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e6fabf5989124f761b3defd1b94688d10b30e02e049d389ec9455590343ea83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee1ed359-7387-4c0e-8ac1-a9410abca7b7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years. ", "original_text": "Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults. "}, "hash": "133f7acc9d21287fac7c8c5eca44e0040e92626204983089e8d971895f2a9cbb", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n", "start_char_idx": 1790, "end_char_idx": 2022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee1ed359-7387-4c0e-8ac1-a9410abca7b7": {"__data__": {"id_": "ee1ed359-7387-4c0e-8ac1-a9410abca7b7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years. ", "original_text": "Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e65a7921-c951-4ffd-9585-d58d2bbcba40", "node_type": "1", "metadata": {"window": "And with that, I'll turn it over to Britt for additional comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n", "original_text": "We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68ada0f34d5b09e4bd7ee3ccfb959d2d4432b6d1551adb74028fc2ca46c624ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d48acfd3-d1b6-4c55-9be9-6669913d9c6d", "node_type": "1", "metadata": {"window": "Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n", "original_text": "We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n"}, "hash": "70f4fcabe9fee5445eacc2da003e4569b2748e185cd132c9f053a9959d3a27d2", "class_name": "RelatedNodeInfo"}}, "text": "Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults. ", "start_char_idx": 2022, "end_char_idx": 2148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d48acfd3-d1b6-4c55-9be9-6669913d9c6d": {"__data__": {"id_": "d48acfd3-d1b6-4c55-9be9-6669913d9c6d", "embedding": null, "metadata": {"window": "Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n", "original_text": "We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee1ed359-7387-4c0e-8ac1-a9410abca7b7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years. ", "original_text": "Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3ab4edd7d317abd3776fed81caaf142f118ee49118a6d7f4cd597b1cd8e7b3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1c0ba64-8de4-4151-8c80-21c2256cf398", "node_type": "1", "metadata": {"window": "We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n", "original_text": "We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n"}, "hash": "10c751a07f7ade500c51310347b1e65994ffdb0e18958c756bedf5dd8b0761c6", "class_name": "RelatedNodeInfo"}}, "text": "We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n", "start_char_idx": 2148, "end_char_idx": 2363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1c0ba64-8de4-4151-8c80-21c2256cf398": {"__data__": {"id_": "d1c0ba64-8de4-4151-8c80-21c2256cf398", "embedding": null, "metadata": {"window": "We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n", "original_text": "We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d48acfd3-d1b6-4c55-9be9-6669913d9c6d", "node_type": "1", "metadata": {"window": "Thank you, Brian.  We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n", "original_text": "We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "090e40c70033821bd342b8fd14b53ea0cdadfce7f09d5e9dc41fdb05e606f01c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc90cf59-e1ab-4bee-b70b-02205082f107", "node_type": "1", "metadata": {"window": "Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise. ", "original_text": "We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years. "}, "hash": "951910b1371ee0422946ab3a8f50fce2b9c50045af4f80c3dacbd4a45885fc8f", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n", "start_char_idx": 2363, "end_char_idx": 2612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc90cf59-e1ab-4bee-b70b-02205082f107": {"__data__": {"id_": "dc90cf59-e1ab-4bee-b70b-02205082f107", "embedding": null, "metadata": {"window": "Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise. ", "original_text": "We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1c0ba64-8de4-4151-8c80-21c2256cf398", "node_type": "1", "metadata": {"window": "We're pleased with our second quarter results, which reflect another quarter of solid \nperformance, driven by operational execution and meaningful growth in our US Pharmaceutical and Prescription \nTechnology Solutions segments.  \n \n Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n", "original_text": "We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ef26899a6066315d58d66b44642e22ade3dd2c6914a28e130b3475780059fba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b242efd6-72de-4fd7-a8b7-3c5f987717d4", "node_type": "1", "metadata": {"window": "We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results. ", "original_text": "We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n"}, "hash": "086ec48a3210fef340fee3218f5dd04a1dbd2d05180be62bbb50fa939c08dfc2", "class_name": "RelatedNodeInfo"}}, "text": "We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years. ", "start_char_idx": 2612, "end_char_idx": 2787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b242efd6-72de-4fd7-a8b7-3c5f987717d4": {"__data__": {"id_": "b242efd6-72de-4fd7-a8b7-3c5f987717d4", "embedding": null, "metadata": {"window": "We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results. ", "original_text": "We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc90cf59-e1ab-4bee-b70b-02205082f107", "node_type": "1", "metadata": {"window": "Before I turn to our consolidated results, I want to highlight one item that impacted our second quarter GAAP -only \nresults.  We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise. ", "original_text": "We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc5f10dce18a1ce86e67a8685b793c7d11f169288ad1a2510c2a93bc097b3eae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67465d60-f60b-4b41-937b-e4058353d822", "node_type": "1", "metadata": {"window": "We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n", "original_text": "We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n"}, "hash": "bd42db58458751ed1c81b4ece06222acfe33379edec6bc6c8c6573fcbda54082", "class_name": "RelatedNodeInfo"}}, "text": "We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n", "start_char_idx": 2787, "end_char_idx": 3014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67465d60-f60b-4b41-937b-e4058353d822": {"__data__": {"id_": "67465d60-f60b-4b41-937b-e4058353d822", "embedding": null, "metadata": {"window": "We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n", "original_text": "We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b242efd6-72de-4fd7-a8b7-3c5f987717d4", "node_type": "1", "metadata": {"window": "We recorded a pre -tax GAAP provision for bad debts of $210  million, or $155 million after tax, within the \nUS Pharmaceutical segment for uncollected trade accounts receivable related to Rite Aid's bankruptcy.  \n \n We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results. ", "original_text": "We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e909f56961059bff4c63b57335a9b61610d8dfb21cd56841c2b08913fdc613c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c39c8600-7544-4dd6-a4b7-636149c3b394", "node_type": "1", "metadata": {"window": "We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "original_text": "The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise. "}, "hash": "a29126e856c6cf37878d9080896677dfb91107a943f97ff0f5d0a5339247aa50", "class_name": "RelatedNodeInfo"}}, "text": "We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n", "start_char_idx": 3014, "end_char_idx": 3251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c39c8600-7544-4dd6-a4b7-636149c3b394": {"__data__": {"id_": "c39c8600-7544-4dd6-a4b7-636149c3b394", "embedding": null, "metadata": {"window": "We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "original_text": "The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67465d60-f60b-4b41-937b-e4058353d822", "node_type": "1", "metadata": {"window": "We anticipate recording an additional provision for bad debts of $511 million in the third quarter of fis cal 2024 for \ntrade accounts receivable that McKesson recognized from sales to Rite Aid in October 2023 prior to its \nbankruptcy petition.  \n \n We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n", "original_text": "We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3562a33448f44c36ab728773aa7047656ea9b2de6a205220215e240dfa959ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd4d7f90-9c8f-4f03-8622-e179c3a0e470", "node_type": "1", "metadata": {"window": "We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "original_text": "Let me start \nwith a review of our second quarter results. "}, "hash": "1e5395912aebb94aa731d86acb0321a031cf9e6b0fd65e2bbbf54e76a6f9324e", "class_name": "RelatedNodeInfo"}}, "text": "The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise. ", "start_char_idx": 3251, "end_char_idx": 3353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd4d7f90-9c8f-4f03-8622-e179c3a0e470": {"__data__": {"id_": "cd4d7f90-9c8f-4f03-8622-e179c3a0e470", "embedding": null, "metadata": {"window": "We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "original_text": "Let me start \nwith a review of our second quarter results. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c39c8600-7544-4dd6-a4b7-636149c3b394", "node_type": "1", "metadata": {"window": "We continue to provide distribution services to Rite Aid post their bankruptcy filing, providing the same efficiency \nand operational excellence as we have for over 20 years.  We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "original_text": "The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "050c46d996dc2f4c80f92c373d517e98c4f6439e5bf26849cc5aa925d1240484", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7176cd73-2572-4d55-8ff6-448ef711773e", "node_type": "1", "metadata": {"window": "We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "original_text": "McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n"}, "hash": "19f4aba87c639a2b5327f625820279acfc49ac5589815d085417c5f88b572e4b", "class_name": "RelatedNodeInfo"}}, "text": "Let me start \nwith a review of our second quarter results. ", "start_char_idx": 3353, "end_char_idx": 3412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7176cd73-2572-4d55-8ff6-448ef711773e": {"__data__": {"id_": "7176cd73-2572-4d55-8ff6-448ef711773e", "embedding": null, "metadata": {"window": "We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "original_text": "McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd4d7f90-9c8f-4f03-8622-e179c3a0e470", "node_type": "1", "metadata": {"window": "We're operating pursuant to an interim agreement for \ndistribution services, which is pending final court approval, includes reduced credit terms of seven days and \ncertain other items as Rite Aid conti nues to reorganize.  \n \n We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "original_text": "Let me start \nwith a review of our second quarter results. ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15131b35d7535300b108c97bd248b472868ffd0bec78b28775945471ad65269a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f36d4aef-36b1-4cbc-a902-c0b2a531af73", "node_type": "1", "metadata": {"window": "The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "original_text": "Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  "}, "hash": "883416021def13685e0436ad7279f38a380078542c6f9abb5a03686398dca831", "class_name": "RelatedNodeInfo"}}, "text": "McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n", "start_char_idx": 3412, "end_char_idx": 3572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f36d4aef-36b1-4cbc-a902-c0b2a531af73": {"__data__": {"id_": "f36d4aef-36b1-4cbc-a902-c0b2a531af73", "embedding": null, "metadata": {"window": "The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "original_text": "Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8455ac46c3535feac9cbc3436321a13d1a68df14baf0e47d42545e4f24fe8db5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7176cd73-2572-4d55-8ff6-448ef711773e", "node_type": "1", "metadata": {"window": "We are closely monitoring developments, and we anticipate this customer event will not have a material impact on \nour fiscal 2024 adjusted earnings per diluted share results, our liquidity position, and ongoing business \noperations.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "original_text": "McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c8ab209192b13fce0bab20f53bcb65de2299e2b763d0e713f98e946666f6623", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d71d4bd-760a-47d7-a303-5d253994d5b8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "4a7dde9dd3099294f2188b79de10ae045fa3b4a30ca6f11d34898944ff0ea0e7", "class_name": "RelatedNodeInfo"}}, "text": "Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "start_char_idx": 3572, "end_char_idx": 3827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d71d4bd-760a-47d7-a303-5d253994d5b8": {"__data__": {"id_": "5d71d4bd-760a-47d7-a303-5d253994d5b8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f36d4aef-36b1-4cbc-a902-c0b2a531af73", "node_type": "1", "metadata": {"window": "The remainder of my comments will refer to our fiscal 2024 adjusted results unless I state otherwise.  Let me start \nwith a review of our second quarter results.  McKesson delivered solid growth in the second quarter, led by strong \nperformance in the US Pharmace utical and Prescription Technology Solutions segments.  \n \n Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "original_text": "Our focus and execution against our company priorities position us to generate consistent, solid financial results \nwhile continuing to evolve and grow our diversified portfolio through focused strateg ic investments in oncology \nand biopharma services.  ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ff9291c41e976ea2e97bbb00aa1b203d5b16eb8b84a260a3f81022a67429cb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65249795-f6db-480c-af00-ffbb19a13472", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n"}, "hash": "864009d809094e7f9ea91252010db9a56475a0fa3234844cc6c87decc3ba0abf", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65249795-f6db-480c-af00-ffbb19a13472": {"__data__": {"id_": "65249795-f6db-480c-af00-ffbb19a13472", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d71d4bd-760a-47d7-a303-5d253994d5b8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "501c9f0c4598959f3fc14627b9688c6ffcf38b5b89b00fda2ca86a2a349af80d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "106d56e1-d7dc-41cb-a3a8-80459617f901", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n", "original_text": "Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses. "}, "hash": "93be53a03f03441c73a09979a080d85d6ee1de1df70d6397f65e0c484a9f16e0", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n", "start_char_idx": 16, "end_char_idx": 418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "106d56e1-d7dc-41cb-a3a8-80459617f901": {"__data__": {"id_": "106d56e1-d7dc-41cb-a3a8-80459617f901", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n", "original_text": "Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65249795-f6db-480c-af00-ffbb19a13472", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b67856daf69145cded6d04957f90091f8185cb6890ec6ca4fb82f3852375b27a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f272b6c-2310-4273-81c8-e85308b333e1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter. ", "original_text": "Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n"}, "hash": "0e7fa16d364e34de0f1a756415892dac9001301ae6e3910e5764d986abbeddbf", "class_name": "RelatedNodeInfo"}}, "text": "Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses. ", "start_char_idx": 418, "end_char_idx": 848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f272b6c-2310-4273-81c8-e85308b333e1": {"__data__": {"id_": "2f272b6c-2310-4273-81c8-e85308b333e1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter. ", "original_text": "Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "106d56e1-d7dc-41cb-a3a8-80459617f901", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n", "original_text": "Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88cd04e1e9f05504e98b0b430f8bf5b6a11542c9fddba2626896ec1308499b3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d793bf5-70a8-42a9-81e0-a48a98f45eaf", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n", "original_text": "Gross profit was $3 billion for the quarter, a decrease of 1%. "}, "hash": "d67d9dc72b160bca527c82f2d31b6eb1abb85829c2dfe3b878f5c377b0eae5c0", "class_name": "RelatedNodeInfo"}}, "text": "Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n", "start_char_idx": 848, "end_char_idx": 961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d793bf5-70a8-42a9-81e0-a48a98f45eaf": {"__data__": {"id_": "8d793bf5-70a8-42a9-81e0-a48a98f45eaf", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n", "original_text": "Gross profit was $3 billion for the quarter, a decrease of 1%. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f272b6c-2310-4273-81c8-e85308b333e1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter. ", "original_text": "Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "669c1f7f6f11539542e1dafa7d17a3088f2f9222445530a2e07cac76cf935f23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcb88488-d179-4c20-a7eb-f1a09d2fc76d", "node_type": "1", "metadata": {"window": "Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments. ", "original_text": "And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n"}, "hash": "ce4430d28df7d9dbb46349632d06eeb14400f89c904fb76e2201f1888ca554d6", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was $3 billion for the quarter, a decrease of 1%. ", "start_char_idx": 961, "end_char_idx": 1024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcb88488-d179-4c20-a7eb-f1a09d2fc76d": {"__data__": {"id_": "bcb88488-d179-4c20-a7eb-f1a09d2fc76d", "embedding": null, "metadata": {"window": "Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments. ", "original_text": "And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d793bf5-70a8-42a9-81e0-a48a98f45eaf", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n", "original_text": "Gross profit was $3 billion for the quarter, a decrease of 1%. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7476e098c2f71c24151a07df73f09be30f26c1cb35756914a2a6b6b375b932e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32c789bd-dd4c-4755-90af-c2fc3a0dd67e", "node_type": "1", "metadata": {"window": "Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment. ", "original_text": "Operating expenses decreased 2% in the quarter. "}, "hash": "995110ba6841c1b3deea0ff781b3acf08322f471a42677fd48ee464bf5cd3e3b", "class_name": "RelatedNodeInfo"}}, "text": "And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n", "start_char_idx": 1024, "end_char_idx": 1269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32c789bd-dd4c-4755-90af-c2fc3a0dd67e": {"__data__": {"id_": "32c789bd-dd4c-4755-90af-c2fc3a0dd67e", "embedding": null, "metadata": {"window": "Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment. ", "original_text": "Operating expenses decreased 2% in the quarter. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcb88488-d179-4c20-a7eb-f1a09d2fc76d", "node_type": "1", "metadata": {"window": "Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments. ", "original_text": "And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5cec693cbbd23ad1cb45f6258fa4fd57361922b65a8ffcd83a92d3e6c292a7ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e82ce1e-5b39-40ff-bf7a-e6a905472a8d", "node_type": "1", "metadata": {"window": "Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n", "original_text": "And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n"}, "hash": "e98f8a3206f87a0c66b56347cb47384aa908b1a98756cf315729d637cacf63d4", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses decreased 2% in the quarter. ", "start_char_idx": 1269, "end_char_idx": 1317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e82ce1e-5b39-40ff-bf7a-e6a905472a8d": {"__data__": {"id_": "9e82ce1e-5b39-40ff-bf7a-e6a905472a8d", "embedding": null, "metadata": {"window": "Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n", "original_text": "And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32c789bd-dd4c-4755-90af-c2fc3a0dd67e", "node_type": "1", "metadata": {"window": "Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment. ", "original_text": "Operating expenses decreased 2% in the quarter. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "280fb2ddf01de2bacfde0f3dde7ebb9899d9118b179d22f68d618cb2272fc0cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "736ba005-0d65-4fea-a9f8-b05e6d2fa71d", "node_type": "1", "metadata": {"window": "And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million. ", "original_text": "Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments. "}, "hash": "4c9c1baf80b461a1018d97289732600c79a3c6e6eb49a1966ba218983f6c3e76", "class_name": "RelatedNodeInfo"}}, "text": "And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n", "start_char_idx": 1317, "end_char_idx": 1655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "736ba005-0d65-4fea-a9f8-b05e6d2fa71d": {"__data__": {"id_": "736ba005-0d65-4fea-a9f8-b05e6d2fa71d", "embedding": null, "metadata": {"window": "And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million. ", "original_text": "Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e82ce1e-5b39-40ff-bf7a-e6a905472a8d", "node_type": "1", "metadata": {"window": "Gross profit was $3 billion for the quarter, a decrease of 1%.  And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n", "original_text": "And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5aac8e9c7bdd7afaa229cf3bf08858e743c959d5e83dca870a01eb934e06513d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdaf8d9e-5b44-4d5a-930f-425542220d10", "node_type": "1", "metadata": {"window": "Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year. ", "original_text": "This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment. "}, "hash": "4bffee81bc5c39cff983515ae9a7026c782dfef8f5ab08e74fc3997912902395", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments. ", "start_char_idx": 1655, "end_char_idx": 1824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdaf8d9e-5b44-4d5a-930f-425542220d10": {"__data__": {"id_": "cdaf8d9e-5b44-4d5a-930f-425542220d10", "embedding": null, "metadata": {"window": "Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year. ", "original_text": "This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "736ba005-0d65-4fea-a9f8-b05e6d2fa71d", "node_type": "1", "metadata": {"window": "And when excluding the impact of our European \nbusiness operations and completed divestitures, second quarter gross profit increased 8%, primarily  a result of \ngrowth in the US Pharmaceutical and Prescription Technology Solutions segments.  \n \n Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million. ", "original_text": "Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58991b6ae85f8103a940d10e4a020373bf3f672f9ca920f2e34a22c63ce8979f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2210c980-3a8c-4f85-98eb-1cc5524413ca", "node_type": "1", "metadata": {"window": "And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year. ", "original_text": "When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n"}, "hash": "87aaeaf6cd65872e2bb9e49c7c55b3e620f348db43416af612f3d078de327c4b", "class_name": "RelatedNodeInfo"}}, "text": "This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment. ", "start_char_idx": 1824, "end_char_idx": 2054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2210c980-3a8c-4f85-98eb-1cc5524413ca": {"__data__": {"id_": "2210c980-3a8c-4f85-98eb-1cc5524413ca", "embedding": null, "metadata": {"window": "And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year. ", "original_text": "When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdaf8d9e-5b44-4d5a-930f-425542220d10", "node_type": "1", "metadata": {"window": "Operating expenses decreased 2% in the quarter.  And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year. ", "original_text": "This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b55187bca4127227193eea4d4fbacae3494f8db9a52ebf9940e4f78fcefc6b0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb3d594d-ea2b-401c-934f-a93d68a2c168", "node_type": "1", "metadata": {"window": "Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n", "original_text": "Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million. "}, "hash": "f61f6caf046ba407acc5335413b1e1336f2c2efc362e39d48938d3b4adf59b95", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n", "start_char_idx": 2054, "end_char_idx": 2264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb3d594d-ea2b-401c-934f-a93d68a2c168": {"__data__": {"id_": "cb3d594d-ea2b-401c-934f-a93d68a2c168", "embedding": null, "metadata": {"window": "Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n", "original_text": "Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2210c980-3a8c-4f85-98eb-1cc5524413ca", "node_type": "1", "metadata": {"window": "And when excluding the impact of our European business \noperations, including completed divestitures, operating expenses increased 9% year over year, which included \napproximately 2% from costs related to the second half fiscal 2023 acquisitions of our Rx Saving Solutions and \nthe joint venture with Sarah Cannon Research Institute.  \n \n Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year. ", "original_text": "When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9429bc42351e1384fc4f8bdb2502f7d60fae44a7899a67828430a32b785c633", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c445187d-a6f1-48ee-ac78-c611656d76a9", "node_type": "1", "metadata": {"window": "This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth. ", "original_text": "Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year. "}, "hash": "e009bab1faa33bdaa8e7e526c0cf19a43d7feb892b06857ea6b51c7941b7b13e", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million. ", "start_char_idx": 2264, "end_char_idx": 2395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c445187d-a6f1-48ee-ac78-c611656d76a9": {"__data__": {"id_": "c445187d-a6f1-48ee-ac78-c611656d76a9", "embedding": null, "metadata": {"window": "This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth. ", "original_text": "Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb3d594d-ea2b-401c-934f-a93d68a2c168", "node_type": "1", "metadata": {"window": "Second quarter operating profit increased 1% to $1.2 billion, again primarily driven by growth in our US \nPharmaceutical and Prescription Technology Solutions segments.  This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n", "original_text": "Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f641ff3663f9ec4db4f412270e42d5ad89a27c0ab5100735c0dc09980933b9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4532ac5-83f9-4d50-a9be-526c53e1e961", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n", "original_text": "Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year. "}, "hash": "8f82a8b529855817df5d597c0e46b0e0f8d6beea127401618b8e27e2ae2bc222", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year. ", "start_char_idx": 2395, "end_char_idx": 2508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4532ac5-83f9-4d50-a9be-526c53e1e961": {"__data__": {"id_": "f4532ac5-83f9-4d50-a9be-526c53e1e961", "embedding": null, "metadata": {"window": "When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n", "original_text": "Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c445187d-a6f1-48ee-ac78-c611656d76a9", "node_type": "1", "metadata": {"window": "This was partially offset by slower growth in our \nMedical -Surgical Solutions segment, including lower illness season tes ting and the completed divestitures of our \nEuropean business operations within the International segment.  When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth. ", "original_text": "Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7be837fdfd885472216aca7bdee25b0dbb6955e82be0f7e5eeac1c98c8adfa15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "008bd8e3-9937-4fc3-9653-88f03780a8f3", "node_type": "1", "metadata": {"window": "Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture. ", "original_text": "Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n"}, "hash": "e4be957b13f6ddbd73e99cf0a287b453130066af7be78490f616c73fb17bd0ab", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year. ", "start_char_idx": 2508, "end_char_idx": 2632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "008bd8e3-9937-4fc3-9653-88f03780a8f3": {"__data__": {"id_": "008bd8e3-9937-4fc3-9653-88f03780a8f3", "embedding": null, "metadata": {"window": "Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture. ", "original_text": "Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4532ac5-83f9-4d50-a9be-526c53e1e961", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19-related \nitems in fiscal 2023 and losses associated with McKesson Ventures equity investments in fiscal 2023 and 2024, \noperating profit increased 12% in the quarter.  \n \n Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n", "original_text": "Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e7913b0bbeb477a09fddf8916153d208e29d58a2b89f9da27b278f8ff856478", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28fd884d-62eb-4c64-963a-65406bc55702", "node_type": "1", "metadata": {"window": "Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture.  These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "original_text": "Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth. "}, "hash": "8e9d2289a9496d1d4ac4d1b59e47e7640638893a298f9ab641097dfee98cb6f1", "class_name": "RelatedNodeInfo"}}, "text": "Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n", "start_char_idx": 2632, "end_char_idx": 2863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28fd884d-62eb-4c64-963a-65406bc55702": {"__data__": {"id_": "28fd884d-62eb-4c64-963a-65406bc55702", "embedding": null, "metadata": {"window": "Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture.  These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "original_text": "Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "008bd8e3-9937-4fc3-9653-88f03780a8f3", "node_type": "1", "metadata": {"window": "Moving below the line, the effective tax rate was 23.5%, which included recognition of a net discrete tax expense \nof $12 million.  Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture. ", "original_text": "Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef0cb2a77a7a38fec6cfd529ca869a2df9883dab47a772d9d3bd4c47e58a8140", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3b11c1a-875a-4056-8422-e2c597c1d407", "node_type": "1", "metadata": {"window": "Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture.  These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "original_text": "Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n"}, "hash": "988b3564f577c7487f19b8354bef3977abc6766fd87ffc7cb8d00c6fd07b5c01", "class_name": "RelatedNodeInfo"}}, "text": "Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth. ", "start_char_idx": 2863, "end_char_idx": 3085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3b11c1a-875a-4056-8422-e2c597c1d407": {"__data__": {"id_": "e3b11c1a-875a-4056-8422-e2c597c1d407", "embedding": null, "metadata": {"window": "Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture.  These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "original_text": "Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28fd884d-62eb-4c64-963a-65406bc55702", "node_type": "1", "metadata": {"window": "Second quarter diluted weighted average shares outstanding was 134.8 mil lion, a decrease of 6% \nyear over year.  Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture.  These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "original_text": "Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "144826600f348d705201d7b26836df1cba72d2b7d2a9016a23c214d1cafe94b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "802ab5a9-c3ed-4c93-9312-a549f8cce853", "node_type": "1", "metadata": {"window": "Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture.  These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "original_text": "We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture. "}, "hash": "fa89ca16580cb538a479769806426bb7153a36c92677b460f51b91131a0736e8", "class_name": "RelatedNodeInfo"}}, "text": "Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n", "start_char_idx": 3085, "end_char_idx": 3721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "802ab5a9-c3ed-4c93-9312-a549f8cce853": {"__data__": {"id_": "802ab5a9-c3ed-4c93-9312-a549f8cce853", "embedding": null, "metadata": {"window": "Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture.  These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "original_text": "We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3b11c1a-875a-4056-8422-e2c597c1d407", "node_type": "1", "metadata": {"window": "Consolidated second quarter earnings per diluted share were $6.23, which represents an increase \nof 3% over the prior year.  Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture.  These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "original_text": "Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60cf378ac022a13b6ad88c23b6197cb9c6c8dc683ee7768c84935d9c5413a99c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e14e1345-00be-4abf-98a3-02f6ccc0c1c5", "node_type": "1", "metadata": {"window": "Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture.  These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "original_text": "These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n "}, "hash": "65a3ac2fd2d33d89d90d7e92eb41f188dd8068df72a5ceddabb64563ec07b416", "class_name": "RelatedNodeInfo"}}, "text": "We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture. ", "start_char_idx": 3721, "end_char_idx": 3978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e14e1345-00be-4abf-98a3-02f6ccc0c1c5": {"__data__": {"id_": "e14e1345-00be-4abf-98a3-02f6ccc0c1c5", "embedding": null, "metadata": {"window": "Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture.  These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "original_text": "These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2b04763-7209-440a-81fe-2271126d7243", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5d69d9970d46e556ca8b6dcc0c06e04ddfadbefa5a465191a80d8e3856533ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "802ab5a9-c3ed-4c93-9312-a549f8cce853", "node_type": "1", "metadata": {"window": "Excluding COVID -19-related items during the second quarter of fiscal 2023 and losses \nwithin ou r McKesson Ventures portfolio in fiscal 2023 and 2024, second quarter earnings per diluted share was \nup 14% over the prior year.  \n \n Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture.  These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "original_text": "We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture. ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85117361646c005891a23655da70d6f3cdf79c17eab3f44f2c08b28cb0e1e205", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0006a17-5e64-4924-b1a3-267f92071ab1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions. ", "original_text": "McKesson Corp.  "}, "hash": "88859025a9bcc8df886a1dd74a526d7315dccb6e226d76561e8be000234ba6c1", "class_name": "RelatedNodeInfo"}}, "text": "These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "start_char_idx": 3978, "end_char_idx": 4096, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0006a17-5e64-4924-b1a3-267f92071ab1": {"__data__": {"id_": "e0006a17-5e64-4924-b1a3-267f92071ab1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e14e1345-00be-4abf-98a3-02f6ccc0c1c5", "node_type": "1", "metadata": {"window": "Turning to our second quarter segment results, which can be found on slides 7 through 11 and starting in US \nPharmaceutical, th e US Pharmaceutical segment delivered continued momentum and strong operating profit \ngrowth.  Our ability to drive sustainable growth in this segment reflects a few factors: the efficiency of our scaled \ndistribution operations; the investments that we're ma king to unlock new capabilities that will further expand and \nstrengthen our value proposition for our customers and partners; a balanced approach to managing a broad \nportfolio of pharmaceutical products, inclusive of our ClarusONE generic sourcing operatio ns, bolstering our \ncompetitive position and enabling a minimal approach to customer demand, new product launches, and market \nmovements; and continued investment in expansion in our broad oncology platform.  \n \n We are pleased with the growth momentum across ou r oncology assets, from provider solutions in the US \noncology network, data and insights through Ontada, and expanded clinical trial capabilities through our Sarah \nCannon Research Institute joint venture.  These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "original_text": "These assets contributed to revenue and operating p rofit results in the \nquarter which exceeded our expectations.  \n ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce72dba97128bac282ae8bd464d9e1d87a1b760be2cefcc645dab0a0af84891e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e7a7a13-72c7-4e84-9c87-30c182fb2e70", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year. "}, "hash": "45fb4ce631c9923c7f3fa3028f61cc3c198dbcd4c524df38c935362c754ffe13", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e7a7a13-72c7-4e84-9c87-30c182fb2e70": {"__data__": {"id_": "2e7a7a13-72c7-4e84-9c87-30c182fb2e70", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0006a17-5e64-4924-b1a3-267f92071ab1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3d7a87d2b7be3f4a8a0660e23b56ddfc6af34d02b78c4032d7c975f28e94022", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e235e13-4723-4953-8de9-3f939b64a775", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n", "original_text": "Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications. "}, "hash": "7a79d524dee416c7d3a48c4efdb089ae269919eb7dbdd692df40c717d59b3a8a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year. ", "start_char_idx": 16, "end_char_idx": 259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e235e13-4723-4953-8de9-3f939b64a775": {"__data__": {"id_": "4e235e13-4723-4953-8de9-3f939b64a775", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n", "original_text": "Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e7a7a13-72c7-4e84-9c87-30c182fb2e70", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f41f676979b1d7784f75df53badc7c5a8b7ec2b8da17d7c0b96db18151f992b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f62febf-2573-4544-b6b6-b10f3e43ba4e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services. ", "original_text": "These increases were partially offset by branded -to-generic conversions. "}, "hash": "7b7747b71aac66fc8978782efd65f15ff020da0cbf4b34f8f0ec72e49c005179", "class_name": "RelatedNodeInfo"}}, "text": "Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications. ", "start_char_idx": 259, "end_char_idx": 432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f62febf-2573-4544-b6b6-b10f3e43ba4e": {"__data__": {"id_": "6f62febf-2573-4544-b6b6-b10f3e43ba4e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services. ", "original_text": "These increases were partially offset by branded -to-generic conversions. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e235e13-4723-4953-8de9-3f939b64a775", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n", "original_text": "Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb816ca056aeadfc62a45f4eb0d600d0a7cf19841ac75d93189a2aaffb27a2a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c61f8c65-f278-44b1-a699-df9d6a14fd09", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs. ", "original_text": "The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter. "}, "hash": "a0acb466cff5e5effb464adbfab0d0cb37783550576865a83be8932445cf07e9", "class_name": "RelatedNodeInfo"}}, "text": "These increases were partially offset by branded -to-generic conversions. ", "start_char_idx": 432, "end_char_idx": 506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c61f8c65-f278-44b1-a699-df9d6a14fd09": {"__data__": {"id_": "c61f8c65-f278-44b1-a699-df9d6a14fd09", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs. ", "original_text": "The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f62febf-2573-4544-b6b6-b10f3e43ba4e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services. ", "original_text": "These increases were partially offset by branded -to-generic conversions. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd65670522296798a2f35b66a792786c13012b1bdab595a5711844876c51352b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "853087ed-1a62-4ba9-b10b-d0967ce68258", "node_type": "1", "metadata": {"window": "Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n", "original_text": "As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n"}, "hash": "802e6c2586621d03c2226821c32dcf974907216792d0039b419995c7583dd451", "class_name": "RelatedNodeInfo"}}, "text": "The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter. ", "start_char_idx": 506, "end_char_idx": 584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "853087ed-1a62-4ba9-b10b-d0967ce68258": {"__data__": {"id_": "853087ed-1a62-4ba9-b10b-d0967ce68258", "embedding": null, "metadata": {"window": "Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n", "original_text": "As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c61f8c65-f278-44b1-a699-df9d6a14fd09", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs. ", "original_text": "The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bf45ba4315840578b14e1f7e1ccebb7606cc00a54fa5ed19835d8f84e1cbd8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcea30d0-32fa-414f-9404-08a95fa79b2e", "node_type": "1", "metadata": {"window": "These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n", "original_text": "In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services. "}, "hash": "d507b5ab3d89df6c191c1ed566dfc98dfe508ea1cd907a6c6d0ec2af73e7f206", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n", "start_char_idx": 584, "end_char_idx": 724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcea30d0-32fa-414f-9404-08a95fa79b2e": {"__data__": {"id_": "fcea30d0-32fa-414f-9404-08a95fa79b2e", "embedding": null, "metadata": {"window": "These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n", "original_text": "In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "853087ed-1a62-4ba9-b10b-d0967ce68258", "node_type": "1", "metadata": {"window": "Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n", "original_text": "As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c501d3465e5b80f7e9e1f757eadb45f8788b69b34e7e05c146e710ea1754ccb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "862d76c3-05ed-406b-bb92-7a657ef232d1", "node_type": "1", "metadata": {"window": "The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n", "original_text": "Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs. "}, "hash": "34de3c7bdc288a0d8618b2ce6200ecd0db6884076d00890c78b35002d9ec1d43", "class_name": "RelatedNodeInfo"}}, "text": "In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services. ", "start_char_idx": 724, "end_char_idx": 933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "862d76c3-05ed-406b-bb92-7a657ef232d1": {"__data__": {"id_": "862d76c3-05ed-406b-bb92-7a657ef232d1", "embedding": null, "metadata": {"window": "The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n", "original_text": "Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcea30d0-32fa-414f-9404-08a95fa79b2e", "node_type": "1", "metadata": {"window": "These increases were partially offset by branded -to-generic conversions.  The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n", "original_text": "In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71574e2af8689fe4d6cce4bb9f6932395c1d8af76a45a373484a082af26d1c82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8349c93f-ffef-4c66-b6f7-4d933a7df87d", "node_type": "1", "metadata": {"window": "As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million. ", "original_text": "When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n"}, "hash": "6c4ca84c4e779d295e9befb3ef2141b3dac1850e2f371efbdf122254470a93b1", "class_name": "RelatedNodeInfo"}}, "text": "Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs. ", "start_char_idx": 933, "end_char_idx": 1129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8349c93f-ffef-4c66-b6f7-4d933a7df87d": {"__data__": {"id_": "8349c93f-ffef-4c66-b6f7-4d933a7df87d", "embedding": null, "metadata": {"window": "As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million. ", "original_text": "When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "862d76c3-05ed-406b-bb92-7a657ef232d1", "node_type": "1", "metadata": {"window": "The \ngrowth of GLP -1 medications provided a revenue tailwind in the quarter.  As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n", "original_text": "Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d7ccea04803cb5f43f437640ded893b3d07eb27949e950e0ebf33321e32858c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c85f7f7-da51-4056-a640-cdd2dda68851", "node_type": "1", "metadata": {"window": "In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business. ", "original_text": "Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n"}, "hash": "3652e7dbd0aeb3b3ac1db04634922d794959dcc7a85335d0b5cbabddd12b1fc7", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n", "start_char_idx": 1129, "end_char_idx": 1321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c85f7f7-da51-4056-a640-cdd2dda68851": {"__data__": {"id_": "1c85f7f7-da51-4056-a640-cdd2dda68851", "embedding": null, "metadata": {"window": "In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business. ", "original_text": "Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8349c93f-ffef-4c66-b6f7-4d933a7df87d", "node_type": "1", "metadata": {"window": "As a reminder, we generally recognize \nlower margin r ates for the distribution of GLP -1 medications in the US Pharmaceutical segment.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million. ", "original_text": "When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49c0955d4bb6af8dff8ea6f284f3fec981da7ff0debc593f6fb03afd67b37490", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dac093a6-3498-4cfa-b2ec-16a8933673af", "node_type": "1", "metadata": {"window": "Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n", "original_text": "The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n"}, "hash": "10c2cb57d3f65473da962e95cc7ac25e13162c94c15f89c7082644f1b78a9f68", "class_name": "RelatedNodeInfo"}}, "text": "Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n", "start_char_idx": 1321, "end_char_idx": 1546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dac093a6-3498-4cfa-b2ec-16a8933673af": {"__data__": {"id_": "dac093a6-3498-4cfa-b2ec-16a8933673af", "embedding": null, "metadata": {"window": "Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n", "original_text": "The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c85f7f7-da51-4056-a640-cdd2dda68851", "node_type": "1", "metadata": {"window": "In our Prescription Technology Solutions segment, the growth of GLP -1 medications, like other new brand \nlaunches, has led to increased demand for our access solutions, such a s prior authorization services.  Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business. ", "original_text": "Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1976c70bbb3c9a10e7f65480214e9c1328ddfb42a7ddc83abcd7371b65b4ca8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb0e9a82-13b3-4ed7-acd6-e8215dfd0bae", "node_type": "1", "metadata": {"window": "When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program. ", "original_text": "For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million. "}, "hash": "826a712c088ada56ba727658a3fe4270085e9a275ffa6981fa65be57cb5e269c", "class_name": "RelatedNodeInfo"}}, "text": "The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n", "start_char_idx": 1546, "end_char_idx": 1747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb0e9a82-13b3-4ed7-acd6-e8215dfd0bae": {"__data__": {"id_": "fb0e9a82-13b3-4ed7-acd6-e8215dfd0bae", "embedding": null, "metadata": {"window": "When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program. ", "original_text": "For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dac093a6-3498-4cfa-b2ec-16a8933673af", "node_type": "1", "metadata": {"window": "Second \nquarter US Pharmaceutical operating profit increased 8% to $815 million, driven by growth in the distribution of \nspecialty products and increased contributions from our generic programs.  When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n", "original_text": "The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a24a5359c7be216d716410e76c4c40617343db9eb165643f57527d1df8519d91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f79329e2-eb8c-4962-9a04-00e44f7b4fd8", "node_type": "1", "metadata": {"window": "Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n", "original_text": "Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business. "}, "hash": "db4d5d4acc63f7d08dd3d1466248124fcaf8f6c18f87683067e9f2c3137b54f6", "class_name": "RelatedNodeInfo"}}, "text": "For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million. ", "start_char_idx": 1747, "end_char_idx": 1879, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f79329e2-eb8c-4962-9a04-00e44f7b4fd8": {"__data__": {"id_": "f79329e2-eb8c-4962-9a04-00e44f7b4fd8", "embedding": null, "metadata": {"window": "Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n", "original_text": "Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb0e9a82-13b3-4ed7-acd6-e8215dfd0bae", "node_type": "1", "metadata": {"window": "When excluding the impact of C OVID -\n19 vaccine distribution in the second quarter of fiscal 2023, the US Pharmaceutical segment delivered operating \nprofit growth of 15% year over year.  \n \n Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program. ", "original_text": "For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca1ab8fdd191910d15b442cabd1cc3f659814d61356a9af2cf8f68b7a8fa58c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3703d69c-f842-4711-8724-5d831da6d6e0", "node_type": "1", "metadata": {"window": "The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests. ", "original_text": "The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n"}, "hash": "f8f301fff48e99c67c01af1ba04787fb414f77f99bce5791944045551e88c374", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business. ", "start_char_idx": 1879, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3703d69c-f842-4711-8724-5d831da6d6e0": {"__data__": {"id_": "3703d69c-f842-4711-8724-5d831da6d6e0", "embedding": null, "metadata": {"window": "The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests. ", "original_text": "The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f79329e2-eb8c-4962-9a04-00e44f7b4fd8", "node_type": "1", "metadata": {"window": "Moving to Prescription Technology Solutions, the strong results in the second quarter demonstrate the  success of \nour product portfolio and the partnerships with biopharma manufacturers that we've developed over the years. \n The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n", "original_text": "Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9f331930a0cb369f15d5bf1f5602e2adc7740eed4ec516e00ebd6030476b021", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71718816-4600-442a-b2b2-9387d39ce464", "node_type": "1", "metadata": {"window": "For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n", "original_text": "In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program. "}, "hash": "8c350172fc03518f40502eb0095b91d6b9a7bc22559dfca8a25f4e92d7adf918", "class_name": "RelatedNodeInfo"}}, "text": "The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n", "start_char_idx": 2112, "end_char_idx": 2331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71718816-4600-442a-b2b2-9387d39ce464": {"__data__": {"id_": "71718816-4600-442a-b2b2-9387d39ce464", "embedding": null, "metadata": {"window": "For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n", "original_text": "In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3703d69c-f842-4711-8724-5d831da6d6e0", "node_type": "1", "metadata": {"window": "The strength of our differentiated capabilities and partnerships position in testing captured demand driven by \nstrong prescription util ization trends, including the growth of GLP -1 medications.  \n \n For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests. ", "original_text": "The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f390fffd77870f2c882deaea52a5a17552296748b739d2e1091213bb81341d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4765183-d2d1-46f0-995a-26e7f1f1fc30", "node_type": "1", "metadata": {"window": "Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes. ", "original_text": "The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n"}, "hash": "6f4700566d64187c15c938a4d32a682f2ee9df1ef601e453c2c70103004d0f71", "class_name": "RelatedNodeInfo"}}, "text": "In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program. ", "start_char_idx": 2331, "end_char_idx": 2637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4765183-d2d1-46f0-995a-26e7f1f1fc30": {"__data__": {"id_": "b4765183-d2d1-46f0-995a-26e7f1f1fc30", "embedding": null, "metadata": {"window": "Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes. ", "original_text": "The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71718816-4600-442a-b2b2-9387d39ce464", "node_type": "1", "metadata": {"window": "For the second quarter, revenues increased 12% year over year to $1.1 billion, and operating profit increased \n48% to $209 million.  Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n", "original_text": "In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fcb718e2ff21d605a31247474a5f36dd9c50869c4c25c2b80695dd2af4c5ff8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8607371d-9010-4ddf-a736-d47c51569fb0", "node_type": "1", "metadata": {"window": "The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n", "original_text": "Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests. "}, "hash": "9e95a3934c76f447ec16e6de0bea75873d06577bd873c402b356bd574fa4fcaf", "class_name": "RelatedNodeInfo"}}, "text": "The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n", "start_char_idx": 2637, "end_char_idx": 2831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8607371d-9010-4ddf-a736-d47c51569fb0": {"__data__": {"id_": "8607371d-9010-4ddf-a736-d47c51569fb0", "embedding": null, "metadata": {"window": "The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n", "original_text": "Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4765183-d2d1-46f0-995a-26e7f1f1fc30", "node_type": "1", "metadata": {"window": "Second quarter results reflected increased prescription transacti on volumes, which drove \nhigher demand for our access solutions, primarily related to prior authorization services and growth in our third -\nparty logistics business.  The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes. ", "original_text": "The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "841b19789ac18ac0f9d6b08dd143b92c7d026ac64dbe85532ffb867c135379be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "651c3af4-e637-4ef6-8d8e-d41de41f0d7f", "node_type": "1", "metadata": {"window": "In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results. ", "original_text": "When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n"}, "hash": "422fd236d8659dbb7001c07440163b7e90f663e27eff8a0b4b2f969b24a03fca", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests. ", "start_char_idx": 2831, "end_char_idx": 3078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "651c3af4-e637-4ef6-8d8e-d41de41f0d7f": {"__data__": {"id_": "651c3af4-e637-4ef6-8d8e-d41de41f0d7f", "embedding": null, "metadata": {"window": "In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results. ", "original_text": "When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8607371d-9010-4ddf-a736-d47c51569fb0", "node_type": "1", "metadata": {"window": "The year -over-year growth also included higher operating expenses in the second \nquarter of f iscal 2023, which resulted from the timing of increased head count to support customer annual \nverification activities.  \n \n In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n", "original_text": "Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ab40a324a052e2a2093009495c81be12c04ab51d088d808ff8c683de3c3ac7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec0bbc61-9b29-4187-84ac-f8a16dfebb1f", "node_type": "1", "metadata": {"window": "The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year. ", "original_text": "Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes. "}, "hash": "ffde79fe404acc01e3b96dca2f52da5af3cde500b3600c3011749fe5df993004", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n", "start_char_idx": 3078, "end_char_idx": 3315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec0bbc61-9b29-4187-84ac-f8a16dfebb1f": {"__data__": {"id_": "ec0bbc61-9b29-4187-84ac-f8a16dfebb1f", "embedding": null, "metadata": {"window": "The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year. ", "original_text": "Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "651c3af4-e637-4ef6-8d8e-d41de41f0d7f", "node_type": "1", "metadata": {"window": "In Medical -Surgical Solutions, revenues were $2.8 billion in the quarter, which was flat to the prior year, resulting \nfrom anticipated l ower sales of COVID -19 tests and lower contribution from kitting, storage, and distribution of \nancillary supplies for the US government's COVID -19 vaccine program.  The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results. ", "original_text": "When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de364df5508556fa7035f78f346ed2d5387f3ab8f15d4271a737268c1abf939a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "440a777e-c664-49eb-afd9-1924042df52b", "node_type": "1", "metadata": {"window": "Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%. ", "original_text": "The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n"}, "hash": "787d1e6a56a90d19f5a22ea6b65b84ec4d624247bf2a623d996bd87ba3cac819", "class_name": "RelatedNodeInfo"}}, "text": "Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes. ", "start_char_idx": 3315, "end_char_idx": 3430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "440a777e-c664-49eb-afd9-1924042df52b": {"__data__": {"id_": "440a777e-c664-49eb-afd9-1924042df52b", "embedding": null, "metadata": {"window": "Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%. ", "original_text": "The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec0bbc61-9b29-4187-84ac-f8a16dfebb1f", "node_type": "1", "metadata": {"window": "The anticipated lower COVID -19-related \nrevenues were partially offset by growth in the exten ded care business and increased distribution of \npharmaceuticals in the primary care business.  \n \n Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year. ", "original_text": "Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3724bf0af47d8d516732686c8248ebcd8040923d2620d45ec836a5cb14738e3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95151d2a-de23-476b-9861-65680feaa7f9", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n", "original_text": "Next, let me address our international results. "}, "hash": "578119dcf1b70f0aee5a15b9a6f6bdc2646e3bd4b9a594419d02b7291031a526", "class_name": "RelatedNodeInfo"}}, "text": "The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n", "start_char_idx": 3430, "end_char_idx": 3667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95151d2a-de23-476b-9861-65680feaa7f9": {"__data__": {"id_": "95151d2a-de23-476b-9861-65680feaa7f9", "embedding": null, "metadata": {"window": "When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n", "original_text": "Next, let me address our international results. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "440a777e-c664-49eb-afd9-1924042df52b", "node_type": "1", "metadata": {"window": "Operating profit was $254 million, a decrease of 17%, driven by anticipated lower contributions from kitting, \nstorage, and distribution of ancillary supplies for  the US government's COVID -19 vaccine program and lower \nsales of COVID -19 tests.  When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%. ", "original_text": "The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88ee8e1f5147f54439517a5313b43c9531ca23d89f88ad1500d385b4ba43f414", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e991af1-e722-4f0d-8c05-ca463e391acf", "node_type": "1", "metadata": {"window": "Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year. ", "original_text": "Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year. "}, "hash": "842730cefa91dcfc94b87d826920af78b7ae77e2d3517a5ead6dcaa390762f93", "class_name": "RelatedNodeInfo"}}, "text": "Next, let me address our international results. ", "start_char_idx": 3667, "end_char_idx": 3715, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e991af1-e722-4f0d-8c05-ca463e391acf": {"__data__": {"id_": "6e991af1-e722-4f0d-8c05-ca463e391acf", "embedding": null, "metadata": {"window": "Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year. ", "original_text": "Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95151d2a-de23-476b-9861-65680feaa7f9", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19-related items in the second quarter of fiscal \n2023, the segment delivered operating profit growth of 5%, driven by increased volumes of n utritional \nsupplements in the extended care business.  \n \n Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n", "original_text": "Next, let me address our international results. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2689064377b5a95dc8124c895387b11218dfaa7ef9bea8e7cf055d043489500", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee28d2da-ff73-4bc8-8419-c04eff582e23", "node_type": "1", "metadata": {"window": "The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year.  During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "original_text": "And operating profit was $89 million, a decrease of 35%. "}, "hash": "faa2114d32ee7ea20361895591f9f52f4d85259fc67840ee1edbd7bb0ce0ec24", "class_name": "RelatedNodeInfo"}}, "text": "Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year. ", "start_char_idx": 3715, "end_char_idx": 3800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee28d2da-ff73-4bc8-8419-c04eff582e23": {"__data__": {"id_": "ee28d2da-ff73-4bc8-8419-c04eff582e23", "embedding": null, "metadata": {"window": "The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year.  During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "original_text": "And operating profit was $89 million, a decrease of 35%. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e991af1-e722-4f0d-8c05-ca463e391acf", "node_type": "1", "metadata": {"window": "Based on IQVIA and other market indications, the second quarter exhibited moderating primary care market \nvolumes.  The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year. ", "original_text": "Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fefded9df0123d483d55218385da61ea350de63ee034a7f840c70fdf5148c427", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4a903d5-bc2b-4024-a1dd-65b026655966", "node_type": "1", "metadata": {"window": "Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year.  During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "original_text": "Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n"}, "hash": "ac95dbe9552795df8dfd8ccff425b18775ce4b23a8688a1ec57cfde205bd935f", "class_name": "RelatedNodeInfo"}}, "text": "And operating profit was $89 million, a decrease of 35%. ", "start_char_idx": 3800, "end_char_idx": 3857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4a903d5-bc2b-4024-a1dd-65b026655966": {"__data__": {"id_": "d4a903d5-bc2b-4024-a1dd-65b026655966", "embedding": null, "metadata": {"window": "Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year.  During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "original_text": "Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee28d2da-ff73-4bc8-8419-c04eff582e23", "node_type": "1", "metadata": {"window": "The Medical -Surgical Solutions second quarter growth rate reflects these market indicat ions, which was \npartially related to a slower start to the illness season, including illness season testing, when compared to the \nprior year.  \n \n Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year.  During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "original_text": "And operating profit was $89 million, a decrease of 35%. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71941fadfda4da33daa75e08fe39ae5332d88f4e248710164506aa49c8ffa665", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2183ad8e-27f8-4ece-80a8-ea528c8bdf26", "node_type": "1", "metadata": {"window": "Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year.  During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "original_text": "Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year. "}, "hash": "262b83f2ebd0134f09315a971178cddb0bd8fddd0836d9ac6e938dcb21e65e9c", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n", "start_char_idx": 3857, "end_char_idx": 3980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2183ad8e-27f8-4ece-80a8-ea528c8bdf26": {"__data__": {"id_": "2183ad8e-27f8-4ece-80a8-ea528c8bdf26", "embedding": null, "metadata": {"window": "Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year.  During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "original_text": "Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4a903d5-bc2b-4024-a1dd-65b026655966", "node_type": "1", "metadata": {"window": "Next, let me address our international results.  Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year.  During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "original_text": "Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4316ac9ce36736652de9ee5c850bdcc8916d4bae3128361ff78a4592f397c010", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe418c13-0da1-4d25-8c79-2be95d4e4e28", "node_type": "1", "metadata": {"window": "And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year.  During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "original_text": "During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within "}, "hash": "aa7b3e486f30f0e5e8624e2c03f1f1612d4f40e8007633a078a2a986a422f302", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year. ", "start_char_idx": 3980, "end_char_idx": 4101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe418c13-0da1-4d25-8c79-2be95d4e4e28": {"__data__": {"id_": "fe418c13-0da1-4d25-8c79-2be95d4e4e28", "embedding": null, "metadata": {"window": "And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year.  During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "original_text": "During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ddc2184420456f5e2580080b7fa810849d5bb96284c5085dbd352b710d834f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2183ad8e-27f8-4ece-80a8-ea528c8bdf26", "node_type": "1", "metadata": {"window": "Revenues in the second quarter were $3.5 billion, a decrease of \n44% year over year.  And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year.  During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "original_text": "Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year. ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4aa137ee2e9a3302a6859293f76638751469f6a5382dc020f35fdb5beb9dae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e4ee8e3-209f-4f12-9f63-cd567aee03aa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio. ", "original_text": "McKesson Corp.  "}, "hash": "06492b4ccaf31d4169bc4a0d97ce2129d02f2d807baeee6675f1f160478e40b8", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "start_char_idx": 4101, "end_char_idx": 4206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e4ee8e3-209f-4f12-9f63-cd567aee03aa": {"__data__": {"id_": "3e4ee8e3-209f-4f12-9f63-cd567aee03aa", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe418c13-0da1-4d25-8c79-2be95d4e4e28", "node_type": "1", "metadata": {"window": "And operating profit was $89 million, a decrease of 35%.  Second quarter results reflect the \nyear-over-year effects of the completed divestitures within our European business.  \n \n Wrapping up our segment review, corporate expenses were $159 million in the quarter, an increase of 10% year \nover year.  During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "original_text": "During the quarter, we had losses of $10 million or $0.06 per share related to equity investments within ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c79d2cd05c9540b447c81455cdb60a33357572c0f7632d7be950b74c40afbe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3afa40c-abc0-4582-b705-e707b3f045f9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n"}, "hash": "186372d388963f1ee4799f5c4631aa2e4620e2c85e7a69a5ebabda3a13eb161f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3afa40c-abc0-4582-b705-e707b3f045f9": {"__data__": {"id_": "d3afa40c-abc0-4582-b705-e707b3f045f9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e4ee8e3-209f-4f12-9f63-cd567aee03aa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ef9cfa6d4616bb4b8371f29fbc577fcc1a07ea46b1c954e7deb83d358c18e15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "476d4a0e-69cd-4e28-9094-00d90a2023e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12. ", "original_text": "As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies. "}, "hash": "80ae9f567028cf7a04dbecccc2f7579e625f4c5bb2469a03a5c6baf7495dcaf0", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n", "start_char_idx": 16, "end_char_idx": 303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "476d4a0e-69cd-4e28-9094-00d90a2023e2": {"__data__": {"id_": "476d4a0e-69cd-4e28-9094-00d90a2023e2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12. ", "original_text": "As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3afa40c-abc0-4582-b705-e707b3f045f9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4225c98e2e427c9a012886ee2eb690981d0a52961299a5c000cb9c237bb34a8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5626723f-0507-46a6-9350-1cba8865b80f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents. ", "original_text": "We're pleased with the insights and results that we are obtaining through this portfolio. "}, "hash": "7c6140e772375f2305b9013799d3d070e2395c01c4f9ae82932f507daf7565fc", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies. ", "start_char_idx": 303, "end_char_idx": 435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5626723f-0507-46a6-9350-1cba8865b80f": {"__data__": {"id_": "5626723f-0507-46a6-9350-1cba8865b80f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents. ", "original_text": "We're pleased with the insights and results that we are obtaining through this portfolio. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "476d4a0e-69cd-4e28-9094-00d90a2023e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12. ", "original_text": "As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc5ed02f73788acc2006235c69816157fc020b29f13a471cc27c411e4ca80cb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8554ff92-a7f8-412d-83e4-81216d31664e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths. ", "original_text": "The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n"}, "hash": "9ecdb75f14b6a4aafa9e9f9c6b85bdfeb7fdcacf2ebb709b1685daf8ad1b17b8", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with the insights and results that we are obtaining through this portfolio. ", "start_char_idx": 435, "end_char_idx": 525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8554ff92-a7f8-412d-83e4-81216d31664e": {"__data__": {"id_": "8554ff92-a7f8-412d-83e4-81216d31664e", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths. ", "original_text": "The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5626723f-0507-46a6-9350-1cba8865b80f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents. ", "original_text": "We're pleased with the insights and results that we are obtaining through this portfolio. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8588f70206adb265555e0935933bcf017e83e074c04be511740b53a433139ac3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5d37080-976e-46fe-9649-1cacc4f3407b", "node_type": "1", "metadata": {"window": "As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims. ", "original_text": "Turning now to cash flows and capital deployment, which can be found on slide 12. "}, "hash": "32dd224919ec7de482259ed3c8f836ed20745441575aacbd909cece29b3493e2", "class_name": "RelatedNodeInfo"}}, "text": "The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n", "start_char_idx": 525, "end_char_idx": 795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5d37080-976e-46fe-9649-1cacc4f3407b": {"__data__": {"id_": "f5d37080-976e-46fe-9649-1cacc4f3407b", "embedding": null, "metadata": {"window": "As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims. ", "original_text": "Turning now to cash flows and capital deployment, which can be found on slide 12. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8554ff92-a7f8-412d-83e4-81216d31664e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths. ", "original_text": "The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a498e5d12a06974eba2eb781ac6bc1683eb2ad6e26df6bbff26c9f08626abe90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "646feb55-22f3-40cc-b1f6-293f27c7bded", "node_type": "1", "metadata": {"window": "We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n", "original_text": "We ended the quarter with \n$2.5 billion in cash and cash equivalents. "}, "hash": "84e172a7062bf88d226b3d315602ee4872441cdbd3bf4b506b31387e79bf7666", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to cash flows and capital deployment, which can be found on slide 12. ", "start_char_idx": 795, "end_char_idx": 877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "646feb55-22f3-40cc-b1f6-293f27c7bded": {"__data__": {"id_": "646feb55-22f3-40cc-b1f6-293f27c7bded", "embedding": null, "metadata": {"window": "We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n", "original_text": "We ended the quarter with \n$2.5 billion in cash and cash equivalents. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5d37080-976e-46fe-9649-1cacc4f3407b", "node_type": "1", "metadata": {"window": "As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims. ", "original_text": "Turning now to cash flows and capital deployment, which can be found on slide 12. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "930f607990d703b850b0dc96f7878fde8a2882087ef68a321c2108181a90f8b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e805ea42-3077-442d-8a04-9710b3f06c2d", "node_type": "1", "metadata": {"window": "The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities. ", "original_text": "We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths. "}, "hash": "7320af24f2e5d213cb8850c88b4dcc3635ec50016088b29336ed4cb18fc036f5", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with \n$2.5 billion in cash and cash equivalents. ", "start_char_idx": 877, "end_char_idx": 947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e805ea42-3077-442d-8a04-9710b3f06c2d": {"__data__": {"id_": "e805ea42-3077-442d-8a04-9710b3f06c2d", "embedding": null, "metadata": {"window": "The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities. ", "original_text": "We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "646feb55-22f3-40cc-b1f6-293f27c7bded", "node_type": "1", "metadata": {"window": "We're pleased with the insights and results that we are obtaining through this portfolio.  The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n", "original_text": "We ended the quarter with \n$2.5 billion in cash and cash equivalents. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "085ab49fbf66f8e64c3b671bb91584785932bccd5d5811d05d99d55306e98a3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34af672f-fcd4-44c3-aaae-97e43d68880a", "node_type": "1", "metadata": {"window": "Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n", "original_text": "Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims. "}, "hash": "dd0e1f8152c8baae9084c435c20e64ef0e27b5ffc7f505f24a5ca438003cf145", "class_name": "RelatedNodeInfo"}}, "text": "We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths. ", "start_char_idx": 947, "end_char_idx": 1060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34af672f-fcd4-44c3-aaae-97e43d68880a": {"__data__": {"id_": "34af672f-fcd4-44c3-aaae-97e43d68880a", "embedding": null, "metadata": {"window": "Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n", "original_text": "Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e805ea42-3077-442d-8a04-9710b3f06c2d", "node_type": "1", "metadata": {"window": "The \nimpac ts on consolidated financials can be influenced by the performance of each individual investment quarter -to-\nquarter and, as a result, McKesson's investments may result in gains or losses, the timing and magnitude of \nwhich can vary for each investment.  \n \n Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities. ", "original_text": "We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "431ecf43bf767f9923d22ceb573fbb752cf702024f16e4a6ffc88bc8a7784933", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1682cc8-f37c-4245-a87f-75aa20abf557", "node_type": "1", "metadata": {"window": "We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook. ", "original_text": "As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n"}, "hash": "fe6d8c928b8e8ce12f3495a09d79068699c14539980548006120b5101aeb6af6", "class_name": "RelatedNodeInfo"}}, "text": "Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims. ", "start_char_idx": 1060, "end_char_idx": 1225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1682cc8-f37c-4245-a87f-75aa20abf557": {"__data__": {"id_": "f1682cc8-f37c-4245-a87f-75aa20abf557", "embedding": null, "metadata": {"window": "We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook. ", "original_text": "As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34af672f-fcd4-44c3-aaae-97e43d68880a", "node_type": "1", "metadata": {"window": "Turning now to cash flows and capital deployment, which can be found on slide 12.  We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n", "original_text": "Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e4cb457f88782e7d9635907e916ccca1392a3a3fe35a708778489a6cc2c6c06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a8ee8f6-50a0-4d55-a095-bec3b7757973", "node_type": "1", "metadata": {"window": "We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis. ", "original_text": "During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities. "}, "hash": "47b1f7c9f1d68756d092b412ebc38fc53cee3661377154cfc8b0e99013e5f4a4", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n", "start_char_idx": 1225, "end_char_idx": 1456, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a8ee8f6-50a0-4d55-a095-bec3b7757973": {"__data__": {"id_": "3a8ee8f6-50a0-4d55-a095-bec3b7757973", "embedding": null, "metadata": {"window": "We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis. ", "original_text": "During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1682cc8-f37c-4245-a87f-75aa20abf557", "node_type": "1", "metadata": {"window": "We ended the quarter with \n$2.5 billion in cash and cash equivalents.  We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook. ", "original_text": "As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ddba9f2d71df2223cbda1557cbb4ccfb749ea2c2d68c828c95aa0074ff456ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "367c8837-7271-4af7-9f97-c8c1ecc54607", "node_type": "1", "metadata": {"window": "Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis. ", "original_text": "Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n"}, "hash": "8d03ab7bd7d7871185a12341a6e026354247e9e09aca34800718e62750e76d1f", "class_name": "RelatedNodeInfo"}}, "text": "During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities. ", "start_char_idx": 1456, "end_char_idx": 1712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "367c8837-7271-4af7-9f97-c8c1ecc54607": {"__data__": {"id_": "367c8837-7271-4af7-9f97-c8c1ecc54607", "embedding": null, "metadata": {"window": "Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis. ", "original_text": "Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a8ee8f6-50a0-4d55-a095-bec3b7757973", "node_type": "1", "metadata": {"window": "We delivered free cash flow of $825 million in the second quarter and \n$4.3 billion for the trailing 12 mo nths.  Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis. ", "original_text": "During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b695fab8c1bb5de0360560a770f2ec004482727bba7be137a624e541a5b6009", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3faf8d91-87fc-4392-a026-d5194fce73b8", "node_type": "1", "metadata": {"window": "As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024. ", "original_text": "Now, let me discuss our updated outlook. "}, "hash": "2732eb512263ff8d13053cd267bd29e7dc94d942ed45117862bbbd71e24a5945", "class_name": "RelatedNodeInfo"}}, "text": "Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n", "start_char_idx": 1712, "end_char_idx": 1870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3faf8d91-87fc-4392-a026-d5194fce73b8": {"__data__": {"id_": "3faf8d91-87fc-4392-a026-d5194fce73b8", "embedding": null, "metadata": {"window": "As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024. ", "original_text": "Now, let me discuss our updated outlook. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "367c8837-7271-4af7-9f97-c8c1ecc54607", "node_type": "1", "metadata": {"window": "Our cash balance and free cash flow in the second quarter included \npayments totaling $529 million associated with settlement agreements for opioid -related claims.  As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis. ", "original_text": "Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "277a2bfe1156f0f9a1c3594ddf52a81b8d325378f36f37210f857c3521c7a275", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca6e771a-b583-4a19-a161-0ce7aa649008", "node_type": "1", "metadata": {"window": "During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n", "original_text": "As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis. "}, "hash": "b6ebbcd3b3fb4c8f981615ba1ec3f663030f3da189e3e081996bbc337d5fc689", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me discuss our updated outlook. ", "start_char_idx": 1870, "end_char_idx": 1911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca6e771a-b583-4a19-a161-0ce7aa649008": {"__data__": {"id_": "ca6e771a-b583-4a19-a161-0ce7aa649008", "embedding": null, "metadata": {"window": "During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n", "original_text": "As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3faf8d91-87fc-4392-a026-d5194fce73b8", "node_type": "1", "metadata": {"window": "As a reminder, \nour cash position, working capital metrics, and resulting cash flows can  each be impacted by time, which includes \nthe day of the week that the quarter ends on and, therefore, can vary from quarter to quarter.  \n \n During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024. ", "original_text": "Now, let me discuss our updated outlook. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27009cafad37559aec66a952889aedabc378bb8eded74d313e3bf850f7d3e0b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc51ee90-dcd9-4be8-be3d-e4d328d7e04b", "node_type": "1", "metadata": {"window": "Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments. ", "original_text": "The following metrics are provided on an adjusted non -GAAP basis. "}, "hash": "d94559692395a6e7b3e006f650bdecb33b255ed350c387a45461e276af7a1202", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis. ", "start_char_idx": 1911, "end_char_idx": 1988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc51ee90-dcd9-4be8-be3d-e4d328d7e04b": {"__data__": {"id_": "cc51ee90-dcd9-4be8-be3d-e4d328d7e04b", "embedding": null, "metadata": {"window": "Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments. ", "original_text": "The following metrics are provided on an adjusted non -GAAP basis. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca6e771a-b583-4a19-a161-0ce7aa649008", "node_type": "1", "metadata": {"window": "During the first six months of the fiscal year, we made $264 million of capital expenditures, which included \ninvestmen ts in new and existing distribution centers as well as investments in technology, data and analytics to \nsupport our growth priorities.  Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n", "original_text": "As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1a16d775d79d9931f92bca719bc53798741ce77d0e898e915239244bd1b540a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33d2dca6-d3cc-4cb6-ba69-345a46005396", "node_type": "1", "metadata": {"window": "Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year. ", "original_text": "The guidance I'm providing today \nrelates t o fiscal 2024. "}, "hash": "3b361bc8af1f8a01419e347b635a1afc49dca228ed43b5943f7b3857ff36eb22", "class_name": "RelatedNodeInfo"}}, "text": "The following metrics are provided on an adjusted non -GAAP basis. ", "start_char_idx": 1988, "end_char_idx": 2055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33d2dca6-d3cc-4cb6-ba69-345a46005396": {"__data__": {"id_": "33d2dca6-d3cc-4cb6-ba69-345a46005396", "embedding": null, "metadata": {"window": "Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year. ", "original_text": "The guidance I'm providing today \nrelates t o fiscal 2024. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc51ee90-dcd9-4be8-be3d-e4d328d7e04b", "node_type": "1", "metadata": {"window": "Year to date, we returned $1.7 billion of cash to shareholders, which included $1.5 \nbillion of share repurchases and $149  million in dividend payments.  \n \n Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments. ", "original_text": "The following metrics are provided on an adjusted non -GAAP basis. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e4fdf3fe9a8fb8acf6d63a0e05a89ef3cc5dec0e7046e2bdc15350e0b4f86a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cade10ac-0cfc-42c6-b4c0-e94e66024366", "node_type": "1", "metadata": {"window": "As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%. ", "original_text": "And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n"}, "hash": "34285b8b21acca9b8a3ca78a044a8d64b66a06b379acc18cb813e9d851e8146e", "class_name": "RelatedNodeInfo"}}, "text": "The guidance I'm providing today \nrelates t o fiscal 2024. ", "start_char_idx": 2055, "end_char_idx": 2114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cade10ac-0cfc-42c6-b4c0-e94e66024366": {"__data__": {"id_": "cade10ac-0cfc-42c6-b4c0-e94e66024366", "embedding": null, "metadata": {"window": "As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%. ", "original_text": "And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33d2dca6-d3cc-4cb6-ba69-345a46005396", "node_type": "1", "metadata": {"window": "Now, let me discuss our updated outlook.  As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year. ", "original_text": "The guidance I'm providing today \nrelates t o fiscal 2024. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "409c4b5d0ca68959b98655ca164469f2d2224402620ba91212926c51a2b7d6e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb1e8c15-8c8d-405e-9719-f1345f19bfd7", "node_type": "1", "metadata": {"window": "The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n", "original_text": "Let me start with the outlook for our segments. "}, "hash": "40a1fc5eb4de95c6e2ed5724d13a62c16c99be40c1cd32aff604f57444491865", "class_name": "RelatedNodeInfo"}}, "text": "And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n", "start_char_idx": 2114, "end_char_idx": 2231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb1e8c15-8c8d-405e-9719-f1345f19bfd7": {"__data__": {"id_": "cb1e8c15-8c8d-405e-9719-f1345f19bfd7", "embedding": null, "metadata": {"window": "The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n", "original_text": "Let me start with the outlook for our segments. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cade10ac-0cfc-42c6-b4c0-e94e66024366", "node_type": "1", "metadata": {"window": "As a reminder, we do not provide forward -looking guidance on a GAAP \nbasis.  The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%. ", "original_text": "And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9896566bf851de0d0e632a73e5edae3673199c460ed2d9bc6150edad89364a00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebe62b77-1dbb-49ee-8359-f02a11f91a2b", "node_type": "1", "metadata": {"window": "The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter. ", "original_text": "For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year. "}, "hash": "cbc5da9534152a6fea1702e7f2a29387cbb8151d2a2cb9d7d59edc053d6d52a8", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with the outlook for our segments. ", "start_char_idx": 2231, "end_char_idx": 2279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebe62b77-1dbb-49ee-8359-f02a11f91a2b": {"__data__": {"id_": "ebe62b77-1dbb-49ee-8359-f02a11f91a2b", "embedding": null, "metadata": {"window": "The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter. ", "original_text": "For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb1e8c15-8c8d-405e-9719-f1345f19bfd7", "node_type": "1", "metadata": {"window": "The following metrics are provided on an adjusted non -GAAP basis.  The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n", "original_text": "Let me start with the outlook for our segments. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd9aa4e61652bfb23cf2e023c1aab7ee49fab0f0750c82ed3e16ed8b27e413be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74ba9c67-177c-4e16-a2ec-9176acc7a670", "node_type": "1", "metadata": {"window": "And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023. ", "original_text": "Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%. "}, "hash": "efe6686cf58b6cc605a5938e6201198f7f7452385857ee0487e81b864daf38e6", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year. ", "start_char_idx": 2279, "end_char_idx": 2425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74ba9c67-177c-4e16-a2ec-9176acc7a670": {"__data__": {"id_": "74ba9c67-177c-4e16-a2ec-9176acc7a670", "embedding": null, "metadata": {"window": "And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023. ", "original_text": "Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebe62b77-1dbb-49ee-8359-f02a11f91a2b", "node_type": "1", "metadata": {"window": "The guidance I'm providing today \nrelates t o fiscal 2024.  And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter. ", "original_text": "For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c3b94373d1762d5f2caeb80c942ac4d9de3b7f6bf161d2d9099f4be14accb27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74a4e738-fd84-4207-9c37-d6362c69e3a7", "node_type": "1", "metadata": {"window": "Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical. ", "original_text": "This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n"}, "hash": "a4b3567f1ae602c8e769d3c425c3acf1ee56f509be0be772a773c9dcb6d8c4bd", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%. ", "start_char_idx": 2425, "end_char_idx": 2552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74a4e738-fd84-4207-9c37-d6362c69e3a7": {"__data__": {"id_": "74a4e738-fd84-4207-9c37-d6362c69e3a7", "embedding": null, "metadata": {"window": "Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical. ", "original_text": "This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74ba9c67-177c-4e16-a2ec-9176acc7a670", "node_type": "1", "metadata": {"window": "And a full list of our assumptions can be found on slides 13 through 17 in our supplemental \nslide presentation.  \n \n Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023. ", "original_text": "Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2565ef685835824deae383992102e8d8e6ce5992b19f2b8c4624d74d37ff7cc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff610da7-3d46-4044-95f3-ff6bd6d234a0", "node_type": "1", "metadata": {"window": "For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n", "original_text": "Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter. "}, "hash": "6456b4f63c2e9f08cc437b862d041c7857c407aa361ca00022706eaf07a0aab9", "class_name": "RelatedNodeInfo"}}, "text": "This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n", "start_char_idx": 2552, "end_char_idx": 2786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff610da7-3d46-4044-95f3-ff6bd6d234a0": {"__data__": {"id_": "ff610da7-3d46-4044-95f3-ff6bd6d234a0", "embedding": null, "metadata": {"window": "For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n", "original_text": "Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74a4e738-fd84-4207-9c37-d6362c69e3a7", "node_type": "1", "metadata": {"window": "Let me start with the outlook for our segments.  For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical. ", "original_text": "This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbfdd0a166ebde79f56501cdb09ae9d551222e44e97aaf84efae1b30e5b61791", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77830810-92d0-4d00-a14c-299bdc7ed1d8", "node_type": "1", "metadata": {"window": "Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%. ", "original_text": "We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023. "}, "hash": "47a8d28ede828075afe15554658eea99e2e74651d2f94e7d3a7b8cad8b81e8c0", "class_name": "RelatedNodeInfo"}}, "text": "Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter. ", "start_char_idx": 2786, "end_char_idx": 2943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77830810-92d0-4d00-a14c-299bdc7ed1d8": {"__data__": {"id_": "77830810-92d0-4d00-a14c-299bdc7ed1d8", "embedding": null, "metadata": {"window": "Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%. ", "original_text": "We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff610da7-3d46-4044-95f3-ff6bd6d234a0", "node_type": "1", "metadata": {"window": "For the full year, we now anticipate US Pharmaceutical revenues \nto increase 13% to 15% and operating profit to increase 6% to 8% year over year.  Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n", "original_text": "Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aecf15a3d9b0a50dab8c74039b9001e5af65be0250ace9b7935e9317ec784101", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a2d49e9-f361-4002-b72f-cb3336077e19", "node_type": "1", "metadata": {"window": "This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n", "original_text": "We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical. "}, "hash": "a28540c3c159223b94343e50b4a2384371482badb101bcf800ac84f16ff7186f", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023. ", "start_char_idx": 2943, "end_char_idx": 3191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a2d49e9-f361-4002-b72f-cb3336077e19": {"__data__": {"id_": "5a2d49e9-f361-4002-b72f-cb3336077e19", "embedding": null, "metadata": {"window": "This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n", "original_text": "We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77830810-92d0-4d00-a14c-299bdc7ed1d8", "node_type": "1", "metadata": {"window": "Excluding the impact of \nCOVID -19 vaccine distribution in fiscal 2023, we anticipate operating profit to increase 11% to 14%.  This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%. ", "original_text": "We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2796c53512acd371a93f6cc4768d0216c8db56e4beb1fdc551a0edd1541ec60c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e069f5a7-a9f0-4ef4-b5cf-ca5d46161725", "node_type": "1", "metadata": {"window": "Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "original_text": "However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n"}, "hash": "78bf0fd4d15a44700a427330fd962b9d1bc5cc2c6de0e98c1b53b03edf07170d", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical. ", "start_char_idx": 3191, "end_char_idx": 3287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e069f5a7-a9f0-4ef4-b5cf-ca5d46161725": {"__data__": {"id_": "e069f5a7-a9f0-4ef4-b5cf-ca5d46161725", "embedding": null, "metadata": {"window": "Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "original_text": "However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a2d49e9-f361-4002-b72f-cb3336077e19", "node_type": "1", "metadata": {"window": "This updated \nsegment outlook incorporates the strong second quarte r performance as well as further growth in our generic \nsourcing programs and specialty distribution, including our differentiated Plasma and Biologics business.  \n \n Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n", "original_text": "We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a586794f09eec009731855b7ea34b8cd457b5b8f02c7c2c78a0319fea465293", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60d30000-6677-4407-910b-fbe3173886ec", "node_type": "1", "metadata": {"window": "We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%. "}, "hash": "4ccbbe4e7f96917f4de84b1b71cec368bbbb9ef5c9af4bab95d26f28bf1bd230", "class_name": "RelatedNodeInfo"}}, "text": "However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n", "start_char_idx": 3287, "end_char_idx": 3431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60d30000-6677-4407-910b-fbe3173886ec": {"__data__": {"id_": "60d30000-6677-4407-910b-fbe3173886ec", "embedding": null, "metadata": {"window": "We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e069f5a7-a9f0-4ef4-b5cf-ca5d46161725", "node_type": "1", "metadata": {"window": "Our full -year outlook assumes that volumes related to GLP -1 medications will remain elevated c ompared to the \nprior year and may vary quarter to quarter.  We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "original_text": "However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b8268c10b560b0d13fea1902bcc3bac16697c940ed6ae7eab5580b3e4eec613", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ddcf847-cdcf-4aee-a502-3d780023ae61", "node_type": "1", "metadata": {"window": "We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "original_text": "We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n"}, "hash": "dfcc2ee252ab1a82021250f1ee9e78893053216b99fa2e0f18b96e12ea14ddd6", "class_name": "RelatedNodeInfo"}}, "text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%. ", "start_char_idx": 3431, "end_char_idx": 3524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ddcf847-cdcf-4aee-a502-3d780023ae61": {"__data__": {"id_": "4ddcf847-cdcf-4aee-a502-3d780023ae61", "embedding": null, "metadata": {"window": "We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "original_text": "We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60d30000-6677-4407-910b-fbe3173886ec", "node_type": "1", "metadata": {"window": "We anticipate the consolidated GLP -1 medication revenue and \noperating profit growth compared to prior year will slow in our fiscal fourth quarter, reflecting the inflection in \nvolumes for these med ications in the fourth quarter of fiscal 2023.  We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%. ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb1e29fc7c3a8df912770efcbf496ff651eafb4288b181e3cded49e38d871402", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68d48f0c-fa74-49fa-9a07-ee7905290629", "node_type": "1", "metadata": {"window": "However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "original_text": "We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n "}, "hash": "8b9bab413c5163e0af7f234a681506d6496b99a42fb0b28792836cc5ed313136", "class_name": "RelatedNodeInfo"}}, "text": "We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n", "start_char_idx": 3524, "end_char_idx": 3686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68d48f0c-fa74-49fa-9a07-ee7905290629": {"__data__": {"id_": "68d48f0c-fa74-49fa-9a07-ee7905290629", "embedding": null, "metadata": {"window": "However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "original_text": "We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40832261-ef49-453b-9285-febb5c4ed003", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8e726f6d7f02c8026b959ccc62d0da70cd678cbcd79aba5801f824fe04e850", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ddcf847-cdcf-4aee-a502-3d780023ae61", "node_type": "1", "metadata": {"window": "We anticipate GLP -1 medications will continue \nto be a revenue tailwind for US Pharmaceutical.  However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "original_text": "We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1caffeb87ca129e2945b79310d640ae4f9dc7fb6f5ddc6caba21e5dce1026898", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8a58821-b376-4a79-adff-d52f64c45987", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023. ", "original_text": "McKesson Corp.  "}, "hash": "b472a4b9d3cd833316a16ca6f806ed24cb26989e0c6e9f6e722f551508cbf2f9", "class_name": "RelatedNodeInfo"}}, "text": "We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "start_char_idx": 3686, "end_char_idx": 4067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8a58821-b376-4a79-adff-d52f64c45987": {"__data__": {"id_": "d8a58821-b376-4a79-adff-d52f64c45987", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68d48f0c-fa74-49fa-9a07-ee7905290629", "node_type": "1", "metadata": {"window": "However, distribution of these medications has a lower \ndistribution margin rate profile and represents a headwind t o prior -year results.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 7% to 13%.  We have \nincreased our operating profit growth outlook to 18% to 22%, reflecting strong momentum in our access solutions \nand strong first hal f performance.  \n \n We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "original_text": "We may continue to see quarter -to-quarter variability in this segment, driven by prescription and transaction \nvolumes, the timing, pace and trajectory of new product drug launches, the timing and size of investments to \nsupport and expand ou r product portfolio, and the annual verification programs that we provide for our customers \nthat occur in our fiscal fourth quarter.  \n ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c87ef8209196ee94ee3251cba9d8bdfd6ac683d8dfdfd6596bbce633aa7488c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3355088-b9b1-4625-b46f-22b018242a38", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities. "}, "hash": "c494b0fb2c69d0319cf07bcc3e539c675ed1035a5874a16ce60b5e3b31bbeac2", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3355088-b9b1-4625-b46f-22b018242a38": {"__data__": {"id_": "b3355088-b9b1-4625-b46f-22b018242a38", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8a58821-b376-4a79-adff-d52f64c45987", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "770fca2d2055e855bcf69f14b75851c39ef7a5819c698d9c8174ace5196fd736", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf58b6fd-cb8f-4542-ab1f-92d62408bb35", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n", "original_text": "In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n"}, "hash": "95ef0df6abdfffa1c0d4175de0857fe1d38cfaed82a78698a939165bbbcda3d6", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities. ", "start_char_idx": 16, "end_char_idx": 342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf58b6fd-cb8f-4542-ab1f-92d62408bb35": {"__data__": {"id_": "bf58b6fd-cb8f-4542-ab1f-92d62408bb35", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n", "original_text": "In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3355088-b9b1-4625-b46f-22b018242a38", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ff9534ff545f1e1a8334dd8aab6c91d96c7ff20949f1c71dabd5626fa22519f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71e90ea6-8b33-4d22-97a3-4187875f6dca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier. ", "original_text": "For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023. "}, "hash": "1320a21a0f25942b24cdd054f37d01c32796b695406602593b5e568aa5cba6aa", "class_name": "RelatedNodeInfo"}}, "text": "In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n", "start_char_idx": 342, "end_char_idx": 505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71e90ea6-8b33-4d22-97a3-4187875f6dca": {"__data__": {"id_": "71e90ea6-8b33-4d22-97a3-4187875f6dca", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier. ", "original_text": "For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf58b6fd-cb8f-4542-ab1f-92d62408bb35", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n", "original_text": "In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa9da9f879f4948bb259fd053e4722b6bfe0c2b20ce8b7f12cc3da9a3351185f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "078c991d-8e3c-4333-aa27-ccff3bc58d22", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024. ", "original_text": "And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results. "}, "hash": "c85abe0993f4ccd653e2cd7eb7fe8b725d67785bcae8e56d93f21951d40cad2d", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023. ", "start_char_idx": 505, "end_char_idx": 613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "078c991d-8e3c-4333-aa27-ccff3bc58d22": {"__data__": {"id_": "078c991d-8e3c-4333-aa27-ccff3bc58d22", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024. ", "original_text": "And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71e90ea6-8b33-4d22-97a3-4187875f6dca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier. ", "original_text": "For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cde381768d230969d37cb8c7a5dedf59571086c853313fefa6bf8c154d34d36e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18171c3e-763a-403e-8bed-5c5a13030af4", "node_type": "1", "metadata": {"window": "In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n", "original_text": "Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n"}, "hash": "f51573851917937bc9b382957f810722ac4796b3f49af0a7cb4b61068ca4ec1d", "class_name": "RelatedNodeInfo"}}, "text": "And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results. ", "start_char_idx": 613, "end_char_idx": 705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18171c3e-763a-403e-8bed-5c5a13030af4": {"__data__": {"id_": "18171c3e-763a-403e-8bed-5c5a13030af4", "embedding": null, "metadata": {"window": "In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n", "original_text": "Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "078c991d-8e3c-4333-aa27-ccff3bc58d22", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024. ", "original_text": "And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "630b5bc927eabcb99ff1e59768aec8275a46295220fdf67a25292153a2cf8b9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8013649d-d6b7-4416-b0b7-921a95a72c78", "node_type": "1", "metadata": {"window": "For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base. ", "original_text": "Our outlook incorporates the second quarter results, which I discussed earlier. "}, "hash": "25e000957ea43f8dc547eac5930c4135336c1b5997884f53e630ce8cbe12d343", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n", "start_char_idx": 705, "end_char_idx": 853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8013649d-d6b7-4416-b0b7-921a95a72c78": {"__data__": {"id_": "8013649d-d6b7-4416-b0b7-921a95a72c78", "embedding": null, "metadata": {"window": "For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base. ", "original_text": "Our outlook incorporates the second quarter results, which I discussed earlier. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18171c3e-763a-403e-8bed-5c5a13030af4", "node_type": "1", "metadata": {"window": "In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n", "original_text": "Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902b299b47a774707668e80f25dc020f929e020dca9acd250a5e6d22a4b19f89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01d4f833-a017-43a2-ba58-a80bae53d6e5", "node_type": "1", "metadata": {"window": "And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices. ", "original_text": "We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024. "}, "hash": "deb7f62637a0f859f7f1f6ba03821b9db41a373021bb2515a2c590122a69c9b3", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook incorporates the second quarter results, which I discussed earlier. ", "start_char_idx": 853, "end_char_idx": 933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01d4f833-a017-43a2-ba58-a80bae53d6e5": {"__data__": {"id_": "01d4f833-a017-43a2-ba58-a80bae53d6e5", "embedding": null, "metadata": {"window": "And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices. ", "original_text": "We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8013649d-d6b7-4416-b0b7-921a95a72c78", "node_type": "1", "metadata": {"window": "For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023.  And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base. ", "original_text": "Our outlook incorporates the second quarter results, which I discussed earlier. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "495f1db0103883f5d93ceeb005672f6eabfec4ebdfde36f452a8c4814100234c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b50109fc-3ecf-4cc0-b360-d3dc524a6923", "node_type": "1", "metadata": {"window": "Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n", "original_text": "Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n"}, "hash": "fea64496597240a265387794dfc18790cf16a09b6255b3ff043068281f51f8b7", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024. ", "start_char_idx": 933, "end_char_idx": 1103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b50109fc-3ecf-4cc0-b360-d3dc524a6923": {"__data__": {"id_": "b50109fc-3ecf-4cc0-b360-d3dc524a6923", "embedding": null, "metadata": {"window": "Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n", "original_text": "Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01d4f833-a017-43a2-ba58-a80bae53d6e5", "node_type": "1", "metadata": {"window": "And the \nimpact from COVID -19-related items will remain immaterial to fiscal 2024 results.  Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices. ", "original_text": "We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9071ea9b38d2d6767a55fd10c24c726cfe1c91b981657028bfa48a24179692d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e63f3de-af33-48dc-a0a1-37e38698e2da", "node_type": "1", "metadata": {"window": "Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%. ", "original_text": "Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base. "}, "hash": "03b28086d939e70e8aa83995e47e1f6ac9a2744358d58f07f6c41c80eaa6bf67", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n", "start_char_idx": 1103, "end_char_idx": 1233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e63f3de-af33-48dc-a0a1-37e38698e2da": {"__data__": {"id_": "5e63f3de-af33-48dc-a0a1-37e38698e2da", "embedding": null, "metadata": {"window": "Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%. ", "original_text": "Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b50109fc-3ecf-4cc0-b360-d3dc524a6923", "node_type": "1", "metadata": {"window": "Excluding the impact of COVID -\n19-related items from fiscal 2023 results, we anticipate operating profit to increase 5% to  7% year over year.  \n \n Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n", "original_text": "Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f35d6ebb560557e932ffac10279351ffdc10a503e68870e5d93a0d7abf01fc54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae365e17-0063-4cec-b588-f6a4306c5921", "node_type": "1", "metadata": {"window": "We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023. ", "original_text": "These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices. "}, "hash": "1da7407313975d987e99aca1a23c45af94950b61cd40ace1d342e600dac6c68e", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base. ", "start_char_idx": 1233, "end_char_idx": 1420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae365e17-0063-4cec-b588-f6a4306c5921": {"__data__": {"id_": "ae365e17-0063-4cec-b588-f6a4306c5921", "embedding": null, "metadata": {"window": "We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023. ", "original_text": "These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e63f3de-af33-48dc-a0a1-37e38698e2da", "node_type": "1", "metadata": {"window": "Our outlook incorporates the second quarter results, which I discussed earlier.  We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%. ", "original_text": "Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b86664beea43bb1358d67cea5904b50df06427242d9af504f8efe77ce7c69137", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e138e13-d591-4559-af3c-f74f0945ba8f", "node_type": "1", "metadata": {"window": "Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n", "original_text": "We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n"}, "hash": "22de30689df82e98f054ec7c48d48bf7bcea143e7bb8d042c8806a5583e8653e", "class_name": "RelatedNodeInfo"}}, "text": "These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices. ", "start_char_idx": 1420, "end_char_idx": 1597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e138e13-d591-4559-af3c-f74f0945ba8f": {"__data__": {"id_": "6e138e13-d591-4559-af3c-f74f0945ba8f", "embedding": null, "metadata": {"window": "Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n", "original_text": "We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae365e17-0063-4cec-b588-f6a4306c5921", "node_type": "1", "metadata": {"window": "We anticipate the general market \nmoderations in primary care foot traffic, in part driven by a modest illness season, may persist through the \nremainder of fiscal 2024.  Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023. ", "original_text": "These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "149a767e57c393760024e6f69d9bb58589fcc1cbdf24f9a0654ad6ffd52c2616", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "650448db-0406-43b2-88e7-348db0833488", "node_type": "1", "metadata": {"window": "Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%. ", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%. "}, "hash": "937c73466b76b83f1f7cfe4b27df514da2116d84e415b5a7ec7234b0ce4013e8", "class_name": "RelatedNodeInfo"}}, "text": "We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n", "start_char_idx": 1597, "end_char_idx": 1772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "650448db-0406-43b2-88e7-348db0833488": {"__data__": {"id_": "650448db-0406-43b2-88e7-348db0833488", "embedding": null, "metadata": {"window": "Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%. ", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e138e13-d591-4559-af3c-f74f0945ba8f", "node_type": "1", "metadata": {"window": "Additionally, first half fiscal 2023 results benefited from an extended illness season, \nwhich did not repeat in fiscal 2024.  \n \n Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n", "original_text": "We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2da2abf205d63ddc11bc9449eb726fff21b5fd3715fe2d407b122729df5e443", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78713d44-e577-4941-bacc-9cbbf6aed611", "node_type": "1", "metadata": {"window": "These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance. ", "original_text": "This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023. "}, "hash": "e8f250fe62320b0b13eb80d697dc43b63de737e15dc5628c11ecc237622d09e4", "class_name": "RelatedNodeInfo"}}, "text": "Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%. ", "start_char_idx": 1772, "end_char_idx": 1908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78713d44-e577-4941-bacc-9cbbf6aed611": {"__data__": {"id_": "78713d44-e577-4941-bacc-9cbbf6aed611", "embedding": null, "metadata": {"window": "These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance. ", "original_text": "This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "650448db-0406-43b2-88e7-348db0833488", "node_type": "1", "metadata": {"window": "Our outlook includes continued investments in our scaled distribution network, adding state -of-the-art automation \nand regulatory capabilities to serve the breadth of our customer base.  These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%. ", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4cb8d10ca1ef123143982876291e213d9bd5b6e752d9823f39a1090df16fd47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "217258a4-679a-4bbd-9ab5-c55b7228a0e1", "node_type": "1", "metadata": {"window": "We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter. ", "original_text": "In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n"}, "hash": "0dcdcb35b2aef4516d916be24e65c170b6bf0599d4a961b4aa78a7a4b2c4e9ec", "class_name": "RelatedNodeInfo"}}, "text": "This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023. ", "start_char_idx": 1908, "end_char_idx": 2065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "217258a4-679a-4bbd-9ab5-c55b7228a0e1": {"__data__": {"id_": "217258a4-679a-4bbd-9ab5-c55b7228a0e1", "embedding": null, "metadata": {"window": "We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter. ", "original_text": "In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78713d44-e577-4941-bacc-9cbbf6aed611", "node_type": "1", "metadata": {"window": "These distribution network investments \nsupport the breadth of our non -acute customers and broader cold chain distribution, for example, COVID vaccines \nfor physician offices.  We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance. ", "original_text": "This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "787b1f7e61dfb13b116e2bcffe0330d9c59984bbde8914e0fa0296986a844657", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0166089b-7a14-4800-8526-5a811dee11f4", "node_type": "1", "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n", "original_text": "Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%. "}, "hash": "873b88a67df2ce3704ad1a886e732c39621e8644b2b50560ff88329c4a2b022f", "class_name": "RelatedNodeInfo"}}, "text": "In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n", "start_char_idx": 2065, "end_char_idx": 2362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0166089b-7a14-4800-8526-5a811dee11f4": {"__data__": {"id_": "0166089b-7a14-4800-8526-5a811dee11f4", "embedding": null, "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n", "original_text": "Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "217258a4-679a-4bbd-9ab5-c55b7228a0e1", "node_type": "1", "metadata": {"window": "We also antici pate further investments in data and analytics to expand the channel reach for \nour medical supplies, pharmaceuticals, and private brand product portfolio.  \n \n Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter. ", "original_text": "In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a14397c373b740bb922487731a99b28f069e6b7944b62a2a575b356e228f8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80c556d3-695a-475e-a4f1-4711e41ae663", "node_type": "1", "metadata": {"window": "This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n", "original_text": "The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance. "}, "hash": "aabf4ccb9bbe513b7fbd0c88f6bd40cc347a1bcb2c25850c0dd0fbea2be1d98b", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%. ", "start_char_idx": 2362, "end_char_idx": 2466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80c556d3-695a-475e-a4f1-4711e41ae663": {"__data__": {"id_": "80c556d3-695a-475e-a4f1-4711e41ae663", "embedding": null, "metadata": {"window": "This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n", "original_text": "The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0166089b-7a14-4800-8526-5a811dee11f4", "node_type": "1", "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 30% to 34% and operating  profit to \ndecline by 23% to 29%.  This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n", "original_text": "Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29298dd96ebbe1bdd71df65deaf40d4521b3cb09ae55fc4b16ae871306f7a57e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bf1ead5-c37e-45e7-a49a-1618d87882f7", "node_type": "1", "metadata": {"window": "In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion. ", "original_text": "However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter. "}, "hash": "3dfba38e772a788e0b8bfa870ea9d28b579e9ad48b583989c8eee9b19f4b9696", "class_name": "RelatedNodeInfo"}}, "text": "The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance. ", "start_char_idx": 2466, "end_char_idx": 2607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bf1ead5-c37e-45e7-a49a-1618d87882f7": {"__data__": {"id_": "7bf1ead5-c37e-45e7-a49a-1618d87882f7", "embedding": null, "metadata": {"window": "In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion. ", "original_text": "However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80c556d3-695a-475e-a4f1-4711e41ae663", "node_type": "1", "metadata": {"window": "This year -over-year decrease includes a loss of operating profit contribution from \nEuropean businesses and transactions that we closed during fiscal 2023.  In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n", "original_text": "The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "483ff460c5e388a6403f0e25a0fb44738f6c71db828f230d9e57dce36a3ce37a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db23293a-9394-4155-93e4-45cf595973ce", "node_type": "1", "metadata": {"window": "Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares. ", "original_text": "As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n"}, "hash": "541815864e1a0efae0f9fe35c91af337795ef9dd99e10855ccd2b17dec0a53f2", "class_name": "RelatedNodeInfo"}}, "text": "However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter. ", "start_char_idx": 2607, "end_char_idx": 2705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db23293a-9394-4155-93e4-45cf595973ce": {"__data__": {"id_": "db23293a-9394-4155-93e4-45cf595973ce", "embedding": null, "metadata": {"window": "Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares. ", "original_text": "As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bf1ead5-c37e-45e7-a49a-1618d87882f7", "node_type": "1", "metadata": {"window": "In the Corporate segment, we anticipate \nexpenses to be in the range  of $600 million to $660 million, which include losses associated with McKesson \nVentures equity investments recorded in the first half of the year and the elevated technology spend to support \nthe growth of our businesses.  \n \n Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion. ", "original_text": "However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e388b31b779b52d8aa6fd9c366e977a22779ba376ecc8387c66490c32fabe037", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3db48716-d93b-4318-b01d-c5b0293e5562", "node_type": "1", "metadata": {"window": "The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n", "original_text": "And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n"}, "hash": "2a986bcdfa324f3e80f78cb912b2298d6424495cfa9bc14da815e7586e7ddad0", "class_name": "RelatedNodeInfo"}}, "text": "As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n", "start_char_idx": 2705, "end_char_idx": 2811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3db48716-d93b-4318-b01d-c5b0293e5562": {"__data__": {"id_": "3db48716-d93b-4318-b01d-c5b0293e5562", "embedding": null, "metadata": {"window": "The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n", "original_text": "And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db23293a-9394-4155-93e4-45cf595973ce", "node_type": "1", "metadata": {"window": "Moving below the line, we anticip ate the full -year effective tax rate to be approximately 18% to 19%.  The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares. ", "original_text": "As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1db02682c0a7271293b8acc293999d453457fe26d32addb10fc901bf607e2585", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb67fbaf-e0b9-4b1b-8d4c-ffe664d00e83", "node_type": "1", "metadata": {"window": "However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40. ", "original_text": "Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion. "}, "hash": "58002e37fb88986dff94c0a40b899419d22c6c4ae03e5514026e3441901e4199", "class_name": "RelatedNodeInfo"}}, "text": "And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n", "start_char_idx": 2811, "end_char_idx": 2999, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb67fbaf-e0b9-4b1b-8d4c-ffe664d00e83": {"__data__": {"id_": "cb67fbaf-e0b9-4b1b-8d4c-ffe664d00e83", "embedding": null, "metadata": {"window": "However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40. ", "original_text": "Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3db48716-d93b-4318-b01d-c5b0293e5562", "node_type": "1", "metadata": {"window": "The timing of \ndiscrete tax items is difficult to predict, and therefore we typically do not provide quarterly effective tax rate \nguidance.  However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n", "original_text": "And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9f80ab2344210fda1030bf1e52b8d557018e4257d77d8c8bbed78fbea69583d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e344ba0-2d13-47c0-8aba-a230472e19a2", "node_type": "1", "metadata": {"window": "As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year. ", "original_text": "Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares. "}, "hash": "9fd0089447404c646e2b999be0b14c8b1346a35a3c2ee65f898e79b8f6793f38", "class_name": "RelatedNodeInfo"}}, "text": "Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion. ", "start_char_idx": 2999, "end_char_idx": 3121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e344ba0-2d13-47c0-8aba-a230472e19a2": {"__data__": {"id_": "5e344ba0-2d13-47c0-8aba-a230472e19a2", "embedding": null, "metadata": {"window": "As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year. ", "original_text": "Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb67fbaf-e0b9-4b1b-8d4c-ffe664d00e83", "node_type": "1", "metadata": {"window": "However, our outlook includes recognition of a d iscrete tax benefit in our fiscal third quarter.  As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40. ", "original_text": "Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f33ba8bd8c6208f491c475e0fcec6b16e96573284a77b8971442bf2037e009fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b7ef5cf-869d-4d0b-aa97-c9976739c9e8", "node_type": "1", "metadata": {"window": "And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n", "original_text": "As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n"}, "hash": "e5c264fd9ec2a72a31b81f80a65d1b73c3d0ecfd874c77b87dcf75111c7ed047", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares. ", "start_char_idx": 3121, "end_char_idx": 3205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b7ef5cf-869d-4d0b-aa97-c9976739c9e8": {"__data__": {"id_": "6b7ef5cf-869d-4d0b-aa97-c9976739c9e8", "embedding": null, "metadata": {"window": "And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n", "original_text": "As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e344ba0-2d13-47c0-8aba-a230472e19a2", "node_type": "1", "metadata": {"window": "As a result, \nwe anticipate the third quarter tax rate to be lower as compared to the fourth quarter.  \n \n And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year. ", "original_text": "Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4566340fd2abbebd2a379d3c1bed9dd50d6b0c91487f8a27e5c5280e5cbb8d74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d087842-f64e-47f8-895c-6e16be6c9892", "node_type": "1", "metadata": {"window": "Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "original_text": "In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40. "}, "hash": "32cd1d5c5e28d9f42b06d3c91b88cd05b43dd2cd505a3224a14d5e037bfba1e9", "class_name": "RelatedNodeInfo"}}, "text": "As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n", "start_char_idx": 3205, "end_char_idx": 3362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d087842-f64e-47f8-895c-6e16be6c9892": {"__data__": {"id_": "6d087842-f64e-47f8-895c-6e16be6c9892", "embedding": null, "metadata": {"window": "Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "original_text": "In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b7ef5cf-869d-4d0b-aa97-c9976739c9e8", "node_type": "1", "metadata": {"window": "And finally, we now anticipate income attributable to non -controlling interests to be in the range of $15 5 million to \n$175 million, reflecting ClarusONE's generic sourcing success.  \n \n Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n", "original_text": "As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "acd1580c3bd81beb66afe3aa613daaa24c7670541156a3efd471f665a5a7ce01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b78858b2-1ce1-4ee3-9c61-f6bbc54e5e8a", "node_type": "1", "metadata": {"window": "Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "original_text": "We anticipate operating profit will be flat to 4% decline compared  to the \nprior year. "}, "hash": "856e91a531ad3d608ee7558267d2e8262b559c5f319a49f318cace1e19d8d23e", "class_name": "RelatedNodeInfo"}}, "text": "In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40. ", "start_char_idx": 3362, "end_char_idx": 3634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b78858b2-1ce1-4ee3-9c61-f6bbc54e5e8a": {"__data__": {"id_": "b78858b2-1ce1-4ee3-9c61-f6bbc54e5e8a", "embedding": null, "metadata": {"window": "Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "original_text": "We anticipate operating profit will be flat to 4% decline compared  to the \nprior year. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d087842-f64e-47f8-895c-6e16be6c9892", "node_type": "1", "metadata": {"window": "Turning to cash flow and capital deployment, we anticipate free cash flow of approximately $3.7 billion to $4.1 \nbillion.  Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "original_text": "In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb1e5841d5ee10bec2a5969655a2b1e9f01174d945d9ec621a9d44b6524f43d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0759844b-05bc-451e-87eb-dbd9880a33a8", "node_type": "1", "metadata": {"window": "As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "original_text": "When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n"}, "hash": "361e8737778ea9a8e489462a45858328b717ecc567a09a5f63a1457adf8936d7", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate operating profit will be flat to 4% decline compared  to the \nprior year. ", "start_char_idx": 3634, "end_char_idx": 3722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0759844b-05bc-451e-87eb-dbd9880a33a8": {"__data__": {"id_": "0759844b-05bc-451e-87eb-dbd9880a33a8", "embedding": null, "metadata": {"window": "As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "original_text": "When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b78858b2-1ce1-4ee3-9c61-f6bbc54e5e8a", "node_type": "1", "metadata": {"window": "Our outlook incorporates plans to repurchase approximately  $3.5 billion of shares.  As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "original_text": "We anticipate operating profit will be flat to 4% decline compared  to the \nprior year. ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b66fb76238184c1cd6666af20ff3d15db4043689a28eed24ac5264a8dccd8c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f12b87e9-9376-4719-ad72-3a7acea2886c", "node_type": "1", "metadata": {"window": "In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "original_text": "As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US "}, "hash": "1059e5f99efad5504799c45f1c3714c02a459936db9ff87bb816fe14133d26e0", "class_name": "RelatedNodeInfo"}}, "text": "When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n", "start_char_idx": 3722, "end_char_idx": 3829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f12b87e9-9376-4719-ad72-3a7acea2886c": {"__data__": {"id_": "f12b87e9-9376-4719-ad72-3a7acea2886c", "embedding": null, "metadata": {"window": "In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "original_text": "As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bec930383cf1104021c4ebdccf8ef20f9d8d419c63110223b8928b3fc7d1ff0e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0759844b-05bc-451e-87eb-dbd9880a33a8", "node_type": "1", "metadata": {"window": "As a result of the share \nrepurchase activity, we estimate weighted average diluted shares outstanding to be in the range of approximately \n134 million.  \n \n In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "original_text": "When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9faf8ea6aebc45be7a330684559de39ac0fc32aa8378b1ffe8290e443bf1777", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bb13c14-106b-49a8-b26a-5f3294358d8b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items. ", "original_text": "McKesson Corp.  "}, "hash": "b545f75d258f71e754f17bae876a57b12d34def58acdf15449eefa3eb6ff29fc", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "start_char_idx": 3829, "end_char_idx": 4158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bb13c14-106b-49a8-b26a-5f3294358d8b": {"__data__": {"id_": "7bb13c14-106b-49a8-b26a-5f3294358d8b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f12b87e9-9376-4719-ad72-3a7acea2886c", "node_type": "1", "metadata": {"window": "In summary, as a result of solid performance in the second quarter of fiscal 20 24 combined with our outlook for \nthe remainder of the fiscal year, we are increasing and narrowing our earnings per diluted share outlook for fiscal \n2024 to a new range of $26.80 to $27.40.  We anticipate operating profit will be flat to 4% decline compared  to the \nprior year.  When excluding certain items, we anticipate operating profit to increase by 6% to 10% year -over-year.  \n \n As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "original_text": "As a reminder, certain items include the following: net gains and losses associated with McKesson Ventures \nequity investments in fisc al 2023 and 2024; a $0.65 benefit related to the early termination of the tax receivable \nagreement with Change Healthcare in fiscal 2023; and $1.90 related to COVID -19-related items in our US ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a52889ef5b9effcf52e48e192174a342cf54cbcc24acd4ce03af8f00633079a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e828a7a-4359-4272-a0de-2c4526224613", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023. "}, "hash": "5bdb3483e130ffbd83bcd03841fa24d953979838f63c116f88d561f0948d2701", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e828a7a-4359-4272-a0de-2c4526224613": {"__data__": {"id_": "3e828a7a-4359-4272-a0de-2c4526224613", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bb13c14-106b-49a8-b26a-5f3294358d8b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "efe62b79138e6cbfe6678814a0e461a3fd29ea4f886698dc4d750ab7a77564b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f449e9d5-2680-48eb-9a22-7545f20c23ab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n", "original_text": "We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n"}, "hash": "616b199dfc855744b99d3a38fdb4080cf0edeb7fd691379c5ca2bc8746f5227c", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023. ", "start_char_idx": 16, "end_char_idx": 243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f449e9d5-2680-48eb-9a22-7545f20c23ab": {"__data__": {"id_": "f449e9d5-2680-48eb-9a22-7545f20c23ab", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n", "original_text": "We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e828a7a-4359-4272-a0de-2c4526224613", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "327d1069044a28fe9b1a235275639c399519d8c0797d5d1d1af55c652d4ed818", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc5f993b-a600-412a-a762-6586a6628130", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance . ", "original_text": "The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items. "}, "hash": "f610e7fc9aa2986e3dceb711d6109235d0b0eb880e70ec8fc30015721eb5588e", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n", "start_char_idx": 243, "end_char_idx": 362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc5f993b-a600-412a-a762-6586a6628130": {"__data__": {"id_": "cc5f993b-a600-412a-a762-6586a6628130", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance . ", "original_text": "The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f449e9d5-2680-48eb-9a22-7545f20c23ab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n", "original_text": "We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "862c0dd7d112aae5cda5b91963a8b19835be6565e323dc795c5187c4244884c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "983ed34e-1e32-4ca6-b5ec-7cb5739ce916", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n", "original_text": "When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n"}, "hash": "54f214fa602dd06b81bd751e33aa8d65c0f01830bcd54ca90b72abded1a06db7", "class_name": "RelatedNodeInfo"}}, "text": "The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items. ", "start_char_idx": 362, "end_char_idx": 539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "983ed34e-1e32-4ca6-b5ec-7cb5739ce916": {"__data__": {"id_": "983ed34e-1e32-4ca6-b5ec-7cb5739ce916", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n", "original_text": "When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc5f993b-a600-412a-a762-6586a6628130", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance . ", "original_text": "The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7bd9a5c9f43be15bff64b958f8ab8385cadb347286603370894792f8f240cea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1a99c45-1286-4e54-bd2d-8a7501edd5d9", "node_type": "1", "metadata": {"window": "We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n ", "original_text": "We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n"}, "hash": "a6153924ef8eba0c0529ddbb07405bef5110221b61272dda7856d71cde32ee8e", "class_name": "RelatedNodeInfo"}}, "text": "When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n", "start_char_idx": 539, "end_char_idx": 708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1a99c45-1286-4e54-bd2d-8a7501edd5d9": {"__data__": {"id_": "d1a99c45-1286-4e54-bd2d-8a7501edd5d9", "embedding": null, "metadata": {"window": "We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n ", "original_text": "We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "983ed34e-1e32-4ca6-b5ec-7cb5739ce916", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n", "original_text": "When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba26a555e022b811798e2e4a4dd282e2f7479ddd81e646ac8fce994ca98a2c8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e1dc4fc-a8be-447c-aba8-bd31ee5d3774", "node_type": "1", "metadata": {"window": "The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "In closing, we are pleased with our strong first half performance . "}, "hash": "ef6e910c16327a184e369c098364f2b2bd51689e7cf3e799f2fc102bee7c295c", "class_name": "RelatedNodeInfo"}}, "text": "We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n", "start_char_idx": 708, "end_char_idx": 966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e1dc4fc-a8be-447c-aba8-bd31ee5d3774": {"__data__": {"id_": "5e1dc4fc-a8be-447c-aba8-bd31ee5d3774", "embedding": null, "metadata": {"window": "The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "In closing, we are pleased with our strong first half performance . ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1a99c45-1286-4e54-bd2d-8a7501edd5d9", "node_type": "1", "metadata": {"window": "We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n ", "original_text": "We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bafcb2d7804c015e64c21a1f82aa1cda57157aad7c02ee9535b51bf0ea13a589", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd8df5ac-876f-408a-b3cf-acda29c036fa", "node_type": "1", "metadata": {"window": "When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch. ", "original_text": "The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n"}, "hash": "514863a9ea97c23b16087867fe2ee7f0c26567f9a427e612a9385a90c24933bf", "class_name": "RelatedNodeInfo"}}, "text": "In closing, we are pleased with our strong first half performance . ", "start_char_idx": 966, "end_char_idx": 1034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd8df5ac-876f-408a-b3cf-acda29c036fa": {"__data__": {"id_": "fd8df5ac-876f-408a-b3cf-acda29c036fa", "embedding": null, "metadata": {"window": "When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch. ", "original_text": "The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e1dc4fc-a8be-447c-aba8-bd31ee5d3774", "node_type": "1", "metadata": {"window": "The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items.  When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "In closing, we are pleased with our strong first half performance . ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5fba0feb7a50c8d0409d493801bba22d67361cf04a765c4890aa566caab72f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5583d1d3-19e4-4c9e-a9cd-67d60a2fd4ec", "node_type": "1", "metadata": {"window": "We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n ", "original_text": "And with that, let's move to the Q&A.  \n "}, "hash": "f894d8cd3cb7bcb236dd2d1e08abde885dbbf709ae406c2cba046af46b6cd246", "class_name": "RelatedNodeInfo"}}, "text": "The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n", "start_char_idx": 1034, "end_char_idx": 1245, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5583d1d3-19e4-4c9e-a9cd-67d60a2fd4ec": {"__data__": {"id_": "5583d1d3-19e4-4c9e-a9cd-67d60a2fd4ec", "embedding": null, "metadata": {"window": "We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n ", "original_text": "And with that, let's move to the Q&A.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd8df5ac-876f-408a-b3cf-acda29c036fa", "node_type": "1", "metadata": {"window": "When further excluding the contribution from the \nrunoff of our European operations, earnings per diluted share growth is indicated at 18% to 20% for the full year.  \n \n We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch. ", "original_text": "The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "629861d6ac1f9af265f8850fd09172ab41a6f1326a3a343b5a7b7ebdecbf9045", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4d68945-6500-4833-9688-76b1a193ed5e", "node_type": "1", "metadata": {"window": "In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "57c50af0f8ff838fbdf7600e9ce38e2586d988bfa8c01174acae95c99e58d43e", "class_name": "RelatedNodeInfo"}}, "text": "And with that, let's move to the Q&A.  \n ", "start_char_idx": 1245, "end_char_idx": 1286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4d68945-6500-4833-9688-76b1a193ed5e": {"__data__": {"id_": "b4d68945-6500-4833-9688-76b1a193ed5e", "embedding": null, "metadata": {"window": "In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5583d1d3-19e4-4c9e-a9cd-67d60a2fd4ec", "node_type": "1", "metadata": {"window": "We also anticipate the fiscal third quarter to be stronger th an the fiscal fourth quarter based on the development \nof prescription transactions, patient visits, internal investments, and the recognition of a discrete tax benefit in the \nthird quarter.  \n \n In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n ", "original_text": "And with that, let's move to the Q&A.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55cb8e08354b03d01f2ae7ef1293f52dab3d2601f0a9d7d2bf8b806654f52f1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fec005ef-241e-4854-a081-91ca96f25da1", "node_type": "1", "metadata": {"window": "The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS. ", "original_text": "[Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch. "}, "hash": "8018f6516d17474e05e0b85a9ad41fe51b1180106b191782999dfcff689e2517", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 1286, "end_char_idx": 1616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fec005ef-241e-4854-a081-91ca96f25da1": {"__data__": {"id_": "fec005ef-241e-4854-a081-91ca96f25da1", "embedding": null, "metadata": {"window": "The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS. ", "original_text": "[Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4d68945-6500-4833-9688-76b1a193ed5e", "node_type": "1", "metadata": {"window": "In closing, we are pleased with our strong first half performance .  The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50de43ccf5329fafa73b991a56c342236e4804f3f4ee40cf5f9b943568fcc642", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e20a84ad-c979-4d89-8425-d16e9198feaa", "node_type": "1", "metadata": {"window": "And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half. ", "original_text": "Please go ahead.  \n "}, "hash": "2d313ff2e36c225751c50e2b25fe63c60939bfbb29cb7d31813c7c06e3c6af47", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch. ", "start_char_idx": 1616, "end_char_idx": 1715, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e20a84ad-c979-4d89-8425-d16e9198feaa": {"__data__": {"id_": "e20a84ad-c979-4d89-8425-d16e9198feaa", "embedding": null, "metadata": {"window": "And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half. ", "original_text": "Please go ahead.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fec005ef-241e-4854-a081-91ca96f25da1", "node_type": "1", "metadata": {"window": "The momentum across the business, including \ngrowth in our oncology and biopharma services platforms, positions us to deliver for our customers and our \npartners and to create sustainable shareholder value.  \n \n And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS. ", "original_text": "[Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7c851a0c8a2028a6dfdc28a1262185177931ec31be01e7b28809aa9412c0d9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45bf2742-8ad8-4a5a-a86e-29dd9261a92c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. "}, "hash": "50adc1c892cc5d6589da4583f2c97ab767ade68d12606bdc89bf80695c7a0b67", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1715, "end_char_idx": 1735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45bf2742-8ad8-4a5a-a86e-29dd9261a92c": {"__data__": {"id_": "45bf2742-8ad8-4a5a-a86e-29dd9261a92c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e20a84ad-c979-4d89-8425-d16e9198feaa", "node_type": "1", "metadata": {"window": "And with that, let's move to the Q&A.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half. ", "original_text": "Please go ahead.  \n ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e34db5f400a890e3aba4dfbb97184c56e89ac8f0948a7a1d992d27bf0730e47c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06259041-cce0-4f47-8768-619c5ab075c9", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops? ", "original_text": "I'd like to focus on RxTS. "}, "hash": "5fa6da78137b810643511a56ae9b23fc016411ded88e42edcc9fb669efe367a9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "start_char_idx": 1735, "end_char_idx": 2067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06259041-cce0-4f47-8768-619c5ab075c9": {"__data__": {"id_": "06259041-cce0-4f47-8768-619c5ab075c9", "embedding": null, "metadata": {"window": "[Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops? ", "original_text": "I'd like to focus on RxTS. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45bf2742-8ad8-4a5a-a86e-29dd9261a92c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTIO N AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85ebbcfd225ff7e26e77c9b43733f3f77ec100b6cb092d86bfb7c113b4310bf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e44589c-c42e-42f6-ab0e-a9f029c89efe", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n ", "original_text": "And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half. "}, "hash": "23396d8303ba9bce66e118e573fc94696679c1d8dce02ae753d13b95237169c0", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to focus on RxTS. ", "start_char_idx": 2067, "end_char_idx": 2094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e44589c-c42e-42f6-ab0e-a9f029c89efe": {"__data__": {"id_": "9e44589c-c42e-42f6-ab0e-a9f029c89efe", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n ", "original_text": "And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06259041-cce0-4f47-8768-619c5ab075c9", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question will come from Eric Percher with Nephron \nResearch.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops? ", "original_text": "I'd like to focus on RxTS. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59ed8065e57ccf320609612b55c437779d6f47c89239741d3f98f7b2a5bf2ebe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "639b3ea0-269f-46bb-b4a6-53f9deb77da6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n"}, "hash": "3a8ca987a563283d195c7181ba14950e550efc8a0efd18e8623e85cfa0f66dd6", "class_name": "RelatedNodeInfo"}}, "text": "And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half. ", "start_char_idx": 2094, "end_char_idx": 2243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "639b3ea0-269f-46bb-b4a6-53f9deb77da6": {"__data__": {"id_": "639b3ea0-269f-46bb-b4a6-53f9deb77da6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e44589c-c42e-42f6-ab0e-a9f029c89efe", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n ", "original_text": "And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2291b3368e2ee7bacb558f98100eb154f592732cc589956e7c28ab6d9b783236", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57087c94-2f63-4c3a-812a-2b44ab9bbccb", "node_type": "1", "metadata": {"window": "I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question. ", "original_text": "And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops? "}, "hash": "64a72c5a667ca33e03f266d146f2502323d0b278611b80da4468ca3f4def43f7", "class_name": "RelatedNodeInfo"}}, "text": "Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n", "start_char_idx": 2243, "end_char_idx": 2464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57087c94-2f63-4c3a-812a-2b44ab9bbccb": {"__data__": {"id_": "57087c94-2f63-4c3a-812a-2b44ab9bbccb", "embedding": null, "metadata": {"window": "I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question. ", "original_text": "And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops? ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "639b3ea0-269f-46bb-b4a6-53f9deb77da6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00f6c8c1031dd2fe220aa4b493cfbebf63e30ec34b551e5c8753841a02f3188c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1253432-51bd-409c-b3c1-78de87ec998e", "node_type": "1", "metadata": {"window": "And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that. ", "original_text": "And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n "}, "hash": "b59055559d23b98a60fcc040ca13f2c6a8bfe7433bb7e5c1f471eab520312b47", "class_name": "RelatedNodeInfo"}}, "text": "And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops? ", "start_char_idx": 2464, "end_char_idx": 2574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1253432-51bd-409c-b3c1-78de87ec998e": {"__data__": {"id_": "b1253432-51bd-409c-b3c1-78de87ec998e", "embedding": null, "metadata": {"window": "And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that. ", "original_text": "And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57087c94-2f63-4c3a-812a-2b44ab9bbccb", "node_type": "1", "metadata": {"window": "I'd like to focus on RxTS.  And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question. ", "original_text": "And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops? ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16c21faa7f63a30b69a3dc978be52e6681de152f316862755ef748f05f8cfa02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8417452f-586c-4c9a-a048-fb73e277b09c", "node_type": "1", "metadata": {"window": "Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "6b84a8a4fbe8cf669888cb74a35580c6b03466ba37638738942a69c6036e989e", "class_name": "RelatedNodeInfo"}}, "text": "And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n ", "start_char_idx": 2574, "end_char_idx": 2718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8417452f-586c-4c9a-a048-fb73e277b09c": {"__data__": {"id_": "8417452f-586c-4c9a-a048-fb73e277b09c", "embedding": null, "metadata": {"window": "Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1253432-51bd-409c-b3c1-78de87ec998e", "node_type": "1", "metadata": {"window": "And specifically, Britt, you mentioned that the guidance reflects a strong Q2, \nbut it sounded like there's a range of outcomes for the second half.  Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that. ", "original_text": "And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2652ef36d824dbd8795c1a6a03de606bdd3593895d19368034caef9bc8def2cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1a75981-6a1c-4b95-8a84-a4be28fe8acc", "node_type": "1", "metadata": {"window": "And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends. ", "original_text": "A \nEric, thanks for that question. "}, "hash": "7a4d8d9447638d169bce73639dea9bb7f174e8fc035b2f4d8fec69a634f6f89f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2718, "end_char_idx": 3078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1a75981-6a1c-4b95-8a84-a4be28fe8acc": {"__data__": {"id_": "b1a75981-6a1c-4b95-8a84-a4be28fe8acc", "embedding": null, "metadata": {"window": "And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends. ", "original_text": "A \nEric, thanks for that question. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8417452f-586c-4c9a-a048-fb73e277b09c", "node_type": "1", "metadata": {"window": "Can you provide some context on whether \nrevenue upside that you've seen this year on delivering on prior authori zation for GLP -1s has been tied to \nmanufacturer programs versus the volume of scripts being written?  \n \n And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d05c100b297b8ccf9918781bfc7b0b807512059adcb24aae0cce629e4bf921c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2852b7ba-8a3a-4d6d-97a0-daa31246ed89", "node_type": "1", "metadata": {"window": "And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from. ", "original_text": "I'll start, and then certainly, I'll let  Brian add on to that. "}, "hash": "588b0fa35f137bba5497836e083e94168159a9982c75d73f1c182f54f2ed9fc6", "class_name": "RelatedNodeInfo"}}, "text": "A \nEric, thanks for that question. ", "start_char_idx": 3078, "end_char_idx": 3113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2852b7ba-8a3a-4d6d-97a0-daa31246ed89": {"__data__": {"id_": "2852b7ba-8a3a-4d6d-97a0-daa31246ed89", "embedding": null, "metadata": {"window": "And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from. ", "original_text": "I'll start, and then certainly, I'll let  Brian add on to that. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1a75981-6a1c-4b95-8a84-a4be28fe8acc", "node_type": "1", "metadata": {"window": "And would we be wrong to assume somewhat conservative or some conservatism here on how second half \ndevelops?  And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends. ", "original_text": "A \nEric, thanks for that question. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "775d7a79bea896bf41dd2cc13d8518cf7e744c9b072cc39ab012e00c76e39ee6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a0a1fd9-62d8-4b0c-b3f1-3c418fc0423c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example. ", "original_text": "You really touched on a lot of \nthe factors that we look at when we think about this segment. "}, "hash": "a7c830b6a3ca6801c32f81e6f23552eee7ad749ffb5b8c93609cc9032d7b8cc7", "class_name": "RelatedNodeInfo"}}, "text": "I'll start, and then certainly, I'll let  Brian add on to that. ", "start_char_idx": 3113, "end_char_idx": 3177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a0a1fd9-62d8-4b0c-b3f1-3c418fc0423c": {"__data__": {"id_": "5a0a1fd9-62d8-4b0c-b3f1-3c418fc0423c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example. ", "original_text": "You really touched on a lot of \nthe factors that we look at when we think about this segment. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2852b7ba-8a3a-4d6d-97a0-daa31246ed89", "node_type": "1", "metadata": {"window": "And last, I'll ask, are there particular indi cators such as denial rates or new starts that you look for as \nyou're modeling this business?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from. ", "original_text": "I'll start, and then certainly, I'll let  Brian add on to that. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd891d0168e57ab4f133a428ecd408d5cf385e8b154cb6aeedff602d484f2c14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2424b627-5321-41cb-833b-348cdc39fde0", "node_type": "1", "metadata": {"window": "A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs. ", "original_text": "As I mentioned, we've seen continued stable and \nstrong utilization trends. "}, "hash": "9affa7b83a8441e66b820c9ff3ea39b5b7b27ecb0505f8f08ff657351433f0e0", "class_name": "RelatedNodeInfo"}}, "text": "You really touched on a lot of \nthe factors that we look at when we think about this segment. ", "start_char_idx": 3177, "end_char_idx": 3271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2424b627-5321-41cb-833b-348cdc39fde0": {"__data__": {"id_": "2424b627-5321-41cb-833b-348cdc39fde0", "embedding": null, "metadata": {"window": "A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs. ", "original_text": "As I mentioned, we've seen continued stable and \nstrong utilization trends. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a0a1fd9-62d8-4b0c-b3f1-3c418fc0423c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example. ", "original_text": "You really touched on a lot of \nthe factors that we look at when we think about this segment. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "329fecf5842e993a7673fb85825f42551ab802afc0c25f2823dda805dda8e4e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b633d9d6-299b-4781-8f49-9343bcb2609d", "node_type": "1", "metadata": {"window": "I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n", "original_text": "And that certainly drives transactions, which our services benefi t from. "}, "hash": "0763830566e635b253cc20915a4b27fc1e89c058048e6ba193830058a61e6af7", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned, we've seen continued stable and \nstrong utilization trends. ", "start_char_idx": 3271, "end_char_idx": 3347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b633d9d6-299b-4781-8f49-9343bcb2609d": {"__data__": {"id_": "b633d9d6-299b-4781-8f49-9343bcb2609d", "embedding": null, "metadata": {"window": "I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n", "original_text": "And that certainly drives transactions, which our services benefi t from. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2424b627-5321-41cb-833b-348cdc39fde0", "node_type": "1", "metadata": {"window": "A \nEric, thanks for that question.  I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs. ", "original_text": "As I mentioned, we've seen continued stable and \nstrong utilization trends. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee5d4468f7c25acf3c3ea162d5d5b5a62c84b93888c838f1257ff164c690a060", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25ec641f-2318-4982-b470-2ef9047621ce", "node_type": "1", "metadata": {"window": "You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those. ", "original_text": "Effectively, we've \nseen continued growth in GLP -1 medications, as an example. "}, "hash": "1ac1f7a205d6102adf460d53da656d41cc4bb5bda9bf6202777fab4215e95b13", "class_name": "RelatedNodeInfo"}}, "text": "And that certainly drives transactions, which our services benefi t from. ", "start_char_idx": 3347, "end_char_idx": 3421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25ec641f-2318-4982-b470-2ef9047621ce": {"__data__": {"id_": "25ec641f-2318-4982-b470-2ef9047621ce", "embedding": null, "metadata": {"window": "You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those. ", "original_text": "Effectively, we've \nseen continued growth in GLP -1 medications, as an example. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b633d9d6-299b-4781-8f49-9343bcb2609d", "node_type": "1", "metadata": {"window": "I'll start, and then certainly, I'll let  Brian add on to that.  You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n", "original_text": "And that certainly drives transactions, which our services benefi t from. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e08b26efa5751fe7b2755c304144a9d901e7429991642241543076628cda7668", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bffa589-bc38-4c83-8e4a-e48214a54036", "node_type": "1", "metadata": {"window": "As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories. ", "original_text": "And our services, primarily prior authorization, \nsupport those programs. "}, "hash": "ebdbd5cc8059ea3476abb0a0ceb03c96140a10481ae59ffbdc82eecf29d96402", "class_name": "RelatedNodeInfo"}}, "text": "Effectively, we've \nseen continued growth in GLP -1 medications, as an example. ", "start_char_idx": 3421, "end_char_idx": 3501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bffa589-bc38-4c83-8e4a-e48214a54036": {"__data__": {"id_": "7bffa589-bc38-4c83-8e4a-e48214a54036", "embedding": null, "metadata": {"window": "As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories. ", "original_text": "And our services, primarily prior authorization, \nsupport those programs. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25ec641f-2318-4982-b470-2ef9047621ce", "node_type": "1", "metadata": {"window": "You really touched on a lot of \nthe factors that we look at when we think about this segment.  As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those. ", "original_text": "Effectively, we've \nseen continued growth in GLP -1 medications, as an example. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "514f66a80464a12cbb33e0587e66c5ef75e59f7e4fb99a9e68045b74cb63f528", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5e99e2e-6b5e-4d76-960b-c1d4a0ced4e8", "node_type": "1", "metadata": {"window": "And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories.  And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "original_text": "So we've seen growth from that aspect.  \n \n"}, "hash": "ac480a2f4395b433afadd6c12285245c51daa6874379abf8d6771dda2a012106", "class_name": "RelatedNodeInfo"}}, "text": "And our services, primarily prior authorization, \nsupport those programs. ", "start_char_idx": 3501, "end_char_idx": 3575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5e99e2e-6b5e-4d76-960b-c1d4a0ced4e8": {"__data__": {"id_": "e5e99e2e-6b5e-4d76-960b-c1d4a0ced4e8", "embedding": null, "metadata": {"window": "And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories.  And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "original_text": "So we've seen growth from that aspect.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bffa589-bc38-4c83-8e4a-e48214a54036", "node_type": "1", "metadata": {"window": "As I mentioned, we've seen continued stable and \nstrong utilization trends.  And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories. ", "original_text": "And our services, primarily prior authorization, \nsupport those programs. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "394aa81e6ae2bdda5cb9df93c5f588940ca3dea80f1529ebf7b581c12e7ea724", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e74ca2c0-c751-49f6-a4a2-cc9c3a6e7c2d", "node_type": "1", "metadata": {"window": "Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories.  And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "original_text": "As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those. "}, "hash": "b6eb39592472cd9ba6b47a5bb2061e4b2cf67713a45cd840718d7fcae4080236", "class_name": "RelatedNodeInfo"}}, "text": "So we've seen growth from that aspect.  \n \n", "start_char_idx": 3575, "end_char_idx": 3618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e74ca2c0-c751-49f6-a4a2-cc9c3a6e7c2d": {"__data__": {"id_": "e74ca2c0-c751-49f6-a4a2-cc9c3a6e7c2d", "embedding": null, "metadata": {"window": "Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories.  And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "original_text": "As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5e99e2e-6b5e-4d76-960b-c1d4a0ced4e8", "node_type": "1", "metadata": {"window": "And that certainly drives transactions, which our services benefi t from.  Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories.  And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "original_text": "So we've seen growth from that aspect.  \n \n", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "721d61b8a0120f0b92c9dd844a6c3509115cb4fd14185048a4ce16a4a0346297", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eec4193d-f52e-4333-8089-8a136316074a", "node_type": "1", "metadata": {"window": "And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories.  And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "original_text": "As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories. "}, "hash": "6f9b18804474524015263d4df1ada3cb04f10b8ec9218dd0254d94d61813c499", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those. ", "start_char_idx": 3618, "end_char_idx": 3830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eec4193d-f52e-4333-8089-8a136316074a": {"__data__": {"id_": "eec4193d-f52e-4333-8089-8a136316074a", "embedding": null, "metadata": {"window": "And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories.  And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "original_text": "As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e74ca2c0-c751-49f6-a4a2-cc9c3a6e7c2d", "node_type": "1", "metadata": {"window": "Effectively, we've \nseen continued growth in GLP -1 medications, as an example.  And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories.  And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "original_text": "As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c255691aaae6e915af5b8a0f4fd37fc00feffee790beccf965987a1d9c6e9fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81eacb08-620d-4e56-ba64-5cda584949ca", "node_type": "1", "metadata": {"window": "So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories.  And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "original_text": "And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  "}, "hash": "2b538350dc8f773b60be83cd8610182cd0f83695815a3bf12f86a839d6922e0e", "class_name": "RelatedNodeInfo"}}, "text": "As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories. ", "start_char_idx": 3830, "end_char_idx": 4021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81eacb08-620d-4e56-ba64-5cda584949ca": {"__data__": {"id_": "81eacb08-620d-4e56-ba64-5cda584949ca", "embedding": null, "metadata": {"window": "So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories.  And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "original_text": "And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6ce7973-9853-4b98-938e-358edd69e3e3", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71b986a71e4a43b769c714a12889a452905f163a15982ecb53237412c70f5aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eec4193d-f52e-4333-8089-8a136316074a", "node_type": "1", "metadata": {"window": "And our services, primarily prior authorization, \nsupport those programs.  So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories.  And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "original_text": "As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories. ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1a885a52dfc5597f34e8f897b23a0228e82e8493b806d8e0e00ddfcc0a6b468", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e9e6cfd-8311-4c15-a539-9d9ab0e03329", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n ", "original_text": "McKesson Corp.  "}, "hash": "d8ee3af69fe0de84e00e5270084e977dfc1b20fe6585c7cb7fa47dafacabdfb0", "class_name": "RelatedNodeInfo"}}, "text": "And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "start_char_idx": 4021, "end_char_idx": 4164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e9e6cfd-8311-4c15-a539-9d9ab0e03329": {"__data__": {"id_": "3e9e6cfd-8311-4c15-a539-9d9ab0e03329", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81eacb08-620d-4e56-ba64-5cda584949ca", "node_type": "1", "metadata": {"window": "So we've seen growth from that aspect.  \n \n As I mentioned in my remarks, there are a number of thing s that can create some variability and certainly can \ndrive \u2013 decided from a revenue and operating profit perspective, and you touched on a few of those.  As I \nmentioned, prescription utilization is one of those, certainly the timing and pace and the traject ory of drug \nlaunches, the GLP -1 category being one of those drug launch categories.  And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "original_text": "And certainly the timing of certain other \nprograms like the annual verification programs that we do for our customers in the fourth quarter.  ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a673625b4513ffc3b0e85ad3bc618d09ae4a1d866d9dff1b3c66df9b83aba785", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b7414ea-62ec-4491-9da8-2dd398151a95", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends. "}, "hash": "a1a6e519a7fbbbdeefbd7a3dcde377edf6b97de7048c84f76bc49a4a71921b29", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b7414ea-62ec-4491-9da8-2dd398151a95": {"__data__": {"id_": "3b7414ea-62ec-4491-9da8-2dd398151a95", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e9e6cfd-8311-4c15-a539-9d9ab0e03329", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a21a5f453a7c644b956ddc5d8ff466549de7418d21e76fb23680a4e319731026", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e99081d-d082-4437-8861-3b1a680a8a2a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have. "}, "hash": "9471d58d7a64c01c4aeda7f9c0e7ca46f8665a067596ef691c8a6ba724981df2", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends. ", "start_char_idx": 16, "end_char_idx": 230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e99081d-d082-4437-8861-3b1a680a8a2a": {"__data__": {"id_": "1e99081d-d082-4437-8861-3b1a680a8a2a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b7414ea-62ec-4491-9da8-2dd398151a95", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7139161c69deabe48d7db5b0e98f688da652c7f59253665986e286714d6d6c4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "976834b0-5036-4a1e-bb26-4ea70d5c93ac", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n "}, "hash": "ac53123bbc45acef49a73285a92105347ef5235c042eca2864cd60ddf41a1b7f", "class_name": "RelatedNodeInfo"}}, "text": "We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have. ", "start_char_idx": 230, "end_char_idx": 371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "976834b0-5036-4a1e-bb26-4ea70d5c93ac": {"__data__": {"id_": "976834b0-5036-4a1e-bb26-4ea70d5c93ac", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e99081d-d082-4437-8861-3b1a680a8a2a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0706b6e94434e472a0ff6695026dc2396f1a13241b114bf13e4c7e6c2e779047", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84694601-1a3a-44ab-984e-e6320ca968db", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  "}, "hash": "c8ed10ecd7cd80299af03f283af1c316e05eba4a4c70f2eae59d08280dd14c8d", "class_name": "RelatedNodeInfo"}}, "text": "And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n ", "start_char_idx": 371, "end_char_idx": 464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84694601-1a3a-44ab-984e-e6320ca968db": {"__data__": {"id_": "84694601-1a3a-44ab-984e-e6320ca968db", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "976834b0-5036-4a1e-bb26-4ea70d5c93ac", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "original_text": "And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76c1cc2975989b82286442b596a95f55ff1dc9686602e38d2572faecb9ceae74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bc3f217-0761-408d-b701-e8da5317118c", "node_type": "1", "metadata": {"window": "We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n ", "original_text": "A \nNext question, please?  \n "}, "hash": "69eea1acbd401409d3b37691dbf2902b62f2e6537c64da80cd6d410dafb5724c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "start_char_idx": 464, "end_char_idx": 807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bc3f217-0761-408d-b701-e8da5317118c": {"__data__": {"id_": "4bc3f217-0761-408d-b701-e8da5317118c", "embedding": null, "metadata": {"window": "We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n ", "original_text": "A \nNext question, please?  \n ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84694601-1a3a-44ab-984e-e6320ca968db", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0aad5a85ecb76e802f9f2065af743033bcfd45a81674b0cfe8562b4553d7f8b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c1262f5-755d-491e-b639-df0ad2966d40", "node_type": "1", "metadata": {"window": "And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. "}, "hash": "edec3f1e557292b2f7847415d3b0019b88a4d51a95b9e01b88b6c90436bd3e85", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 807, "end_char_idx": 836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c1262f5-755d-491e-b639-df0ad2966d40": {"__data__": {"id_": "5c1262f5-755d-491e-b639-df0ad2966d40", "embedding": null, "metadata": {"window": "And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bc3f217-0761-408d-b701-e8da5317118c", "node_type": "1", "metadata": {"window": "We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n ", "original_text": "A \nNext question, please?  \n ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31ffc1e34a7587911e75814a547085211fd8a81323cfc433bfc3a57bac74d883", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43a8508b-bc8c-4298-893d-b23f27c7e155", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area. ", "original_text": "And next will be Lisa Gill with JPMorgan. "}, "hash": "bb08e5666ab5a264a581b3d52da9f63de0a2ef5d47ca6333d3e25a6c33a2ebcd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "start_char_idx": 836, "end_char_idx": 1132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43a8508b-bc8c-4298-893d-b23f27c7e155": {"__data__": {"id_": "43a8508b-bc8c-4298-893d-b23f27c7e155", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area. ", "original_text": "And next will be Lisa Gill with JPMorgan. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c1262f5-755d-491e-b639-df0ad2966d40", "node_type": "1", "metadata": {"window": "And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f65da22d63ede331e1e01497d3985a940fb192e37bf973dc94d9043f4a293e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03eab41f-3f30-45ca-9cac-46b1e7a486e2", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n", "original_text": "Please go ahead.  \n "}, "hash": "848784cfa64fa58d46ac893f58cdc27b862cbfba5560827cbbb13620398d017c", "class_name": "RelatedNodeInfo"}}, "text": "And next will be Lisa Gill with JPMorgan. ", "start_char_idx": 1132, "end_char_idx": 1174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03eab41f-3f30-45ca-9cac-46b1e7a486e2": {"__data__": {"id_": "03eab41f-3f30-45ca-9cac-46b1e7a486e2", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n", "original_text": "Please go ahead.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43a8508b-bc8c-4298-893d-b23f27c7e155", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area. ", "original_text": "And next will be Lisa Gill with JPMorgan. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "265419c34ebb42f175e56a4f923d210e54ce8c2aaacc26ea13e1b5d175914f6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f87f680-61a9-46f4-824e-42df1d6df50b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. "}, "hash": "3d9a0342441085a58e015775a0ebb57cd7ee26b4f16cb721b8ad2908c271be05", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1174, "end_char_idx": 1194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f87f680-61a9-46f4-824e-42df1d6df50b": {"__data__": {"id_": "6f87f680-61a9-46f4-824e-42df1d6df50b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03eab41f-3f30-45ca-9cac-46b1e7a486e2", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n", "original_text": "Please go ahead.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f877530329bb37886906684cae0765b9946e07747bbb45a1700f0111c14b0af1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c67d36e1-8dd9-4332-bec7-fc208892acc7", "node_type": "1", "metadata": {"window": "And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism? ", "original_text": "Britt, I've got to  stick on this area. "}, "hash": "6918a6433a0ee67ec1115b6edd1224e3f02ba740b1187b8f86dc7beb632a58d8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "start_char_idx": 1194, "end_char_idx": 1536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c67d36e1-8dd9-4332-bec7-fc208892acc7": {"__data__": {"id_": "c67d36e1-8dd9-4332-bec7-fc208892acc7", "embedding": null, "metadata": {"window": "And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism? ", "original_text": "Britt, I've got to  stick on this area. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f87f680-61a9-46f4-824e-42df1d6df50b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you.  And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f098c92d1fbccd7288f2166b70a2dbc29be3649cc5a3ea720e40a53fda057358", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bde88ed6-5ec3-4f87-8945-b146f491bb3c", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave? ", "original_text": "Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n"}, "hash": "4f4a33a42ab91ebbf2b7fcaaf2b9739bb7fd7ae65eee129fa5f43a3ee3cedf92", "class_name": "RelatedNodeInfo"}}, "text": "Britt, I've got to  stick on this area. ", "start_char_idx": 1536, "end_char_idx": 1576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bde88ed6-5ec3-4f87-8945-b146f491bb3c": {"__data__": {"id_": "bde88ed6-5ec3-4f87-8945-b146f491bb3c", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave? ", "original_text": "Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c67d36e1-8dd9-4332-bec7-fc208892acc7", "node_type": "1", "metadata": {"window": "And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism? ", "original_text": "Britt, I've got to  stick on this area. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "736c5130ff21747167e9ecf8d06743cada169df473173e820558c37b6c3e91c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0896dd9-e721-4c47-9238-0c19f6d3284b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program? ", "original_text": "The growth rate will come down. "}, "hash": "e85f21eb2bc9bfd2ff13773506d54d1a939f0d4b27d2a3ce162b8362c9dd4865", "class_name": "RelatedNodeInfo"}}, "text": "Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n", "start_char_idx": 1576, "end_char_idx": 1864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0896dd9-e721-4c47-9238-0c19f6d3284b": {"__data__": {"id_": "e0896dd9-e721-4c47-9238-0c19f6d3284b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program? ", "original_text": "The growth rate will come down. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bde88ed6-5ec3-4f87-8945-b146f491bb3c", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave? ", "original_text": "Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40e0eca84bd138e649cd3cd9b977ae4aad8414fa5e8797d0f4ea09ca1a625dfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b634e5b9-0648-4952-88c1-b51f189046bf", "node_type": "1", "metadata": {"window": "Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n ", "original_text": "So is this conservatism? "}, "hash": "d102316d893265b49eb106519958e8ecbb2d63a4c23b030a2f7c12493400206b", "class_name": "RelatedNodeInfo"}}, "text": "The growth rate will come down. ", "start_char_idx": 1864, "end_char_idx": 1896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b634e5b9-0648-4952-88c1-b51f189046bf": {"__data__": {"id_": "b634e5b9-0648-4952-88c1-b51f189046bf", "embedding": null, "metadata": {"window": "Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n ", "original_text": "So is this conservatism? ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0896dd9-e721-4c47-9238-0c19f6d3284b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program? ", "original_text": "The growth rate will come down. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5149cf137ef0c9cecf509c5ef6c799948da1ba7352248f9d11bf1448cca142fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d650c1c-849a-49d2-8f3b-2a71ce9927fe", "node_type": "1", "metadata": {"window": "Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Is there incremental programs and expenses that you \nhave? "}, "hash": "c2dd08d82d15d665ecababa0f3e4e177d7b090f9d2a8ca234f2f921934661c2b", "class_name": "RelatedNodeInfo"}}, "text": "So is this conservatism? ", "start_char_idx": 1896, "end_char_idx": 1921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d650c1c-849a-49d2-8f3b-2a71ce9927fe": {"__data__": {"id_": "2d650c1c-849a-49d2-8f3b-2a71ce9927fe", "embedding": null, "metadata": {"window": "Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Is there incremental programs and expenses that you \nhave? ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b634e5b9-0648-4952-88c1-b51f189046bf", "node_type": "1", "metadata": {"window": "Britt, I've got to  stick on this area.  Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n ", "original_text": "So is this conservatism? ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1eeb1fad808a3b95c208466e8935d49d11eafa3ebccdd19ad2f4a4fb5e9cc83f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de70e9e1-1aab-497c-815c-42c33653de53", "node_type": "1", "metadata": {"window": "The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Is it any changes in the program? "}, "hash": "2c9427f1c7346cdd3d535d5f24cc921108ddc28b1760a486bda7e8b9927e77fc", "class_name": "RelatedNodeInfo"}}, "text": "Is there incremental programs and expenses that you \nhave? ", "start_char_idx": 1921, "end_char_idx": 1980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de70e9e1-1aab-497c-815c-42c33653de53": {"__data__": {"id_": "de70e9e1-1aab-497c-815c-42c33653de53", "embedding": null, "metadata": {"window": "The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Is it any changes in the program? ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d650c1c-849a-49d2-8f3b-2a71ce9927fe", "node_type": "1", "metadata": {"window": "Just really want to understand, if I take the numbers that \nyou talked about and the updated guidance for the second half of the year, it looks like the margin in Prescription \nTechnology Solutions will come down pretty dramatically vers us what we saw in the first half of the year.  \n \n The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Is there incremental programs and expenses that you \nhave? ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b553076e295e8e29c80ff49f5a669cf3028313f783650a4f009ace1426df8a47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80ae8165-1fb8-4bdb-8f65-cf72a5e4fca0", "node_type": "1", "metadata": {"window": "So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs. ", "original_text": "I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n "}, "hash": "51c10417128ec38760dd893e9f62ea466521ca923f9815c97a9ac6bc389fc6a6", "class_name": "RelatedNodeInfo"}}, "text": "Is it any changes in the program? ", "start_char_idx": 1980, "end_char_idx": 2014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80ae8165-1fb8-4bdb-8f65-cf72a5e4fca0": {"__data__": {"id_": "80ae8165-1fb8-4bdb-8f65-cf72a5e4fca0", "embedding": null, "metadata": {"window": "So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs. ", "original_text": "I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de70e9e1-1aab-497c-815c-42c33653de53", "node_type": "1", "metadata": {"window": "The growth rate will come down.  So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Is it any changes in the program? ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7400df7e60a14af5b9a665ddcfafbce18c4818e1489b6385e59a0a912f92ff3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d85816db-0669-41ac-9632-ed67630be329", "node_type": "1", "metadata": {"window": "Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "a5d1de67e133a857652bd7605bc1745376efd4041305749e535cd3775a47675e", "class_name": "RelatedNodeInfo"}}, "text": "I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n ", "start_char_idx": 2014, "end_char_idx": 2179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d85816db-0669-41ac-9632-ed67630be329": {"__data__": {"id_": "d85816db-0669-41ac-9632-ed67630be329", "embedding": null, "metadata": {"window": "Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80ae8165-1fb8-4bdb-8f65-cf72a5e4fca0", "node_type": "1", "metadata": {"window": "So is this conservatism?  Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs. ", "original_text": "I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18121f76da45bebcaa8106657ca7efb7b5ab914ae8eb022fcb875646e14d5f9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94a7b6c9-e477-4473-adcc-57fa80c63877", "node_type": "1", "metadata": {"window": "Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business. ", "original_text": "A \nYeah. "}, "hash": "736283718fa5ee7ef09e2dcdadc54560856a62de957e87593a088e0d9b49b51d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2179, "end_char_idx": 2539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94a7b6c9-e477-4473-adcc-57fa80c63877": {"__data__": {"id_": "94a7b6c9-e477-4473-adcc-57fa80c63877", "embedding": null, "metadata": {"window": "Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business. ", "original_text": "A \nYeah. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d85816db-0669-41ac-9632-ed67630be329", "node_type": "1", "metadata": {"window": "Is there incremental programs and expenses that you \nhave?  Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6bc18d9e9f11eeca9a5dd198b9748465308aa5f9da670cd66ced35818f896f88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42f1cd31-6b0b-49ee-90a2-4a161d7e66a3", "node_type": "1", "metadata": {"window": "I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter. ", "original_text": "A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs. "}, "hash": "637abbdd12e0db5cbf3b0b27fd311756dcade9926e1951b6077da3385e0af6d1", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2539, "end_char_idx": 2548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42f1cd31-6b0b-49ee-90a2-4a161d7e66a3": {"__data__": {"id_": "42f1cd31-6b0b-49ee-90a2-4a161d7e66a3", "embedding": null, "metadata": {"window": "I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter. ", "original_text": "A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94a7b6c9-e477-4473-adcc-57fa80c63877", "node_type": "1", "metadata": {"window": "Is it any changes in the program?  I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business. ", "original_text": "A \nYeah. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0f52f9e5c744d7063444084b8d2de16693dac4379cb551f527d99f8ee3ecdf4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a1e181b-5b1c-44ec-b565-f5d2b385c5e4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n", "original_text": "As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n"}, "hash": "add1ea6c2d1c820beb5107d6d07abd5f3459be281765e7fb6932040ae9da531c", "class_name": "RelatedNodeInfo"}}, "text": "A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs. ", "start_char_idx": 2548, "end_char_idx": 2702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a1e181b-5b1c-44ec-b565-f5d2b385c5e4": {"__data__": {"id_": "9a1e181b-5b1c-44ec-b565-f5d2b385c5e4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n", "original_text": "As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42f1cd31-6b0b-49ee-90a2-4a161d7e66a3", "node_type": "1", "metadata": {"window": "I'm just trying to understand how to think about this busine ss on kind of a \nnormalized basis and again, how would we think about first half versus second half?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter. ", "original_text": "A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bfe50a587eb8ace4d95335322ccf9eb4592ba4aef9c15aed2b467b6a3628c368", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81c4e016-8598-4db0-bce5-5766c004465e", "node_type": "1", "metadata": {"window": "A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate. ", "original_text": "The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business. "}, "hash": "9c18fe3a8e6c3e3c707635d784e00408a08343d1684d88446a7d15e91bdda15f", "class_name": "RelatedNodeInfo"}}, "text": "As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n", "start_char_idx": 2702, "end_char_idx": 2820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81c4e016-8598-4db0-bce5-5766c004465e": {"__data__": {"id_": "81c4e016-8598-4db0-bce5-5766c004465e", "embedding": null, "metadata": {"window": "A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate. ", "original_text": "The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a1e181b-5b1c-44ec-b565-f5d2b385c5e4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n", "original_text": "As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8e90c90b809b47cc4e39a9b76609aa13afe572749928adb31b214b25e12349b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99a48401-0475-43a0-87ea-07fc2748ca8f", "node_type": "1", "metadata": {"window": "A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year. ", "original_text": "And that business tends to have some variability from quarter to quarter. "}, "hash": "5f3d52ecfa7005fc13fc502480ff4f545b87f1d88192a2b5b2ad529e62414ed0", "class_name": "RelatedNodeInfo"}}, "text": "The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business. ", "start_char_idx": 2820, "end_char_idx": 2967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99a48401-0475-43a0-87ea-07fc2748ca8f": {"__data__": {"id_": "99a48401-0475-43a0-87ea-07fc2748ca8f", "embedding": null, "metadata": {"window": "A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year. ", "original_text": "And that business tends to have some variability from quarter to quarter. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81c4e016-8598-4db0-bce5-5766c004465e", "node_type": "1", "metadata": {"window": "A \nYeah.  A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate. ", "original_text": "The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edfdf095a95974e2c173fd63e151f872cb1060d034821e7bcf330534f3875596", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9adfeab-35a0-4b5a-8a90-4e61301db7bd", "node_type": "1", "metadata": {"window": "As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n", "original_text": "It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n"}, "hash": "357a68ffdf5dddca425f396d724d13bc54a799f3468fde9b221900200c2ca682", "class_name": "RelatedNodeInfo"}}, "text": "And that business tends to have some variability from quarter to quarter. ", "start_char_idx": 2967, "end_char_idx": 3041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9adfeab-35a0-4b5a-8a90-4e61301db7bd": {"__data__": {"id_": "c9adfeab-35a0-4b5a-8a90-4e61301db7bd", "embedding": null, "metadata": {"window": "As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n", "original_text": "It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99a48401-0475-43a0-87ea-07fc2748ca8f", "node_type": "1", "metadata": {"window": "A couple things, this is a business that is \u2013 one, I think you need to look at on a full -year basis for items \nsuch as our annual verification programs.  As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year. ", "original_text": "And that business tends to have some variability from quarter to quarter. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91387bffaa7fe6b76151c797c900b453042fd0f2930fad3eb775b9f5dd847b69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb9e23a8-433e-4fc6-a54a-3160ed6e1095", "node_type": "1", "metadata": {"window": "The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component. ", "original_text": "The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate. "}, "hash": "118620c8fba045988fd5503b505987ef11974aceb81b135844964a0a343a6871", "class_name": "RelatedNodeInfo"}}, "text": "It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n", "start_char_idx": 3041, "end_char_idx": 3153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb9e23a8-433e-4fc6-a54a-3160ed6e1095": {"__data__": {"id_": "eb9e23a8-433e-4fc6-a54a-3160ed6e1095", "embedding": null, "metadata": {"window": "The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component. ", "original_text": "The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9adfeab-35a0-4b5a-8a90-4e61301db7bd", "node_type": "1", "metadata": {"window": "As an example, it's a very different set of programs that we provide, has \ndifferent revenue and margin profiles.  \n \n The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n", "original_text": "It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ea31e9390b941086c7c604d0c695a0969cc695d747bd2b5f24da380b1514bb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6826c272-4830-4053-ab5e-80d7fb6d9201", "node_type": "1", "metadata": {"window": "And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n ", "original_text": "We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year. "}, "hash": "70d3534cad9a9b3567e61df6154f330927dcebdf0e132df40447601433b80b82", "class_name": "RelatedNodeInfo"}}, "text": "The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate. ", "start_char_idx": 3153, "end_char_idx": 3349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6826c272-4830-4053-ab5e-80d7fb6d9201": {"__data__": {"id_": "6826c272-4830-4053-ab5e-80d7fb6d9201", "embedding": null, "metadata": {"window": "And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n ", "original_text": "We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb9e23a8-433e-4fc6-a54a-3160ed6e1095", "node_type": "1", "metadata": {"window": "The second piece to that is we've talked about in  the past our 3PL business, which has a different margin profile \nfrom the rest of the business.  And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component. ", "original_text": "The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d21e1b1cfbe64ea534985397329a46697797dc2aa6947221489cb3d3467bb080", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79c76ca8-712a-43d3-9ebc-63a7838dcebc", "node_type": "1", "metadata": {"window": "It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n"}, "hash": "a4fb39a24749df775c5dac3b4728cc1cca1f6075cd8e53a577709578328d4b0f", "class_name": "RelatedNodeInfo"}}, "text": "We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year. ", "start_char_idx": 3349, "end_char_idx": 3446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79c76ca8-712a-43d3-9ebc-63a7838dcebc": {"__data__": {"id_": "79c76ca8-712a-43d3-9ebc-63a7838dcebc", "embedding": null, "metadata": {"window": "It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6826c272-4830-4053-ab5e-80d7fb6d9201", "node_type": "1", "metadata": {"window": "And that business tends to have some variability from quarter to quarter.  It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n ", "original_text": "We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ced8e79568f65670541d53a8391b1a587b3d8b5959edcbe52c07837565d25204", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87552d09-624b-4962-8b50-1d24f3b018ce", "node_type": "1", "metadata": {"window": "The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n", "original_text": "But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component. "}, "hash": "910220ce9292987c1dd2721b79102905c776cd19ac30c289d9989afe7ab8dcbf", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n", "start_char_idx": 3446, "end_char_idx": 3537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87552d09-624b-4962-8b50-1d24f3b018ce": {"__data__": {"id_": "87552d09-624b-4962-8b50-1d24f3b018ce", "embedding": null, "metadata": {"window": "The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n", "original_text": "But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79c76ca8-712a-43d3-9ebc-63a7838dcebc", "node_type": "1", "metadata": {"window": "It has a \ngood revenue profile, and certainly comes at a lower margin that we've talked  about in the past.  \n \n The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b84af6b3a495ada0670919d50be377526457bdd979554aca055e2766360e78c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de8827f6-f906-4687-88d1-ca562adfd3b0", "node_type": "1", "metadata": {"window": "We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment. ", "original_text": "So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n "}, "hash": "1da1b6950bad18376fdcd81755a09acb7070981aec8b39eee89c43f050204c2d", "class_name": "RelatedNodeInfo"}}, "text": "But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component. ", "start_char_idx": 3537, "end_char_idx": 3734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de8827f6-f906-4687-88d1-ca562adfd3b0": {"__data__": {"id_": "de8827f6-f906-4687-88d1-ca562adfd3b0", "embedding": null, "metadata": {"window": "We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment. ", "original_text": "So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87552d09-624b-4962-8b50-1d24f3b018ce", "node_type": "1", "metadata": {"window": "The other thing that I would talk about is I mentioned earlier in my remarks, is that GLP -1s are flattening out year \nover year as we get to the fourth quarter because that's what we anticipate.  We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n", "original_text": "But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b225170e6074e36f7e73b6799acece3ad60bd7fe3d530f7043a1e79f7d3b46a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d1b4896-2319-490e-ac38-b7c1878a12b0", "node_type": "1", "metadata": {"window": "Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment.  We're excited about the assets that we have, and we want to make sure we ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "f3b1627fcb8b6d2003948f210e47546551f1a7f79c77592e24ac2526c4ad32bc", "class_name": "RelatedNodeInfo"}}, "text": "So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n ", "start_char_idx": 3734, "end_char_idx": 3918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d1b4896-2319-490e-ac38-b7c1878a12b0": {"__data__": {"id_": "7d1b4896-2319-490e-ac38-b7c1878a12b0", "embedding": null, "metadata": {"window": "Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment.  We're excited about the assets that we have, and we want to make sure we ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de8827f6-f906-4687-88d1-ca562adfd3b0", "node_type": "1", "metadata": {"window": "We saw a significant inflection in \nGLP-1 medication volumes in the fourth quarter of last year.  Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment. ", "original_text": "So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a62d38c45dad2f26892c121eda777d8d36cdfcd6eaa10a3239accaba24cf9c58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58645828-3146-4c6a-9b7e-5e9c72c39053", "node_type": "1", "metadata": {"window": "But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment.  We're excited about the assets that we have, and we want to make sure we ", "original_text": "A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n"}, "hash": "bfc09e3b48e6cb85c89fa9ec521b8330b21a889b6efd62539f1dd033f182ed7b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3918, "end_char_idx": 4262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58645828-3146-4c6a-9b7e-5e9c72c39053": {"__data__": {"id_": "58645828-3146-4c6a-9b7e-5e9c72c39053", "embedding": null, "metadata": {"window": "But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment.  We're excited about the assets that we have, and we want to make sure we ", "original_text": "A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d1b4896-2319-490e-ac38-b7c1878a12b0", "node_type": "1", "metadata": {"window": "Certainly, we've seen elevated levels of GLP -1 \nmedication volumes through this year.  \n \n But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment.  We're excited about the assets that we have, and we want to make sure we ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afc545217e7b21678cf7888701a1c938a58eea74fe9e1d926beda49f0657b013", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d2107d4-8257-41b0-8dce-f1b3e58dbe01", "node_type": "1", "metadata": {"window": "So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment.  We're excited about the assets that we have, and we want to make sure we ", "original_text": "We're excited about this segment. "}, "hash": "5ed37f194cf9725f1e37220c77097efe19e3af2ed16848a3c7aba5a3ac2f6b26", "class_name": "RelatedNodeInfo"}}, "text": "A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n", "start_char_idx": 4262, "end_char_idx": 4498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d2107d4-8257-41b0-8dce-f1b3e58dbe01": {"__data__": {"id_": "8d2107d4-8257-41b0-8dce-f1b3e58dbe01", "embedding": null, "metadata": {"window": "So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment.  We're excited about the assets that we have, and we want to make sure we ", "original_text": "We're excited about this segment. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58645828-3146-4c6a-9b7e-5e9c72c39053", "node_type": "1", "metadata": {"window": "But as you kind of get to a year -over-year, begin to lap that fourth quarter inflection point, that's certainly goi ng to \nbe another factor for the year -over-year and the second half component.  So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment.  We're excited about the assets that we have, and we want to make sure we ", "original_text": "A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f73c510cd943f49431df58a4e98a9ea42c3589753f88bdcfa37a55b75bcf75eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "488d2fdc-6a76-4dd2-9cc5-4a118caf8e0a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment.  We're excited about the assets that we have, and we want to make sure we ", "original_text": "We're excited about the assets that we have, and we want to make sure we "}, "hash": "bd2171c30fb0d15357cdda59b0362b793c8aacdb2368a1ebd5ec2f1dcd76c782", "class_name": "RelatedNodeInfo"}}, "text": "We're excited about this segment. ", "start_char_idx": 4498, "end_char_idx": 4532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "488d2fdc-6a76-4dd2-9cc5-4a118caf8e0a": {"__data__": {"id_": "488d2fdc-6a76-4dd2-9cc5-4a118caf8e0a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment.  We're excited about the assets that we have, and we want to make sure we ", "original_text": "We're excited about the assets that we have, and we want to make sure we ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edfa9425-2aee-487f-958d-c03b51919faa", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d1c162f6d286491b2c69c98bacad2b7d18ee6a7da99c9189cd4586532a9addf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d2107d4-8257-41b0-8dce-f1b3e58dbe01", "node_type": "1", "metadata": {"window": "So I think there's a lot of things going on \nhere, but if you look at the business on an annual basis, I think you'll see very good consistent revenue and \noperating profit growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment.  We're excited about the assets that we have, and we want to make sure we ", "original_text": "We're excited about this segment. ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2d00a3ead7f2d606879d572ccaa19ceaf1e78e2ab19e6649efa6d7d27b5abe4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6f38ff4-cf60-4a5a-b3b2-1b51f2e360ee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  "}, "hash": "67d21bb1d14305ce1a8b13105895c8097b040c095244a52b420f80c3f2116a5d", "class_name": "RelatedNodeInfo"}}, "text": "We're excited about the assets that we have, and we want to make sure we ", "start_char_idx": 4532, "end_char_idx": 4605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6f38ff4-cf60-4a5a-b3b2-1b51f2e360ee": {"__data__": {"id_": "d6f38ff4-cf60-4a5a-b3b2-1b51f2e360ee", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "488d2fdc-6a76-4dd2-9cc5-4a118caf8e0a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThe only thing I would add to that, Britt, is that if you look at the growth and the trajectory the segment has had \nhistorically, we continue to also reinvest in product extensions,  new product enhancements, new products overall. \n We're excited about this segment.  We're excited about the assets that we have, and we want to make sure we ", "original_text": "We're excited about the assets that we have, and we want to make sure we ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4f308af5db170ef9dc9fc25cc15e03c8803caf0bfd6820cb3d0313e8f13b96a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e264f6b1-dc46-4ebe-9417-778c3798ecc9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well. "}, "hash": "3ab04d8f677673f2126410d0c81eb8a35070cf45035f6bd3c1fdca86d31bad59", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e264f6b1-dc46-4ebe-9417-778c3798ecc9": {"__data__": {"id_": "e264f6b1-dc46-4ebe-9417-778c3798ecc9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6f38ff4-cf60-4a5a-b3b2-1b51f2e360ee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e995945f10104456ddd1d453f28a1b7504666e4a7db8c51cf203d0509d9c74e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e32e4dcd-b6d5-422f-b64e-cd2650959e65", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen. ", "original_text": "And all those investments are  reflected in our \nFY 2024 outlook.  \n "}, "hash": "75f6c1bfdde0656d406ea7be8c85fd79aa128eb0fc0ff7f33fc7eec90f7d5c48", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well. ", "start_char_idx": 16, "end_char_idx": 252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e32e4dcd-b6d5-422f-b64e-cd2650959e65": {"__data__": {"id_": "e32e4dcd-b6d5-422f-b64e-cd2650959e65", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen. ", "original_text": "And all those investments are  reflected in our \nFY 2024 outlook.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e264f6b1-dc46-4ebe-9417-778c3798ecc9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "efd47743d663714d5ff920516eaeff2fe126fc8269a32c15f9b1e1f11e2039bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "138c6e8e-13f3-406b-8dd9-9dfbbb65c814", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  "}, "hash": "8ab1794e5a5a0ec05e8837de2d7a2f69b50e6b3500507217013f799b76f8b624", "class_name": "RelatedNodeInfo"}}, "text": "And all those investments are  reflected in our \nFY 2024 outlook.  \n ", "start_char_idx": 252, "end_char_idx": 321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "138c6e8e-13f3-406b-8dd9-9dfbbb65c814": {"__data__": {"id_": "138c6e8e-13f3-406b-8dd9-9dfbbb65c814", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e32e4dcd-b6d5-422f-b64e-cd2650959e65", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen. ", "original_text": "And all those investments are  reflected in our \nFY 2024 outlook.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae389aa547e4df43b342182a883880390e14f62c263b3cc955bfe73c05260f9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bccaad9f-5fee-43bf-8786-b2a4091995aa", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah. ", "original_text": "A \nNext question, please?  \n "}, "hash": "656d6082a1ea344077dc282766b4bec76c5d574f66921b4683e4f6c62307078f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "start_char_idx": 321, "end_char_idx": 664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bccaad9f-5fee-43bf-8786-b2a4091995aa": {"__data__": {"id_": "bccaad9f-5fee-43bf-8786-b2a4091995aa", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah. ", "original_text": "A \nNext question, please?  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "138c6e8e-13f3-406b-8dd9-9dfbbb65c814", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "527383c727299d99ad2839dfd0585658b55fc4ee638523c40540e67de50cf01e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a13b8701-a2f5-40f5-afce-5a1266380f21", "node_type": "1", "metadata": {"window": "And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen. "}, "hash": "64713a084445f02f80bd19166a2478efd3e7b6b840cb7a948678e90a79354b4f", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 664, "end_char_idx": 693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a13b8701-a2f5-40f5-afce-5a1266380f21": {"__data__": {"id_": "a13b8701-a2f5-40f5-afce-5a1266380f21", "embedding": null, "metadata": {"window": "And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bccaad9f-5fee-43bf-8786-b2a4091995aa", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah. ", "original_text": "A \nNext question, please?  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7623fcdd618c3fcf7cd7cacbe818bbbb2085cd000a5c0887572a68c3b781d0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d705a4f8-5837-4cdd-80d0-62a2aae34c61", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves. ", "original_text": "Please go ahead.  \n "}, "hash": "db89dc28af362abbee7f5b56d5f2a172849400b20ef41d04c091f86ca7ca9899", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen. ", "start_char_idx": 693, "end_char_idx": 1024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d705a4f8-5837-4cdd-80d0-62a2aae34c61": {"__data__": {"id_": "d705a4f8-5837-4cdd-80d0-62a2aae34c61", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves. ", "original_text": "Please go ahead.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a13b8701-a2f5-40f5-afce-5a1266380f21", "node_type": "1", "metadata": {"window": "And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c92a0360e605b88d9f09194d558cf1b3de42e17e34a119388a5d1b694a656bc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3c538ff-11fe-4b80-baae-4aedfcb15bff", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah. "}, "hash": "bb76cb6c969095d12a851e0848bd5397336e41b5938fec8146963ac090611b8e", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1024, "end_char_idx": 1044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3c538ff-11fe-4b80-baae-4aedfcb15bff": {"__data__": {"id_": "b3c538ff-11fe-4b80-baae-4aedfcb15bff", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d705a4f8-5837-4cdd-80d0-62a2aae34c61", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves. ", "original_text": "Please go ahead.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7401cb695828c1929da99e93f8fca371213d2c0c45747a11cfeb9de9220b8032", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2a73b60-1c4c-40df-9ed9-a499b5f7a3b7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that? ", "original_text": "Thanks for taking the question. "}, "hash": "0dc9222ffa0d7b3612d61f1ba55727b0e685a208445ea75566ac2aa62a4cd719", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah. ", "start_char_idx": 1044, "end_char_idx": 1360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2a73b60-1c4c-40df-9ed9-a499b5f7a3b7": {"__data__": {"id_": "c2a73b60-1c4c-40df-9ed9-a499b5f7a3b7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that? ", "original_text": "Thanks for taking the question. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3c538ff-11fe-4b80-baae-4aedfcb15bff", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d66cd291b66736dd923b1728c348dc035b3afb32c427ee4b8306115e89c1623", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02d0b9a9-c8fe-414b-9a4b-ef12e9ecb010", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n ", "original_text": "I'd like to ask about the Rite Aid on the reserves. "}, "hash": "40a5ab1355f664b0eccf17b00ef955e08ab27efafb22ecbcec0e1c8ff5b423f2", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 1360, "end_char_idx": 1392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02d0b9a9-c8fe-414b-9a4b-ef12e9ecb010": {"__data__": {"id_": "02d0b9a9-c8fe-414b-9a4b-ef12e9ecb010", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n ", "original_text": "I'd like to ask about the Rite Aid on the reserves. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2a73b60-1c4c-40df-9ed9-a499b5f7a3b7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with TD Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that? ", "original_text": "Thanks for taking the question. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17a0a587a107eee0834ecc6559ffff94e2c71491a73b319cb7215fc5256f33fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "644fd851-3482-4056-b628-db3fb6e16805", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize. "}, "hash": "8c128390e573fe252f5146008f23f383aef5881c71856e8da1ad631ef0e74a43", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to ask about the Rite Aid on the reserves. ", "start_char_idx": 1392, "end_char_idx": 1444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "644fd851-3482-4056-b628-db3fb6e16805": {"__data__": {"id_": "644fd851-3482-4056-b628-db3fb6e16805", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02d0b9a9-c8fe-414b-9a4b-ef12e9ecb010", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n ", "original_text": "I'd like to ask about the Rite Aid on the reserves. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16f5e40cf18398e9155607271ea7269c724b7e3122d8e409df08c6016dff797e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d46858f1-5f9a-4aba-b37a-ffe36a6ea742", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question. ", "original_text": "The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that? "}, "hash": "572994ecf1bd57c76c85ca542c48d071e8755ade15bdca176dbdc7605b4c1dbd", "class_name": "RelatedNodeInfo"}}, "text": "I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize. ", "start_char_idx": 1444, "end_char_idx": 1570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d46858f1-5f9a-4aba-b37a-ffe36a6ea742": {"__data__": {"id_": "d46858f1-5f9a-4aba-b37a-ffe36a6ea742", "embedding": null, "metadata": {"window": "Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question. ", "original_text": "The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that? ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "644fd851-3482-4056-b628-db3fb6e16805", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, TD Cowen  Q \nYeah.  Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc598884bca9dfa4d089db57738241c80f0bfde5de4c05d0a73340a935f50e6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80b43d39-42dc-4e1f-8998-b4fd653cb5fc", "node_type": "1", "metadata": {"window": "I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions. ", "original_text": "And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n "}, "hash": "70168b9076d1d7a053a696a4e1de9321f594b587a60c210b3d24af197414429b", "class_name": "RelatedNodeInfo"}}, "text": "The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that? ", "start_char_idx": 1570, "end_char_idx": 1685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80b43d39-42dc-4e1f-8998-b4fd653cb5fc": {"__data__": {"id_": "80b43d39-42dc-4e1f-8998-b4fd653cb5fc", "embedding": null, "metadata": {"window": "I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions. ", "original_text": "And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d46858f1-5f9a-4aba-b37a-ffe36a6ea742", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question. ", "original_text": "The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that? ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd8d435e7d5d63ea713bd1573995863334c637a5dc81db3e0354406f57d62186", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43665b06-91d1-477a-8cd1-2dbe62a52f28", "node_type": "1", "metadata": {"window": "I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "7437cab6a27ac0022c1ba14ffd63f39b487213d0d1dc0d47e75640b515db8092", "class_name": "RelatedNodeInfo"}}, "text": "And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n ", "start_char_idx": 1685, "end_char_idx": 1814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43665b06-91d1-477a-8cd1-2dbe62a52f28": {"__data__": {"id_": "43665b06-91d1-477a-8cd1-2dbe62a52f28", "embedding": null, "metadata": {"window": "I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80b43d39-42dc-4e1f-8998-b4fd653cb5fc", "node_type": "1", "metadata": {"window": "I'd like to ask about the Rite Aid on the reserves.  I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions. ", "original_text": "And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9fec8b9d10d3cddf063568073206a7d4107d28474e7354959a32d21731628ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84d60b68-85e8-4fb0-851a-76bb251f4c5f", "node_type": "1", "metadata": {"window": "The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30. ", "original_text": "A \nSure, I appreciate the question. "}, "hash": "92241b026da30472803944173082eb6a7bbe28f1e97f41076b1b9a5ce67a1920", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1814, "end_char_idx": 2174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84d60b68-85e8-4fb0-851a-76bb251f4c5f": {"__data__": {"id_": "84d60b68-85e8-4fb0-851a-76bb251f4c5f", "embedding": null, "metadata": {"window": "The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30. ", "original_text": "A \nSure, I appreciate the question. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43665b06-91d1-477a-8cd1-2dbe62a52f28", "node_type": "1", "metadata": {"window": "I know you kind of \nreached a settlement with Rite Aid for ongoing supply of pharmaceuticals for Rite Aid as they reorganize.  The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc404c61dc4b32c4bb7ab9bf774754e3a5f00125575381a7f6cb68e9229fa540", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7702a4da-7f91-4bd1-94e6-2c4fd9ddb3cd", "node_type": "1", "metadata": {"window": "And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced. ", "original_text": "Let me just go back to some of my earlier comments because I think that these \nare good questions. "}, "hash": "313b4b2fa86eb47e5a5043d39f7df3c6ec899a1de9ab479a786390693fd312ec", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure, I appreciate the question. ", "start_char_idx": 2174, "end_char_idx": 2210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7702a4da-7f91-4bd1-94e6-2c4fd9ddb3cd": {"__data__": {"id_": "7702a4da-7f91-4bd1-94e6-2c4fd9ddb3cd", "embedding": null, "metadata": {"window": "And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced. ", "original_text": "Let me just go back to some of my earlier comments because I think that these \nare good questions. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84d60b68-85e8-4fb0-851a-76bb251f4c5f", "node_type": "1", "metadata": {"window": "The \nreserves that you've taken, can you talk a little bit about how you're going to approach collections on that?  And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30. ", "original_text": "A \nSure, I appreciate the question. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36e23ac9e28e705c068eead43d3c5e054e852253b50b3361eaadf9f43e979f91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "395c1813-476c-4b7f-9351-552f258f35d6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n", "original_text": "First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n"}, "hash": "d87504c9db7beea9cf4e8e66ba5eb4b3aca15cd25b3b0d631ed6a6cfbf744657", "class_name": "RelatedNodeInfo"}}, "text": "Let me just go back to some of my earlier comments because I think that these \nare good questions. ", "start_char_idx": 2210, "end_char_idx": 2309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "395c1813-476c-4b7f-9351-552f258f35d6": {"__data__": {"id_": "395c1813-476c-4b7f-9351-552f258f35d6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n", "original_text": "First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7702a4da-7f91-4bd1-94e6-2c4fd9ddb3cd", "node_type": "1", "metadata": {"window": "And \nhow should we think about that in terms of the way you reserve for it and the way we should think about the cash \nflows?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced. ", "original_text": "Let me just go back to some of my earlier comments because I think that these \nare good questions. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e1bf1552c02946af033a26a61cea051e4afd3f146006f14bdbc348933050da5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c70a7641-0ecf-4027-be30-fa1e2a2b1c37", "node_type": "1", "metadata": {"window": "A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms. ", "original_text": "We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30. "}, "hash": "fd5b14ce3ac031bc99ca2479a03ee6dc3796b3c38a3b1d9a365dcfa15d605ed8", "class_name": "RelatedNodeInfo"}}, "text": "First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n", "start_char_idx": 2309, "end_char_idx": 2486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c70a7641-0ecf-4027-be30-fa1e2a2b1c37": {"__data__": {"id_": "c70a7641-0ecf-4027-be30-fa1e2a2b1c37", "embedding": null, "metadata": {"window": "A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms. ", "original_text": "We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "395c1813-476c-4b7f-9351-552f258f35d6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n", "original_text": "First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cff077eafd8e3c2fa8c50c12c73564a1ff92fa2eef1ff1ae6ab73200099e2cc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af437074-5df7-486c-af37-88017691c4eb", "node_type": "1", "metadata": {"window": "Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days. ", "original_text": "That's the $210 million that I referenced. "}, "hash": "fbd172e4c35bc8590593d530816ae45ccf13c18627cfc1b5b1e07bbdfe0a77db", "class_name": "RelatedNodeInfo"}}, "text": "We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30. ", "start_char_idx": 2486, "end_char_idx": 2631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af437074-5df7-486c-af37-88017691c4eb": {"__data__": {"id_": "af437074-5df7-486c-af37-88017691c4eb", "embedding": null, "metadata": {"window": "Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days. ", "original_text": "That's the $210 million that I referenced. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c70a7641-0ecf-4027-be30-fa1e2a2b1c37", "node_type": "1", "metadata": {"window": "A \nSure, I appreciate the question.  Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms. ", "original_text": "We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea256850220544f391fcdbcb35219eaefc7a568b6c9584280ae99102cdb4c1fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87612999-ece1-42ae-846d-16726d4c2a75", "node_type": "1", "metadata": {"window": "First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement. ", "original_text": "We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n"}, "hash": "688053a8d7f11674b2fbe201d21fd7696c33ade70455766cedfc84e5144997c3", "class_name": "RelatedNodeInfo"}}, "text": "That's the $210 million that I referenced. ", "start_char_idx": 2631, "end_char_idx": 2674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87612999-ece1-42ae-846d-16726d4c2a75": {"__data__": {"id_": "87612999-ece1-42ae-846d-16726d4c2a75", "embedding": null, "metadata": {"window": "First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement. ", "original_text": "We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af437074-5df7-486c-af37-88017691c4eb", "node_type": "1", "metadata": {"window": "Let me just go back to some of my earlier comments because I think that these \nare good questions.  First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days. ", "original_text": "That's the $210 million that I referenced. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37db451ada270f8a00a57d5286b2449aa82057236ac7e5a21406a916f5d26603", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "503209c8-7a32-4ab7-8212-4ae8ad21f8ae", "node_type": "1", "metadata": {"window": "We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n ", "original_text": "We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms. "}, "hash": "0ba2619ba8473985c00b26af27a1d818d3dcae21fb4f052572ab6f7faa4575cb", "class_name": "RelatedNodeInfo"}}, "text": "We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n", "start_char_idx": 2674, "end_char_idx": 2857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "503209c8-7a32-4ab7-8212-4ae8ad21f8ae": {"__data__": {"id_": "503209c8-7a32-4ab7-8212-4ae8ad21f8ae", "embedding": null, "metadata": {"window": "We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n ", "original_text": "We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87612999-ece1-42ae-846d-16726d4c2a75", "node_type": "1", "metadata": {"window": "First of all, we continue to provide distribution services to Rite Aid, as we have for over 20 \nyears, and we're proud to be a distributor for Rite Aid and their customers.  \n \n We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement. ", "original_text": "We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "598eadf7ec9ac97ddf1207c87ddda4e1473f59944893eccb5c648b3804d82f1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efb746b1-cbab-4c09-9ef1-de7d49cc618e", "node_type": "1", "metadata": {"window": "That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "They have shorter credit terms of seven days. "}, "hash": "92fb98946dba9db8bacc62360d177d501bc526948853df8ea5e8ca19e30e199f", "class_name": "RelatedNodeInfo"}}, "text": "We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms. ", "start_char_idx": 2857, "end_char_idx": 2996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efb746b1-cbab-4c09-9ef1-de7d49cc618e": {"__data__": {"id_": "efb746b1-cbab-4c09-9ef1-de7d49cc618e", "embedding": null, "metadata": {"window": "That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "They have shorter credit terms of seven days. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "503209c8-7a32-4ab7-8212-4ae8ad21f8ae", "node_type": "1", "metadata": {"window": "We did record a provision in the third quarter for those sales that we consider to be uncollected trade accounts \nreceivable as of September 30.  That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n ", "original_text": "We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb6da52e41b6e16b4dcd7a0c5b524ef2b673ee36261850820287dd93033da884", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b36c795-7f2a-4d0b-bb9e-de47d1561cd5", "node_type": "1", "metadata": {"window": "We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "There are other aspects to the interim \nagreement. "}, "hash": "cf9f8276f17ad38ca91c0efb36f693944b8bf245cb773fdb95eb47664cf856cc", "class_name": "RelatedNodeInfo"}}, "text": "They have shorter credit terms of seven days. ", "start_char_idx": 2996, "end_char_idx": 3042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b36c795-7f2a-4d0b-bb9e-de47d1561cd5": {"__data__": {"id_": "2b36c795-7f2a-4d0b-bb9e-de47d1561cd5", "embedding": null, "metadata": {"window": "We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "There are other aspects to the interim \nagreement. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efb746b1-cbab-4c09-9ef1-de7d49cc618e", "node_type": "1", "metadata": {"window": "That's the $210 million that I referenced.  We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "They have shorter credit terms of seven days. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1aa1de810328da64d1f740dfaf09d8958c1df8f23cc5c0d0a20c1f4f05b943a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad8eedd4-17a5-4a70-b485-5c77c350394b", "node_type": "1", "metadata": {"window": "We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies. ", "original_text": "But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n "}, "hash": "549555cf394e66a0ab787ff994e821104862220c9b2c3f94bd4c21e53f5e87fa", "class_name": "RelatedNodeInfo"}}, "text": "There are other aspects to the interim \nagreement. ", "start_char_idx": 3042, "end_char_idx": 3093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad8eedd4-17a5-4a70-b485-5c77c350394b": {"__data__": {"id_": "ad8eedd4-17a5-4a70-b485-5c77c350394b", "embedding": null, "metadata": {"window": "We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies. ", "original_text": "But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b36c795-7f2a-4d0b-bb9e-de47d1561cd5", "node_type": "1", "metadata": {"window": "We  anticipate an additional provision \nthat will be recorded in our third quarter, so those sales up until they're back to their bankruptcy filing, and that's \nthe $511 million.  \n \n We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "There are other aspects to the interim \nagreement. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d17560d46ec1fff8bb3bee0d52279f393bbc58297f0498751479b8619f4c8d8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d01675a-6247-4e5b-93d0-f7f86271aa21", "node_type": "1", "metadata": {"window": "They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  "}, "hash": "2d006824b08a5cf2af6648357ee468b1ac26867afb90fba02d60bf6b4d419c8f", "class_name": "RelatedNodeInfo"}}, "text": "But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n ", "start_char_idx": 3093, "end_char_idx": 3264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d01675a-6247-4e5b-93d0-f7f86271aa21": {"__data__": {"id_": "3d01675a-6247-4e5b-93d0-f7f86271aa21", "embedding": null, "metadata": {"window": "They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad8eedd4-17a5-4a70-b485-5c77c350394b", "node_type": "1", "metadata": {"window": "We have an interim agreement in place that is still pending final court approval,  and that interim agreement has \ndifferent credit terms.  They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies. ", "original_text": "But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2f6a3d369f272adbb8de380be61c128818ff30408598f0416e83f95e8e6bc2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1fdccdc-8924-4518-b686-9c3a7cb2f103", "node_type": "1", "metadata": {"window": "There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys. ", "original_text": "A \nNext question, please?  \n "}, "hash": "5ceb586909fff6be01bc2d3ca5adb25c2e40d6c359e3b6fddde780f417dc78dc", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "start_char_idx": 321, "end_char_idx": 664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1fdccdc-8924-4518-b686-9c3a7cb2f103": {"__data__": {"id_": "d1fdccdc-8924-4518-b686-9c3a7cb2f103", "embedding": null, "metadata": {"window": "There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys. ", "original_text": "A \nNext question, please?  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d01675a-6247-4e5b-93d0-f7f86271aa21", "node_type": "1", "metadata": {"window": "They have shorter credit terms of seven days.  There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "765b10b02a6600b6b25328af112c0296484d54935bfbc9c8a9685a1ffeec4357", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e777fbfd-bbb0-45c5-99e1-405b83ff2185", "node_type": "1", "metadata": {"window": "But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies. "}, "hash": "9249a1e48e9d53a4311768b716cb5b29b0dcbda0a7c5d5578489dbff48fa197e", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 664, "end_char_idx": 693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e777fbfd-bbb0-45c5-99e1-405b83ff2185": {"__data__": {"id_": "e777fbfd-bbb0-45c5-99e1-405b83ff2185", "embedding": null, "metadata": {"window": "But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1fdccdc-8924-4518-b686-9c3a7cb2f103", "node_type": "1", "metadata": {"window": "There are other aspects to the interim \nagreement.  But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys. ", "original_text": "A \nNext question, please?  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31641a4eba470acaa601b6b2c622d2c0e9a827e326bf83c7c5bfffd638a9c29e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09d86c9a-0ff8-4ea0-b503-e7bfc44bdfd9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward? ", "original_text": "Please go ahead.  \n "}, "hash": "7e91048b2cd97913d67ff4f4fd031de2b03b09e52f1711ee0da312d82a16e917", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies. ", "start_char_idx": 3636, "end_char_idx": 3970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09d86c9a-0ff8-4ea0-b503-e7bfc44bdfd9": {"__data__": {"id_": "09d86c9a-0ff8-4ea0-b503-e7bfc44bdfd9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward? ", "original_text": "Please go ahead.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e777fbfd-bbb0-45c5-99e1-405b83ff2185", "node_type": "1", "metadata": {"window": "But the key thing for this call and for this group is that those credit terms are on seven -day terms, \nwhich are different than what we had in the previous agreement.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f88bc5b960e0e4586b9f46f802e7e29cd7fde5c98495a2e43a4ea0b16f51174d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e034b24-7fc0-44ff-87d6-b1b2e08ae4cd", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys. "}, "hash": "b4891ce8d38d5659538e3b7ca9c15e0bd34c9cdc7984df9bcdbc3f1c56c5c972", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1024, "end_char_idx": 1044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e034b24-7fc0-44ff-87d6-b1b2e08ae4cd": {"__data__": {"id_": "4e034b24-7fc0-44ff-87d6-b1b2e08ae4cd", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09d86c9a-0ff8-4ea0-b503-e7bfc44bdfd9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward? ", "original_text": "Please go ahead.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1bd0fe0ca6cced422a2e1682d08916b21c6697d6ca642d575b0ea1d560f1c90d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cc6e394-663e-4da3-b15e-c635ba67e05e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side. "}, "hash": "1391fcfb7f99b943f3d645b8e87230129dc2447ef5ef0b01c7fbf1d611e749a9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys. ", "start_char_idx": 3990, "end_char_idx": 4333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cc6e394-663e-4da3-b15e-c635ba67e05e": {"__data__": {"id_": "8cc6e394-663e-4da3-b15e-c635ba67e05e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e034b24-7fc0-44ff-87d6-b1b2e08ae4cd", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80a4f760c6effd458958a2dfc0012eeba9a3b5aed1e6989a9e477e1f71a09c29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52c6e7b8-b914-40d1-8e92-49b6ff39f027", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward? "}, "hash": "25da4cdc9c1fe934f498757f1c2f1c85651ec4f1e7f5de5031ee85d10939071e", "class_name": "RelatedNodeInfo"}}, "text": "Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side. ", "start_char_idx": 4333, "end_char_idx": 4488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52c6e7b8-b914-40d1-8e92-49b6ff39f027": {"__data__": {"id_": "52c6e7b8-b914-40d1-8e92-49b6ff39f027", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward? ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cc6e394-663e-4da3-b15e-c635ba67e05e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side. ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96203d63b8567ffe3657b5fb48a1050ef1d98ec882e86b2e23faef071596acbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7708729b-ad37-4cd6-b7b3-fd67aedae6db", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Thanks.  \n "}, "hash": "6fa56d36f9175fb7ed8b63dc9e8c3cc0a70e56670fd67cd7af7d8681b8fb0c3b", "class_name": "RelatedNodeInfo"}}, "text": "How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward? ", "start_char_idx": 4488, "end_char_idx": 4598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7708729b-ad37-4cd6-b7b3-fd67aedae6db": {"__data__": {"id_": "7708729b-ad37-4cd6-b7b3-fd67aedae6db", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Thanks.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52c6e7b8-b914-40d1-8e92-49b6ff39f027", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward? ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1dc5a387bac9ee316834fba6bc4be1746823c9aac441c202a90a22c6f89c5c71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6b75e3e-5f93-400f-a17b-0421a43c1d46", "node_type": "1", "metadata": {"window": "Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "09269daa63c523620c66457b8b9c229bb4f66048828c7d82021dd034c082434b", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 4598, "end_char_idx": 4609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6b75e3e-5f93-400f-a17b-0421a43c1d46": {"__data__": {"id_": "d6b75e3e-5f93-400f-a17b-0421a43c1d46", "embedding": null, "metadata": {"window": "Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df6fd61c71e8f532bb34a482d2772b8d2084cbdd4f250884d3a81abb830e388f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7708729b-ad37-4cd6-b7b3-fd67aedae6db", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey, good afternoon guys.  Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Thanks.  \n ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31e11531844de492e64bb4ecf1b1d243acd44c9d81f39e07a0500ae38813f281", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "939cc6b2-073a-42a8-9de6-ca88e711b4b6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage. ", "original_text": "McKesson Corp.  "}, "hash": "16e21c458544c51d2cf81f41cba5c3b0108162c8b0fc34797a9b9cf946c300f2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 321, "end_char_idx": 592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "939cc6b2-073a-42a8-9de6-ca88e711b4b6": {"__data__": {"id_": "939cc6b2-073a-42a8-9de6-ca88e711b4b6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6b75e3e-5f93-400f-a17b-0421a43c1d46", "node_type": "1", "metadata": {"window": "Britt, just a quick question for me as I think about your operating expense line, pretty \ngood levels of improvement there, especially on the margin side.  How should we be thinking about the \nsustainability  of operating expenses and potential gains going forward?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c8cf1a64a7cd036f60cab791983aa183b7eb95b83ba7fb24a1c86beb145d027", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9316232-53e5-4c7d-8c8f-9659f838898b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "52940cc3d5e6d159b9f773d394d08ec351c286c47e1a107e8d434243fe02b54e", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9316232-53e5-4c7d-8c8f-9659f838898b": {"__data__": {"id_": "a9316232-53e5-4c7d-8c8f-9659f838898b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "939cc6b2-073a-42a8-9de6-ca88e711b4b6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0423a07f02315124458913d463a8a6e6c070b831bb61917f2321938d89a0a5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69cd5e5c-8cf9-42f9-ab43-67a33e578a06", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness. ", "original_text": "A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline. "}, "hash": "02ef37fa7b933f79a0e1eecb1ca9cabaeed3436e2d3ed8581efbeae7db38d897", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69cd5e5c-8cf9-42f9-ab43-67a33e578a06": {"__data__": {"id_": "69cd5e5c-8cf9-42f9-ab43-67a33e578a06", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness. ", "original_text": "A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9316232-53e5-4c7d-8c8f-9659f838898b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7da8d5472dd6698771f91bada712d9cf7e8f7e438cb068678f7bfa72defcbfa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e8c18ae-9df5-48ed-af84-df01a216bcb1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers. ", "original_text": "And the efficiency of our operations \nallows us to drive operating margin leverage. "}, "hash": "446325fed54637d7d8b5f4c98c0d85c04f14706981bf0a38f5398cfa4dcc3f3f", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline. ", "start_char_idx": 269, "end_char_idx": 463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e8c18ae-9df5-48ed-af84-df01a216bcb1": {"__data__": {"id_": "7e8c18ae-9df5-48ed-af84-df01a216bcb1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers. ", "original_text": "And the efficiency of our operations \nallows us to drive operating margin leverage. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69cd5e5c-8cf9-42f9-ab43-67a33e578a06", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness. ", "original_text": "A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2021c82c85402c1eecca1a0385ebfffb672c4722de5249fcb6fc2949ee51ae76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0ad1adb-ab7a-413c-b60a-a18e8be1e43b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n", "original_text": "We've been able to do that for a long period of time.  \n \n"}, "hash": "c8c6e401ae85cce129190898e2e4e7ca2cd173ab216b8469d03c5e985edabf60", "class_name": "RelatedNodeInfo"}}, "text": "And the efficiency of our operations \nallows us to drive operating margin leverage. ", "start_char_idx": 463, "end_char_idx": 547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0ad1adb-ab7a-413c-b60a-a18e8be1e43b": {"__data__": {"id_": "d0ad1adb-ab7a-413c-b60a-a18e8be1e43b", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n", "original_text": "We've been able to do that for a long period of time.  \n \n", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e8c18ae-9df5-48ed-af84-df01a216bcb1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers. ", "original_text": "And the efficiency of our operations \nallows us to drive operating margin leverage. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8185cb788e545bed7edb10189423fea1449a917d25ae370260ef5a7a597eaef6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "016e63bf-3cd8-484e-bf46-ca01a0677ae6", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics. ", "original_text": "The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness. "}, "hash": "d801af2b866451536c202472ea738ba3eeb7d632049a21989d2b08924f13c9b5", "class_name": "RelatedNodeInfo"}}, "text": "We've been able to do that for a long period of time.  \n \n", "start_char_idx": 547, "end_char_idx": 605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "016e63bf-3cd8-484e-bf46-ca01a0677ae6": {"__data__": {"id_": "016e63bf-3cd8-484e-bf46-ca01a0677ae6", "embedding": null, "metadata": {"window": "A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics. ", "original_text": "The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0ad1adb-ab7a-413c-b60a-a18e8be1e43b", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n", "original_text": "We've been able to do that for a long period of time.  \n \n", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4b81e93fdabf9edc0999b4ea756bafd9dd1f913f7e26934969a72b4cda1667a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c59335e9-fad3-4ee5-8770-5ccb93f45e5f", "node_type": "1", "metadata": {"window": "And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers. ", "original_text": "Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers. "}, "hash": "99f45c37a48e1bbac3ce652d27756f89d5144772422495bbe0f6a22b648147f1", "class_name": "RelatedNodeInfo"}}, "text": "The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness. ", "start_char_idx": 605, "end_char_idx": 729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c59335e9-fad3-4ee5-8770-5ccb93f45e5f": {"__data__": {"id_": "c59335e9-fad3-4ee5-8770-5ccb93f45e5f", "embedding": null, "metadata": {"window": "And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers. ", "original_text": "Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "016e63bf-3cd8-484e-bf46-ca01a0677ae6", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics. ", "original_text": "The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9329905f668743a00a5e6384b7485fb50853bcbec8b5344bd1127cad6e5178e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11241e03-24fe-4375-b2c5-eca66f14922d", "node_type": "1", "metadata": {"window": "We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n ", "original_text": "But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n"}, "hash": "6d27ef0a03f51c7a2a94c6230c3a79ea3de9a0bc4825fc4d2b00476d7af760dd", "class_name": "RelatedNodeInfo"}}, "text": "Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers. ", "start_char_idx": 729, "end_char_idx": 915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11241e03-24fe-4375-b2c5-eca66f14922d": {"__data__": {"id_": "11241e03-24fe-4375-b2c5-eca66f14922d", "embedding": null, "metadata": {"window": "We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n ", "original_text": "But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c59335e9-fad3-4ee5-8770-5ccb93f45e5f", "node_type": "1", "metadata": {"window": "And the efficiency of our operations \nallows us to drive operating margin leverage.  We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers. ", "original_text": "Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "adf483124024c51af70e1285c42937cd6d3cae0770d437d690a83e66608152c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2a621d0-b0d1-48cb-9e26-f88ac341fc69", "node_type": "1", "metadata": {"window": "The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "We're also inve sting in data and analytics. "}, "hash": "9a220db7e0aa679af2bbc4355adaf44f79ebff2ace599686c98e551b41b3f775", "class_name": "RelatedNodeInfo"}}, "text": "But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n", "start_char_idx": 915, "end_char_idx": 1140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2a621d0-b0d1-48cb-9e26-f88ac341fc69": {"__data__": {"id_": "f2a621d0-b0d1-48cb-9e26-f88ac341fc69", "embedding": null, "metadata": {"window": "The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "We're also inve sting in data and analytics. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11241e03-24fe-4375-b2c5-eca66f14922d", "node_type": "1", "metadata": {"window": "We've been able to do that for a long period of time.  \n \n The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n ", "original_text": "But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0be7d5a5bd302cff6480190a04ef175a093d4928dbe024e634f6f4e06056c611", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30dc2ca8-db52-4ccd-88f9-6168ff24b0f8", "node_type": "1", "metadata": {"window": "Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers. "}, "hash": "eaac374eeafdd082087a018c12fe949c9f304a0987ec67560506a119991b2034", "class_name": "RelatedNodeInfo"}}, "text": "We're also inve sting in data and analytics. ", "start_char_idx": 1140, "end_char_idx": 1185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30dc2ca8-db52-4ccd-88f9-6168ff24b0f8": {"__data__": {"id_": "30dc2ca8-db52-4ccd-88f9-6168ff24b0f8", "embedding": null, "metadata": {"window": "Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2a621d0-b0d1-48cb-9e26-f88ac341fc69", "node_type": "1", "metadata": {"window": "The success that we've seen i n many of our segments really has allowed us to continue to reinvest back into the \nbusiness.  Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "We're also inve sting in data and analytics. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca6535ba2097239d4ddcaf5fc7940ace970c6efc395ccb24eb6cc6eb9966e9aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92bf1974-bd24-404e-802c-1bc461f9c442", "node_type": "1", "metadata": {"window": "But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird. ", "original_text": "So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n "}, "hash": "7fdf812643dd307ba55e3f873524e149d1f6c0a69b330a27cce9ae1eec147719", "class_name": "RelatedNodeInfo"}}, "text": "We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers. ", "start_char_idx": 1185, "end_char_idx": 1302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92bf1974-bd24-404e-802c-1bc461f9c442": {"__data__": {"id_": "92bf1974-bd24-404e-802c-1bc461f9c442", "embedding": null, "metadata": {"window": "But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird. ", "original_text": "So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30dc2ca8-db52-4ccd-88f9-6168ff24b0f8", "node_type": "1", "metadata": {"window": "Brian just mentioned what we've been doing at Rx Savings Solutions or should I say, RxTS, where \nwe've been reinvesting to drive additional programs and capabilitie s for our customers.  But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "acb149a1cedc6062acd4bd654c2a12072aa9b92e5a18f6d71074dea30ea48c37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ae82133-8ae7-4f71-9aa1-155e6446a39c", "node_type": "1", "metadata": {"window": "We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  "}, "hash": "c9c2ecf55db51a937099eaee1d5dceb9542df467fe223e39e8c24869dcb0ae53", "class_name": "RelatedNodeInfo"}}, "text": "So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n ", "start_char_idx": 1302, "end_char_idx": 1502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ae82133-8ae7-4f71-9aa1-155e6446a39c": {"__data__": {"id_": "5ae82133-8ae7-4f71-9aa1-155e6446a39c", "embedding": null, "metadata": {"window": "We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92bf1974-bd24-404e-802c-1bc461f9c442", "node_type": "1", "metadata": {"window": "But as I mentioned in my \ncomments, we've also been investing in distribution network capabilities, additional automation and regulatory \ncapabilities that are going to benefit not only our operations, but our customers.  \n \n We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird. ", "original_text": "So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2ae1496f65f4d437683e91f9d8106b8eab809a83489ffc4e89c73687e2fc2de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63d1df18-9522-413a-8b13-3e8679207b33", "node_type": "1", "metadata": {"window": "We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nNext question, please?  \n "}, "hash": "3c9037b6a2744c38b93896ed64a43f580709bdffaef9ce648e09989a0452c5e9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "start_char_idx": 1502, "end_char_idx": 1845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63d1df18-9522-413a-8b13-3e8679207b33": {"__data__": {"id_": "63d1df18-9522-413a-8b13-3e8679207b33", "embedding": null, "metadata": {"window": "We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ae82133-8ae7-4f71-9aa1-155e6446a39c", "node_type": "1", "metadata": {"window": "We're also inve sting in data and analytics.  We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44646854dd49b3fe51e0ce878f4c5bf5394d28e63f6a5dcc6bd6211f31c86015", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c415461e-528e-4eba-999f-ca3847a6608c", "node_type": "1", "metadata": {"window": "So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird. "}, "hash": "dc1270b79392d8e6faa4097f2750a5b02eb0cb8d4deee94d47eb166c5911ebcf", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 1845, "end_char_idx": 1874, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c415461e-528e-4eba-999f-ca3847a6608c": {"__data__": {"id_": "c415461e-528e-4eba-999f-ca3847a6608c", "embedding": null, "metadata": {"window": "So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63d1df18-9522-413a-8b13-3e8679207b33", "node_type": "1", "metadata": {"window": "We think that's going to be important to drive efficiency of our \noperations and the capabilities for our customers.  So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dea435907161c751da7bc0b1255a25ba6eb08d05bbe967fd2f651c951ee0430e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0c8b9b5-c651-4fad-b069-d9b354bf2abb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric. ", "original_text": "Please go ahead.  \n "}, "hash": "7cbb75ba1203fe3b77df3a38bb5cebccf9c9dee43336aea2884642b704f1098f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird. ", "start_char_idx": 1874, "end_char_idx": 2202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0c8b9b5-c651-4fad-b069-d9b354bf2abb": {"__data__": {"id_": "b0c8b9b5-c651-4fad-b069-d9b354bf2abb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric. ", "original_text": "Please go ahead.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c415461e-528e-4eba-999f-ca3847a6608c", "node_type": "1", "metadata": {"window": "So you should expect to see us continue to deliver operating \nmargin leverage, but to continue to invest against  our programs, our capabilities on behalf of those efficiencies \nand our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f39dd87edcf6f2698ecd8bd9e73d6e4c2cc3d4ba2c161b71b5432ef4948026fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a579ff11-8272-4039-8319-29cfd3e9f01e", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric.  Was that me? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "6eac5cc874d9a66be82bf4f8590d219293e1bd6b001e23b743c4b835d6dc9970", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 2202, "end_char_idx": 2222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a579ff11-8272-4039-8319-29cfd3e9f01e": {"__data__": {"id_": "a579ff11-8272-4039-8319-29cfd3e9f01e", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric.  Was that me? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0c8b9b5-c651-4fad-b069-d9b354bf2abb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric. ", "original_text": "Please go ahead.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbbc108941122ed32f222a2e85366591b37ac3b248db174947ec4f2242e77287", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfaa2fed-46e6-41b8-81a4-7ff22e1ae193", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric.  Was that me?  I heard a beep here.  \n ", "original_text": "Q \nHi. "}, "hash": "1c803825860a9fbce7a9dfc8c8fef308300f4bdf4e3ed8668e62631a7008925f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 2222, "end_char_idx": 2554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfaa2fed-46e6-41b8-81a4-7ff22e1ae193": {"__data__": {"id_": "dfaa2fed-46e6-41b8-81a4-7ff22e1ae193", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric.  Was that me?  I heard a beep here.  \n ", "original_text": "Q \nHi. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a579ff11-8272-4039-8319-29cfd3e9f01e", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric.  Was that me? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5280b8a25c6076a979bfd993e6f6023b038942f536789bd2656b4890c139b656", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18f5283b-f8b8-41dc-bbd5-8d34b94e52a0", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric.  Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "This is Eric. "}, "hash": "ef41046bbe145be664f3d6497c355f54073f06f2ce8d455f2aa748e519d237c8", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHi. ", "start_char_idx": 2554, "end_char_idx": 2561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18f5283b-f8b8-41dc-bbd5-8d34b94e52a0": {"__data__": {"id_": "18f5283b-f8b8-41dc-bbd5-8d34b94e52a0", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric.  Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "This is Eric. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfaa2fed-46e6-41b8-81a4-7ff22e1ae193", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric.  Was that me?  I heard a beep here.  \n ", "original_text": "Q \nHi. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5098f8c228fbb5185ac4ac869ef5073fc03e6123c7cb0bd55c09ddb268ec218", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30abf15d-78ac-4af7-b5ae-b1c44de431f4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric.  Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n ", "original_text": "Was that me? "}, "hash": "96264e1b9d43e6b6d547ee930f9563e0f015b51df585f6fd7d50cb4fcedc3b2a", "class_name": "RelatedNodeInfo"}}, "text": "This is Eric. ", "start_char_idx": 2561, "end_char_idx": 2575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30abf15d-78ac-4af7-b5ae-b1c44de431f4": {"__data__": {"id_": "30abf15d-78ac-4af7-b5ae-b1c44de431f4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric.  Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n ", "original_text": "Was that me? ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18f5283b-f8b8-41dc-bbd5-8d34b94e52a0", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric.  Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "This is Eric. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f550e3f82f61b6ec38f6796023a1f834a97308cc60ea088cc3f5946dde5e1fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "184439a9-24cb-427d-a3c0-038121719e59", "node_type": "1", "metadata": {"window": "Q \nHi.  This is Eric.  Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "I heard a beep here.  \n "}, "hash": "e2074a3e8ef2d082fe4a25347380babbd81801618a8a8fadd5b8d283bef49859", "class_name": "RelatedNodeInfo"}}, "text": "Was that me? ", "start_char_idx": 2575, "end_char_idx": 2588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "184439a9-24cb-427d-a3c0-038121719e59": {"__data__": {"id_": "184439a9-24cb-427d-a3c0-038121719e59", "embedding": null, "metadata": {"window": "Q \nHi.  This is Eric.  Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "I heard a beep here.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30abf15d-78ac-4af7-b5ae-b1c44de431f4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nHi.  This is Eric.  Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n ", "original_text": "Was that me? ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "334d51daa1d7b2d252b17cf3adff148f91d5a45ffa10cabceadc21df1286ea05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b64daaf-f1ac-484a-8a47-c8a59b7218d8", "node_type": "1", "metadata": {"window": "This is Eric.  Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "01160cf33a0702886b215de5145222077460dec2a73f8c1680692d65d6935aef", "class_name": "RelatedNodeInfo"}}, "text": "I heard a beep here.  \n ", "start_char_idx": 2588, "end_char_idx": 2612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b64daaf-f1ac-484a-8a47-c8a59b7218d8": {"__data__": {"id_": "0b64daaf-f1ac-484a-8a47-c8a59b7218d8", "embedding": null, "metadata": {"window": "This is Eric.  Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "184439a9-24cb-427d-a3c0-038121719e59", "node_type": "1", "metadata": {"window": "Q \nHi.  This is Eric.  Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "I heard a beep here.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc3c5967430285a133f451ba12d41e6968f4570283eedacc9a120aa25b5f35f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c1343b3-8203-4a36-96c4-1a557f2e734a", "node_type": "1", "metadata": {"window": "Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "A \nThat's you.  \n "}, "hash": "d77d6eaa238a74d6a6d4d2bee8f73cea892e8cbf0848f6fec36f20eff61512e6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2612, "end_char_idx": 2956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c1343b3-8203-4a36-96c4-1a557f2e734a": {"__data__": {"id_": "9c1343b3-8203-4a36-96c4-1a557f2e734a", "embedding": null, "metadata": {"window": "Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "A \nThat's you.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b64daaf-f1ac-484a-8a47-c8a59b7218d8", "node_type": "1", "metadata": {"window": "This is Eric.  Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a54cba71da5bff078d6f230448e61422be57322e09ae8211abe3ba1937ef6b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0ea2e97-ac20-4bb5-a2dc-663243f68066", "node_type": "1", "metadata": {"window": "I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  "}, "hash": "d066255cf88a9a301dc21d348033d5570d9e5acffe417893ca3f6b0300b0f027", "class_name": "RelatedNodeInfo"}}, "text": "A \nThat's you.  \n ", "start_char_idx": 2956, "end_char_idx": 2974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0ea2e97-ac20-4bb5-a2dc-663243f68066": {"__data__": {"id_": "c0ea2e97-ac20-4bb5-a2dc-663243f68066", "embedding": null, "metadata": {"window": "I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c1343b3-8203-4a36-96c4-1a557f2e734a", "node_type": "1", "metadata": {"window": "Was that me?  I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "A \nThat's you.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "970877c260f00491ba65d85767f8e47bad089caced9f8eed45e0f8a872810fe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8c88cb2-64cf-435a-93f3-7d6cbb4b4d29", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nYeah.  \n "}, "hash": "90e8cc258fffad6929fa7bf3a24f4a09aaa4b0e248c9371fcd30f892746fe060", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "start_char_idx": 1502, "end_char_idx": 1845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8c88cb2-64cf-435a-93f3-7d6cbb4b4d29": {"__data__": {"id_": "a8c88cb2-64cf-435a-93f3-7d6cbb4b4d29", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nYeah.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0ea2e97-ac20-4bb5-a2dc-663243f68066", "node_type": "1", "metadata": {"window": "I heard a beep here.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5e8e4d713bb8fc5e8e6cece399aef1835566fcdcc225ba2b5f0b942eb3426e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b2eb280-ff0b-4e9d-aafe-0cb4779d0e8b", "node_type": "1", "metadata": {"window": "A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "068fa7d55c41397f9e90a68c29092e6a22c8dc909857e0e565d87ee0d558db23", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah.  \n ", "start_char_idx": 3317, "end_char_idx": 3329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b2eb280-ff0b-4e9d-aafe-0cb4779d0e8b": {"__data__": {"id_": "2b2eb280-ff0b-4e9d-aafe-0cb4779d0e8b", "embedding": null, "metadata": {"window": "A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8c88cb2-64cf-435a-93f3-7d6cbb4b4d29", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "A \nYeah.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6ec81fb42923bfb784aa4e24c1dc8ca646f518da17869eee6a0759593701a87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "682560b9-c269-41e2-ab07-22e391a11edf", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks. ", "original_text": "A \nHey, Eric.  \n "}, "hash": "ebd933825fd61645ed41a72897eaf28d1d3f75a8f5a9332534917a10e5987821", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 3329, "end_char_idx": 3689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "682560b9-c269-41e2-ab07-22e391a11edf": {"__data__": {"id_": "682560b9-c269-41e2-ab07-22e391a11edf", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks. ", "original_text": "A \nHey, Eric.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b2eb280-ff0b-4e9d-aafe-0cb4779d0e8b", "node_type": "1", "metadata": {"window": "A \nThat's you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d10096fc3afe0feed58370b48b5b5c8f2055761afdd989972a4dfb46264f32f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd2beeab-4318-495b-8d47-a10b355035b5", "node_type": "1", "metadata": {"window": "A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks.  Hi, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "448ce7e026f85a3b200264c2519c3870798d8a1b46d73f11810336f2b61f35b3", "class_name": "RelatedNodeInfo"}}, "text": "A \nHey, Eric.  \n ", "start_char_idx": 3689, "end_char_idx": 3706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd2beeab-4318-495b-8d47-a10b355035b5": {"__data__": {"id_": "bd2beeab-4318-495b-8d47-a10b355035b5", "embedding": null, "metadata": {"window": "A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks.  Hi, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "682560b9-c269-41e2-ab07-22e391a11edf", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks. ", "original_text": "A \nHey, Eric.  \n ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ace264ad5e1d2aaba914e29b20879580d5cc89a1bcb47e049f60280353436a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38c183a0-6ae6-4089-9b32-85d4850edd96", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care. ", "original_text": "Q \nGood, okay. "}, "hash": "aa7c11a50fe5b6b67460435c29f1ab1f0b3f18b169ebf10ba89f68fc47841ac0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 2222, "end_char_idx": 2554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38c183a0-6ae6-4089-9b32-85d4850edd96": {"__data__": {"id_": "38c183a0-6ae6-4089-9b32-85d4850edd96", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care. ", "original_text": "Q \nGood, okay. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd2beeab-4318-495b-8d47-a10b355035b5", "node_type": "1", "metadata": {"window": "A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks.  Hi, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db75415a20336e269dfb424da051abaa73555527efd426027b32b0416c462696", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3161b90-25f9-4483-96ff-9aeda7abd865", "node_type": "1", "metadata": {"window": "A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood. ", "original_text": "Thanks. "}, "hash": "c0d2dcfcbe900475a7e3e599016436bf19b4f802fe28bfd7d82cb1c297a77345", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood, okay. ", "start_char_idx": 4038, "end_char_idx": 4053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3161b90-25f9-4483-96ff-9aeda7abd865": {"__data__": {"id_": "d3161b90-25f9-4483-96ff-9aeda7abd865", "embedding": null, "metadata": {"window": "A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood. ", "original_text": "Thanks. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38c183a0-6ae6-4089-9b32-85d4850edd96", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care. ", "original_text": "Q \nGood, okay. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3707628ac8e71cc1369ba64635bc6e71b5ddcbad58c1a3851416ae8c92d43be8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "942583d2-185d-45c4-809c-baa72f84268f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere. ", "original_text": "Hi, guys. "}, "hash": "4349faa7493b7734589d098877b567d341482c8ea1b2e5a26a18e3584637ab3a", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 4053, "end_char_idx": 4061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "942583d2-185d-45c4-809c-baa72f84268f": {"__data__": {"id_": "942583d2-185d-45c4-809c-baa72f84268f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere. ", "original_text": "Hi, guys. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3161b90-25f9-4483-96ff-9aeda7abd865", "node_type": "1", "metadata": {"window": "A \nHey, Eric.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood. ", "original_text": "Thanks. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bfe52164c67c55c487680288cd66580f23a564d4ae6beb1af55e7a45c53aa425", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fac79b6-f991-416d-9ffc-b25a4afe8426", "node_type": "1", "metadata": {"window": "Q \nGood, okay.  Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere.  I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "original_text": "I wanted to hit on the Med -Surg segment, specifically primary care. "}, "hash": "fe87599f3b34665d3c105b256ef926570a23a902bf5a5df7da2354bbe499dded", "class_name": "RelatedNodeInfo"}}, "text": "Hi, guys. ", "start_char_idx": 4061, "end_char_idx": 4071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fac79b6-f991-416d-9ffc-b25a4afe8426": {"__data__": {"id_": "9fac79b6-f991-416d-9ffc-b25a4afe8426", "embedding": null, "metadata": {"window": "Q \nGood, okay.  Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere.  I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "original_text": "I wanted to hit on the Med -Surg segment, specifically primary care. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "942583d2-185d-45c4-809c-baa72f84268f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGood, okay.  Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere. ", "original_text": "Hi, guys. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21bc69d4d97658c0b42e111a63ff85ecd2c060de252cc1aac35eab16a1f486af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41dc5d34-e6b1-4aa2-baf9-7d3ff0dd3755", "node_type": "1", "metadata": {"window": "Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere.  I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "original_text": "I think your \ncomments on slow start low ramp in the illness season is, I think, well understood. "}, "hash": "56e38cf10a01d42a6e4a68b7b46d20604a2776b8c97629546faf8af795046208", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to hit on the Med -Surg segment, specifically primary care. ", "start_char_idx": 4071, "end_char_idx": 4140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41dc5d34-e6b1-4aa2-baf9-7d3ff0dd3755": {"__data__": {"id_": "41dc5d34-e6b1-4aa2-baf9-7d3ff0dd3755", "embedding": null, "metadata": {"window": "Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere.  I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "original_text": "I think your \ncomments on slow start low ramp in the illness season is, I think, well understood. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fac79b6-f991-416d-9ffc-b25a4afe8426", "node_type": "1", "metadata": {"window": "Q \nGood, okay.  Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere.  I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "original_text": "I wanted to hit on the Med -Surg segment, specifically primary care. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02d889f66852b0a8230601b933a95f0e3a4b3a8bf24837384a55be2e8bed6b58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "245fde81-8036-4ea1-a6e4-360c0dae83d4", "node_type": "1", "metadata": {"window": "Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere.  I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "original_text": "We've seen that elsewhere. "}, "hash": "0d92b3d5f15f086adb962fb9d8aeb16a88f47ee7005e2e19e8437493018f0142", "class_name": "RelatedNodeInfo"}}, "text": "I think your \ncomments on slow start low ramp in the illness season is, I think, well understood. ", "start_char_idx": 4140, "end_char_idx": 4238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "245fde81-8036-4ea1-a6e4-360c0dae83d4": {"__data__": {"id_": "245fde81-8036-4ea1-a6e4-360c0dae83d4", "embedding": null, "metadata": {"window": "Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere.  I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "original_text": "We've seen that elsewhere. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41dc5d34-e6b1-4aa2-baf9-7d3ff0dd3755", "node_type": "1", "metadata": {"window": "Thanks.  Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere.  I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "original_text": "I think your \ncomments on slow start low ramp in the illness season is, I think, well understood. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff48ea416212a75a5b7c64b5766afc5921b408c2fc7e0ceb1189eeb1cf360b62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5742528-678d-4fa7-af09-1333c4abb696", "node_type": "1", "metadata": {"window": "I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere.  I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "original_text": "I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  "}, "hash": "adc28add009b1b893a0bddfc0d206088ca406c73cdc521f41ca86e7bec19f130", "class_name": "RelatedNodeInfo"}}, "text": "We've seen that elsewhere. ", "start_char_idx": 4238, "end_char_idx": 4265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5742528-678d-4fa7-af09-1333c4abb696": {"__data__": {"id_": "f5742528-678d-4fa7-af09-1333c4abb696", "embedding": null, "metadata": {"window": "I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere.  I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "original_text": "I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d88db23884ee71f1f6e0f06d4fa6cc76ae7039e882c089a48b37cba3ea643b15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "245fde81-8036-4ea1-a6e4-360c0dae83d4", "node_type": "1", "metadata": {"window": "Hi, guys.  I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere.  I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "original_text": "We've seen that elsewhere. ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f4769d9530c082f61a9586da7b45cc103d54abb36b11b65f8dc36fbb3e61535", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4744cde-bfea-4f21-8643-ed39d469b1a7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend. ", "original_text": "McKesson Corp.  "}, "hash": "758c92972f5afceb713c612ae578fbdbf720059a51b4fbfab8e2974f4acd57aa", "class_name": "RelatedNodeInfo"}}, "text": "I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "start_char_idx": 4265, "end_char_idx": 4388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4744cde-bfea-4f21-8643-ed39d469b1a7": {"__data__": {"id_": "c4744cde-bfea-4f21-8643-ed39d469b1a7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5742528-678d-4fa7-af09-1333c4abb696", "node_type": "1", "metadata": {"window": "I wanted to hit on the Med -Surg segment, specifically primary care.  I think your \ncomments on slow start low ramp in the illness season is, I think, well understood.  We've seen that elsewhere.  I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "original_text": "I'm \ncurious what else you might have seen in the quarter that could lend some color on the lower  primary care \nvolumes.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa8b9a701fe50202d8c806443a800ae65ee4a91c0539176ec787161fface6427", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb0c48c0-6d46-44d5-ae87-c5cbe4d02a7d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter? ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies. "}, "hash": "f4bae3b7e709a5711299580331cff4cccff4dc4f0f09d82de4a8aa210b43fffe", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb0c48c0-6d46-44d5-ae87-c5cbe4d02a7d": {"__data__": {"id_": "bb0c48c0-6d46-44d5-ae87-c5cbe4d02a7d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter? ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4744cde-bfea-4f21-8643-ed39d469b1a7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91e4445021d54c07b7cabbee9a15ed2417469af26976411f2a5e38370ba22a71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a07af77-c58a-43b7-9d6e-11fa4b12d9a9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n ", "original_text": "I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will. "}, "hash": "685790d2b1fb2957cd41c6a876e64c97c87501b375cb03521bb93d0897fefb3a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies. ", "start_char_idx": 16, "end_char_idx": 235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a07af77-c58a-43b7-9d6e-11fa4b12d9a9": {"__data__": {"id_": "8a07af77-c58a-43b7-9d6e-11fa4b12d9a9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n ", "original_text": "I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb0c48c0-6d46-44d5-ae87-c5cbe4d02a7d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter? ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e603787098230345fa7008f3b3df801df96648f63a94badfd145647e498b6242", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "115f51a0-eeb8-470a-9756-8be997faff8f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend. "}, "hash": "a0f9d70c54cf9b08793ecb72f92c45fcf83fb932f051723a092fcb04a53d392d", "class_name": "RelatedNodeInfo"}}, "text": "I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will. ", "start_char_idx": 235, "end_char_idx": 331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "115f51a0-eeb8-470a-9756-8be997faff8f": {"__data__": {"id_": "115f51a0-eeb8-470a-9756-8be997faff8f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a07af77-c58a-43b7-9d6e-11fa4b12d9a9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n ", "original_text": "I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68b721baf9c3a7f2a26a3d25bdc2efbd6caefb2eb2c48738660f64153d64b8cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dba3de62-4e36-404b-b507-7403a5fedb75", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes. ", "original_text": "And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter? "}, "hash": "38bf7c7db1ca58c7117414ef91503f2bf97f21669f56087c359284dc0e9b0be8", "class_name": "RelatedNodeInfo"}}, "text": "But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend. ", "start_char_idx": 331, "end_char_idx": 431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dba3de62-4e36-404b-b507-7403a5fedb75": {"__data__": {"id_": "dba3de62-4e36-404b-b507-7403a5fedb75", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes. ", "original_text": "And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter? ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "115f51a0-eeb8-470a-9756-8be997faff8f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb9b1f7c4101fe3e2fccc6d095c636055694c6b1a6212800d28d03bc7fcd6be5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0dd65b08-d006-4e2f-8c56-49d69e1e4f44", "node_type": "1", "metadata": {"window": "I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric. ", "original_text": "Thank you.  \n "}, "hash": "34b28dfbd31f037fb67cce47f7116829692a1d929099a1d225502092400b09f2", "class_name": "RelatedNodeInfo"}}, "text": "And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter? ", "start_char_idx": 431, "end_char_idx": 538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0dd65b08-d006-4e2f-8c56-49d69e1e4f44": {"__data__": {"id_": "0dd65b08-d006-4e2f-8c56-49d69e1e4f44", "embedding": null, "metadata": {"window": "I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric. ", "original_text": "Thank you.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dba3de62-4e36-404b-b507-7403a5fedb75", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes. ", "original_text": "And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter? ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9fb53e3d989b534650032edbd00f9aa620613372a5ad1ee8f57ffd5b5473421", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "984201fa-3e0f-415d-852a-6f8b61c039b1", "node_type": "1", "metadata": {"window": "But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "e078883afde838befab4871dd7c34d556ccf5d0792b55de692929308e0bfab8d", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 538, "end_char_idx": 552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "984201fa-3e0f-415d-852a-6f8b61c039b1": {"__data__": {"id_": "984201fa-3e0f-415d-852a-6f8b61c039b1", "embedding": null, "metadata": {"window": "But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0dd65b08-d006-4e2f-8c56-49d69e1e4f44", "node_type": "1", "metadata": {"window": "I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric. ", "original_text": "Thank you.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a99e5fde78dd83da80e065bac8d3007ea804c9187b3583cbd5bdd4edb8b1ec81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be7c162e-8228-4357-a065-0f73da381f61", "node_type": "1", "metadata": {"window": "And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time. ", "original_text": "A \nYes. "}, "hash": "86958d0497ae6ae91aed683c5792b6a288aedfb873151850b2733cf259f18dd3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 552, "end_char_idx": 896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be7c162e-8228-4357-a065-0f73da381f61": {"__data__": {"id_": "be7c162e-8228-4357-a065-0f73da381f61", "embedding": null, "metadata": {"window": "And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time. ", "original_text": "A \nYes. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "984201fa-3e0f-415d-852a-6f8b61c039b1", "node_type": "1", "metadata": {"window": "But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend.  And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33cac20558a20b4d0caf5026e6850bd0ab6fe3d9ee40d13644d3d217de393855", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f64fb6eb-7160-492a-ace8-85615791a07b", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year. ", "original_text": "Thank you, Eric. "}, "hash": "a96ba7a2437fb9e459a307ec33d878c15395958acf1fd9f24519d749f554bfe6", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes. ", "start_char_idx": 896, "end_char_idx": 904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f64fb6eb-7160-492a-ace8-85615791a07b": {"__data__": {"id_": "f64fb6eb-7160-492a-ace8-85615791a07b", "embedding": null, "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year. ", "original_text": "Thank you, Eric. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be7c162e-8228-4357-a065-0f73da381f61", "node_type": "1", "metadata": {"window": "And if you could, could you quantify the rate of growth change that you saw during the \nSeptember quarter?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time. ", "original_text": "A \nYes. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0946e08d5bba5f451cfe05e4589064dc7a6808916e362428d3f25278579de130", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d3ef225-6de7-4c62-8f37-0dfd9564a8ad", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n", "original_text": "And we've heard many of those same themes and trends. "}, "hash": "5a79b263616b10c9eeecb82214013130bb87818aeffecc2999ae05575966dfb7", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Eric. ", "start_char_idx": 904, "end_char_idx": 921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d3ef225-6de7-4c62-8f37-0dfd9564a8ad": {"__data__": {"id_": "9d3ef225-6de7-4c62-8f37-0dfd9564a8ad", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n", "original_text": "And we've heard many of those same themes and trends. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f64fb6eb-7160-492a-ace8-85615791a07b", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year. ", "original_text": "Thank you, Eric. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec35f50fbfd48480e70386e8ad2b75e71660a635a89c8c26be57064f24cafc36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e35b2ec8-9983-445c-b28f-5dcbbe37a1d8", "node_type": "1", "metadata": {"window": "A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down. ", "original_text": "I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time. "}, "hash": "01c73cf34d91b6899e62946cbe54b16cddfba48a0960d2032ab596fa2210fed1", "class_name": "RelatedNodeInfo"}}, "text": "And we've heard many of those same themes and trends. ", "start_char_idx": 921, "end_char_idx": 975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e35b2ec8-9983-445c-b28f-5dcbbe37a1d8": {"__data__": {"id_": "e35b2ec8-9983-445c-b28f-5dcbbe37a1d8", "embedding": null, "metadata": {"window": "A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down. ", "original_text": "I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d3ef225-6de7-4c62-8f37-0dfd9564a8ad", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n", "original_text": "And we've heard many of those same themes and trends. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "576d1fa47b294272c5676d8fd758e4f380ee7f0afa1fe1b4d2f31b6194f935ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f217a758-c1e9-4750-8e5d-6d906578cc01", "node_type": "1", "metadata": {"window": "Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down. ", "original_text": "And I think \u2013 so we're clearly lapping an abnormal ly high year. "}, "hash": "2abad4400d20487f6a0af09c00c7ea383501686f90769a0cada69cb3e5730e99", "class_name": "RelatedNodeInfo"}}, "text": "I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time. ", "start_char_idx": 975, "end_char_idx": 1161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f217a758-c1e9-4750-8e5d-6d906578cc01": {"__data__": {"id_": "f217a758-c1e9-4750-8e5d-6d906578cc01", "embedding": null, "metadata": {"window": "Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down. ", "original_text": "And I think \u2013 so we're clearly lapping an abnormal ly high year. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e35b2ec8-9983-445c-b28f-5dcbbe37a1d8", "node_type": "1", "metadata": {"window": "A \nYes.  Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down. ", "original_text": "I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffcb370611240a7d83699e81dde69cdf3a30ac3b80e249b0831cdeb4393aad02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1335f309-c1c4-4827-8921-14dd29b98ab1", "node_type": "1", "metadata": {"window": "And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down. ", "original_text": "And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n"}, "hash": "37c5e460b668bb48d2089b4995f18e75dc75e1e6595ee08cceadfc48da4e05ba", "class_name": "RelatedNodeInfo"}}, "text": "And I think \u2013 so we're clearly lapping an abnormal ly high year. ", "start_char_idx": 1161, "end_char_idx": 1226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1335f309-c1c4-4827-8921-14dd29b98ab1": {"__data__": {"id_": "1335f309-c1c4-4827-8921-14dd29b98ab1", "embedding": null, "metadata": {"window": "And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down. ", "original_text": "And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f217a758-c1e9-4750-8e5d-6d906578cc01", "node_type": "1", "metadata": {"window": "Thank you, Eric.  And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down. ", "original_text": "And I think \u2013 so we're clearly lapping an abnormal ly high year. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e73cc2333f83b9fcfeecb44c05e4799da98a831b1486c5e23f358ba232fdb71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f22ecf2f-704c-459a-8d54-d840ffed4f53", "node_type": "1", "metadata": {"window": "I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n ", "original_text": "The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down. "}, "hash": "1363968e3cc517a9ff75b1bbcdd5d10affa702a0d52385a239e20c43471ce71d", "class_name": "RelatedNodeInfo"}}, "text": "And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n", "start_char_idx": 1226, "end_char_idx": 1392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f22ecf2f-704c-459a-8d54-d840ffed4f53": {"__data__": {"id_": "f22ecf2f-704c-459a-8d54-d840ffed4f53", "embedding": null, "metadata": {"window": "I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n ", "original_text": "The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1335f309-c1c4-4827-8921-14dd29b98ab1", "node_type": "1", "metadata": {"window": "And we've heard many of those same themes and trends.  I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down. ", "original_text": "And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c004a0f663c43794187747903a119be24a5f352deb8d515b83eb89f47bbb2a93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fcf37e7-44a5-4e96-aa82-0ee476c7f7ed", "node_type": "1", "metadata": {"window": "And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "It does also \nshow telemedicine visits are down. "}, "hash": "53d1eab248718cbbb8d0f5c4ad5b73142b26cdf219c5ebfb4612f9d78e9f3068", "class_name": "RelatedNodeInfo"}}, "text": "The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down. ", "start_char_idx": 1392, "end_char_idx": 1493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fcf37e7-44a5-4e96-aa82-0ee476c7f7ed": {"__data__": {"id_": "5fcf37e7-44a5-4e96-aa82-0ee476c7f7ed", "embedding": null, "metadata": {"window": "And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "It does also \nshow telemedicine visits are down. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f22ecf2f-704c-459a-8d54-d840ffed4f53", "node_type": "1", "metadata": {"window": "I mean clearly, a big one is last \nyear, in this call, we would have been talking about the so -called triple -demic and the RSV and flu and COVID \nkind of all hitting at the same time.  And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n ", "original_text": "The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1aaefdee6cb69035706665d214be185fb104404c667ee738e5c0b95da4cbe54b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51cba07e-63ed-4079-aef4-3068854f5449", "node_type": "1", "metadata": {"window": "And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers. ", "original_text": "We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down. "}, "hash": "242bb5f05bd123be980690d4ea1398e998ed44629bd8fdc53a9d59a3b10cd1f5", "class_name": "RelatedNodeInfo"}}, "text": "It does also \nshow telemedicine visits are down. ", "start_char_idx": 1493, "end_char_idx": 1542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51cba07e-63ed-4079-aef4-3068854f5449": {"__data__": {"id_": "51cba07e-63ed-4079-aef4-3068854f5449", "embedding": null, "metadata": {"window": "And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers. ", "original_text": "We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fcf37e7-44a5-4e96-aa82-0ee476c7f7ed", "node_type": "1", "metadata": {"window": "And I think \u2013 so we're clearly lapping an abnormal ly high year.  And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "It does also \nshow telemedicine visits are down. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6835d285041195ab56debf568c92af2df05fea80f88a296197b2e929e5207af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35e05103-4ac2-44c3-8437-d4dbb6dbcc1b", "node_type": "1", "metadata": {"window": "The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them. ", "original_text": "And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n "}, "hash": "3b4ab36caed77a6668da2a5af1bdf7145ca3c8ff62ff7e6266a3efbf006e6724", "class_name": "RelatedNodeInfo"}}, "text": "We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down. ", "start_char_idx": 1542, "end_char_idx": 1650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35e05103-4ac2-44c3-8437-d4dbb6dbcc1b": {"__data__": {"id_": "35e05103-4ac2-44c3-8437-d4dbb6dbcc1b", "embedding": null, "metadata": {"window": "The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them. ", "original_text": "And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51cba07e-63ed-4079-aef4-3068854f5449", "node_type": "1", "metadata": {"window": "And then I think \nyou fast forward to the trends we're seeing this year, they're probably lower than what we would have expected at \nthe beginning of the outset.  \n \n The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers. ", "original_text": "We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e8e26f743c2590435385809a595951e40f2dd2be93a3dd6c1b36c34531dc638", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e65e9898-064f-45ed-940e-814dcc3b412e", "node_type": "1", "metadata": {"window": "It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "de1a8474cbc6627ce346adddcccf81b5b9482011e9eee1df2851c95f003b0e27", "class_name": "RelatedNodeInfo"}}, "text": "And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n ", "start_char_idx": 1650, "end_char_idx": 1758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e65e9898-064f-45ed-940e-814dcc3b412e": {"__data__": {"id_": "e65e9898-064f-45ed-940e-814dcc3b412e", "embedding": null, "metadata": {"window": "It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35e05103-4ac2-44c3-8437-d4dbb6dbcc1b", "node_type": "1", "metadata": {"window": "The data that we've looked at, the IQVIA data you can reference does show the foo t traffic is down.  It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them. ", "original_text": "And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7738214333b390f1e88d659b9202e36d7b075cc124f1bb370e674777e230a98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ac507cd-8906-4fe3-bd51-bf06924db27f", "node_type": "1", "metadata": {"window": "We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "original_text": "A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers. "}, "hash": "658c1438e7688f642b6393ec193bd69385e7a4d93ccaa76f275a6b5346f60c67", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1758, "end_char_idx": 2118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ac507cd-8906-4fe3-bd51-bf06924db27f": {"__data__": {"id_": "7ac507cd-8906-4fe3-bd51-bf06924db27f", "embedding": null, "metadata": {"window": "We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "original_text": "A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e65e9898-064f-45ed-940e-814dcc3b412e", "node_type": "1", "metadata": {"window": "It does also \nshow telemedicine visits are down.  We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e9fbb43a73d0187ad1be0aa86e0529a6c6fa3ea3793eace7804cb03621b04e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9718400-e164-4845-9fff-1ef632bdb386", "node_type": "1", "metadata": {"window": "And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n ", "original_text": "We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them. "}, "hash": "c0690b31ad0afbceabfe6361919bb1232c1c3426ce44d3017107908465f0a1fc", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers. ", "start_char_idx": 2118, "end_char_idx": 2309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9718400-e164-4845-9fff-1ef632bdb386": {"__data__": {"id_": "f9718400-e164-4845-9fff-1ef632bdb386", "embedding": null, "metadata": {"window": "And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n ", "original_text": "We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ac507cd-8906-4fe3-bd51-bf06924db27f", "node_type": "1", "metadata": {"window": "We sort of don't think structurally the need to consume healthcare services in \nthis country has gone down.  And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "original_text": "A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb1f399aeaf8b1e03f999a58fd16136c043ebb25a2717b37fa8be6bae37e6f3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45cee48e-a4b3-45b9-a9c5-efc0b41573d6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n "}, "hash": "2dba7e1b47ceb9fb1fa973af6289b9b8363b08a0b387ef9125769e1960d96a05", "class_name": "RelatedNodeInfo"}}, "text": "We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them. ", "start_char_idx": 2309, "end_char_idx": 2578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45cee48e-a4b3-45b9-a9c5-efc0b41573d6": {"__data__": {"id_": "45cee48e-a4b3-45b9-a9c5-efc0b41573d6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9718400-e164-4845-9fff-1ef632bdb386", "node_type": "1", "metadata": {"window": "And so that's why Britt provided the context he did for our guidance through the \nremainder of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n ", "original_text": "We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54e17d313da4f6abb42694aa746f493d15957577543b2c554a1af55b8450cb40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e76d6005-55df-4edf-b080-ea39484900e9", "node_type": "1", "metadata": {"window": "A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.  "}, "hash": "89381440d8ee7a1b852a1ac34525d6c154a603b30eef2c3783942027f061e2a2", "class_name": "RelatedNodeInfo"}}, "text": "So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n ", "start_char_idx": 2578, "end_char_idx": 2729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e76d6005-55df-4edf-b080-ea39484900e9": {"__data__": {"id_": "e76d6005-55df-4edf-b080-ea39484900e9", "embedding": null, "metadata": {"window": "A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45cee48e-a4b3-45b9-a9c5-efc0b41573d6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44dd48a573a846ed7f0081f28b9562304c3a41e8b075e9455e1ece695b98e793", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96a36c16-eb7b-4521-951b-4036efbfedc2", "node_type": "1", "metadata": {"window": "We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "original_text": "A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n "}, "hash": "af72b652fcce0c113982d8c26c59c82a19ee5dc17b88b0a3487509d9d9373d23", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "start_char_idx": 2729, "end_char_idx": 3074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96a36c16-eb7b-4521-951b-4036efbfedc2": {"__data__": {"id_": "96a36c16-eb7b-4521-951b-4036efbfedc2", "embedding": null, "metadata": {"window": "We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "original_text": "A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e76d6005-55df-4edf-b080-ea39484900e9", "node_type": "1", "metadata": {"window": "A \nAnd, Eric, I would just also point out that we are extremely well positioned across all alternate sites of care and \nthe confidence that we have in that position to service our customers.  We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c579aedb41478ca39ef0a85a35469cdef513e2040de638f948c6f052a79c91d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9150b70-1314-4d1d-ac4a-7718328b773f", "node_type": "1", "metadata": {"window": "So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  "}, "hash": "f105e99861b215007693094f26f4a508bb68dc035f4f3e12f7406228c1fca9a8", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n ", "start_char_idx": 3074, "end_char_idx": 3244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9150b70-1314-4d1d-ac4a-7718328b773f": {"__data__": {"id_": "b9150b70-1314-4d1d-ac4a-7718328b773f", "embedding": null, "metadata": {"window": "So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96a36c16-eb7b-4521-951b-4036efbfedc2", "node_type": "1", "metadata": {"window": "We're continuing to make investments, and \nI talked about some of the investments that we are making not only in distribution capabilities in the network, but \nalso in data and analytics to help support our customer s and the product portfolio that we provide to them.  So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "original_text": "A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e472950fd1d9bf4233d6d29866d6503e5a2ba9e29786d3eadbdf1aa281d7ae3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8873bae8-17fb-4a62-a238-8eeb788b0bc4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question. ", "original_text": "A \nNext question, please?  \n "}, "hash": "00ed4eb89d2ff512485d0b7c3fd91e2afd06b37b9eef1e657553488d38620c12", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "start_char_idx": 3244, "end_char_idx": 3587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8873bae8-17fb-4a62-a238-8eeb788b0bc4": {"__data__": {"id_": "8873bae8-17fb-4a62-a238-8eeb788b0bc4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question. ", "original_text": "A \nNext question, please?  \n ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9150b70-1314-4d1d-ac4a-7718328b773f", "node_type": "1", "metadata": {"window": "So we \nhave a lot of confidence in the position and the capabilities that we have, and the investments that we're making \nare a reflection of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3040fe3d74166c230d7b8ab560395b49bcf487bb96c0648aabdd6198e95b6333", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45580cb6-b8cd-4b2b-b92f-e0bcc8378c9c", "node_type": "1", "metadata": {"window": "A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. "}, "hash": "64e7ade07c3447015e9be9dd6d82137e82158390b86b65435c2fed79f9e6a099", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 3587, "end_char_idx": 3616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45580cb6-b8cd-4b2b-b92f-e0bcc8378c9c": {"__data__": {"id_": "45580cb6-b8cd-4b2b-b92f-e0bcc8378c9c", "embedding": null, "metadata": {"window": "A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8873bae8-17fb-4a62-a238-8eeb788b0bc4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, M cKesson Corp.   A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question. ", "original_text": "A \nNext question, please?  \n ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8aabf96efb5fbf17854f55fab60239477ea492892b2db3051fc9c5767942a8f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "845d9639-6cdc-4b4d-803e-d25d90fb1b91", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like. ", "original_text": "Please go ahead.  \n "}, "hash": "8ce755f16a1a558ba2a265ec53edeea8cc576d49f92a645093812d5541d57a22", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "start_char_idx": 3616, "end_char_idx": 3943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "845d9639-6cdc-4b4d-803e-d25d90fb1b91": {"__data__": {"id_": "845d9639-6cdc-4b4d-803e-d25d90fb1b91", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like. ", "original_text": "Please go ahead.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45580cb6-b8cd-4b2b-b92f-e0bcc8378c9c", "node_type": "1", "metadata": {"window": "A \nAnd we do think macro trends support the continued migration of care into these alternate sites or these more \ncommunity -based settings, so we're well positioned.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6c3a4618220b492df81583d837c7987e41e5b3caa857d1a0250800c8a21cb01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9235aed-3c87-4b45-a384-6d2c9fc92826", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question. "}, "hash": "e6985d29429aea78b925e487bcd6a322a88e65041cd834a0dec965f47c643960", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 3943, "end_char_idx": 3963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9235aed-3c87-4b45-a384-6d2c9fc92826": {"__data__": {"id_": "b9235aed-3c87-4b45-a384-6d2c9fc92826", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "845d9639-6cdc-4b4d-803e-d25d90fb1b91", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like. ", "original_text": "Please go ahead.  \n ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4365456fef96d4e4016002c269c21ebae37c48570c1d1969c2d294db653f7306", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87482f32-db25-4685-97ba-8c3ce39d3951", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing? ", "original_text": "The Pharma segment growth continues to be really impressive. "}, "hash": "c46d56339eb0c20a0829451618e78e976c718a5d107efe179670061ecf96d69e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question. ", "start_char_idx": 3963, "end_char_idx": 4319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87482f32-db25-4685-97ba-8c3ce39d3951": {"__data__": {"id_": "87482f32-db25-4685-97ba-8c3ce39d3951", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing? ", "original_text": "The Pharma segment growth continues to be really impressive. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9235aed-3c87-4b45-a384-6d2c9fc92826", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eefbe279e812471b40eda6c02a72c457e0e391aebb9bb6200bea19ae6b7e359b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf860181-b991-42ad-8139-6d3924711d2f", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing?  How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "original_text": "And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like. "}, "hash": "8d6c2fdea8d72df6e6ebf468fbf739844d68c983361d67f241e9e07e50196943", "class_name": "RelatedNodeInfo"}}, "text": "The Pharma segment growth continues to be really impressive. ", "start_char_idx": 4319, "end_char_idx": 4380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf860181-b991-42ad-8139-6d3924711d2f": {"__data__": {"id_": "cf860181-b991-42ad-8139-6d3924711d2f", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing?  How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "original_text": "And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87482f32-db25-4685-97ba-8c3ce39d3951", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing? ", "original_text": "The Pharma segment growth continues to be really impressive. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3db824a92a90f6c82a21936a3987b2f274577912e2de0b266b10f2a7c70faabc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "538567be-0010-4241-b5c1-50605cf897dc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing?  How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "original_text": "Can you talk about how the mix is evolving? "}, "hash": "ee65cbb6c8a605621c061374c852979e453a5d54d78fe04d557bfd889859756c", "class_name": "RelatedNodeInfo"}}, "text": "And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like. ", "start_char_idx": 4380, "end_char_idx": 4517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "538567be-0010-4241-b5c1-50605cf897dc": {"__data__": {"id_": "538567be-0010-4241-b5c1-50605cf897dc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing?  How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "original_text": "Can you talk about how the mix is evolving? ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf860181-b991-42ad-8139-6d3924711d2f", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing?  How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "original_text": "And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like. ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07eb4140d383ab9d1c00be63aff45b06b0fb8fdb7be077f977c6eff266bdf995", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f181b1b-e080-4ca7-b3a7-923ebb39a8c9", "node_type": "1", "metadata": {"window": "The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing?  How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "original_text": "Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing? "}, "hash": "a54937d376ecc3a276dbde60af78bc4c36717b32477c8e2b06a8a0abac6f8d4e", "class_name": "RelatedNodeInfo"}}, "text": "Can you talk about how the mix is evolving? ", "start_char_idx": 4517, "end_char_idx": 4561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f181b1b-e080-4ca7-b3a7-923ebb39a8c9": {"__data__": {"id_": "3f181b1b-e080-4ca7-b3a7-923ebb39a8c9", "embedding": null, "metadata": {"window": "The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing?  How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "original_text": "Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing? ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "538567be-0010-4241-b5c1-50605cf897dc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nHi, thanks for taking my question.  The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing?  How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "original_text": "Can you talk about how the mix is evolving? ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82935f7bd6b2347a0dc48d7aee8a472c765532c7341e700de5cc86584131f277", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfd4a658-256b-41dd-ba5b-31ae45e14034", "node_type": "1", "metadata": {"window": "And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing?  How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "original_text": "How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  "}, "hash": "a351e3d23c8724df18f1c91e5ecafd7462071952ff9e2ac013c91209f008816b", "class_name": "RelatedNodeInfo"}}, "text": "Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing? ", "start_char_idx": 4561, "end_char_idx": 4675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfd4a658-256b-41dd-ba5b-31ae45e14034": {"__data__": {"id_": "bfd4a658-256b-41dd-ba5b-31ae45e14034", "embedding": null, "metadata": {"window": "And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing?  How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "original_text": "How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8a850a414d888cddd9ed3b4f286979b3465ad28b56620668fbe2880b1949e6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f181b1b-e080-4ca7-b3a7-923ebb39a8c9", "node_type": "1", "metadata": {"window": "The Pharma segment growth continues to be really impressive.  And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing?  How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "original_text": "Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing? ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc3451f281eb19ca2a92078b9b5243481816072e74e0b3d72cc52d246c2e284", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7a516f0-10eb-4b2a-b957-179fdcf03f33", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n", "original_text": "McKesson Corp.  "}, "hash": "5adc866c989add3f506bf2e0e4df767b248a508c62d0d3f10c29e388470cad41", "class_name": "RelatedNodeInfo"}}, "text": "How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "start_char_idx": 4675, "end_char_idx": 4775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7a516f0-10eb-4b2a-b957-179fdcf03f33": {"__data__": {"id_": "d7a516f0-10eb-4b2a-b957-179fdcf03f33", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfd4a658-256b-41dd-ba5b-31ae45e14034", "node_type": "1", "metadata": {"window": "And I'm \nguessing it's more than just the typical fundamentals of pharma distribution with generic pricing or generic mix and \nthe like.  Can you talk about how the mix is evolving?  Maybe is it some of your oncology businesses, some of the \nclinics you purchased recently that are c ontributing?  How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "original_text": "How is that mix changing currently to drive this sort of \noutsized EBIT growth that you're seeing?  ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "136abc41e20effaf97a55ccfeab183fcb89656854fadf9862844b650272cd08d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f2f0c7a-c2c9-417f-8d86-5860ae35a44b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "b7e46ffac305d6b844a21b13bba4fba6b75f91ac244bec9dbfa60b5ddf4c9fcf", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f2f0c7a-c2c9-417f-8d86-5860ae35a44b": {"__data__": {"id_": "6f2f0c7a-c2c9-417f-8d86-5860ae35a44b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7a516f0-10eb-4b2a-b957-179fdcf03f33", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "440041aecb996728355d4fc1cdaf6e6f712e5236bfeb6b750d15faaca481db36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7c2aa1d-fe3d-40ec-a898-379976e561ee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n", "original_text": "A \nThanks for the question. "}, "hash": "a951430a39367f1f073efaab25fa1b422cb1ac95596135289233d3f110731a0d", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7c2aa1d-fe3d-40ec-a898-379976e561ee": {"__data__": {"id_": "b7c2aa1d-fe3d-40ec-a898-379976e561ee", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n", "original_text": "A \nThanks for the question. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f2f0c7a-c2c9-417f-8d86-5860ae35a44b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3688e6ef938d6f3900a1bcf3bda78a1ce5135bda92e358a98e62b8b67455376a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bc818f8-3fff-4e2f-bef6-22339d9447f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow. ", "original_text": "Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n"}, "hash": "15a685d56ce5f5add3d937c7107e788aeb088b51594fdf2c7e20a820e62ba66f", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the question. ", "start_char_idx": 269, "end_char_idx": 297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bc818f8-3fff-4e2f-bef6-22339d9447f1": {"__data__": {"id_": "0bc818f8-3fff-4e2f-bef6-22339d9447f1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow. ", "original_text": "Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7c2aa1d-fe3d-40ec-a898-379976e561ee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n", "original_text": "A \nThanks for the question. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1b7de391d3979489b7cf0b199b829985bdf1ae953803df0c3919e7797532809", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85a333e6-1eed-4ae4-a932-09b03d58e180", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months. ", "original_text": "And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates. "}, "hash": "8a090a649015b73a5d33031292e4d74642f676e267c9056509c3ecb035f981ed", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n", "start_char_idx": 297, "end_char_idx": 388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85a333e6-1eed-4ae4-a932-09b03d58e180": {"__data__": {"id_": "85a333e6-1eed-4ae4-a932-09b03d58e180", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months. ", "original_text": "And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bc818f8-3fff-4e2f-bef6-22339d9447f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow. ", "original_text": "Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df22e13a48c81abe29c3a0d7002a92495c2ed8d631fc11e169dd6cd892085f09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4d3bcb0-1500-475d-bf68-316165f34a42", "node_type": "1", "metadata": {"window": "A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform. ", "original_text": "I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n"}, "hash": "5fa0718ec77356f0fd94fdff043131eeeebc38e05bfc402a4c17ddca6edac98f", "class_name": "RelatedNodeInfo"}}, "text": "And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates. ", "start_char_idx": 388, "end_char_idx": 699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4d3bcb0-1500-475d-bf68-316165f34a42": {"__data__": {"id_": "f4d3bcb0-1500-475d-bf68-316165f34a42", "embedding": null, "metadata": {"window": "A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform. ", "original_text": "I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85a333e6-1eed-4ae4-a932-09b03d58e180", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months. ", "original_text": "And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17bdd2bbf97767b8bfc17211765c883a609ff37a84674b450ce143df589be2d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "606fde0a-ef53-459f-8481-3c276a88c89e", "node_type": "1", "metadata": {"window": "Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs. ", "original_text": "Our oncology business continues to grow. "}, "hash": "15a20262a2ce22bc796e54389d94a136d064656f95f53ae4d9a52ec8008a8117", "class_name": "RelatedNodeInfo"}}, "text": "I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n", "start_char_idx": 699, "end_char_idx": 863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "606fde0a-ef53-459f-8481-3c276a88c89e": {"__data__": {"id_": "606fde0a-ef53-459f-8481-3c276a88c89e", "embedding": null, "metadata": {"window": "Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs. ", "original_text": "Our oncology business continues to grow. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4d3bcb0-1500-475d-bf68-316165f34a42", "node_type": "1", "metadata": {"window": "A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform. ", "original_text": "I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfd2a9dc3fe85b0276d09c3c3baf02792fbb1e226fe5d6d03004409a6eca8274", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0d315ce-0598-4950-a21b-b71441d1c22d", "node_type": "1", "metadata": {"window": "And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n ", "original_text": "We've added four practices in seven geographies and over 200 \nproviders in the last 12 months. "}, "hash": "470cc3c5a69fc3eb17267d44116a86436067fa7e34dff35ba234983b334e803e", "class_name": "RelatedNodeInfo"}}, "text": "Our oncology business continues to grow. ", "start_char_idx": 863, "end_char_idx": 904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0d315ce-0598-4950-a21b-b71441d1c22d": {"__data__": {"id_": "b0d315ce-0598-4950-a21b-b71441d1c22d", "embedding": null, "metadata": {"window": "And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n ", "original_text": "We've added four practices in seven geographies and over 200 \nproviders in the last 12 months. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "606fde0a-ef53-459f-8481-3c276a88c89e", "node_type": "1", "metadata": {"window": "Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs. ", "original_text": "Our oncology business continues to grow. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "946e6c1674679d9f6a3238cd4974e9aba24789cbe878ad5d929896e0c1d35c2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a107b99-186e-4fd1-a9a6-65188cb69aa1", "node_type": "1", "metadata": {"window": "I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.  ", "original_text": "And that's certainly going to be additive to the overall oncology platform. "}, "hash": "de27273a17304fde75ae9c278fbaeed0c29c4fdcc487972a8400d91ff6f65cba", "class_name": "RelatedNodeInfo"}}, "text": "We've added four practices in seven geographies and over 200 \nproviders in the last 12 months. ", "start_char_idx": 904, "end_char_idx": 999, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a107b99-186e-4fd1-a9a6-65188cb69aa1": {"__data__": {"id_": "6a107b99-186e-4fd1-a9a6-65188cb69aa1", "embedding": null, "metadata": {"window": "I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.  ", "original_text": "And that's certainly going to be additive to the overall oncology platform. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0d315ce-0598-4950-a21b-b71441d1c22d", "node_type": "1", "metadata": {"window": "And the investments that we've made in oncology are certainly adding to that, but the efficiency that we have and \nthe scale that we have with retail national accounts and our ability to providing ser vice specialty are really driving \na lot of this, in particular, as you think about stable utilization rates.  I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n ", "original_text": "We've added four practices in seven geographies and over 200 \nproviders in the last 12 months. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35a5e5a7790ae726c76b1f14f227d3eac16d563653a904b10e1c17df4218cd73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47920934-9c55-4b79-b8fd-bce27428e71c", "node_type": "1", "metadata": {"window": "Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs. "}, "hash": "7d908de0999258afe11ca123bdbca3007673e218a5597c61508419dfd6883a86", "class_name": "RelatedNodeInfo"}}, "text": "And that's certainly going to be additive to the overall oncology platform. ", "start_char_idx": 999, "end_char_idx": 1075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47920934-9c55-4b79-b8fd-bce27428e71c": {"__data__": {"id_": "47920934-9c55-4b79-b8fd-bce27428e71c", "embedding": null, "metadata": {"window": "Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a107b99-186e-4fd1-a9a6-65188cb69aa1", "node_type": "1", "metadata": {"window": "I also talked about the success that we're \nseeing at ClarusONE and with our generic programs, and we saw good contribution from generics during the  \nquarter.  \n \n Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.  ", "original_text": "And that's certainly going to be additive to the overall oncology platform. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b440684fa7bdca80b4c33b86b569355d2826ac5f0d38449c9464ff7e30204118", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85ad8abe-3af4-435d-9d74-43a966e5b99a", "node_type": "1", "metadata": {"window": "We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi. ", "original_text": "So that's driving the majority of the growth that we're seeing at this \npoint.  \n "}, "hash": "8187b4cfe3d31d14476126f0c432681b8714a1735b44846f46619030edc6c8c5", "class_name": "RelatedNodeInfo"}}, "text": "But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs. ", "start_char_idx": 1075, "end_char_idx": 1252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85ad8abe-3af4-435d-9d74-43a966e5b99a": {"__data__": {"id_": "85ad8abe-3af4-435d-9d74-43a966e5b99a", "embedding": null, "metadata": {"window": "We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi. ", "original_text": "So that's driving the majority of the growth that we're seeing at this \npoint.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47920934-9c55-4b79-b8fd-bce27428e71c", "node_type": "1", "metadata": {"window": "Our oncology business continues to grow.  We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c056d85c46d4e7bd47d63cf19a43522c52250ee2541b6f6c160ae0790ba651", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1648fe0b-94f0-4021-abb0-805908cea60e", "node_type": "1", "metadata": {"window": "And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.  "}, "hash": "6ba1e80e1315e29c1e2ff5770785b24c15829c6057dbd6d35a987ad1a05ac756", "class_name": "RelatedNodeInfo"}}, "text": "So that's driving the majority of the growth that we're seeing at this \npoint.  \n ", "start_char_idx": 1252, "end_char_idx": 1334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1648fe0b-94f0-4021-abb0-805908cea60e": {"__data__": {"id_": "1648fe0b-94f0-4021-abb0-805908cea60e", "embedding": null, "metadata": {"window": "And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85ad8abe-3af4-435d-9d74-43a966e5b99a", "node_type": "1", "metadata": {"window": "We've added four practices in seven geographies and over 200 \nproviders in the last 12 months.  And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi. ", "original_text": "So that's driving the majority of the growth that we're seeing at this \npoint.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40b12be99f76cc9c982d0c4865363cb8decb2a0e61ec308626fc2521c5911f56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84d92655-2f4e-4a8e-aa1b-f454bb8ce721", "node_type": "1", "metadata": {"window": "But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "A \nNext question, please?  \n "}, "hash": "1ec7b528e863715481dd173c2e619aaa2554eab4d8003498219c1589a499c15c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.  ", "start_char_idx": 1334, "end_char_idx": 1678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84d92655-2f4e-4a8e-aa1b-f454bb8ce721": {"__data__": {"id_": "84d92655-2f4e-4a8e-aa1b-f454bb8ce721", "embedding": null, "metadata": {"window": "But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1648fe0b-94f0-4021-abb0-805908cea60e", "node_type": "1", "metadata": {"window": "And that's certainly going to be additive to the overall oncology platform.  But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a225ad8eab69fe3c983c49b80b515ab93856d0b506cd9a4d68c41d0fe6cc261", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62e6612a-a112-4b85-8ac2-f4dde018a919", "node_type": "1", "metadata": {"window": "So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi. "}, "hash": "30b9dd6035a9259fd4fdef0ff37c2958dd567b1112459cd0cb0da0ea8ae3a796", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 1678, "end_char_idx": 1707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62e6612a-a112-4b85-8ac2-f4dde018a919": {"__data__": {"id_": "62e6612a-a112-4b85-8ac2-f4dde018a919", "embedding": null, "metadata": {"window": "So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84d92655-2f4e-4a8e-aa1b-f454bb8ce721", "node_type": "1", "metadata": {"window": "But what \nwe're seeing is just a st able utilization growth in prescription volume, our ability to be efficient for our customers to \ncontinue to provide good generic programs.  So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1f0528fd95aba4fcc2c8530bdd1f5ff073fe58bb0b7c9bd2f49bf920204825b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2956441-b01d-4cf7-a420-c08d9199453a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year. ", "original_text": "Please go ahead.  \n "}, "hash": "795d543f0d62c284a26ae201721788c2aaaeeda580e12541bebe3288d3528173", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi. ", "start_char_idx": 1707, "end_char_idx": 2038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2956441-b01d-4cf7-a420-c08d9199453a": {"__data__": {"id_": "e2956441-b01d-4cf7-a420-c08d9199453a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year. ", "original_text": "Please go ahead.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62e6612a-a112-4b85-8ac2-f4dde018a919", "node_type": "1", "metadata": {"window": "So that's driving the majority of the growth that we're seeing at this \npoint.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f57d69f34f73f0e1b612d4598c727044ea470675352ea71e2348e918976c3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "986aa329-e126-4d7b-b7c8-8e117dc74402", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  "}, "hash": "60dd42138b7fbe5d5e4261c17b6b5a62e50925e0c02f89f6692e68913ab30c56", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 2038, "end_char_idx": 2058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "986aa329-e126-4d7b-b7c8-8e117dc74402": {"__data__": {"id_": "986aa329-e126-4d7b-b7c8-8e117dc74402", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2956441-b01d-4cf7-a420-c08d9199453a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Inve stor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year. ", "original_text": "Please go ahead.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6eb499e45050d6d75e3be74d509c3e122d516edaf3e2eb5049e77e4c68c7696c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "623b473b-bd76-455c-a032-2c250688e504", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics. ", "original_text": "Q \nHi, thanks for taking the question. "}, "hash": "6aa5d80d0158315bc08b364111cebbd9704b7c0a69f7eecdf33a54228a84c1f0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "start_char_idx": 2058, "end_char_idx": 2391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "623b473b-bd76-455c-a032-2c250688e504": {"__data__": {"id_": "623b473b-bd76-455c-a032-2c250688e504", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics. ", "original_text": "Q \nHi, thanks for taking the question. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "986aa329-e126-4d7b-b7c8-8e117dc74402", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1dddd35e04682336be934f5f42b23ccea48ae533e4043c8efc3f84dfe9565f09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36f80ce9-4c5f-4b93-a6e9-499840629056", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n ", "original_text": "I want to go back to the  Medical segment and the cadence for the remainder of \nthe year. "}, "hash": "1bd71b3416c1b6c0945fba37aabad01750b0c56288187bef9fb653e2d43df380", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHi, thanks for taking the question. ", "start_char_idx": 2391, "end_char_idx": 2430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36f80ce9-4c5f-4b93-a6e9-499840629056": {"__data__": {"id_": "36f80ce9-4c5f-4b93-a6e9-499840629056", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n ", "original_text": "I want to go back to the  Medical segment and the cadence for the remainder of \nthe year. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "623b473b-bd76-455c-a032-2c250688e504", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics. ", "original_text": "Q \nHi, thanks for taking the question. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6eb39c5da78d2dd68272a1b36a9e49dc051136a823bc8d8b3b6de5402554edb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a310f70-e162-4942-b620-ae70095580dc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.  ", "original_text": "If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins. "}, "hash": "a513a0869d0849182d6890aa7430bbca4545686e0c041367c9c64bace8ed107f", "class_name": "RelatedNodeInfo"}}, "text": "I want to go back to the  Medical segment and the cadence for the remainder of \nthe year. ", "start_char_idx": 2430, "end_char_idx": 2520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a310f70-e162-4942-b620-ae70095580dc": {"__data__": {"id_": "4a310f70-e162-4942-b620-ae70095580dc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.  ", "original_text": "If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36f80ce9-4c5f-4b93-a6e9-499840629056", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n ", "original_text": "I want to go back to the  Medical segment and the cadence for the remainder of \nthe year. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10264dadb699d0e6dcd1828a072297e26f00f88619cd86291e191d23cef421b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eae26ce9-4f15-4374-ae50-8c34b74ab955", "node_type": "1", "metadata": {"window": "Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan. ", "original_text": "You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics. "}, "hash": "a5f4ee0b86cbaf66ea6fec546497f2999b7c07962e22227110c43a4549ea132e", "class_name": "RelatedNodeInfo"}}, "text": "If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins. ", "start_char_idx": 2520, "end_char_idx": 2662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eae26ce9-4f15-4374-ae50-8c34b74ab955": {"__data__": {"id_": "eae26ce9-4f15-4374-ae50-8c34b74ab955", "embedding": null, "metadata": {"window": "Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan. ", "original_text": "You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a310f70-e162-4942-b620-ae70095580dc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.  ", "original_text": "If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "feee6ea93e7a3db71f0c157dbf0d1f445d3ec09a2b5687b082afbd2bd9cec54f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9642904c-d1b1-426b-a3e9-fd53e389f78a", "node_type": "1", "metadata": {"window": "I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n ", "original_text": "How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n "}, "hash": "086dbcaac86e165ce560b35f9eb0e4bd91bc6edb03587ba170ecb6bcdb332fcc", "class_name": "RelatedNodeInfo"}}, "text": "You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics. ", "start_char_idx": 2662, "end_char_idx": 2774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9642904c-d1b1-426b-a3e9-fd53e389f78a": {"__data__": {"id_": "9642904c-d1b1-426b-a3e9-fd53e389f78a", "embedding": null, "metadata": {"window": "I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n ", "original_text": "How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eae26ce9-4f15-4374-ae50-8c34b74ab955", "node_type": "1", "metadata": {"window": "Q \nHi, thanks for taking the question.  I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan. ", "original_text": "You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a4d5313c434bf05deea7fc86fce4d8be727af251fe87a0dace365420ba0b2f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e6f584e-e8dc-43e1-8d20-b93027151441", "node_type": "1", "metadata": {"window": "If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.  "}, "hash": "08338716afffb405be384139613c0c9a700399bdb8598a5c3e440473a73900c5", "class_name": "RelatedNodeInfo"}}, "text": "How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n ", "start_char_idx": 2774, "end_char_idx": 2935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e6f584e-e8dc-43e1-8d20-b93027151441": {"__data__": {"id_": "1e6f584e-e8dc-43e1-8d20-b93027151441", "embedding": null, "metadata": {"window": "If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9642904c-d1b1-426b-a3e9-fd53e389f78a", "node_type": "1", "metadata": {"window": "I want to go back to the  Medical segment and the cadence for the remainder of \nthe year.  If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n ", "original_text": "How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97b5de444a96f445f5054f31e5dbe14feaee790014f15f0affc2c7fab4edfda5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1debfc02-c90c-495d-a86f-327283ac34c1", "node_type": "1", "metadata": {"window": "You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n ", "original_text": "A \nYes, it's a great question, Dan. "}, "hash": "ef16d3cc7e7412531fedcbdf3187b4f155727c916c17a049816d44191761ebbf", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2935, "end_char_idx": 3296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1debfc02-c90c-495d-a86f-327283ac34c1": {"__data__": {"id_": "1debfc02-c90c-495d-a86f-327283ac34c1", "embedding": null, "metadata": {"window": "You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n ", "original_text": "A \nYes, it's a great question, Dan. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e6f584e-e8dc-43e1-8d20-b93027151441", "node_type": "1", "metadata": {"window": "If I just look at guidance, it implies around a 4% increase in both revenue and AOI from the first half to \nthe second half, so flat margins.  You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0d053be51650f8e576edc6fa518e224fad08edb8064d766b71d481a40f2936f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "914ec3cc-ee49-4afb-bb48-7adcb4209ff4", "node_type": "1", "metadata": {"window": "How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "original_text": "I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n "}, "hash": "91bff68df169a5dda87fcc8f834f45286039b74794a1bba165adda65019a9ef3", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes, it's a great question, Dan. ", "start_char_idx": 3296, "end_char_idx": 3332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "914ec3cc-ee49-4afb-bb48-7adcb4209ff4": {"__data__": {"id_": "914ec3cc-ee49-4afb-bb48-7adcb4209ff4", "embedding": null, "metadata": {"window": "How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "original_text": "I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1debfc02-c90c-495d-a86f-327283ac34c1", "node_type": "1", "metadata": {"window": "You mentioned a less severe flu season and some inv estments you're making in \ndistribution and data analytics.  How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n ", "original_text": "A \nYes, it's a great question, Dan. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4de7e87d41d5ee3964c75cfd445f27136fdb59dddab46ce4c6e0a5aac9b7478f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "061376ca-db2c-4a9d-9c2f-ab27ba4e786f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  "}, "hash": "dcd4ed0a9a0131c207372dcf4073c6f7ce46adc690c86d7f78688926cc171a38", "class_name": "RelatedNodeInfo"}}, "text": "I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n ", "start_char_idx": 3332, "end_char_idx": 3465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "061376ca-db2c-4a9d-9c2f-ab27ba4e786f": {"__data__": {"id_": "061376ca-db2c-4a9d-9c2f-ab27ba4e786f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "914ec3cc-ee49-4afb-bb48-7adcb4209ff4", "node_type": "1", "metadata": {"window": "How should we be thinking about the cadence of AOI for the next two quarters, \nparticularly as we think about some of those larger investments you're making?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "original_text": "I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b4e97c8c604838b260d27c46837044f9c59d438cb34ed17587b0a9dd25e23a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53096818-c6d9-4d9c-9fe9-f8728ef5be2a", "node_type": "1", "metadata": {"window": "A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question please?  \n "}, "hash": "f2f6bec078868910f3cc868a06e35655c1a011ad67991fec228b52835afffbf2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "start_char_idx": 3465, "end_char_idx": 3808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53096818-c6d9-4d9c-9fe9-f8728ef5be2a": {"__data__": {"id_": "53096818-c6d9-4d9c-9fe9-f8728ef5be2a", "embedding": null, "metadata": {"window": "A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question please?  \n ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "061376ca-db2c-4a9d-9c2f-ab27ba4e786f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Offi cer & Executive Vice President, McKesson Corp.   A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d61987decc2bd6c99ae982a26a0704d9205a9b8000d962d26042e283924aadf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "875bfa49-3199-4c5a-b969-ae447d744ac1", "node_type": "1", "metadata": {"window": "I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. "}, "hash": "20148a3da29986d03c981705f17740d8527ed40c0e61a5e33447f1f12241ab0a", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question please?  \n ", "start_char_idx": 3808, "end_char_idx": 3836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "875bfa49-3199-4c5a-b969-ae447d744ac1": {"__data__": {"id_": "875bfa49-3199-4c5a-b969-ae447d744ac1", "embedding": null, "metadata": {"window": "I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53096818-c6d9-4d9c-9fe9-f8728ef5be2a", "node_type": "1", "metadata": {"window": "A \nYes, it's a great question, Dan.  I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question please?  \n ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6904dda4c5e56169b3db6c751295c02627ea4081208510c1843194015eb2a616", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a3834c4-cd50-4e05-a2bc-815ba41302c1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n", "original_text": "Please go ahead.  \n "}, "hash": "931e8456f2d90351bd9a8d8d36b8c6fe5a860b54dfab9aca56e2a3fc374fb4b2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "start_char_idx": 3836, "end_char_idx": 4171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a3834c4-cd50-4e05-a2bc-815ba41302c1": {"__data__": {"id_": "4a3834c4-cd50-4e05-a2bc-815ba41302c1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n", "original_text": "Please go ahead.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "875bfa49-3199-4c5a-b969-ae447d744ac1", "node_type": "1", "metadata": {"window": "I think for modeling purposes, I would guide you to model something very similar \nin terms of growth rates to the second quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "933e861038c59189fb67cab3af57dff5f7095367e91dd612a86292501a398969", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62fa8959-8242-48a3-ba24-855eef515840", "node_type": "1", "metadata": {"window": "A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  "}, "hash": "803933fafe5e17f9327da1124a240cfd5a90b95613461a9ebb167dffba9defd8", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 2038, "end_char_idx": 2058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62fa8959-8242-48a3-ba24-855eef515840": {"__data__": {"id_": "62fa8959-8242-48a3-ba24-855eef515840", "embedding": null, "metadata": {"window": "A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a3834c4-cd50-4e05-a2bc-815ba41302c1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n", "original_text": "Please go ahead.  \n ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27fe25e78da00c997a9a922ca8cb0f135df419e34f18f5119e5fb7223183f29c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "502ec097-5874-4f60-b187-5295babe8d81", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "original_text": "Q \nGood afternoon and thanks for taking the questions, one for Brian. "}, "hash": "c387aa3391d70be2dbd507e3c9f151cbedb8c1c02f067727ce5e50b2c1715d47", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 4191, "end_char_idx": 4508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "502ec097-5874-4f60-b187-5295babe8d81": {"__data__": {"id_": "502ec097-5874-4f60-b187-5295babe8d81", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "original_text": "Q \nGood afternoon and thanks for taking the questions, one for Brian. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62fa8959-8242-48a3-ba24-855eef515840", "node_type": "1", "metadata": {"window": "A \nNext question please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9b95bbc5eaaf681ab7cc3beb690912c0d07e012b3f751e10cd879cfb01f9337", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d19f299-3b68-4093-9ce5-f1b9169636c0", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "original_text": "You mention ed the strength of ClarusONE. \n"}, "hash": "e4e349b37b53690a29475f6e3dac30f29764d0381673122d1fdebeebe0692452", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood afternoon and thanks for taking the questions, one for Brian. ", "start_char_idx": 4508, "end_char_idx": 4578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d19f299-3b68-4093-9ce5-f1b9169636c0": {"__data__": {"id_": "8d19f299-3b68-4093-9ce5-f1b9169636c0", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "original_text": "You mention ed the strength of ClarusONE. \n", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "502ec097-5874-4f60-b187-5295babe8d81", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "original_text": "Q \nGood afternoon and thanks for taking the questions, one for Brian. ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a95c399002657d5b2da5d00c3a461fbc0ff85bbaa501b2d6841213d2f3b62717", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0fd6692-d25b-4ad8-84cc-bdb0a5bec585", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "original_text": "Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  "}, "hash": "40403782e4b818d683807a21f267af172bb2da4d31e37302fe4a75e3129612f7", "class_name": "RelatedNodeInfo"}}, "text": "You mention ed the strength of ClarusONE. \n", "start_char_idx": 4578, "end_char_idx": 4621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0fd6692-d25b-4ad8-84cc-bdb0a5bec585": {"__data__": {"id_": "e0fd6692-d25b-4ad8-84cc-bdb0a5bec585", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "original_text": "Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "655ff34e-0463-4636-b472-ebdfd130922f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eceb412a633b11521e348e3d183d276b10ae27f12dbba6ddfaed2d71222090", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d19f299-3b68-4093-9ce5-f1b9169636c0", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "original_text": "You mention ed the strength of ClarusONE. \n", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31d993ca9322409b1dfcc3fd204fd0f4cd06374d09ee0528491e278e41168ab3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dd2083e-5103-4590-81f1-3833e234b3fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time? ", "original_text": "McKesson Corp.  "}, "hash": "43c102ebca70cbd2491b79d5250c929ea17222be37b80521a6e7364ffc6be41a", "class_name": "RelatedNodeInfo"}}, "text": "Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "start_char_idx": 4621, "end_char_idx": 4733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dd2083e-5103-4590-81f1-3833e234b3fb": {"__data__": {"id_": "8dd2083e-5103-4590-81f1-3833e234b3fb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time? ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0fd6692-d25b-4ad8-84cc-bdb0a5bec585", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon and thanks for taking the questions, one for Brian.  You mention ed the strength of ClarusONE. \n Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "original_text": "Given the recent customer bankruptcy you mentioned, are you assuming any volume lost for ClarusONE over \ntime?  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd514d44a0cd0583c70c77d5a1968154288ae026e6ca6d152a87adf7558ba854", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "234894fa-bcd9-4f39-87ca-14f793cc9cd7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt. "}, "hash": "6b24ebd3da01b8d4febac2ba206b80990beda9aaceda1b2a43d768cd2661504e", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "234894fa-bcd9-4f39-87ca-14f793cc9cd7": {"__data__": {"id_": "234894fa-bcd9-4f39-87ca-14f793cc9cd7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dd2083e-5103-4590-81f1-3833e234b3fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time? ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30356019f3c727cc2a404927d8e7496eda2503c2c61a31fbf88b08fced8ac554", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64c1a63f-2e39-4c45-be3e-a4d0a77aca59", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Within the RxTS segment, you guys did a large restructuring in March. "}, "hash": "819ef5dc945d901e1e6c0167f27ba8b4a1d052dcc03c2b1d48a23b690700c305", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt. ", "start_char_idx": 16, "end_char_idx": 207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64c1a63f-2e39-4c45-be3e-a4d0a77aca59": {"__data__": {"id_": "64c1a63f-2e39-4c45-be3e-a4d0a77aca59", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Within the RxTS segment, you guys did a large restructuring in March. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "234894fa-bcd9-4f39-87ca-14f793cc9cd7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd911146a38f0d35b0eb693782c5f301f66d276ae4f7e51c672de625fb780662", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da9053f3-2d07-4256-8f45-5dd93a4412b6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE. ", "original_text": "Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time? "}, "hash": "8cb3c9a81f43257cd97689049dd07f8649b7225e105168887413c22e54292bc5", "class_name": "RelatedNodeInfo"}}, "text": "Within the RxTS segment, you guys did a large restructuring in March. ", "start_char_idx": 207, "end_char_idx": 277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da9053f3-2d07-4256-8f45-5dd93a4412b6": {"__data__": {"id_": "da9053f3-2d07-4256-8f45-5dd93a4412b6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE. ", "original_text": "Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time? ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64c1a63f-2e39-4c45-be3e-a4d0a77aca59", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Within the RxTS segment, you guys did a large restructuring in March. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba9acfaa8d298f12c22831dffb3bf72c6b47a9027b6df2257071f372050096ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4ec92a3-d28b-4d37-a34a-d871f0dbb1c6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart. ", "original_text": "Thanks.  \n "}, "hash": "54fc3d8423352d39a2bb9358379e8c7547fa0a3dced295b508e3edc751954eb2", "class_name": "RelatedNodeInfo"}}, "text": "Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time? ", "start_char_idx": 277, "end_char_idx": 390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4ec92a3-d28b-4d37-a34a-d871f0dbb1c6": {"__data__": {"id_": "d4ec92a3-d28b-4d37-a34a-d871f0dbb1c6", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart. ", "original_text": "Thanks.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da9053f3-2d07-4256-8f45-5dd93a4412b6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE. ", "original_text": "Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time? ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47edd580d4925133e42787348a5b64cc86ce86f5b2559df36148be207c7d4963", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5565ee3-094e-49a7-9900-8bc4139457a5", "node_type": "1", "metadata": {"window": "Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "249c24f2fdc0127ffc5ccf75650b3cad7d9c8ff6989b3abd0719c3f2a7b149c9", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 390, "end_char_idx": 401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5565ee3-094e-49a7-9900-8bc4139457a5": {"__data__": {"id_": "c5565ee3-094e-49a7-9900-8bc4139457a5", "embedding": null, "metadata": {"window": "Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4ec92a3-d28b-4d37-a34a-d871f0dbb1c6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart. ", "original_text": "Thanks.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5c0ab7d25b5aa25ce634282066381672124ff57de205dada262fb9c3711e684", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f49c33b6-4fb2-41c2-af55-c7a5c9f6a957", "node_type": "1", "metadata": {"window": "Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there. ", "original_text": "A \nLet me start with your question on ClarusONE. "}, "hash": "9b5ca43225efdf262ebfaf19dbee3ce31dafe0f30e7a025e8e68176127cad777", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 401, "end_char_idx": 745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f49c33b6-4fb2-41c2-af55-c7a5c9f6a957": {"__data__": {"id_": "f49c33b6-4fb2-41c2-af55-c7a5c9f6a957", "embedding": null, "metadata": {"window": "Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there. ", "original_text": "A \nLet me start with your question on ClarusONE. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5565ee3-094e-49a7-9900-8bc4139457a5", "node_type": "1", "metadata": {"window": "Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f367f71b8b1803550294ccc2f8a2e8007d84a54158b56f02bfdbc6171df205ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d17605cf-f4b5-4b7d-84ef-6cf4bccea578", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow. ", "original_text": "We obviously have a scaled sourcing engine and partnership with \nWalmart. "}, "hash": "6da152a3e0ecd2b755ad6f051560fb46f4eb16bb4d4155824940a0fb6e78f8bb", "class_name": "RelatedNodeInfo"}}, "text": "A \nLet me start with your question on ClarusONE. ", "start_char_idx": 745, "end_char_idx": 794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d17605cf-f4b5-4b7d-84ef-6cf4bccea578": {"__data__": {"id_": "d17605cf-f4b5-4b7d-84ef-6cf4bccea578", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow. ", "original_text": "We obviously have a scaled sourcing engine and partnership with \nWalmart. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f49c33b6-4fb2-41c2-af55-c7a5c9f6a957", "node_type": "1", "metadata": {"window": "Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there. ", "original_text": "A \nLet me start with your question on ClarusONE. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f679acb848b13aa286277ddacdba2ddebb42b9b15ec8613dc151b21e68cf5a5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cbd1918-37d1-4822-ada8-98b51c9b9a23", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business. ", "original_text": "We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles. "}, "hash": "65a8a1c099e6d78cadf0a6b7b487da3286837eec837e4c28e86963fc1bfb6154", "class_name": "RelatedNodeInfo"}}, "text": "We obviously have a scaled sourcing engine and partnership with \nWalmart. ", "start_char_idx": 794, "end_char_idx": 868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cbd1918-37d1-4822-ada8-98b51c9b9a23": {"__data__": {"id_": "9cbd1918-37d1-4822-ada8-98b51c9b9a23", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business. ", "original_text": "We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d17605cf-f4b5-4b7d-84ef-6cf4bccea578", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow. ", "original_text": "We obviously have a scaled sourcing engine and partnership with \nWalmart. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca85223edc8a1f9be331db8b275e1ae118ac99e91d04f5e6124010a33caa8300", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbd194c6-0bd9-43b0-b9cf-1131fb20b70b", "node_type": "1", "metadata": {"window": "A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n ", "original_text": "And so we're very confident in our position there. "}, "hash": "ee627c56ddc9c426b9785f0a03cc574c93686415c0b83683472f509f1958a507", "class_name": "RelatedNodeInfo"}}, "text": "We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles. ", "start_char_idx": 868, "end_char_idx": 986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbd194c6-0bd9-43b0-b9cf-1131fb20b70b": {"__data__": {"id_": "fbd194c6-0bd9-43b0-b9cf-1131fb20b70b", "embedding": null, "metadata": {"window": "A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n ", "original_text": "And so we're very confident in our position there. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cbd1918-37d1-4822-ada8-98b51c9b9a23", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business. ", "original_text": "We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6bb3fa46864e774a2f89411f9e40995e14251474a7c491a58689e9e5f0ae43f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0af2bae0-63ed-4c8a-b04f-4b84f2b9f747", "node_type": "1", "metadata": {"window": "We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "original_text": "And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow. "}, "hash": "cd4212f2fd9bb445cbc541d623b89fe1093c13975ce5a9100f7141bb9a94946f", "class_name": "RelatedNodeInfo"}}, "text": "And so we're very confident in our position there. ", "start_char_idx": 986, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0af2bae0-63ed-4c8a-b04f-4b84f2b9f747": {"__data__": {"id_": "0af2bae0-63ed-4c8a-b04f-4b84f2b9f747", "embedding": null, "metadata": {"window": "We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "original_text": "And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbd194c6-0bd9-43b0-b9cf-1131fb20b70b", "node_type": "1", "metadata": {"window": "A \nLet me start with your question on ClarusONE.  We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n ", "original_text": "And so we're very confident in our position there. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8ad8b678852e3ad0d0a10075f478f91b3907ac23506488b3c1d3d3d1624c760", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa847e2a-124e-4ffa-a288-89c463beea90", "node_type": "1", "metadata": {"window": "We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian. ", "original_text": "So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business. "}, "hash": "b958cf70971f5af30a6da197a554fb97d002a0684e4321e656d2afe4959f66f9", "class_name": "RelatedNodeInfo"}}, "text": "And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow. ", "start_char_idx": 1037, "end_char_idx": 1152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa847e2a-124e-4ffa-a288-89c463beea90": {"__data__": {"id_": "fa847e2a-124e-4ffa-a288-89c463beea90", "embedding": null, "metadata": {"window": "We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian. ", "original_text": "So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0af2bae0-63ed-4c8a-b04f-4b84f2b9f747", "node_type": "1", "metadata": {"window": "We obviously have a scaled sourcing engine and partnership with \nWalmart.  We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "original_text": "And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a137f47e959b76eec27147f7cf3c78fbcdeb9725b7f660bc80b5e6f059def532", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60fc3f34-ec44-4b05-977e-457e58ae0784", "node_type": "1", "metadata": {"window": "And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023. ", "original_text": "Britt, do you want to take the second?  \n "}, "hash": "fc44b93c9cbba88e9d59e8ca5993e83294dae9d385829d2c3b7da58788106ce2", "class_name": "RelatedNodeInfo"}}, "text": "So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business. ", "start_char_idx": 1152, "end_char_idx": 1256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60fc3f34-ec44-4b05-977e-457e58ae0784": {"__data__": {"id_": "60fc3f34-ec44-4b05-977e-457e58ae0784", "embedding": null, "metadata": {"window": "And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023. ", "original_text": "Britt, do you want to take the second?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa847e2a-124e-4ffa-a288-89c463beea90", "node_type": "1", "metadata": {"window": "We believe we've got leading scale and volume and a very mature team that has been through multiple \nsourcing cycles.  And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian. ", "original_text": "So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b721bf8ca1589ae4b9be5534b99964ebd7d07f8886645e5637a5d16e59a21ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a93a4f98-ebd9-413f-a3f5-195adc191704", "node_type": "1", "metadata": {"window": "And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  "}, "hash": "aff51aac523310728694417d980dd7e4756fc4285ad31551319ca3a2aab7ab28", "class_name": "RelatedNodeInfo"}}, "text": "Britt, do you want to take the second?  \n ", "start_char_idx": 1256, "end_char_idx": 1298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a93a4f98-ebd9-413f-a3f5-195adc191704": {"__data__": {"id_": "a93a4f98-ebd9-413f-a3f5-195adc191704", "embedding": null, "metadata": {"window": "And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60fc3f34-ec44-4b05-977e-457e58ae0784", "node_type": "1", "metadata": {"window": "And so we're very confident in our position there.  And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023. ", "original_text": "Britt, do you want to take the second?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ae9756cb784bd38ea5c4d85563df3506841dfdea1d4ef0f4dd8a6940fe6c3a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee580603-ea2c-4456-a7a9-d0b155d4cf77", "node_type": "1", "metadata": {"window": "So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance. ", "original_text": "A \nYes, I'll take the second one, Brian. "}, "hash": "c1eef59824d5f488d663dfc699a30adeb04172799b308a5f35cf5e2cc7f5bdaa", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "start_char_idx": 1298, "end_char_idx": 1659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee580603-ea2c-4456-a7a9-d0b155d4cf77": {"__data__": {"id_": "ee580603-ea2c-4456-a7a9-d0b155d4cf77", "embedding": null, "metadata": {"window": "So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance. ", "original_text": "A \nYes, I'll take the second one, Brian. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a93a4f98-ebd9-413f-a3f5-195adc191704", "node_type": "1", "metadata": {"window": "And as the pharma business in general grows, \nthe vo lumes that flow through the Clarus sourcing engine also grow.  So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9dc74449c4e8c3cd6dd460c534f6c50ca32476b1f63b75e847310af156fcb768", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dce5764-bb24-4a04-8195-d29e4551ced2", "node_type": "1", "metadata": {"window": "Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n ", "original_text": "As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023. "}, "hash": "3f5938b0b974e308def194a9c0c66f73aaac1ea022135d3c26d35633fb22e90c", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes, I'll take the second one, Brian. ", "start_char_idx": 1659, "end_char_idx": 1700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dce5764-bb24-4a04-8195-d29e4551ced2": {"__data__": {"id_": "4dce5764-bb24-4a04-8195-d29e4551ced2", "embedding": null, "metadata": {"window": "Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n ", "original_text": "As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee580603-ea2c-4456-a7a9-d0b155d4cf77", "node_type": "1", "metadata": {"window": "So we continue to have a lot of confidence in \nClarusONE and their ability to perform for the business.  Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance. ", "original_text": "A \nYes, I'll take the second one, Brian. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "746ec6a1a8db0bc560c317e18e9c27e543a142d9502564c6ae75a203df7ecb39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73da0e7d-4dbb-47b9-9766-f9ca2f28c69e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "We also incurred additional restructuring charges in the  first half of \nfiscal 2024. "}, "hash": "2c5a8fb03c8b04235c4e3c52d03fcc4b64bb0e2346709b6a22497f0da1bde076", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023. ", "start_char_idx": 1700, "end_char_idx": 1825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73da0e7d-4dbb-47b9-9766-f9ca2f28c69e": {"__data__": {"id_": "73da0e7d-4dbb-47b9-9766-f9ca2f28c69e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "We also incurred additional restructuring charges in the  first half of \nfiscal 2024. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dce5764-bb24-4a04-8195-d29e4551ced2", "node_type": "1", "metadata": {"window": "Britt, do you want to take the second?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n ", "original_text": "As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b99bf2a4d85fa22607116475a7ea675b32e949658780af4de1ba92fc0e370b37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6220d9a-2045-4cf9-8571-bc95731864e4", "node_type": "1", "metadata": {"window": "A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n ", "original_text": "And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance. "}, "hash": "6b23cc85f64be1522d703912b056f517b4490a5cd7d6c54b353b61427d16fd16", "class_name": "RelatedNodeInfo"}}, "text": "We also incurred additional restructuring charges in the  first half of \nfiscal 2024. ", "start_char_idx": 1825, "end_char_idx": 1911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6220d9a-2045-4cf9-8571-bc95731864e4": {"__data__": {"id_": "d6220d9a-2045-4cf9-8571-bc95731864e4", "embedding": null, "metadata": {"window": "A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n ", "original_text": "And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73da0e7d-4dbb-47b9-9766-f9ca2f28c69e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "We also incurred additional restructuring charges in the  first half of \nfiscal 2024. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b16c732829d81e816f3d0eeb744d61968ab1740a3f68f7c605aea98cedde1f9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "896b70ca-5110-4758-95df-5b588781b401", "node_type": "1", "metadata": {"window": "As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "original_text": "So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n "}, "hash": "eb6741b5f8853b769c14b5569ba5028ffce37fceb441e35d1678348b730e10e9", "class_name": "RelatedNodeInfo"}}, "text": "And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance. ", "start_char_idx": 1911, "end_char_idx": 2040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "896b70ca-5110-4758-95df-5b588781b401": {"__data__": {"id_": "896b70ca-5110-4758-95df-5b588781b401", "embedding": null, "metadata": {"window": "As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "original_text": "So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6220d9a-2045-4cf9-8571-bc95731864e4", "node_type": "1", "metadata": {"window": "A \nYes, I'll take the second one, Brian.  As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n ", "original_text": "And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbe628319afdc804053136b045d28c05e1845dbe3885bd38801661049f79cad9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f133897-f203-466b-b589-a93214e3e9a6", "node_type": "1", "metadata": {"window": "We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  "}, "hash": "38938f2ec21ab9e050d46d19fabe1c618bf589bdf7ca9acd6e77c6ccd1717472", "class_name": "RelatedNodeInfo"}}, "text": "So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n ", "start_char_idx": 2040, "end_char_idx": 2317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f133897-f203-466b-b589-a93214e3e9a6": {"__data__": {"id_": "8f133897-f203-466b-b589-a93214e3e9a6", "embedding": null, "metadata": {"window": "We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "896b70ca-5110-4758-95df-5b588781b401", "node_type": "1", "metadata": {"window": "As it relates to your question on the restructuring, we did incur certain \ncharges in the fourth quarter of our fiscal 2023.  We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "original_text": "So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8f667ee470cb1a59ec6622baa44cd3ee29dbf36003d5c9bdd5957c163b6ee01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97780a22-77a7-4a65-96e1-380f5c3e37a0", "node_type": "1", "metadata": {"window": "And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "A \nNext question  please?  \n "}, "hash": "dea6e50803266bc6fe6a06024bbc503ff3606b3f7f2dc1c71d61ad55c6b6ac42", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "start_char_idx": 2317, "end_char_idx": 2660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97780a22-77a7-4a65-96e1-380f5c3e37a0": {"__data__": {"id_": "97780a22-77a7-4a65-96e1-380f5c3e37a0", "embedding": null, "metadata": {"window": "And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "A \nNext question  please?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f133897-f203-466b-b589-a93214e3e9a6", "node_type": "1", "metadata": {"window": "We also incurred additional restructuring charges in the  first half of \nfiscal 2024.  And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd47aa383913da79b09564649ea0a366b9f515e5a297276278b5a0789b07f790", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f2a2b35-cbda-43b9-8172-e4c820b0cc22", "node_type": "1", "metadata": {"window": "So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. "}, "hash": "a8ec0829bfb8790c9ebbdc586f0fb1425da095cc4c15ad795b1faffe9d71dd28", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question  please?  \n ", "start_char_idx": 2660, "end_char_idx": 2689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f2a2b35-cbda-43b9-8172-e4c820b0cc22": {"__data__": {"id_": "0f2a2b35-cbda-43b9-8172-e4c820b0cc22", "embedding": null, "metadata": {"window": "So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97780a22-77a7-4a65-96e1-380f5c3e37a0", "node_type": "1", "metadata": {"window": "And so we're still in the process of finalizing the programs and the savings that we have are \ncontemplated within our guidance.  So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "A \nNext question  please?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ad889f45f5651d7e99ceeed7e69728112d06e738df83a4f11bb9ed5e6b2d579", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19efd9f4-ce4c-4e49-9577-0878f116a110", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment? ", "original_text": "Please go ahead.  \n "}, "hash": "d7d2e89e1d9d137b224c89f63b5d4b5ac431528daca1cfa2475511e0678c2131", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "start_char_idx": 2689, "end_char_idx": 3024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19efd9f4-ce4c-4e49-9577-0878f116a110": {"__data__": {"id_": "19efd9f4-ce4c-4e49-9577-0878f116a110", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment? ", "original_text": "Please go ahead.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f2a2b35-cbda-43b9-8172-e4c820b0cc22", "node_type": "1", "metadata": {"window": "So the fact that we started this program in fiscal fourth quarter of 2023, \ncontinue the program, rea lly taking charges and organizing and integrating through the first half of 2024, we \ncertainly haven't seen all of the benefits from those programs to this point in time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20aeeed7980f6b71ce2e16053f6b4185d72b9d83d75662864a557736a2aed3c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cb5c591-c725-4975-b797-062e988b9c9e", "node_type": "1", "metadata": {"window": "A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. "}, "hash": "a65632c7e3bb5bf8030a2a465766f0e459f37c4dd1d6d48899f7bda645104b46", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 3024, "end_char_idx": 3044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cb5c591-c725-4975-b797-062e988b9c9e": {"__data__": {"id_": "2cb5c591-c725-4975-b797-062e988b9c9e", "embedding": null, "metadata": {"window": "A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19efd9f4-ce4c-4e49-9577-0878f116a110", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment? ", "original_text": "Please go ahead.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e565818a436dcfd389232a835d748b7d5dd103458431af69c9909843f5e4b93b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51a2a5d2-3b6f-45fb-a60a-8c0bf65a1c7f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n", "original_text": "LLC  Q \nGreat, thanks for taking the question, two questions here. "}, "hash": "3f4bb4259caaf8f53d8beea5b4127ce59be33be97e525888cf5e1e6c5a97e986", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 3044, "end_char_idx": 3367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51a2a5d2-3b6f-45fb-a60a-8c0bf65a1c7f": {"__data__": {"id_": "51a2a5d2-3b6f-45fb-a60a-8c0bf65a1c7f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n", "original_text": "LLC  Q \nGreat, thanks for taking the question, two questions here. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cb5c591-c725-4975-b797-062e988b9c9e", "node_type": "1", "metadata": {"window": "A \nNext question  please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d2c80478cc276ee51a6aa8dc2ae5951156374e235ce8b3cf5d0ca3f66a97c16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "727b75f1-829c-482d-ba85-e2fa8831c53f", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here? ", "original_text": "I guess, are you seeing the generic or easing gene ric \ndeflation environment? "}, "hash": "ad91be3a989485b08197f6c97981ff12e18af1df4f6fe98221814902764f82c8", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nGreat, thanks for taking the question, two questions here. ", "start_char_idx": 3367, "end_char_idx": 3434, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "727b75f1-829c-482d-ba85-e2fa8831c53f": {"__data__": {"id_": "727b75f1-829c-482d-ba85-e2fa8831c53f", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here? ", "original_text": "I guess, are you seeing the generic or easing gene ric \ndeflation environment? ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51a2a5d2-3b6f-45fb-a60a-8c0bf65a1c7f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n", "original_text": "LLC  Q \nGreat, thanks for taking the question, two questions here. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de3401206536b7fb24aacfc78e062004c65015b0e829075edf329107beb3528d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "357ba806-d4f1-437c-8d44-700e12490def", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus? ", "original_text": "Has that been a material driver for you? "}, "hash": "f17ec503f7ced6945cd97bb51cf28112b821bd3118727873fbdbda9125a3905b", "class_name": "RelatedNodeInfo"}}, "text": "I guess, are you seeing the generic or easing gene ric \ndeflation environment? ", "start_char_idx": 3434, "end_char_idx": 3513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "357ba806-d4f1-437c-8d44-700e12490def": {"__data__": {"id_": "357ba806-d4f1-437c-8d44-700e12490def", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus? ", "original_text": "Has that been a material driver for you? ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "727b75f1-829c-482d-ba85-e2fa8831c53f", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here? ", "original_text": "I guess, are you seeing the generic or easing gene ric \ndeflation environment? ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb641125303a0682e7267b52f87f646d1405614d08a3b046bace70ab230a8a97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a7173d8-24f8-4ce2-9d7a-3c456cba7646", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like? ", "original_text": "Just to follow up on the generic side.  \n \n"}, "hash": "3d87741423ab327d286c7370863a7de8b979fd6367c71cd9f662bc941d73e126", "class_name": "RelatedNodeInfo"}}, "text": "Has that been a material driver for you? ", "start_char_idx": 3513, "end_char_idx": 3554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a7173d8-24f8-4ce2-9d7a-3c456cba7646": {"__data__": {"id_": "3a7173d8-24f8-4ce2-9d7a-3c456cba7646", "embedding": null, "metadata": {"window": "LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like? ", "original_text": "Just to follow up on the generic side.  \n \n", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "357ba806-d4f1-437c-8d44-700e12490def", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus? ", "original_text": "Has that been a material driver for you? ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ec6c17ff305c8aa83998176cd246d69da3ebbe41ee53baf7faa1b823b51fcd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a40bca46-555d-4fae-841e-671d6158a0e6", "node_type": "1", "metadata": {"window": "I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n ", "original_text": "And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here? "}, "hash": "da3da80f483aad143646d4577bceceafd1e167a56ea16eb8a20f4068d95b432d", "class_name": "RelatedNodeInfo"}}, "text": "Just to follow up on the generic side.  \n \n", "start_char_idx": 3554, "end_char_idx": 3597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a40bca46-555d-4fae-841e-671d6158a0e6": {"__data__": {"id_": "a40bca46-555d-4fae-841e-671d6158a0e6", "embedding": null, "metadata": {"window": "I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n ", "original_text": "And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here? ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a7173d8-24f8-4ce2-9d7a-3c456cba7646", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat, thanks for taking the question, two questions here.  I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like? ", "original_text": "Just to follow up on the generic side.  \n \n", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "963194ccb4ef3ef34e8567286c6d2a4a3c35548926712f2493da15b13f251219", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc89b49e-82fd-4edf-9214-6047a51d2bf3", "node_type": "1", "metadata": {"window": "Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Where is the focus? "}, "hash": "06d1d574f4a1c0342939293a44fd93a912247e9a54ec492f9c1a8f297769f3e7", "class_name": "RelatedNodeInfo"}}, "text": "And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here? ", "start_char_idx": 3597, "end_char_idx": 3722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc89b49e-82fd-4edf-9214-6047a51d2bf3": {"__data__": {"id_": "bc89b49e-82fd-4edf-9214-6047a51d2bf3", "embedding": null, "metadata": {"window": "Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Where is the focus? ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a40bca46-555d-4fae-841e-671d6158a0e6", "node_type": "1", "metadata": {"window": "I guess, are you seeing the generic or easing gene ric \ndeflation environment?  Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n ", "original_text": "And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here? ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e77c595c4279230285ea83683d1274110c84d8b4913c1a379ec3a990c9f220fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d700012-1a5b-4944-a2d0-233de6c8835a", "node_type": "1", "metadata": {"window": "Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n ", "original_text": "What  does the M&A pipeline look like? "}, "hash": "d8f5312e104ba64d7371d949040a426019a2a8d556bb692da75e07f9d5376556", "class_name": "RelatedNodeInfo"}}, "text": "Where is the focus? ", "start_char_idx": 3722, "end_char_idx": 3742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d700012-1a5b-4944-a2d0-233de6c8835a": {"__data__": {"id_": "6d700012-1a5b-4944-a2d0-233de6c8835a", "embedding": null, "metadata": {"window": "Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n ", "original_text": "What  does the M&A pipeline look like? ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc89b49e-82fd-4edf-9214-6047a51d2bf3", "node_type": "1", "metadata": {"window": "Has that been a material driver for you?  Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Where is the focus? ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8841e6cc53821d2bf9773514f9f42d81ce71523069d0d700d274d1760ec344e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f312b0fa-7682-43f1-9792-d88f58ecc691", "node_type": "1", "metadata": {"window": "And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Thanks.  \n "}, "hash": "dcb6ca19bf8aaf13cbc525670b0c0ae483820216e9762c8e3607c9a66d700e36", "class_name": "RelatedNodeInfo"}}, "text": "What  does the M&A pipeline look like? ", "start_char_idx": 3742, "end_char_idx": 3781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f312b0fa-7682-43f1-9792-d88f58ecc691": {"__data__": {"id_": "f312b0fa-7682-43f1-9792-d88f58ecc691", "embedding": null, "metadata": {"window": "And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Thanks.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d700012-1a5b-4944-a2d0-233de6c8835a", "node_type": "1", "metadata": {"window": "Just to follow up on the generic side.  \n \n And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n ", "original_text": "What  does the M&A pipeline look like? ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51390a529566ba97a8dcb38e08572861a9ec4eacfdcfdbe170bcc1c7739c48d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88f4fb6d-5446-47fe-9343-784b9fd5e689", "node_type": "1", "metadata": {"window": "Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "5f42884ea1191f82a3daea78f8b83facfac07dfb3ce8f54b772abf8ffeaebbd6", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 390, "end_char_idx": 401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88f4fb6d-5446-47fe-9343-784b9fd5e689": {"__data__": {"id_": "88f4fb6d-5446-47fe-9343-784b9fd5e689", "embedding": null, "metadata": {"window": "Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f312b0fa-7682-43f1-9792-d88f58ecc691", "node_type": "1", "metadata": {"window": "And then on M&A, and you outlined the share repurchases, but how are you thinking about the acquisition \npipeline from here?  Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Thanks.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0de1e70f688f0a8a4630a4a14fffd225265d4eb904b7436af5a533d899d149ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5ad82b5-21a2-40c9-99f0-a98e43a5f64b", "node_type": "1", "metadata": {"window": "What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin. ", "original_text": "A \nBritt, do you want to take the first part?  \n "}, "hash": "8cd8ee01adef14c8232773c39bc52ae9f13ac30b6da46ef989822d17f642f7cc", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 401, "end_char_idx": 745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5ad82b5-21a2-40c9-99f0-a98e43a5f64b": {"__data__": {"id_": "e5ad82b5-21a2-40c9-99f0-a98e43a5f64b", "embedding": null, "metadata": {"window": "What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin. ", "original_text": "A \nBritt, do you want to take the first part?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88f4fb6d-5446-47fe-9343-784b9fd5e689", "node_type": "1", "metadata": {"window": "Where is the focus?  What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "889172e00dd535bebec53f6cd7de3c6ead951aedbc33a9631b2fccf9fd140ec1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db85cca0-3fc9-4780-b136-5a762fcea997", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "82aea89271e5d3979f4bdae92541d4f04d287735bafec73f79fd350f8a5a87d0", "class_name": "RelatedNodeInfo"}}, "text": "A \nBritt, do you want to take the first part?  \n ", "start_char_idx": 4136, "end_char_idx": 4185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db85cca0-3fc9-4780-b136-5a762fcea997": {"__data__": {"id_": "db85cca0-3fc9-4780-b136-5a762fcea997", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5ad82b5-21a2-40c9-99f0-a98e43a5f64b", "node_type": "1", "metadata": {"window": "What  does the M&A pipeline look like?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin. ", "original_text": "A \nBritt, do you want to take the first part?  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04cfaa9414148e2a1cbce6fbac5ae397d5fe277080d79116b7c714ca72e6b03a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04547cdd-d535-4606-9093-ff54bd6fc7c2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really . ", "original_text": "A \nSure, Brian. "}, "hash": "fc0f037b2b8d9422fa2d661c37fbf7dc45d24d45a6981feb60b2d79e35e87663", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 4185, "end_char_idx": 4545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04547cdd-d535-4606-9093-ff54bd6fc7c2": {"__data__": {"id_": "04547cdd-d535-4606-9093-ff54bd6fc7c2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really . ", "original_text": "A \nSure, Brian. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db85cca0-3fc9-4780-b136-5a762fcea997", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7dfaab8d50f80352df3246b89a612cdf3e453b6009d2df00ab81488a245164f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "618e71ba-26dd-48f4-a858-796d4ae92ca8", "node_type": "1", "metadata": {"window": "A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really .  And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "original_text": "Thanks for the question, Erin. "}, "hash": "f997f8f6493d2794918cce11aee9874518b6e207ebb88a40b896a23edeb13826", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure, Brian. ", "start_char_idx": 4545, "end_char_idx": 4561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "618e71ba-26dd-48f4-a858-796d4ae92ca8": {"__data__": {"id_": "618e71ba-26dd-48f4-a858-796d4ae92ca8", "embedding": null, "metadata": {"window": "A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really .  And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "original_text": "Thanks for the question, Erin. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04547cdd-d535-4606-9093-ff54bd6fc7c2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really . ", "original_text": "A \nSure, Brian. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d1bc73aade8b119178383db23b58eed11fa052df213d47e5a79898e16d996be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aeb77279-12d2-4635-9e53-1eeeaf3353ca", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really .  And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "original_text": "As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side. "}, "hash": "2c3de4bd9e9f0b2dda14b94c38f4fdf1e4dca0f6f3ba0ef91242babd06a6bd74", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question, Erin. ", "start_char_idx": 4561, "end_char_idx": 4592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aeb77279-12d2-4635-9e53-1eeeaf3353ca": {"__data__": {"id_": "aeb77279-12d2-4635-9e53-1eeeaf3353ca", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really .  And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "original_text": "As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "618e71ba-26dd-48f4-a858-796d4ae92ca8", "node_type": "1", "metadata": {"window": "A \nBritt, do you want to take the first part?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really .  And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "original_text": "Thanks for the question, Erin. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "696962526c4f1d059e1a18c2659636b5d08e58edd3cda76409834f207a969d7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6430abf5-15db-40aa-a305-684c39157693", "node_type": "1", "metadata": {"window": "A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really .  And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "original_text": "We've been operating in a competitive but stable environment \nnow for a number of years really . "}, "hash": "f9f491579e9b84c7b073d6a1669d8079b4568f8c67e4349a41fd5bebe7d1ad21", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side. ", "start_char_idx": 4592, "end_char_idx": 4718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6430abf5-15db-40aa-a305-684c39157693": {"__data__": {"id_": "6430abf5-15db-40aa-a305-684c39157693", "embedding": null, "metadata": {"window": "A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really .  And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "original_text": "We've been operating in a competitive but stable environment \nnow for a number of years really . ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aeb77279-12d2-4635-9e53-1eeeaf3353ca", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really .  And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "original_text": "As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side. ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4ee656aa557d773988a353f3cf2f1f9404b31d21a668114256a900adbba4b8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55987d1a-75c6-4224-9ff5-13ce761b24aa", "node_type": "1", "metadata": {"window": "Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really .  And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "original_text": "And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n "}, "hash": "80239650fcfdeb6bf4740ba2f4202323da6ad1382e8e2bad7d9bde33957cd796", "class_name": "RelatedNodeInfo"}}, "text": "We've been operating in a competitive but stable environment \nnow for a number of years really . ", "start_char_idx": 4718, "end_char_idx": 4815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55987d1a-75c6-4224-9ff5-13ce761b24aa": {"__data__": {"id_": "55987d1a-75c6-4224-9ff5-13ce761b24aa", "embedding": null, "metadata": {"window": "Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really .  And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "original_text": "And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6247e35f-f81c-4115-8d23-335886009651", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "745f6100cf01744c057137e926351d75539c3249a5ac587340f053cb9f99b91c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6430abf5-15db-40aa-a305-684c39157693", "node_type": "1", "metadata": {"window": "A \nSure, Brian.  Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really .  And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "original_text": "We've been operating in a competitive but stable environment \nnow for a number of years really . ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fcaec809144b77b3574eaa54581a0046e0ee493abe8d32f2090a4f0c5de1973", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a60aa63-719d-49a7-8227-0a6e5bd0c9d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n ", "original_text": "McKesson Corp.  "}, "hash": "7fb742d65c954beb72c90f7bc1009155dfb3ca6cbf2e8957c9bed4d175756379", "class_name": "RelatedNodeInfo"}}, "text": "And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "start_char_idx": 4815, "end_char_idx": 4951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a60aa63-719d-49a7-8227-0a6e5bd0c9d1": {"__data__": {"id_": "2a60aa63-719d-49a7-8227-0a6e5bd0c9d1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55987d1a-75c6-4224-9ff5-13ce761b24aa", "node_type": "1", "metadata": {"window": "Thanks for the question, Erin.  As it relates to generics, our focus continues to be on a strong sourcing \nprogram combined with discipline on the sell side.  We've been operating in a competitive but stable environment \nnow for a number of years really .  And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "original_text": "And we're really not seeing any difference in the second quarter from what \nwe've seen in the previous several quarters before that.  \n ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "567a4f965fd57bf381e890bcbc91d29087ba5160f449987513d38b842e653e4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5225cf70-6e42-482c-b5c7-e52771f04610", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time. "}, "hash": "48bb09cbfd2335e08647b41d244af75c8c57bb19d5dc28a60415ce76ac113ebe", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5225cf70-6e42-482c-b5c7-e52771f04610": {"__data__": {"id_": "5225cf70-6e42-482c-b5c7-e52771f04610", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a60aa63-719d-49a7-8227-0a6e5bd0c9d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71f474f64c920b610e9b0c9b7a5cb98659ea6ede2cb4cdfc907a3cf4e9eab527", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d6ba0bc-0f9a-4fa7-a9e2-2a3a07479de9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A. ", "original_text": "So from a generics perspective, our programs are running very well. "}, "hash": "58e5d4c75ba51b9617988534c2b613a0f8b74203e0302e1c47b048632bab2e47", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time. ", "start_char_idx": 16, "end_char_idx": 314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d6ba0bc-0f9a-4fa7-a9e2-2a3a07479de9": {"__data__": {"id_": "1d6ba0bc-0f9a-4fa7-a9e2-2a3a07479de9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A. ", "original_text": "So from a generics perspective, our programs are running very well. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5225cf70-6e42-482c-b5c7-e52771f04610", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a7bcbc62f7976541b8c5efea93b2168622c42f68d63bf2802502f3f3121dd66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c46680ad-3bde-4a17-af87-458c45f06dd2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth. ", "original_text": "We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n "}, "hash": "f729472f78062a7afc7e2a95c29f14ec9043ec81b40f3666a58a9131973ac688", "class_name": "RelatedNodeInfo"}}, "text": "So from a generics perspective, our programs are running very well. ", "start_char_idx": 314, "end_char_idx": 382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c46680ad-3bde-4a17-af87-458c45f06dd2": {"__data__": {"id_": "c46680ad-3bde-4a17-af87-458c45f06dd2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth. ", "original_text": "We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d6ba0bc-0f9a-4fa7-a9e2-2a3a07479de9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A. ", "original_text": "So from a generics perspective, our programs are running very well. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "269b61439bba49b718596226024bb17ba0cf86721e6180ee59d80f86948b62dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df68edef-101d-4132-aa66-0e1d76a347c5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "fdd0471c85c062b2ce196b9974e3de7c7d0dfeff541c5601cb9879a864aa23ef", "class_name": "RelatedNodeInfo"}}, "text": "We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n ", "start_char_idx": 382, "end_char_idx": 549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df68edef-101d-4132-aa66-0e1d76a347c5": {"__data__": {"id_": "df68edef-101d-4132-aa66-0e1d76a347c5", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c46680ad-3bde-4a17-af87-458c45f06dd2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth. ", "original_text": "We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3d84188b98016d3f912ce845cf93f591e7009d79d60ac952eab4fe00028c51a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e4385b2-fd7d-433c-b4ad-7d237fe711d3", "node_type": "1", "metadata": {"window": "So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that. ", "original_text": "A \nAnd I think the second part of the question was on M&A. "}, "hash": "b52fa27bbf025b3c3d478167400981f2bc7be5d697164c518eec5404a7ae016f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 549, "end_char_idx": 893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e4385b2-fd7d-433c-b4ad-7d237fe711d3": {"__data__": {"id_": "7e4385b2-fd7d-433c-b4ad-7d237fe711d3", "embedding": null, "metadata": {"window": "So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that. ", "original_text": "A \nAnd I think the second part of the question was on M&A. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df68edef-101d-4132-aa66-0e1d76a347c5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "226d9325c3db00eca58de9e49f6b9eaad1da1aba9698a42ac3a8a0ec7feca81e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2ebf41f-e32e-45ba-a6a5-4892e1bffba9", "node_type": "1", "metadata": {"window": "We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars. ", "original_text": "Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth. "}, "hash": "48ca7c8dff1add31fcc6a6e9492f4d34d97a5d7cf0c1b32e6ee8386c0bbbcff3", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd I think the second part of the question was on M&A. ", "start_char_idx": 893, "end_char_idx": 952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2ebf41f-e32e-45ba-a6a5-4892e1bffba9": {"__data__": {"id_": "d2ebf41f-e32e-45ba-a6a5-4892e1bffba9", "embedding": null, "metadata": {"window": "We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars. ", "original_text": "Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e4385b2-fd7d-433c-b4ad-7d237fe711d3", "node_type": "1", "metadata": {"window": "So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that. ", "original_text": "A \nAnd I think the second part of the question was on M&A. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b119450c41db6b068bf216b099ead1c1520acec6e4da1b0a468dea31b6fec54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15d500f0-8012-4b08-98c6-217b2f882773", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n", "original_text": "And so we are and continue to be active on the M&A front. "}, "hash": "d8553c5f48ea13dc97f9ed5e72eefbb6c61a1fc633e342c7f6376e302dceec13", "class_name": "RelatedNodeInfo"}}, "text": "Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth. ", "start_char_idx": 952, "end_char_idx": 1133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15d500f0-8012-4b08-98c6-217b2f882773": {"__data__": {"id_": "15d500f0-8012-4b08-98c6-217b2f882773", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n", "original_text": "And so we are and continue to be active on the M&A front. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2ebf41f-e32e-45ba-a6a5-4892e1bffba9", "node_type": "1", "metadata": {"window": "We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars. ", "original_text": "Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e51bd2e12776f6f73f931cc1ca854c9d57cd6078537d1032c337735a6e5c5cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea34f2a8-a046-441f-ae3b-09eb4551ae14", "node_type": "1", "metadata": {"window": "A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline. ", "original_text": "Now we have a very structured and disciplined \nway we approach that. "}, "hash": "fb4431c94d7cce2d13777e1f4e68d4008aec5ddfc639ecb876d8f69dfed65d9d", "class_name": "RelatedNodeInfo"}}, "text": "And so we are and continue to be active on the M&A front. ", "start_char_idx": 1133, "end_char_idx": 1191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea34f2a8-a046-441f-ae3b-09eb4551ae14": {"__data__": {"id_": "ea34f2a8-a046-441f-ae3b-09eb4551ae14", "embedding": null, "metadata": {"window": "A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline. ", "original_text": "Now we have a very structured and disciplined \nway we approach that. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15d500f0-8012-4b08-98c6-217b2f882773", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott T yler \nChief Executive Officer & Director, McKesson Corp.   A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n", "original_text": "And so we are and continue to be active on the M&A front. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "606e185c0f5484380b7f46fc653230a64c7b62a513983fd07d49b3593b26c9b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "406905ad-f1a5-4331-ac61-f5fe8144720f", "node_type": "1", "metadata": {"window": "Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools. ", "original_text": "First is it's got to be aligned to our stated strategy and particularly our growth pillars. "}, "hash": "8a04426ea0326fc66301a90044d31140f40337fcbfc10b762c6dacbda013b9a7", "class_name": "RelatedNodeInfo"}}, "text": "Now we have a very structured and disciplined \nway we approach that. ", "start_char_idx": 1191, "end_char_idx": 1260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "406905ad-f1a5-4331-ac61-f5fe8144720f": {"__data__": {"id_": "406905ad-f1a5-4331-ac61-f5fe8144720f", "embedding": null, "metadata": {"window": "Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools. ", "original_text": "First is it's got to be aligned to our stated strategy and particularly our growth pillars. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea34f2a8-a046-441f-ae3b-09eb4551ae14", "node_type": "1", "metadata": {"window": "A \nAnd I think the second part of the question was on M&A.  Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline. ", "original_text": "Now we have a very structured and disciplined \nway we approach that. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ebf3d448bcc21fca4272bd8cc4ea872a31fb38d1d88b897c386ee58129358f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68af0010-9111-4b07-a721-ff65d0860da6", "node_type": "1", "metadata": {"window": "And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet. ", "original_text": "A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n"}, "hash": "4d6f22cd321724a4f18f3327d70c7e2e8b14c9814d76f196988db37befd8437a", "class_name": "RelatedNodeInfo"}}, "text": "First is it's got to be aligned to our stated strategy and particularly our growth pillars. ", "start_char_idx": 1260, "end_char_idx": 1352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68af0010-9111-4b07-a721-ff65d0860da6": {"__data__": {"id_": "68af0010-9111-4b07-a721-ff65d0860da6", "embedding": null, "metadata": {"window": "And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet. ", "original_text": "A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "406905ad-f1a5-4331-ac61-f5fe8144720f", "node_type": "1", "metadata": {"window": "Clearly, one of our top priorities for capital deployment is \nto support the growth and the differentiated capabilities we have in our segment s to continue to extend that \ngrowth.  And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools. ", "original_text": "First is it's got to be aligned to our stated strategy and particularly our growth pillars. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67460a0f18e8c2b4409e5b2caf2867b44a780bf0b93c1e80ae313907cd547b2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef273240-8888-4d73-ab17-f8c4fe7ea3da", "node_type": "1", "metadata": {"window": "Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital. ", "original_text": "And then the second step of that process is to layer over a lens of financial discipline. "}, "hash": "e48a2031c750e44b66921dda4b8035cf369b8e90f36af126d44f609d2a70af1c", "class_name": "RelatedNodeInfo"}}, "text": "A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n", "start_char_idx": 1352, "end_char_idx": 1520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef273240-8888-4d73-ab17-f8c4fe7ea3da": {"__data__": {"id_": "ef273240-8888-4d73-ab17-f8c4fe7ea3da", "embedding": null, "metadata": {"window": "Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital. ", "original_text": "And then the second step of that process is to layer over a lens of financial discipline. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68af0010-9111-4b07-a721-ff65d0860da6", "node_type": "1", "metadata": {"window": "And so we are and continue to be active on the M&A front.  Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet. ", "original_text": "A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c8cb5538788e0c906d96eb8a6b94609adab3cc37649b2d05fd685df6c2039f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e3fd54c-1c50-42e2-a3cf-139de5dffb6b", "node_type": "1", "metadata": {"window": "First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n ", "original_text": "We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools. "}, "hash": "a0aa60f4b47c3f45ba5b9692d661f7c5fed24698882c727500b300867f02ba64", "class_name": "RelatedNodeInfo"}}, "text": "And then the second step of that process is to layer over a lens of financial discipline. ", "start_char_idx": 1520, "end_char_idx": 1610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e3fd54c-1c50-42e2-a3cf-139de5dffb6b": {"__data__": {"id_": "7e3fd54c-1c50-42e2-a3cf-139de5dffb6b", "embedding": null, "metadata": {"window": "First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n ", "original_text": "We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef273240-8888-4d73-ab17-f8c4fe7ea3da", "node_type": "1", "metadata": {"window": "Now we have a very structured and disciplined \nway we approach that.  First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital. ", "original_text": "And then the second step of that process is to layer over a lens of financial discipline. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e97f6bf993fa21cd8e561581c8c4a469e9ade165b967e2dd688af89a2b36e6b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69d4e717-b0a3-4cb2-8287-4490e849434f", "node_type": "1", "metadata": {"window": "A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "Obviously, we have share \nrepurchase hurdles that we can meet. "}, "hash": "095e8357257c59e1c6aebcb598932eefa4ef81ae757657a87d0dd24f3b115ea4", "class_name": "RelatedNodeInfo"}}, "text": "We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools. ", "start_char_idx": 1610, "end_char_idx": 1713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69d4e717-b0a3-4cb2-8287-4490e849434f": {"__data__": {"id_": "69d4e717-b0a3-4cb2-8287-4490e849434f", "embedding": null, "metadata": {"window": "A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "Obviously, we have share \nrepurchase hurdles that we can meet. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e3fd54c-1c50-42e2-a3cf-139de5dffb6b", "node_type": "1", "metadata": {"window": "First is it's got to be aligned to our stated strategy and particularly our growth pillars.  A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n ", "original_text": "We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af348e259ce695089d989beb2327bced645192df37d0b72689ff4a1e5d600fb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0313c664-4a4a-43e2-9b61-ccc4bea8e13e", "node_type": "1", "metadata": {"window": "And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n ", "original_text": "So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital. "}, "hash": "72df922c24ea99c43360ac989e73809e853e7a366ed40ac3dfe084fbcde938ad", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, we have share \nrepurchase hurdles that we can meet. ", "start_char_idx": 1713, "end_char_idx": 1776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0313c664-4a4a-43e2-9b61-ccc4bea8e13e": {"__data__": {"id_": "0313c664-4a4a-43e2-9b61-ccc4bea8e13e", "embedding": null, "metadata": {"window": "And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n ", "original_text": "So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69d4e717-b0a3-4cb2-8287-4490e849434f", "node_type": "1", "metadata": {"window": "A nd \nso if you look at recent activities like Rx Savings Solutions or Sarah Cannon joint venture, obviously both very, \nvery tied to our stated growth priorities.  \n \n And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "Obviously, we have share \nrepurchase hurdles that we can meet. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2573012987c2f3fa187973cc878674c285a414b46bc76c31ec3887230bfbf1a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e59953f-f72f-4ede-a4ad-21c00db4f53f", "node_type": "1", "metadata": {"window": "We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI. ", "original_text": "So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n "}, "hash": "a60762067ac3ea1c1eab4da659f973b3307ff64ed7b5f852fa44793a5a5e9cda", "class_name": "RelatedNodeInfo"}}, "text": "So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital. ", "start_char_idx": 1776, "end_char_idx": 1932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e59953f-f72f-4ede-a4ad-21c00db4f53f": {"__data__": {"id_": "1e59953f-f72f-4ede-a4ad-21c00db4f53f", "embedding": null, "metadata": {"window": "We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI. ", "original_text": "So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0313c664-4a4a-43e2-9b61-ccc4bea8e13e", "node_type": "1", "metadata": {"window": "And then the second step of that process is to layer over a lens of financial discipline.  We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n ", "original_text": "So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79eb7f3e137a47460d78d59b4dbab18f6dacabcc7fc8122dbe9b98245620b259", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1012ef1a-302c-466c-93db-9e03614b623e", "node_type": "1", "metadata": {"window": "Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  "}, "hash": "0537447ff929a68a2288ee12898832172443720b608470ebd92eadadfd2de779", "class_name": "RelatedNodeInfo"}}, "text": "So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n ", "start_char_idx": 1932, "end_char_idx": 2084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1012ef1a-302c-466c-93db-9e03614b623e": {"__data__": {"id_": "1012ef1a-302c-466c-93db-9e03614b623e", "embedding": null, "metadata": {"window": "Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e59953f-f72f-4ede-a4ad-21c00db4f53f", "node_type": "1", "metadata": {"window": "We ha ve many uses for \ncapital, some internal investment and efficiencies and technologies and tools.  Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI. ", "original_text": "So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd634d33eb292540130248b74776a0ded3f4174f6138ca49c57d200d28270a6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8c10209-cd60-4e3d-8a29-f13060bc258e", "node_type": "1", "metadata": {"window": "So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys. ", "original_text": "A \nNext question please.  \n "}, "hash": "dd80946aa395fa0040d1372c6145be4d855be745a5c3a354f707b465c1306509", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "start_char_idx": 2084, "end_char_idx": 2427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8c10209-cd60-4e3d-8a29-f13060bc258e": {"__data__": {"id_": "d8c10209-cd60-4e3d-8a29-f13060bc258e", "embedding": null, "metadata": {"window": "So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys. ", "original_text": "A \nNext question please.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1012ef1a-302c-466c-93db-9e03614b623e", "node_type": "1", "metadata": {"window": "Obviously, we have share \nrepurchase hurdles that we can meet.  So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b48ff308ed6b195281a01ab264b1a040f074b058772f015a830f4f694a01c699", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a5b8cc9-26d0-45e3-aa7f-302204df4e23", "node_type": "1", "metadata": {"window": "So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI. "}, "hash": "2597594c707ed5f662ab464dd81b985ea6c9ca48da5235a1fe065f567705a96a", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question please.  \n ", "start_char_idx": 2427, "end_char_idx": 2455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a5b8cc9-26d0-45e3-aa7f-302204df4e23": {"__data__": {"id_": "9a5b8cc9-26d0-45e3-aa7f-302204df4e23", "embedding": null, "metadata": {"window": "So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8c10209-cd60-4e3d-8a29-f13060bc258e", "node_type": "1", "metadata": {"window": "So we bring a lot of financial discipline to the acquisition process to ensure \nthat we're getting good returns for shareholders as we deploy that capital.  So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys. ", "original_text": "A \nNext question please.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8662de69d64d54620fd627af7cb65b485fa7ce792eeb625dd7ffcead1c36f479", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e510806-dd46-4c48-84e4-29545daf0dcc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions. ", "original_text": "Please go ahead.  \n "}, "hash": "f903fafc688ffa30dbec5da1f37b8a3629dde56a19ef0c1bf61b4fcffe26d7d3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI. ", "start_char_idx": 2455, "end_char_idx": 2795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e510806-dd46-4c48-84e4-29545daf0dcc": {"__data__": {"id_": "1e510806-dd46-4c48-84e4-29545daf0dcc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions. ", "original_text": "Please go ahead.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a5b8cc9-26d0-45e3-aa7f-302204df4e23", "node_type": "1", "metadata": {"window": "So if it's on strategy and has the \nappropriate financial return, we're very interested and we continue to develop our business development funnels.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23ded255940310e8ff8ce26a3838a29d72c9eba8016b24d5770272f492f2a874", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f80dcca5-4324-4037-9c49-9ebf2ceb878f", "node_type": "1", "metadata": {"window": "A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys. "}, "hash": "c48839359fadc2be7d8ba0d5217ce578b2634a3ff7e780407a3a5c51895a85f1", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 2795, "end_char_idx": 2815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f80dcca5-4324-4037-9c49-9ebf2ceb878f": {"__data__": {"id_": "f80dcca5-4324-4037-9c49-9ebf2ceb878f", "embedding": null, "metadata": {"window": "A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e510806-dd46-4c48-84e4-29545daf0dcc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions. ", "original_text": "Please go ahead.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a94d1a7b6a32127e916ae5c65d957d74d90e74df0222f5066669173c8e9f990", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c9c650f-ab61-4976-ad37-e4ac260216d0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n", "original_text": "Thanks so much for the question. "}, "hash": "5d4b819fc0a14d4f2b3d6e150af4d2d7d129ce390808ff1440232136c0717b39", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys. ", "start_char_idx": 2815, "end_char_idx": 3150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c9c650f-ab61-4976-ad37-e4ac260216d0": {"__data__": {"id_": "1c9c650f-ab61-4976-ad37-e4ac260216d0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n", "original_text": "Thanks so much for the question. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f80dcca5-4324-4037-9c49-9ebf2ceb878f", "node_type": "1", "metadata": {"window": "A \nNext question please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0aab2ab090b5664778faa66708d6a737be57bf792c718387d4dabea86d61a476", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ce54727-3195-476e-b8b8-36d92515b5d8", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack. ", "original_text": "I had two questions. "}, "hash": "49c3cb2a0c66fb28bebb5fbbad79d0799693dc9e1e147d8621ab455b0e22f684", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question. ", "start_char_idx": 3150, "end_char_idx": 3183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ce54727-3195-476e-b8b8-36d92515b5d8": {"__data__": {"id_": "5ce54727-3195-476e-b8b8-36d92515b5d8", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack. ", "original_text": "I had two questions. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c9c650f-ab61-4976-ad37-e4ac260216d0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n", "original_text": "Thanks so much for the question. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6773776d62e7738612abe2f23ba7271298e949acc5d3953c1640cbbb2207c3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5930807-32dc-47ff-babf-b109e21eb5d8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks? ", "original_text": "One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s? "}, "hash": "26694ad6724e76c9c473f28bb9cc69f6b338503d495a606cc4411b43b59aed07", "class_name": "RelatedNodeInfo"}}, "text": "I had two questions. ", "start_char_idx": 3183, "end_char_idx": 3204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5930807-32dc-47ff-babf-b109e21eb5d8": {"__data__": {"id_": "a5930807-32dc-47ff-babf-b109e21eb5d8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks? ", "original_text": "One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s? ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ce54727-3195-476e-b8b8-36d92515b5d8", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack. ", "original_text": "I had two questions. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da7ba10f80237c7982d712dbaf4379d720248c5723d1f1876663df26fda7392d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c682205-53e6-403b-8cba-7a6a7db27190", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n ", "original_text": "I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n"}, "hash": "54c9783381654ff1075bbab6c9fea9102fd4b2faa07bfaa9484553c201650e9b", "class_name": "RelatedNodeInfo"}}, "text": "One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s? ", "start_char_idx": 3204, "end_char_idx": 3292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c682205-53e6-403b-8cba-7a6a7db27190": {"__data__": {"id_": "4c682205-53e6-403b-8cba-7a6a7db27190", "embedding": null, "metadata": {"window": "Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n ", "original_text": "I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5930807-32dc-47ff-babf-b109e21eb5d8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, guys.  Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks? ", "original_text": "One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s? ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "796bfe243a022b45d1e984af387a2e3b6dad182d5c7e1fe5dd42df3947dbfb5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74fe8ee8-4d9f-459e-8dcf-babbd1b794e1", "node_type": "1", "metadata": {"window": "I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack. "}, "hash": "1850ce87e4598d0e4a1796e049718f2e37262e097350da2f5f39b677d932ee9d", "class_name": "RelatedNodeInfo"}}, "text": "I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n", "start_char_idx": 3292, "end_char_idx": 3508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74fe8ee8-4d9f-459e-8dcf-babbd1b794e1": {"__data__": {"id_": "74fe8ee8-4d9f-459e-8dcf-babbd1b794e1", "embedding": null, "metadata": {"window": "I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c682205-53e6-403b-8cba-7a6a7db27190", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n ", "original_text": "I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3c3337c3a3af53e1b9b5050ee79dfd1b23b917d707605cf35e964289031ebda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd63911e-19f0-4622-b478-eb2c51b6a98f", "node_type": "1", "metadata": {"window": "One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues. ", "original_text": "Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks? "}, "hash": "45d4c4c1e5a715c36d4df6d81ca86bc527040d7aaaf68007c91e5191b4b0246e", "class_name": "RelatedNodeInfo"}}, "text": "And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack. ", "start_char_idx": 3508, "end_char_idx": 3685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd63911e-19f0-4622-b478-eb2c51b6a98f": {"__data__": {"id_": "bd63911e-19f0-4622-b478-eb2c51b6a98f", "embedding": null, "metadata": {"window": "One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues. ", "original_text": "Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks? ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74fe8ee8-4d9f-459e-8dcf-babbd1b794e1", "node_type": "1", "metadata": {"window": "I had two questions.  One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98c2845e9f88befcbf722a866b4bd98ad43b9220cd8c2352a19ff0df4285e159", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5977c4a5-9087-469e-af14-534c2a88d999", "node_type": "1", "metadata": {"window": "I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today. ", "original_text": "Thank you very much.  \n "}, "hash": "22e682775747a95c4e3f279ba0cf12a070d4200487734eb025d0e1cca2e8d26e", "class_name": "RelatedNodeInfo"}}, "text": "Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks? ", "start_char_idx": 3685, "end_char_idx": 3803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5977c4a5-9087-469e-af14-534c2a88d999": {"__data__": {"id_": "5977c4a5-9087-469e-af14-534c2a88d999", "embedding": null, "metadata": {"window": "I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today. ", "original_text": "Thank you very much.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd63911e-19f0-4622-b478-eb2c51b6a98f", "node_type": "1", "metadata": {"window": "One,  on the RxTS business, are you seeing any \nsort of spillover benefit from GLP -1s?  I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues. ", "original_text": "Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks? ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a19dce9465c5ef7e920ef9078400da507b4ff080ac383712779e9f47a2fb6c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0158b870-fbc9-497d-b229-b1ad1169bfd0", "node_type": "1", "metadata": {"window": "And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "890d4b921e208374a6da98c4a176f109d5188f0f0d2b1ad74bcca94f2df37dba", "class_name": "RelatedNodeInfo"}}, "text": "Thank you very much.  \n ", "start_char_idx": 3803, "end_char_idx": 3827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0158b870-fbc9-497d-b229-b1ad1169bfd0": {"__data__": {"id_": "0158b870-fbc9-497d-b229-b1ad1169bfd0", "embedding": null, "metadata": {"window": "And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5977c4a5-9087-469e-af14-534c2a88d999", "node_type": "1", "metadata": {"window": "I'm thinking like either an organization that doesn't use you that does use \nyou because they've heard about this with the GLP -1s or sort of a cross -selling across your group o f services \nwithin this segment.  \n \n And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today. ", "original_text": "Thank you very much.  \n ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2acfe0567f8f2ca34f9a925c57d8e26eb4f9a6761cdc5b7ed092e3682a8dac67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3567e8a3-4d0a-4a79-836c-7c6a9569bfa7", "node_type": "1", "metadata": {"window": "Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena. ", "original_text": "A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues. "}, "hash": "e2d0d52c31ba7b4f4ba289bb8d0e088b5898a514f82e7d694c4923098579b44f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3827, "end_char_idx": 4171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3567e8a3-4d0a-4a79-836c-7c6a9569bfa7": {"__data__": {"id_": "3567e8a3-4d0a-4a79-836c-7c6a9569bfa7", "embedding": null, "metadata": {"window": "Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena. ", "original_text": "A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0158b870-fbc9-497d-b229-b1ad1169bfd0", "node_type": "1", "metadata": {"window": "And then secondarily, on the medical side, one of your competitors on the outpatient side has seen some ordering \nimpact because of sort of website and sort of a cyber -attack.  Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99d214a30e9a9e5ac1e5dc3616d9172d92ff49cc39e61e2765aef3155d2c4a15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73128d29-12e0-4ad2-b369-b162eabbbbd8", "node_type": "1", "metadata": {"window": "Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n", "original_text": "I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today. "}, "hash": "1bee2aed50c663477271e9f4662bcc7c197807bc40ca498c98cb3cb9d043fe05", "class_name": "RelatedNodeInfo"}}, "text": "A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues. ", "start_char_idx": 4171, "end_char_idx": 4273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73128d29-12e0-4ad2-b369-b162eabbbbd8": {"__data__": {"id_": "73128d29-12e0-4ad2-b369-b162eabbbbd8", "embedding": null, "metadata": {"window": "Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n", "original_text": "I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3567e8a3-4d0a-4a79-836c-7c6a9569bfa7", "node_type": "1", "metadata": {"window": "Has that provided any kind of material change in  \ncustomer ordering within that segment in the last couple of weeks?  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena. ", "original_text": "A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "983242b4f3b3e4d3fde993dd95931ca7708cf9066baadf93d477d5d39e77d7d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4144de29-703b-4181-8f07-cd37decacff3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges. ", "original_text": "So we've had a \nlong established relationship with them. "}, "hash": "9a07593ff85105a867727871834f6f0c78a8d9d357f68126c776d3998103eae7", "class_name": "RelatedNodeInfo"}}, "text": "I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today. ", "start_char_idx": 4273, "end_char_idx": 4379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4144de29-703b-4181-8f07-cd37decacff3": {"__data__": {"id_": "4144de29-703b-4181-8f07-cd37decacff3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges. ", "original_text": "So we've had a \nlong established relationship with them. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73128d29-12e0-4ad2-b369-b162eabbbbd8", "node_type": "1", "metadata": {"window": "Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n", "original_text": "I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60e795c4aae3a44d9bab662cf3e9bd5d5ef9033d9d498fc765fbbbd0353cef54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "591f9180-6466-4300-ba60-6f50c6e861f5", "node_type": "1", "metadata": {"window": "A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have. ", "original_text": "And I think we've been well known for quite a long time in that arena. "}, "hash": "266c9e3a363829016ba0d0d89ca8214b9aea691fce2a01d44d2c22a1d5d6b3b9", "class_name": "RelatedNodeInfo"}}, "text": "So we've had a \nlong established relationship with them. ", "start_char_idx": 4379, "end_char_idx": 4436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "591f9180-6466-4300-ba60-6f50c6e861f5": {"__data__": {"id_": "591f9180-6466-4300-ba60-6f50c6e861f5", "embedding": null, "metadata": {"window": "A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have. ", "original_text": "And I think we've been well known for quite a long time in that arena. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4144de29-703b-4181-8f07-cd37decacff3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges. ", "original_text": "So we've had a \nlong established relationship with them. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b512c3d15e0428567c35809ae14e851ee1bf600c63aee25161d2615b43d890f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "906a761f-2716-43d1-ba7a-99ce0aad890d", "node_type": "1", "metadata": {"window": "I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have.  I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "original_text": "So I \ndon't think  you'd be seeing anything material there.  \n \n"}, "hash": "6a52056972e8f4824f591beaab756eda04e725d65a700bc356202c5af7661c45", "class_name": "RelatedNodeInfo"}}, "text": "And I think we've been well known for quite a long time in that arena. ", "start_char_idx": 4436, "end_char_idx": 4507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "906a761f-2716-43d1-ba7a-99ce0aad890d": {"__data__": {"id_": "906a761f-2716-43d1-ba7a-99ce0aad890d", "embedding": null, "metadata": {"window": "I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have.  I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "original_text": "So I \ndon't think  you'd be seeing anything material there.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "591f9180-6466-4300-ba60-6f50c6e861f5", "node_type": "1", "metadata": {"window": "A \nSo the first \u2013 I think your first question was as it relates to RxTS and just opening new avenues.  I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have. ", "original_text": "And I think we've been well known for quite a long time in that arena. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8676485d5915381e83bcbf90c86a256c99b9d9f605ff8af0c312080fbc1994", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abeace1f-abba-4d80-9828-db2f7f955e0d", "node_type": "1", "metadata": {"window": "So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have.  I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "original_text": "And then your second question was as it relates to a competitor ordering challenges. "}, "hash": "46bc39889b34c2b0cc0e5d1525f27154b1c2f1918c351aaaea3e927ccecf0cb6", "class_name": "RelatedNodeInfo"}}, "text": "So I \ndon't think  you'd be seeing anything material there.  \n \n", "start_char_idx": 4507, "end_char_idx": 4571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abeace1f-abba-4d80-9828-db2f7f955e0d": {"__data__": {"id_": "abeace1f-abba-4d80-9828-db2f7f955e0d", "embedding": null, "metadata": {"window": "So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have.  I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "original_text": "And then your second question was as it relates to a competitor ordering challenges. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "906a761f-2716-43d1-ba7a-99ce0aad890d", "node_type": "1", "metadata": {"window": "I would just \nremind you, RxTS is connected to 900,000 providers today and 50,000 -plus pharmacies today.  So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have.  I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "original_text": "So I \ndon't think  you'd be seeing anything material there.  \n \n", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae48971a2eb3c50d32766691a1329ef2bdb46a295a0ccc9a70e4300ebe4e160b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea745388-8e00-4d9b-8d34-cbf8bc3b2f06", "node_type": "1", "metadata": {"window": "And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have.  I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "original_text": "I'm not really not going to \nget into issues a competitor might have. "}, "hash": "76db76642e1ed1133fe7869c2e01ada5b8ea872c68b9cd8b39b4a1e69df2fa7b", "class_name": "RelatedNodeInfo"}}, "text": "And then your second question was as it relates to a competitor ordering challenges. ", "start_char_idx": 4571, "end_char_idx": 4656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea745388-8e00-4d9b-8d34-cbf8bc3b2f06": {"__data__": {"id_": "ea745388-8e00-4d9b-8d34-cbf8bc3b2f06", "embedding": null, "metadata": {"window": "And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have.  I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "original_text": "I'm not really not going to \nget into issues a competitor might have. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abeace1f-abba-4d80-9828-db2f7f955e0d", "node_type": "1", "metadata": {"window": "So we've had a \nlong established relationship with them.  And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have.  I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "original_text": "And then your second question was as it relates to a competitor ordering challenges. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb656c42c44f43e008b16ac9854426f042c253dfe0733c1b305c7e0b8b46cbd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2df43c6d-7463-40a1-a18d-9f0a72a634d0", "node_type": "1", "metadata": {"window": "So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have.  I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "original_text": "I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  "}, "hash": "e2247a607625ae47052759e83ecc8af9e463cd3d6dec793e897cbc85f162e9b7", "class_name": "RelatedNodeInfo"}}, "text": "I'm not really not going to \nget into issues a competitor might have. ", "start_char_idx": 4656, "end_char_idx": 4726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2df43c6d-7463-40a1-a18d-9f0a72a634d0": {"__data__": {"id_": "2df43c6d-7463-40a1-a18d-9f0a72a634d0", "embedding": null, "metadata": {"window": "So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have.  I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "original_text": "I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c84988ef0092913bba02e3d56317d37b32334e0f23e1febd3e0b10e5d7ce053f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea745388-8e00-4d9b-8d34-cbf8bc3b2f06", "node_type": "1", "metadata": {"window": "And I think we've been well known for quite a long time in that arena.  So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have.  I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "original_text": "I'm not really not going to \nget into issues a competitor might have. ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18bf07df8a94230f066ce2c54622781a81be58b5a9b15b03d4dee9609c1a096b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d0be11c-eb36-4cf0-9f86-1b62a35f8dd7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "McKesson Corp.  "}, "hash": "02e71bfe03ea4344fb531b14eddd70f1c24801d4df0aa9b152c65e48fe70868d", "class_name": "RelatedNodeInfo"}}, "text": "I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "start_char_idx": 4726, "end_char_idx": 4922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d0be11c-eb36-4cf0-9f86-1b62a35f8dd7": {"__data__": {"id_": "8d0be11c-eb36-4cf0-9f86-1b62a35f8dd7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2df43c6d-7463-40a1-a18d-9f0a72a634d0", "node_type": "1", "metadata": {"window": "So I \ndon't think  you'd be seeing anything material there.  \n \n And then your second question was as it relates to a competitor ordering challenges.  I'm not really not going to \nget into issues a competitor might have.  I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "original_text": "I don't think we've \u2013 we've spent a little bit of time talk ing about the trends \nthat we saw in the Medical -Surgical business and reviewed those trends, and I think those stand for themselves.  ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1082c5b97844939cf49d1c076077b0307f485a561654304c4011ff98e65eb916", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66b51b19-7f75-4c80-955b-367636bab612", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  "}, "hash": "bbb6d6956f88616a90543b890436dc63f1096b99a18c2c1606bf4a000d3404fa", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66b51b19-7f75-4c80-955b-367636bab612": {"__data__": {"id_": "66b51b19-7f75-4c80-955b-367636bab612", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d0be11c-eb36-4cf0-9f86-1b62a35f8dd7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea532adec6ecc29ec3f992c0c7dec6fd532a6eed9e5d364f4c08891c83f02502", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00565591-5f86-4aed-8754-ddf1842591a7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n ", "original_text": "A \nAnd we have time for one more question, please.  \n "}, "hash": "58679d2c4fedeffafe2d321208e8935620cf9c73ae522e7bbd584bc0b4a07671", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00565591-5f86-4aed-8754-ddf1842591a7": {"__data__": {"id_": "00565591-5f86-4aed-8754-ddf1842591a7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n ", "original_text": "A \nAnd we have time for one more question, please.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66b51b19-7f75-4c80-955b-367636bab612", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7ab5e347de51cfac402f3c7e9fe0cb4ed6446ff1e1502424b40175c2bbbbb31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "408812da-1763-4eec-971f-504f5af430be", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. "}, "hash": "1812fda5cede0a348b79beed16800a0a6aa23d6812d48261a1e39abc610cc678", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd we have time for one more question, please.  \n ", "start_char_idx": 252, "end_char_idx": 306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "408812da-1763-4eec-971f-504f5af430be": {"__data__": {"id_": "408812da-1763-4eec-971f-504f5af430be", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00565591-5f86-4aed-8754-ddf1842591a7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n ", "original_text": "A \nAnd we have time for one more question, please.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4758bb552429ac8f18af6a9cc822e460029066ee2bd65a91bea883af5ddcd202", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74d3793f-15db-491f-8f6f-7ca7d8f64c95", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys. ", "original_text": "That question will come from George Hill with Deutsche Bank. "}, "hash": "0f4039776d699c14d9a0c20e6c7b7c80f7f8cc705d49f6803d68d9246116fde5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "start_char_idx": 306, "end_char_idx": 602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74d3793f-15db-491f-8f6f-7ca7d8f64c95": {"__data__": {"id_": "74d3793f-15db-491f-8f6f-7ca7d8f64c95", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys. ", "original_text": "That question will come from George Hill with Deutsche Bank. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "408812da-1763-4eec-971f-504f5af430be", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72a8a7aba360ade541f5d3e286332db3b8c1eb0fbfcdcf30c7050964a70fc163", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57972ccb-89c3-436d-a566-887c8bc27e28", "node_type": "1", "metadata": {"window": "A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in. ", "original_text": "Please go ahead.  \n "}, "hash": "43253cba57fcf0e7c5bbb9f21ab984b305a77f753b4c2605325e455f021146ae", "class_name": "RelatedNodeInfo"}}, "text": "That question will come from George Hill with Deutsche Bank. ", "start_char_idx": 602, "end_char_idx": 663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57972ccb-89c3-436d-a566-887c8bc27e28": {"__data__": {"id_": "57972ccb-89c3-436d-a566-887c8bc27e28", "embedding": null, "metadata": {"window": "A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in. ", "original_text": "Please go ahead.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74d3793f-15db-491f-8f6f-7ca7d8f64c95", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys. ", "original_text": "That question will come from George Hill with Deutsche Bank. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d483522d1d2e003db571eaa5164f3e6c16935dd073eb311dea2e49f9d87cf771", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f02335ef-5a82-47fc-86ec-a9246770e50c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  "}, "hash": "c1f59db8ee05c5caacabe7f859e66f9d400082763d41744d7d6caa7c6bfcb277", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 663, "end_char_idx": 683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f02335ef-5a82-47fc-86ec-a9246770e50c": {"__data__": {"id_": "f02335ef-5a82-47fc-86ec-a9246770e50c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57972ccb-89c3-436d-a566-887c8bc27e28", "node_type": "1", "metadata": {"window": "A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in. ", "original_text": "Please go ahead.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a798c3f8aff65bdaa4c9ae0f28bec29d5446df0a464747491cb329e71e3b69d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66b5c1e4-c197-498a-a43d-cf2f2d4768aa", "node_type": "1", "metadata": {"window": "That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it. ", "original_text": "Q \nHey, guys. "}, "hash": "88cdfedf0c685489cfbf3d26ff5308adff6ac680df14e6238305c9916d793457", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "start_char_idx": 683, "end_char_idx": 1010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66b5c1e4-c197-498a-a43d-cf2f2d4768aa": {"__data__": {"id_": "66b5c1e4-c197-498a-a43d-cf2f2d4768aa", "embedding": null, "metadata": {"window": "That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it. ", "original_text": "Q \nHey, guys. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f02335ef-5a82-47fc-86ec-a9246770e50c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "317d82ecb79581619c888e09505f833e8659216f29f4ae4288e485d4ec33544e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59f18800-59b1-4237-9f10-f13f2c571680", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I appreciate you sneaking me in. "}, "hash": "ea57828b15154efb83f5273965f1541578d92d5312ae0cba83fc7370462fa579", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHey, guys. ", "start_char_idx": 1010, "end_char_idx": 1024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59f18800-59b1-4237-9f10-f13f2c571680": {"__data__": {"id_": "59f18800-59b1-4237-9f10-f13f2c571680", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I appreciate you sneaking me in. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66b5c1e4-c197-498a-a43d-cf2f2d4768aa", "node_type": "1", "metadata": {"window": "That question will come from George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it. ", "original_text": "Q \nHey, guys. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "796ed788ea3f7c94c44f8ab3de23cdc1c1001ec806ff56dff76f5ab83e994566", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69f37a61-8de9-4409-ae20-877c2539aa65", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n ", "original_text": "I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years. "}, "hash": "006e850553bb4d66c8f959dd5702e4b4f93f66dcdf835d4edfcb56ea349b54ae", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate you sneaking me in. ", "start_char_idx": 1024, "end_char_idx": 1057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69f37a61-8de9-4409-ae20-877c2539aa65": {"__data__": {"id_": "69f37a61-8de9-4409-ae20-877c2539aa65", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n ", "original_text": "I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59f18800-59b1-4237-9f10-f13f2c571680", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I appreciate you sneaking me in. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6745d8c124f1cbff409974d9e90b99ff4df50f5acabd5b772a1e61471984dac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b3396db-e32a-4dc2-b7d3-071f81adf666", "node_type": "1", "metadata": {"window": "Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr. ", "original_text": "I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it. "}, "hash": "2b41b4f34bac8fb109d1c7195b5f4364a4f286a8b752ee2e42d5ef743ca5af22", "class_name": "RelatedNodeInfo"}}, "text": "I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years. ", "start_char_idx": 1057, "end_char_idx": 1163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b3396db-e32a-4dc2-b7d3-071f81adf666": {"__data__": {"id_": "2b3396db-e32a-4dc2-b7d3-071f81adf666", "embedding": null, "metadata": {"window": "Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr. ", "original_text": "I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69f37a61-8de9-4409-ae20-877c2539aa65", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n ", "original_text": "I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6019fdf92b4cbda008fda5d12e8d529e8a9dd94652f58c37d2e6c1353b339a97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84e9070f-4405-4a6b-8c37-0ae0c31a99fb", "node_type": "1", "metadata": {"window": "I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed. ", "original_text": "And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "ce94f3d320fe67b56ef86c1c5399bd8549b25d8abf9679c080673a3440cde74c", "class_name": "RelatedNodeInfo"}}, "text": "I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it. ", "start_char_idx": 1163, "end_char_idx": 1346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84e9070f-4405-4a6b-8c37-0ae0c31a99fb": {"__data__": {"id_": "84e9070f-4405-4a6b-8c37-0ae0c31a99fb", "embedding": null, "metadata": {"window": "I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed. ", "original_text": "And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b3396db-e32a-4dc2-b7d3-071f81adf666", "node_type": "1", "metadata": {"window": "Q \nHey, guys.  I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr. ", "original_text": "I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b37ab674c9765110cf45655c8e9989f8178aa0053671d2757815eff3934f68c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb9cf891-5a7d-4385-bd39-e2c60b2c0aaf", "node_type": "1", "metadata": {"window": "I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n ", "original_text": "A \nIt looks like he dropped off.  \n "}, "hash": "1516dcc121a1679b0bba3051be490764306475752e501f69863bd0748f476b5a", "class_name": "RelatedNodeInfo"}}, "text": "And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1346, "end_char_idx": 1797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb9cf891-5a7d-4385-bd39-e2c60b2c0aaf": {"__data__": {"id_": "bb9cf891-5a7d-4385-bd39-e2c60b2c0aaf", "embedding": null, "metadata": {"window": "I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n ", "original_text": "A \nIt looks like he dropped off.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84e9070f-4405-4a6b-8c37-0ae0c31a99fb", "node_type": "1", "metadata": {"window": "I appreciate you sneaking me in.  I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed. ", "original_text": "And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "585ba2ff3221e6096248f0ed9ea29638e7dfd46f9b7149c7818cf9bfd69a0695", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac3baa9e-b6bf-4b9f-adf6-4c73e6e324cf", "node_type": "1", "metadata": {"window": "I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr. "}, "hash": "d8944d0ccf3ec51e3cc58847feaf38300ae57ea66cbb2b6478f816fd769f4aa5", "class_name": "RelatedNodeInfo"}}, "text": "A \nIt looks like he dropped off.  \n ", "start_char_idx": 1797, "end_char_idx": 1833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac3baa9e-b6bf-4b9f-adf6-4c73e6e324cf": {"__data__": {"id_": "ac3baa9e-b6bf-4b9f-adf6-4c73e6e324cf", "embedding": null, "metadata": {"window": "I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb9cf891-5a7d-4385-bd39-e2c60b2c0aaf", "node_type": "1", "metadata": {"window": "I'll say, Brian and Britt, the oncology business has really been a \nstandout over the last several years.  I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n ", "original_text": "A \nIt looks like he dropped off.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e7f834bb1650505151afbbabdd411dba7f6f9abf999f57729cbd13ca9b2daa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9d42c5d-cb58-4b61-847a-185a771e58db", "node_type": "1", "metadata": {"window": "And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n ", "original_text": "Hill, please proceed. "}, "hash": "33598a68cdb93fd7bc327152aedf49af0c557d0d7f32bc219993a7d01da50a2c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr. ", "start_char_idx": 1833, "end_char_idx": 2122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9d42c5d-cb58-4b61-847a-185a771e58db": {"__data__": {"id_": "f9d42c5d-cb58-4b61-847a-185a771e58db", "embedding": null, "metadata": {"window": "And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n ", "original_text": "Hill, please proceed. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac3baa9e-b6bf-4b9f-adf6-4c73e6e324cf", "node_type": "1", "metadata": {"window": "I was wondering if there's a chance that you guys might give us any kind of \nsense of the scope or scale of the business inside the US drug segment with any type of number around it.  And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05650123b78033f8c11cc7678a0e55cf94023964208edacc85ef0ec35792c631", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5003a0a-16d9-4463-8df5-4b0e057356b7", "node_type": "1", "metadata": {"window": "A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n ", "original_text": "I think we lost him.  \n "}, "hash": "d0712e135483c9524e5664f5f8dd53c589b94185f5b5dd2d9cc7e9c2360540bb", "class_name": "RelatedNodeInfo"}}, "text": "Hill, please proceed. ", "start_char_idx": 2122, "end_char_idx": 2144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5003a0a-16d9-4463-8df5-4b0e057356b7": {"__data__": {"id_": "f5003a0a-16d9-4463-8df5-4b0e057356b7", "embedding": null, "metadata": {"window": "A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n ", "original_text": "I think we lost him.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9d42c5d-cb58-4b61-847a-185a771e58db", "node_type": "1", "metadata": {"window": "And, \nBritt, as a quick  follow -up, I guess given the ongoing agreement with Rite Aid, can you tell...  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n ", "original_text": "Hill, please proceed. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b95d2c357fdfb607e13f059ba06bb2f97f445db45b50eb8280030adf39007af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecbfaff4-b6fe-4204-a9bd-270b06f9b405", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  "}, "hash": "4dc3bdf02b11c35dc52bd2d0731d3eebccc7864a8b287ab1d8ef9c37a39c94be", "class_name": "RelatedNodeInfo"}}, "text": "I think we lost him.  \n ", "start_char_idx": 2144, "end_char_idx": 2168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecbfaff4-b6fe-4204-a9bd-270b06f9b405": {"__data__": {"id_": "ecbfaff4-b6fe-4204-a9bd-270b06f9b405", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5003a0a-16d9-4463-8df5-4b0e057356b7", "node_type": "1", "metadata": {"window": "A \nIt looks like he dropped off.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n ", "original_text": "I think we lost him.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "917e419e14bd4fcb6ee246fa0ed14e145f100bcc053f6880a8a8b47c4ae4df5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62e81f52-27a3-4d23-9542-a8d10a0cf1fd", "node_type": "1", "metadata": {"window": "Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there. ", "original_text": "Q \nCan you hear me?  \n "}, "hash": "2281cf004df51346bdbc7ae466303eede7544afd21e00c36a12fd26829d57458", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "start_char_idx": 683, "end_char_idx": 1010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62e81f52-27a3-4d23-9542-a8d10a0cf1fd": {"__data__": {"id_": "62e81f52-27a3-4d23-9542-a8d10a0cf1fd", "embedding": null, "metadata": {"window": "Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there. ", "original_text": "Q \nCan you hear me?  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecbfaff4-b6fe-4204-a9bd-270b06f9b405", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Mr.  Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa5778b12bd9e1b4387ceda26dd34ce90af66afece3e533316312a621518b5d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9ccf27d-a4c8-402a-b19f-af0964003722", "node_type": "1", "metadata": {"window": "I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n "}, "hash": "fa1b615658d92139dc67420f3436fd6889c5cd2c30a444f943ac83bd926ada6e", "class_name": "RelatedNodeInfo"}}, "text": "Q \nCan you hear me?  \n ", "start_char_idx": 2495, "end_char_idx": 2518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9ccf27d-a4c8-402a-b19f-af0964003722": {"__data__": {"id_": "a9ccf27d-a4c8-402a-b19f-af0964003722", "embedding": null, "metadata": {"window": "I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62e81f52-27a3-4d23-9542-a8d10a0cf1fd", "node_type": "1", "metadata": {"window": "Hill, please proceed.  I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there. ", "original_text": "Q \nCan you hear me?  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fcdba8e1f856652dba17dc5a1f837b174203ff71132ef86b148b4532555ecf7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2016aa0d-5385-483a-9e33-51a6c277e90f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  "}, "hash": "7e01d6a8097075730c58fe1a8c7b63da871513c73be4d425006d85445e2c2a1a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n ", "start_char_idx": 2518, "end_char_idx": 2821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2016aa0d-5385-483a-9e33-51a6c277e90f": {"__data__": {"id_": "2016aa0d-5385-483a-9e33-51a6c277e90f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9ccf27d-a4c8-402a-b19f-af0964003722", "node_type": "1", "metadata": {"window": "I think we lost him.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f01a7eac3f7dfe26839549f0c0460dfd851a80d00f9273ec7f65b2aa8b74153", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87f25a5e-1e48-4879-8485-04d4c482b439", "node_type": "1", "metadata": {"window": "Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n ", "original_text": "Q \nI'm sorry, Britt and Brian, I don't know what happened there. "}, "hash": "2feb62d3db47b113679664e763387aa41988759133040a2acc457d4d16a946d1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "start_char_idx": 683, "end_char_idx": 1010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87f25a5e-1e48-4879-8485-04d4c482b439": {"__data__": {"id_": "87f25a5e-1e48-4879-8485-04d4c482b439", "embedding": null, "metadata": {"window": "Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n ", "original_text": "Q \nI'm sorry, Britt and Brian, I don't know what happened there. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2016aa0d-5385-483a-9e33-51a6c277e90f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9476af6d6ababc7fab46e316d5eb8f8a3c11e1f93270e2cbe2e26c6aca937d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fa7861b-f399-44e3-95ec-9d7d56f528e4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Just the growth of the oncology business has been \npretty impressive over the last couple years. "}, "hash": "ff91d6eab8ccd3633e519bc4ba78fe3cb168a9207f216673679140c58db17dd4", "class_name": "RelatedNodeInfo"}}, "text": "Q \nI'm sorry, Britt and Brian, I don't know what happened there. ", "start_char_idx": 3148, "end_char_idx": 3213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fa7861b-f399-44e3-95ec-9d7d56f528e4": {"__data__": {"id_": "6fa7861b-f399-44e3-95ec-9d7d56f528e4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Just the growth of the oncology business has been \npretty impressive over the last couple years. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87f25a5e-1e48-4879-8485-04d4c482b439", "node_type": "1", "metadata": {"window": "Q \nCan you hear me?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n ", "original_text": "Q \nI'm sorry, Britt and Brian, I don't know what happened there. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "655b7eb235cb8a6fb927038084846c3048b846a316280ae622d4346dcbef7ba3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abfcfdf8-3b10-4f5d-9f74-f8d4ebae662b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture. ", "original_text": "I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment. "}, "hash": "98cdb88e848d1338f3e6346f6b726b2f87489c28f04dd27cff5ca43924a8cc5a", "class_name": "RelatedNodeInfo"}}, "text": "Just the growth of the oncology business has been \npretty impressive over the last couple years. ", "start_char_idx": 3213, "end_char_idx": 3310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abfcfdf8-3b10-4f5d-9f74-f8d4ebae662b": {"__data__": {"id_": "abfcfdf8-3b10-4f5d-9f74-f8d4ebae662b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture. ", "original_text": "I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fa7861b-f399-44e3-95ec-9d7d56f528e4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Yes, go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Just the growth of the oncology business has been \npretty impressive over the last couple years. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "675f680154a5bb0845c62a869379376e1e9e14d313c982f0d9982bad6ed70b77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "350f6442-a8bb-496b-9ca9-d41b510f3aba", "node_type": "1", "metadata": {"window": "Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that. ", "original_text": "Any color would \nbe helpful.  \n "}, "hash": "f04aa0f648d0b8e4935364f8319a5aa56d7ff670c4f95592fba35182beaca504", "class_name": "RelatedNodeInfo"}}, "text": "I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment. ", "start_char_idx": 3310, "end_char_idx": 3477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "350f6442-a8bb-496b-9ca9-d41b510f3aba": {"__data__": {"id_": "350f6442-a8bb-496b-9ca9-d41b510f3aba", "embedding": null, "metadata": {"window": "Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that. ", "original_text": "Any color would \nbe helpful.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abfcfdf8-3b10-4f5d-9f74-f8d4ebae662b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture. ", "original_text": "I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ae95e3f4fed981cc2af29d8b6c1c8f8dafac379b8055d8fb8f975c7a19f94ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3fba988-d68d-4420-8477-839f91f6d1c4", "node_type": "1", "metadata": {"window": "Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "86d9c7ad09f482ec129de8200e74459d215a42d808267f153cd5a96aa4b067b8", "class_name": "RelatedNodeInfo"}}, "text": "Any color would \nbe helpful.  \n ", "start_char_idx": 3477, "end_char_idx": 3509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3fba988-d68d-4420-8477-839f91f6d1c4": {"__data__": {"id_": "b3fba988-d68d-4420-8477-839f91f6d1c4", "embedding": null, "metadata": {"window": "Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "350f6442-a8bb-496b-9ca9-d41b510f3aba", "node_type": "1", "metadata": {"window": "Q \nI'm sorry, Britt and Brian, I don't know what happened there.  Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that. ", "original_text": "Any color would \nbe helpful.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c11f92c6e6825b8f048eb6127fc58fb7fbd2b8c2537be4103f55941495be89ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f523c176-3674-4595-bac9-d1961773372a", "node_type": "1", "metadata": {"window": "I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n ", "original_text": "A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture. "}, "hash": "db6148072b9429ce444d9bc75c520e4f505dc3d3008a8bec6bce79d4c061b3a2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3509, "end_char_idx": 3854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f523c176-3674-4595-bac9-d1961773372a": {"__data__": {"id_": "f523c176-3674-4595-bac9-d1961773372a", "embedding": null, "metadata": {"window": "I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n ", "original_text": "A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3fba988-d68d-4420-8477-839f91f6d1c4", "node_type": "1", "metadata": {"window": "Just the growth of the oncology business has been \npretty impressive over the last couple years.  I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0741f0f42dbef52355ab42777b3bd709f1af0e322a01fa93e18bea5d9b71c4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c4a1136-ca9e-4068-b989-9286f1e5cd3d", "node_type": "1", "metadata": {"window": "Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "So there's a lot of \ncomponents that go into that. "}, "hash": "89ce75f4193519258c5f468e91c26bf8e32aa52ed869b369f63c1c460b412a21", "class_name": "RelatedNodeInfo"}}, "text": "A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture. ", "start_char_idx": 3854, "end_char_idx": 4053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c4a1136-ca9e-4068-b989-9286f1e5cd3d": {"__data__": {"id_": "1c4a1136-ca9e-4068-b989-9286f1e5cd3d", "embedding": null, "metadata": {"window": "Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "So there's a lot of \ncomponents that go into that. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f523c176-3674-4595-bac9-d1961773372a", "node_type": "1", "metadata": {"window": "I was just wondering if you would kind of provide any color to kind of \ngive us some sense of the scope of the scale that business inside the US distribution segment.  Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n ", "original_text": "A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90593e2e420082b7203c31c42f403831441a6d8391099d92a7c01f3677b10e62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07dff9fb-e4f6-4b18-85dd-0e88d6eb57cc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n"}, "hash": "f72b0f5e83da7eb2d6ab8fa0ad8a3d1f0d6456ceab0fabc6f4f3d2eb696b213c", "class_name": "RelatedNodeInfo"}}, "text": "So there's a lot of \ncomponents that go into that. ", "start_char_idx": 4053, "end_char_idx": 4104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07dff9fb-e4f6-4b18-85dd-0e88d6eb57cc": {"__data__": {"id_": "07dff9fb-e4f6-4b18-85dd-0e88d6eb57cc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c4a1136-ca9e-4068-b989-9286f1e5cd3d", "node_type": "1", "metadata": {"window": "Any color would \nbe helpful.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "So there's a lot of \ncomponents that go into that. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56e5378a5995a3e4ace226314b40a938e1be932449a2d184289d07eeeaa3567f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8915deb1-908c-47f9-b49d-4699d6e18e44", "node_type": "1", "metadata": {"window": "A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question? ", "original_text": "So I hope that helps you get an order of magnitude.  \n "}, "hash": "1dc521088a02b730c1d815c150384e39ea1218454caf97c7fefd9a2b0a65a940", "class_name": "RelatedNodeInfo"}}, "text": "I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n", "start_char_idx": 4104, "end_char_idx": 4305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8915deb1-908c-47f9-b49d-4699d6e18e44": {"__data__": {"id_": "8915deb1-908c-47f9-b49d-4699d6e18e44", "embedding": null, "metadata": {"window": "A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question? ", "original_text": "So I hope that helps you get an order of magnitude.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07dff9fb-e4f6-4b18-85dd-0e88d6eb57cc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Sco tt Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d6ae00eab269ca4949b486d5f95955eaac367eb99f127242ab09ce5b68bba60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa645cd8-bb98-4fa7-a914-71d5d975f514", "node_type": "1", "metadata": {"window": "So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "c1a528d184525b5e5019bf142432b8c9c170225acc2251f45ad88112b4dcbd60", "class_name": "RelatedNodeInfo"}}, "text": "So I hope that helps you get an order of magnitude.  \n ", "start_char_idx": 4305, "end_char_idx": 4360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa645cd8-bb98-4fa7-a914-71d5d975f514": {"__data__": {"id_": "aa645cd8-bb98-4fa7-a914-71d5d975f514", "embedding": null, "metadata": {"window": "So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8915deb1-908c-47f9-b49d-4699d6e18e44", "node_type": "1", "metadata": {"window": "A \nWhen we talk about our oncology business, we talk about it as an ecosystem, everything from distribution to GPO \nservices, to iKnowMed EMR, to the community, to Ontada, to the SCRI joint venture.  So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question? ", "original_text": "So I hope that helps you get an order of magnitude.  \n ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab592ceabfbc14324f188ef430969e4bca6ff25508f675b806eec2c65d7ce977", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61db32e0-f1ad-4775-9098-dd77512ec265", "node_type": "1", "metadata": {"window": "I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call. ", "original_text": "Okay. "}, "hash": "3eeb5e7b7f0db0f1cdc51ff034f79523a9a8832f40e0049296be8e65b966c08c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 4360, "end_char_idx": 4705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61db32e0-f1ad-4775-9098-dd77512ec265": {"__data__": {"id_": "61db32e0-f1ad-4775-9098-dd77512ec265", "embedding": null, "metadata": {"window": "I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call. ", "original_text": "Okay. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa645cd8-bb98-4fa7-a914-71d5d975f514", "node_type": "1", "metadata": {"window": "So there's a lot of \ncomponents that go into that.  I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f31ed4c4a66ce07dd917a3715dcf14e823640d3467b37ddaa895df14ded979cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f328cb18-683e-4719-be8a-f9c855cd1bb7", "node_type": "1", "metadata": {"window": "So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call.  I want to conclude by just ", "original_text": "Is that our last question? "}, "hash": "a82d3d99ef692b7fe14452b79a8ce4e064343194e8df72fd59bf1fd385f7b79d", "class_name": "RelatedNodeInfo"}}, "text": "Okay. ", "start_char_idx": 4705, "end_char_idx": 4711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f328cb18-683e-4719-be8a-f9c855cd1bb7": {"__data__": {"id_": "f328cb18-683e-4719-be8a-f9c855cd1bb7", "embedding": null, "metadata": {"window": "So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call.  I want to conclude by just ", "original_text": "Is that our last question? ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61db32e0-f1ad-4775-9098-dd77512ec265", "node_type": "1", "metadata": {"window": "I think what we have provided in terms of a sense of scale and scope is 2,400 -plus \nproviders operating in 27 states, seeing roughly 15 -plus percent of all cancer patients in the community setting. \n So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call. ", "original_text": "Okay. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3625097c9984e0dd0317913f53b752d4b8a0800efd63b7bb8066bbd3cb7fd12b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1d5b40c-cfc5-431f-861c-39d7d7ceb4a3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call.  I want to conclude by just ", "original_text": "Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today. "}, "hash": "542a5d047953f3d214b32e0f41f519408cccbaaa23b8d58caf84a4bc864b8044", "class_name": "RelatedNodeInfo"}}, "text": "Is that our last question? ", "start_char_idx": 4711, "end_char_idx": 4738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1d5b40c-cfc5-431f-861c-39d7d7ceb4a3": {"__data__": {"id_": "a1d5b40c-cfc5-431f-861c-39d7d7ceb4a3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call.  I want to conclude by just ", "original_text": "Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f328cb18-683e-4719-be8a-f9c855cd1bb7", "node_type": "1", "metadata": {"window": "So I hope that helps you get an order of magnitude.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call.  I want to conclude by just ", "original_text": "Is that our last question? ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8cc3090c96fd31a7843754d63b9cc34d0a5784ac597a89454f7879bc88958460", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4888bbfe-7bcb-47cc-85c8-f57f6066a66c", "node_type": "1", "metadata": {"window": "Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call.  I want to conclude by just ", "original_text": "Thank you, operator, for helping facilitate the call. "}, "hash": "2f26255316936dd9ae7b09c26bae69b2d3285321760617c58cfa193c6ed09f3c", "class_name": "RelatedNodeInfo"}}, "text": "Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today. ", "start_char_idx": 4738, "end_char_idx": 4861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4888bbfe-7bcb-47cc-85c8-f57f6066a66c": {"__data__": {"id_": "4888bbfe-7bcb-47cc-85c8-f57f6066a66c", "embedding": null, "metadata": {"window": "Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call.  I want to conclude by just ", "original_text": "Thank you, operator, for helping facilitate the call. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1d5b40c-cfc5-431f-861c-39d7d7ceb4a3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call.  I want to conclude by just ", "original_text": "Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f5c62ad88ac8ee3672997f8694868d04918df065c4d6ab81709a69c72e1c9b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19cfd5f2-37a6-4ec8-8d5c-d540c259cfd7", "node_type": "1", "metadata": {"window": "Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call.  I want to conclude by just ", "original_text": "I want to conclude by just "}, "hash": "ddf724b2c38c483f9f3d203bf4fd8a417282f2364853e673f624bf6ce633f25d", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, operator, for helping facilitate the call. ", "start_char_idx": 4861, "end_char_idx": 4915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19cfd5f2-37a6-4ec8-8d5c-d540c259cfd7": {"__data__": {"id_": "19cfd5f2-37a6-4ec8-8d5c-d540c259cfd7", "embedding": null, "metadata": {"window": "Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call.  I want to conclude by just ", "original_text": "I want to conclude by just ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b883460-44e9-45b1-9944-de806ba8d4c5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a7606d863776771f956afe568aa00dc5c9d02295ccc15431bc85b80fab514f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4888bbfe-7bcb-47cc-85c8-f57f6066a66c", "node_type": "1", "metadata": {"window": "Okay.  Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call.  I want to conclude by just ", "original_text": "Thank you, operator, for helping facilitate the call. ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c86695644114f952532050a3453be04bd08f92468e55fc8fcc57f3fb53178b91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cd71961-48b3-46c9-9df2-a2d478be6df9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n", "original_text": "McKesson Corp.  "}, "hash": "25277f2efbd6680c1563af2121f2f0b78b257a0c34c805dcc58f11718b4fa4f1", "class_name": "RelatedNodeInfo"}}, "text": "I want to conclude by just ", "start_char_idx": 4915, "end_char_idx": 4942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cd71961-48b3-46c9-9df2-a2d478be6df9": {"__data__": {"id_": "5cd71961-48b3-46c9-9df2-a2d478be6df9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19cfd5f2-37a6-4ec8-8d5c-d540c259cfd7", "node_type": "1", "metadata": {"window": "Is that our last question?  Great, thank you, everybody, for the questions, for your interest in McKesson, and \ncertainly for jo ining our call today.  Thank you, operator, for helping facilitate the call.  I want to conclude by just ", "original_text": "I want to conclude by just ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2dd8e206e9f3b33b83ae5162ff545d79bca47400ca0a00a2bd2d1ddd664e9ca8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c96a602b-f06b-4a3a-8c1b-8ad51364421c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results. "}, "hash": "f76a59f468fc34e7194f925f6b4894885b0a37e885d2fa80f36b00f9a16a856a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c96a602b-f06b-4a3a-8c1b-8ad51364421c": {"__data__": {"id_": "c96a602b-f06b-4a3a-8c1b-8ad51364421c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cd71961-48b3-46c9-9df2-a2d478be6df9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f3be71c69a31cf62c6a26225cee96316b62a7c38e5864010c0229110c7bb440", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0b7bf56-57f1-4e67-8bdc-76e8a363552f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team. ", "original_text": "We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n"}, "hash": "a801b9460858f3416cf20d6da7e34998c684099a0c335082fa18a92ab4b83fb8", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results. ", "start_char_idx": 16, "end_char_idx": 242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0b7bf56-57f1-4e67-8bdc-76e8a363552f": {"__data__": {"id_": "a0b7bf56-57f1-4e67-8bdc-76e8a363552f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team. ", "original_text": "We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c96a602b-f06b-4a3a-8c1b-8ad51364421c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions. ", "original_text": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "008015034286c530a39f12605d64096c0a62c3c0b8164051711253b9f18f0e81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34f731ba-8873-4faa-9741-6047ea22acfa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody. ", "original_text": "As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n"}, "hash": "8f171afbc65ad84b95a6f72fd0a8f2e6fddd050575500f5e0d16a2e2a5da7ec1", "class_name": "RelatedNodeInfo"}}, "text": "We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n", "start_char_idx": 242, "end_char_idx": 370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34f731ba-8873-4faa-9741-6047ea22acfa": {"__data__": {"id_": "34f731ba-8873-4faa-9741-6047ea22acfa", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody. ", "original_text": "As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0b7bf56-57f1-4e67-8bdc-76e8a363552f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team. ", "original_text": "We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9455eeaca8cf4a73796f0cb6c36f30fad75c41422913eaf2b1bf3bad24dd3bb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fac7a08-8f03-4975-97f4-0d9966534f8c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n ", "original_text": "And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions. "}, "hash": "d261d1bb6004349211d443acd722af9282775f391be8ceb349e4a2f4de99a92b", "class_name": "RelatedNodeInfo"}}, "text": "As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n", "start_char_idx": 370, "end_char_idx": 483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fac7a08-8f03-4975-97f4-0d9966534f8c": {"__data__": {"id_": "2fac7a08-8f03-4975-97f4-0d9966534f8c", "embedding": null, "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n ", "original_text": "And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34f731ba-8873-4faa-9741-6047ea22acfa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody. ", "original_text": "As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e288f42d64af567780331cc210b992c9d9cb232110db15cb961ef51ccb186ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87415a1b-ff71-41a4-8e5e-15eaf44b6293", "node_type": "1", "metadata": {"window": "We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call. ", "original_text": "It's \nincredibly humbling and proud to be able to lead this talented and dedicated team. "}, "hash": "2236ff9a607cc45f221e520e557b2c9ae1fa88c833d1327164c131e866e70369", "class_name": "RelatedNodeInfo"}}, "text": "And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions. ", "start_char_idx": 483, "end_char_idx": 591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87415a1b-ff71-41a4-8e5e-15eaf44b6293": {"__data__": {"id_": "87415a1b-ff71-41a4-8e5e-15eaf44b6293", "embedding": null, "metadata": {"window": "We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call. ", "original_text": "It's \nincredibly humbling and proud to be able to lead this talented and dedicated team. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fac7a08-8f03-4975-97f4-0d9966534f8c", "node_type": "1", "metadata": {"window": "(MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n ", "original_text": "And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c146112d6ca37733f16dd619565cf4ed8dbc2f944c08a6659d0fc5a2569dd4b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0645bc80-2db2-4256-a51c-ac00444e8e2d", "node_type": "1", "metadata": {"window": "As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "Thanks again, everybody. "}, "hash": "c34d8948cc1a106b468815feb4b28624f1c904575ab0d3485c6a81c0ffc5720a", "class_name": "RelatedNodeInfo"}}, "text": "It's \nincredibly humbling and proud to be able to lead this talented and dedicated team. ", "start_char_idx": 591, "end_char_idx": 680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0645bc80-2db2-4256-a51c-ac00444e8e2d": {"__data__": {"id_": "0645bc80-2db2-4256-a51c-ac00444e8e2d", "embedding": null, "metadata": {"window": "As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "Thanks again, everybody. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87415a1b-ff71-41a4-8e5e-15eaf44b6293", "node_type": "1", "metadata": {"window": "We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call. ", "original_text": "It's \nincredibly humbling and proud to be able to lead this talented and dedicated team. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "967e51843808cce3ceb4e9662ddeb085d613d2cb64a8264f9214d1e8b683a589", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c67c0156-d738-404d-a933-e69ec060c594", "node_type": "1", "metadata": {"window": "And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "I \nhope you all have a terrific evening.  \n "}, "hash": "c65da28a4eb00e3374a9bc5bd480b57798cdf0affc0f66f897ee23c226748287", "class_name": "RelatedNodeInfo"}}, "text": "Thanks again, everybody. ", "start_char_idx": 680, "end_char_idx": 705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c67c0156-d738-404d-a933-e69ec060c594": {"__data__": {"id_": "c67c0156-d738-404d-a933-e69ec060c594", "embedding": null, "metadata": {"window": "And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "I \nhope you all have a terrific evening.  \n ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0645bc80-2db2-4256-a51c-ac00444e8e2d", "node_type": "1", "metadata": {"window": "As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "Thanks again, everybody. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7d8ae67df6f333dbe6ea1ddcf258f80716a6c6845d096e90e392cbcd0233705", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b7ed09c-9801-4dd3-ae70-82cff38dc9be", "node_type": "1", "metadata": {"window": "It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call. "}, "hash": "9f924c7c7cff6c75d4fdbf6490f9f24035ba0c3a2a1ae2f2fb31f876ed824c17", "class_name": "RelatedNodeInfo"}}, "text": "I \nhope you all have a terrific evening.  \n ", "start_char_idx": 705, "end_char_idx": 749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b7ed09c-9801-4dd3-ae70-82cff38dc9be": {"__data__": {"id_": "4b7ed09c-9801-4dd3-ae70-82cff38dc9be", "embedding": null, "metadata": {"window": "It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c67c0156-d738-404d-a933-e69ec060c594", "node_type": "1", "metadata": {"window": "And lastly and importantly, I want to make sure that I thank the McKesson team for all their contributions.  It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "I \nhope you all have a terrific evening.  \n ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ede4b1bf4e902d073273b48cb264ef2aba1b62627b69a10fa6c073d86756061", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91d89b0d-81de-48d9-bec5-addc486e7433", "node_type": "1", "metadata": {"window": "Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information. ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n"}, "hash": "557a1e8dbcd909e7cb65881d0215fa97336ed04ebb254c744707a87fb22483e7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call. ", "start_char_idx": 749, "end_char_idx": 1077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91d89b0d-81de-48d9-bec5-addc486e7433": {"__data__": {"id_": "91d89b0d-81de-48d9-bec5-addc486e7433", "embedding": null, "metadata": {"window": "Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information. ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b7ed09c-9801-4dd3-ae70-82cff38dc9be", "node_type": "1", "metadata": {"window": "It's \nincredibly humbling and proud to be able to lead this talented and dedicated team.  Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e7d6a5d11afae0314732cb81ca3941854ac049a19059b876a0bbc5fe811a089", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72fe6bfc-67a0-4402-a0e0-f5d6e2f18971", "node_type": "1", "metadata": {"window": "I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n"}, "hash": "5e86ad3bf507a6fb061b4c71ddf777aefc26a83816b7dd5d918285abb52e3c6e", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "start_char_idx": 1077, "end_char_idx": 1147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72fe6bfc-67a0-4402-a0e0-f5d6e2f18971": {"__data__": {"id_": "72fe6bfc-67a0-4402-a0e0-f5d6e2f18971", "embedding": null, "metadata": {"window": "I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91d89b0d-81de-48d9-bec5-addc486e7433", "node_type": "1", "metadata": {"window": "Thanks again, everybody.  I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information. ", "original_text": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0035d7d588ef5da0d6f339c89903c8988dcffb13fc6be94fca96b46c6fbc40b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0aa2e7e-395a-415f-8e08-c92998724da6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "8c212b52b4620f0c70822b4bcf147d5aaa0871eb71d86a5ed6e253be95bf9719", "class_name": "RelatedNodeInfo"}}, "text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "start_char_idx": 1147, "end_char_idx": 1356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0aa2e7e-395a-415f-8e08-c92998724da6": {"__data__": {"id_": "b0aa2e7e-395a-415f-8e08-c92998724da6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72fe6bfc-67a0-4402-a0e0-f5d6e2f18971", "node_type": "1", "metadata": {"window": "I \nhope you all have a terrific evening.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bfbe3198eeb6ddaaae5b2378c1282f43e90a568889ad1dd32be113a665db044", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcf32fc4-b9ee-47d3-a732-64d648f17a96", "node_type": "1", "metadata": {"window": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice. ", "original_text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information. "}, "hash": "f0a1ef72432006a30c5e57f6d38299f99a186c15157e6c7c3b6bf23e40c90995", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 1356, "end_char_idx": 1479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcf32fc4-b9ee-47d3-a732-64d648f17a96": {"__data__": {"id_": "dcf32fc4-b9ee-47d3-a732-64d648f17a96", "embedding": null, "metadata": {"window": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice. ", "original_text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0aa2e7e-395a-415f-8e08-c92998724da6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank for joining today's conference call.  You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f11f14d84ee9751d7c77d196973813d33166439216728ac033864f5c30590b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "189075fa-b38b-49ea-abb7-b73a52c54962", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. "}, "hash": "9025ca2b36abdb60a879bae20cb27788ad525baf8b6244154ff952e951e440af", "class_name": "RelatedNodeInfo"}}, "text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information. ", "start_char_idx": 1479, "end_char_idx": 1678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "189075fa-b38b-49ea-abb7-b73a52c54962": {"__data__": {"id_": "189075fa-b38b-49ea-abb7-b73a52c54962", "embedding": null, "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcf32fc4-b9ee-47d3-a732-64d648f17a96", "node_type": "1", "metadata": {"window": "You may now disconnect, and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice. ", "original_text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28532dd06a709d1654e8e6e0940487ced5843c72159ffb9c9edc95974a14583e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f974aa64-ee79-4bec-af6e-791716591297", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. "}, "hash": "ad3d460196a3763374626c87800a1be6e252a846a19d2ea7bae73b7fe763229d", "class_name": "RelatedNodeInfo"}}, "text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 1678, "end_char_idx": 1769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f974aa64-ee79-4bec-af6e-791716591297": {"__data__": {"id_": "f974aa64-ee79-4bec-af6e-791716591297", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "189075fa-b38b-49ea-abb7-b73a52c54962", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "395cbc849d4b01583ebb36362c3c8c2cff4e7f2ac33b6716f52358268376ce07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7ddcdad-3501-4a8d-981c-d18e8f809453", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date  is subject to change without notice. "}, "hash": "9ce85b83f50884ef545d41b744eeae5beb5cd016a80617b87bf7daa2cc54b003", "class_name": "RelatedNodeInfo"}}, "text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "start_char_idx": 1769, "end_char_idx": 2132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7ddcdad-3501-4a8d-981c-d18e8f809453": {"__data__": {"id_": "a7ddcdad-3501-4a8d-981c-d18e8f809453", "embedding": null, "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date  is subject to change without notice. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f974aa64-ee79-4bec-af6e-791716591297", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarant ee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8b93d182d53ef8738d5037b91a72a6268d407c67180e3f315a85ce201b65ac5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b50a5bb-76a2-49b9-985e-1ab64caac5bc", "node_type": "1", "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC. "}, "hash": "7a6ac14b34df948efd156fe12c4a6268315e3ab6eeec73b6e9d4067e2621018c", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed herein on this date  is subject to change without notice. ", "start_char_idx": 2132, "end_char_idx": 2217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b50a5bb-76a2-49b9-985e-1ab64caac5bc": {"__data__": {"id_": "3b50a5bb-76a2-49b9-985e-1ab64caac5bc", "embedding": null, "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7ddcdad-3501-4a8d-981c-d18e8f809453", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date  is subject to change without notice. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64dc13c7ce70ce8d1aafd618de3897416fe2c2098445a585fdb9b9848152bfec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b436f662-6bc5-41a5-a06b-9d1d09443708", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n"}, "hash": "ef799a13028b82185c43b2f8e9bc47aac4207c188a5d294717999994a6a74eef", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 2217, "end_char_idx": 2345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b436f662-6bc5-41a5-a06b-9d1d09443708": {"__data__": {"id_": "b436f662-6bc5-41a5-a06b-9d1d09443708", "embedding": null, "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b50a5bb-76a2-49b9-985e-1ab64caac5bc", "node_type": "1", "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61a9eab00c6b663f7e03096567b6d44aa1db658f3fc02e8b52ad9e111e1e8a60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc2b6964-48fd-4a3b-a545-dff18082ca0f", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "bb7aaec9e7859396ddd1c8df32e5b7a3ca94bc7d81fb7aa3a7b986b14f9bc4a6", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n", "start_char_idx": 2345, "end_char_idx": 2508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc2b6964-48fd-4a3b-a545-dff18082ca0f": {"__data__": {"id_": "fc2b6964-48fd-4a3b-a545-dff18082ca0f", "embedding": null, "metadata": {"window": "Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b436f662-6bc5-41a5-a06b-9d1d09443708", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for informati on purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c58fd53613278ff88353760a648808efe5f9c6f9a66f1b7a1e0f0bc08363b343", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14c911aa-3c05-40d6-96b8-b62a7f35f8fd", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n"}, "hash": "253261fa606c2507ad66e2a554e56e55f8644506881c2ae9bf5a9a530ad13bdb", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 2508, "end_char_idx": 2943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14c911aa-3c05-40d6-96b8-b62a7f35f8fd": {"__data__": {"id_": "14c911aa-3c05-40d6-96b8-b62a7f35f8fd", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc2b6964-48fd-4a3b-a545-dff18082ca0f", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date  is subject to change without notice.  Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6986dd7efada6c1edbb811af599cd42ac784a52793908436b9cc9bd7b896972", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65c0c86a-b933-43db-b875-fbbb1be9b3ae", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "e58011e54c61415099ec7f24b5b692d7fe9171da67ed03c79f03dee9c837adc0", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "start_char_idx": 2943, "end_char_idx": 3623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65c0c86a-b933-43db-b875-fbbb1be9b3ae": {"__data__": {"id_": "65c0c86a-b933-43db-b875-fbbb1be9b3ae", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14c911aa-3c05-40d6-96b8-b62a7f35f8fd", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions o r beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf64130d2ae29a3f0de9240adbc14b1ea526af24e6e84b9a14dfadf2a8cdb204", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "692d1d83-a459-4e26-903e-f91d0a04236c", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. "}, "hash": "b0d921926480129a168a99c5eb01d267f973238120fe4e7f240c3581d35b9467", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 3623, "end_char_idx": 3813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "692d1d83-a459-4e26-903e-f91d0a04236c": {"__data__": {"id_": "692d1d83-a459-4e26-903e-f91d0a04236c", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65c0c86a-b933-43db-b875-fbbb1be9b3ae", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this repor t, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9fdde7b08253f0a68cfa00544aa410003eb7306c71f7bc531f84a3f77ebc3b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ae71482-53d2-4ad7-9aa5-d88b8413ab87", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "222dbaacc744de7086bcd920c836ed29954a10f427e66b6f12cc83ab3e3fb57a", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 3813, "end_char_idx": 3891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ae71482-53d2-4ad7-9aa5-d88b8413ab87": {"__data__": {"id_": "2ae71482-53d2-4ad7-9aa5-d88b8413ab87", "embedding": null, "metadata": {"window": "TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b801e091-c3d8-4737-a7f7-96155bc15a92", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9310244a0c8b39a333d563abf851214ec681882f49a9d7c0732921b39f071114", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "692d1d83-a459-4e26-903e-f91d0a04236c", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPP LIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPL IED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM E XTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAG ES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2023  CallStreet and FactSet CallS treet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46dea3ecc7bbe90684ab7de36be511e62421461ddb8b34e5c92685c3871e5ba6", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 3891, "end_char_idx": 3913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"aa00e485-6a39-40ce-9cbc-92520f1f6570": {"doc_hash": "1ac5ea799f5e0cb30aa562697381ec4c53a75f3a5696f0064f021b428c482622", "ref_doc_id": "033fafe1-146e-4889-91d5-095860852b9e"}, "969653cc-e42c-44dd-9e5b-25b022f5d422": {"doc_hash": "dbefd3bde88137937c3247f1c92f8d5e6eb91f28a7567b0fe55ffe2df1c31818", "ref_doc_id": "033fafe1-146e-4889-91d5-095860852b9e"}, "96af4f32-e99d-4b4b-98bc-80bd2b3c1dd6": {"doc_hash": "77001f73b08355c525e008d442cf1368914eac86423e15bbcee58ace72dfbfcb", "ref_doc_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684"}, "8a220c07-4857-4eea-8522-dd3aa408cbb3": {"doc_hash": "7d195e992027c4fa87d37dec4c8f08218da60ed97a42ed97ddc46f901ab4c00c", "ref_doc_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684"}, "099e83b8-6dfb-44af-b97e-2e1319142825": {"doc_hash": "087b4917854da7185e24ee1ecc65a3afc5b17e12b2392ba006090ec7633dd4f2", "ref_doc_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684"}, "64e00170-b91d-4ad9-87dc-e3f9b8aa1d93": {"doc_hash": "1dcaae3c9f51ad7d5eec2475ed75378034112a3865ead6e2f56f71d65867d23c", "ref_doc_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684"}, "aacafba1-1a00-4b56-90cb-0e3ca421e1bd": {"doc_hash": "d2e3a60b6980a7af880065ce34a3076c37e0621e8be1f83d58bb2591f1400e94", "ref_doc_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684"}, "be0832c2-7b64-4f6a-9832-be1fabddd096": {"doc_hash": "d99a23d823b6eb2183bfaf1a83894141f3eb0494f8dd058b4aed2c69bb25f8ef", "ref_doc_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684"}, "bb2df4f0-ce88-4f48-8afc-f97b6fa1f3f2": {"doc_hash": "bf6566a130f1ea275581c5459d921cce30fc231f6c09a283418492e15cb2baf0", "ref_doc_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684"}, "ae85b463-057e-4d7b-b9a9-76198b013ee3": {"doc_hash": "2cf68c5dd6063221f22145ee7d6418bde803a4409585f35c20e074ab951caf5b", "ref_doc_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684"}, "cd5d8aa2-1c97-4d3c-990e-a8c1a783af1c": {"doc_hash": "0f49dc464463f84229bbb852a8a272f1d5451ae52753828448d19b18b54c7132", "ref_doc_id": "316a22fc-48d0-4d05-a0df-e09aa8f54684"}, "89607f5b-075d-4403-ace2-8c3ff01d6b67": {"doc_hash": "75fec6f8bf230710335b62fb4a901da0c09a1617eeae1626c0c8c87a2c4e0b6b", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "bec546ab-b705-47b3-bb24-4e1c9e6bd82b": {"doc_hash": "939a6285f53838816b27e01a9b4cc7ba1683f981aa14bf650a5d51c2e7661cbc", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "3f432ced-d0cd-4d49-852f-fd9d683ff06a": {"doc_hash": "96b564e7df66f06869e7e89d36c6dabb1eba43004b8627aa91eb1bd5926e1db9", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "8fe9932c-d76e-4660-9a36-a199064dcb15": {"doc_hash": "9c28013bbba15449b495a0076c03d90192cf118b6d606ae0131a9133fa5a1285", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "fcd4a6a1-d4ca-4eff-a32d-75d0e2d34a8c": {"doc_hash": "61bb87ca0745a578bfd46c931100a70f2f84393e2d39789bb924689e8982580f", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "a5454c77-7f12-46a3-99b6-62e659afc5ee": {"doc_hash": "5c42f4a74fffa54429ddf6df413b06da3fb60427a23f9de6fc7e7ac4dd2e9f8e", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "dfe87f8e-2059-415e-9a4c-f049f1d598b9": {"doc_hash": "002f3e21850c540db719fcb22ea94e10ca8140849307dd14f86928ee801bde0a", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "ff8e79a4-1501-4f51-afc8-9773f8489b74": {"doc_hash": "2924035a59437736cab79edafb18409aa7aa0986ba618bbd77641abc552c9764", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "f4763077-f613-44b9-88ce-d8355a607c6d": {"doc_hash": "1f1ebb5d9e95b355d137256cf72e73e77d5ae488c510d685ff60a8d489ce6e85", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "7923f500-16fe-471c-a4b4-ac797127c5b2": {"doc_hash": "1c2debcd30170bf58f78eb4f279ba38418460584817feb001c381396e6cbfcdd", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "847c096e-6794-449e-bf55-f0058d047ca0": {"doc_hash": "589c71446e598609323be3496520b67d26ff5ac5867a667df9e85138728ce541", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "ec6d1691-3ac4-450f-87ea-6d601e20223c": {"doc_hash": "dea5be9e7b4d25efde344e8b62e7faa92e644f004483748c8c82bbc574d152c3", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "677d71d5-b8ea-480c-9827-f328ec625dc8": {"doc_hash": "5e2e21b15095b67ecd97336187230b2ac9ef0b28efe570cfe0db3a2a0ae1272a", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "88eab0df-3c24-4cd8-a362-17e7f528365d": {"doc_hash": "1776c2c8df0d9473fa0cf103a5319c747b8776618dcd5d2e3fe0d15cb14a07c8", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "5fac08a8-9767-422a-ae8e-e739307103f0": {"doc_hash": "22eea024202c16e2da36dc8711203421e6203805d1e1eb652dc35e26350f830f", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "ecb61339-b0ed-4981-83fc-8d8f24f3b1b2": {"doc_hash": "e314c0a19d8dd207b55e26025dd963634cc4bbe1ca1596266b6b2ca32e90385b", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "a63a54dc-7284-45a9-8108-73834e6ece33": {"doc_hash": "01edeb63a7ce521491950dc90edb9f86f9b5b3f4bcce6ab2bfcc6a54a5994e1f", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "1e4ad327-4a0c-4c4c-9eed-9a515569b0ed": {"doc_hash": "8a0d9197943c145fb909effa8df3d0611d303408808ba9b3423f87b85d6fb7d3", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "10ac4c4d-637d-4e21-9cc3-c1de7d6a808c": {"doc_hash": "901001246f545812c9cc3dbc23e1ca891840778442b01e79af0850ca06015536", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "38be99dd-9d12-414b-9be3-908b763e5cff": {"doc_hash": "a9b36994ae3c5d764fea26de6dc1659e4b1e2616224df7c7e81129890fedac0d", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "1382ce07-80e4-4cad-af5b-e523d92140ef": {"doc_hash": "dcf89bc27892e45a7fabfc2cd96dcb06beb16096d9015c4260954aa20b7a00f3", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "7761c5e1-47ef-4aed-b476-5e9e85e31188": {"doc_hash": "909658d7318249db510c5c55a3919a5657e2f9aa9b19f86aca55c41efcf9601d", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "91421e40-6fe8-445e-8eaa-e0004d0ac0fb": {"doc_hash": "0919c8268a85b4acea688e04dd0385321e522263fc5a2528f040694a4f371b61", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "0ed3365b-9098-4934-b77c-067c6c9d55e2": {"doc_hash": "6dbe53cfee9720ad469f857400f3659a7b62dfa33b837e15c3d49ed1ae6d9ec2", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "d59c5b46-c33d-446b-b95c-710031414c5f": {"doc_hash": "e0f72ff9e6c1e04cea07d8a0fcbde924805270869bd150ec4798a817e819b78f", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "bf5497d4-44cb-4b44-b46f-5a34b54e6fe6": {"doc_hash": "b1eb42d6f9934961926e57f15e0ed52930e42e2ff70bb05a81534f97605c538c", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "43b8b382-5630-4fc0-ae99-644fc416b3a9": {"doc_hash": "b0f9f9d4aca0642226049b190253f539b464e520e056b3f2f63b206953169c2b", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "be7f7286-4504-46be-9695-cb59e6de843c": {"doc_hash": "136e27ab935e6b2b6e1e8d7b4235ea1f25c80c0647ba96646464293cf2bfc4c0", "ref_doc_id": "e6eed5f9-8f9a-45f6-bd97-205c2824afd3"}, "f60a01d5-896a-421a-8842-4cf1dbeca723": {"doc_hash": "3b6f28e6b279796e55472489bef4135509781eb9c266be42f806878e59e74360", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "049ab5e4-70bb-4bbd-86bf-8bd53b5718d6": {"doc_hash": "ca941b7cbc334e9ed0240bcb7562830adf258605a89977d270515fba36dcd27a", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "3937c700-7f64-49e1-b4db-f959cf6a3e3e": {"doc_hash": "0d0d302f00198645c19fb043bc6fd9178dfbdeb390d9c29eeccc46857cf7be25", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "6093f32d-cc09-4fee-872e-976950b20214": {"doc_hash": "e872482e899ad2c99df64a8a9887b912dc5b65efb964ed242be62119a4b56874", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "a227b051-baa8-4084-b34c-7fdca65f94f8": {"doc_hash": "7bdba47b0d3657cfe4d9242aff86413d737873e6e7acb72386f49bad176a76ee", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "6d0fe18e-7f02-4d14-8f52-6fbb108f3d58": {"doc_hash": "7722fc47fa3998040fae891115e0809b517d2919b84e186919ba4726e6e83fcd", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "0ff3631f-a09b-4cf5-9bf5-107d5793c8f3": {"doc_hash": "8c13d696205624abe2359dfa23b4ee01f4a8d7523d48eb3986f7447b48cda991", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "fd947ace-bf49-4d25-ae64-74b7e48bc89a": {"doc_hash": "ccf6909b8ffaae137bb6a10338b594d3b5300317f7a77090823a4fe3adebb2fe", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "9e4857d1-f313-42d0-af3c-a3ab00bdac53": {"doc_hash": "fe20329ac34e00aa22670290f63f88c3d39c803b2096771239ff90b49de0a3ed", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "d80afbde-ca1a-470e-8e41-53ef92b9fc1f": {"doc_hash": "7e04f2376767aa3f8b1598a9dcedfe1335e170988861ada298062e506ba68f7d", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "0fc11a11-64ab-4106-9964-47b069027fef": {"doc_hash": "de8a47de9359406de8b4ca2fe87f09a77ce69b121c64528174a7d0cfa6580770", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "0c6fbd94-7199-4dab-974e-46ba7d35c226": {"doc_hash": "ce9dc8a2dfee76440544b97ed6940072cbb9bf487c5fde7631f3e1646ae05448", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "563e362a-50ec-4b1d-86b8-18ae3c373399": {"doc_hash": "97b0f3230c0e8311830c9466d6f93c7cd78abd61e612ed89a619a46818e2b085", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "14c2d3e6-a84b-485d-a3a2-4cc53c92f3a2": {"doc_hash": "c2edfd6565f07ca9722f6ac711b3019f7ae1c0ea6e9028303b6e3a6b13b3778c", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "9960734f-c167-4c11-b315-e9904d5853e5": {"doc_hash": "b0e84dafbf40eb84ea3cca6de4707e634fa8ce150e41e5bcf5b30a9c3b9b66da", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "61b8298d-e5cf-4e4f-8274-a45c0365643e": {"doc_hash": "d9a8566c3ad3f8c9d93ef806e4bb3527e51484498a92acf639274a08a1ccf7fc", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "e2b666f4-9576-4bf8-a9ea-2cc6487dedae": {"doc_hash": "7fe3aa535398d5a0d544f6a519754cda49b05b542b0f2c394c123ebf1e373463", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "16206b8a-d80c-4817-8803-6e52cc4c5e7a": {"doc_hash": "48f23a46e8e068b1d909f3af0c28b8066f3109f9ed11031cc79107f9e3af8a5b", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "bda19614-1ccd-436c-8e1c-135ad9e85cd7": {"doc_hash": "c449abb87eed6d6dac7300be65139b0c10017f1fc0e2d8a6128c1592670a220c", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "2d887fe2-a841-43b8-959a-6d0d0ff70c6f": {"doc_hash": "dcb624ccc4340c8ea418363adda8f1e832a9c84ff4b6deff7d71a92827baa3e5", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "1d01099f-c09f-4bca-aec4-fffb60135758": {"doc_hash": "4f4383f3dbe52da0fe80bf7063180d2a040896bdb2f57b1465ff76bb64114ab4", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "edc9f716-693a-404c-8b6d-3afbe76ec5ab": {"doc_hash": "b4127ff335569a4a7e048870b3774966ea9976fdd5f1cf30668747beea1f14d3", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "955271a0-d83b-4e65-a0c0-ccd5d1b25ce2": {"doc_hash": "20ad3c735fa9c98bac3d3fb866e405e99283bba9c4a952c14cc9e39d48739005", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "f9e51b1f-9051-43fc-972e-fdf50ba193ee": {"doc_hash": "28c7b20dca7f10a405c7da1e2572efa169d304c989c570105086a468761bc65b", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "d0de9f81-6598-4a89-95fb-c8017b7a8dde": {"doc_hash": "96dbfae3f1695316bcc302d6ed1e800014504c17d05d92950268aca70260d029", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "b6c21810-dc96-45ef-a2f7-186ac5afb299": {"doc_hash": "0bafb03789691aae508b90753c9720c6fe90762ae0156d6509e102e1e75fae6a", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "5f340c04-7de7-4c66-99b3-58f027ad8744": {"doc_hash": "c1157fb0fad90c2fc49cfb96c54f0e0a279de4d99368c56924706a33e1ae391c", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "8f4b40e3-8688-4fc9-a8c9-b58adfec6d94": {"doc_hash": "7accdd837bed707844f2af6944b079a096782cc99bac4b865457dde9ea99d280", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "23021893-dc40-4706-b88a-e8ed613ef8ab": {"doc_hash": "00cea8d64b9cdd9d278008730bb873283e4491899cdebd9387f67cdba7f594ec", "ref_doc_id": "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8"}, "4d9a48a6-ce7d-43d4-8649-a81e859efe64": {"doc_hash": "1878d1da20d58973bf5cb07af988d81545a457da85161308b85e4579b7756aea", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "1470b283-4a83-46d3-8542-8f43a11888f5": {"doc_hash": "64b7841a80cdd206b0f396ea206beaab3b3cb92786a38885902432a3e5eee889", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "ccc2af5a-182a-4782-a8c6-ec38da3e0ecc": {"doc_hash": "15879800dd6e2dd5a32f4c35b6225dc258702ca4c988a530adcd49d149321f51", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "97e735c9-0614-47f2-a25d-38e3e508cd1d": {"doc_hash": "ab681acd4596dbd7ffd3a2b02328f7a08e5f32ac1bbea28d6136d8f4f14f1f4c", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "1a695925-ddd8-4b65-a728-6555e526ec82": {"doc_hash": "ab6a21d0733cad0da830185fa0e808f52d9890b53d8ae0696c20996df8d94a5f", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "e7a5a808-47b6-43e9-ac7e-aeea1fec4955": {"doc_hash": "5327f7dc12142c100ae51bad472fb341ab2ed24f9d0ed872c50fb66195628720", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "86d7bf56-226f-4a2d-9b2c-b75ddb75edf9": {"doc_hash": "6334a145e25d0fee6e58dbdb9e22b65a09fc6e41bdac10511a583b9713f2a868", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "5fc91e45-9bd7-4cfc-bd1e-739f157daa65": {"doc_hash": "a399976a335d17c117ba7f1989d242c6132af9b76218b471852dae642399c0ef", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "c8bd62b7-d5af-4ef7-9103-26f962bb6f68": {"doc_hash": "d05d5ee8a6f980c439b14a7fd6a65036b96c2fce78c76db73a9189c56d77af81", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "8d66f7f4-d9b6-4cd7-9cd5-f7d47c3c20f5": {"doc_hash": "6785ce5687cddf147cb56fc6dc04084d51c8818c1176e8ce1febee0c4d517174", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "20380a8e-2054-4f83-a7aa-efd6006ecbb3": {"doc_hash": "708a6d4765bf20fb01dd5aaaee3d2171456a15a1cd7c00423db6263ebd23b687", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "f00bc185-3c6a-49da-9ad2-db7905d52977": {"doc_hash": "367e5af0e41434d1ae3c5e213a458f7c011c9d8986c45260df05f2f44355692c", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "9b79369f-5a99-496e-b105-0adc2695674d": {"doc_hash": "da8e5abd5cd546a1802dd4b3d4ed3ba9e8625216cc0bd5cb848e75ef83f04d66", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "ac8014df-c485-4948-be17-3c27ef9d39a5": {"doc_hash": "6213d360de1e8614177cb2ef98b6c35a7f075a0ff5ec0cc299825ff576f3a373", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "9e2d741d-bdc5-4f56-9740-87e6db1f01b8": {"doc_hash": "e100e5c5d82f60d3469c9b2c9f76d81517c8421f9576029ba356f71246e4044c", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "096940a1-316e-4a56-9f62-a7e2ba68d1ac": {"doc_hash": "789579a89f00ef522b24fbcad3ea4f23f4cdfc0c06a7bebc8c884ae023bc2627", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "e4de5c3c-a595-422f-b68a-980c7ae3741f": {"doc_hash": "2088222d082ed201d6a804eaa37d131315f9e4e8d6f68a8052c0c8331742f2ed", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "20353e6c-8fb6-4be1-99d1-a9e3ce7ab875": {"doc_hash": "3358cec0e6852ccea08cf1770cb77a44cfd064b01ac284283126cc2a050a401b", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "ce023f55-612d-438e-90be-87e6d020e042": {"doc_hash": "aa4ecc786f93a68fdcb86b6effbffbb3f584a3f36f9fc12bfafa1d71c3d2fb55", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "8ff8a047-26a7-41f8-bc0c-ff51b6c491f7": {"doc_hash": "06dfeb4f29a47b785e69225e0fec008fdce42982f91e82ba4cdbd830478ebdfb", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "c6f6325f-30e2-43a5-a417-608eff552b6b": {"doc_hash": "ebe4d40421b4f1cb01dd16c6db1f2fc60db826fbbe35c91821eeb1e9cf18abe7", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "555dcf8e-535a-4c67-8d74-7e13c1cb3a86": {"doc_hash": "f3d15d5e51a64ae693c19b3f6a6e838425f6eaac2dc6217d5db9e41eabfdd121", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "d1668bbc-bfe2-4085-8466-2d852e0113ef": {"doc_hash": "f2feecc3a28c1ffd8af87edb8adb74818f833da0a925e1a3fa725561ad765d94", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "2363fe81-d246-4b6c-a9b2-4cd88aba6ee4": {"doc_hash": "09ffc4c977483d88660e309cad09727fcf13265f9fe65cf15120bdf7a21cadf9", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "79449d2c-1e08-4a82-b4c9-329d750d3a1d": {"doc_hash": "e1dea0b516c689fffccf8df52bc14ec29a1be1d911d25ca3561f88807bf74090", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "336599c8-478f-4ca0-a321-3857cec9d050": {"doc_hash": "faa4317e367e2b027d3b7b6cd9a3175751d245cc24a8f7b3ac16ad76dd9f89ca", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "c3dcff51-7b0f-489b-8996-440bfb94cfd8": {"doc_hash": "a6866d8a641451c926b4f91f29703d7d2dc59a776039be4da6790ac604f1c5dc", "ref_doc_id": "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313"}, "069ff281-071f-4093-83b1-f71404037b2a": {"doc_hash": "d060291f58f1f482fc544269dc7a0048604dc9f1f22617f4eecb8a4f8b8dc0d5", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "9ced5154-0f9c-416b-bcc4-db24e1b2de88": {"doc_hash": "a81aa597aac122c82922f8d12d61e1d85c07ffbb8c7150e14fe02cb805c88524", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "931d355b-630b-4b09-aa6d-1b343aaa2d5f": {"doc_hash": "d15295c41f2220cbb3a99da6a5bc87af21e1c6f6c6c6e36134fade2d3ce1bb2b", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "3eff30c9-3341-43e5-a22d-c257747f6ea4": {"doc_hash": "f50df10cf66282067ad4356106d1abab9013f0a713cb509263c0d28a700f7020", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "613a2b34-abc8-4874-b6a1-3d8a1c570030": {"doc_hash": "0edfa31a2eb03248336a472b865337bba410683ba7f1ac1e8987e8bf6d5e8662", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "46433335-5df7-4bdf-a9d2-7bd68af3d746": {"doc_hash": "d34e52f834df358c0eb4ddab7bf11d3dbcf12b02c9863f0f9e42c5791e3bf53b", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "7e5ebcab-b21a-4263-88fd-cf1ac07f677a": {"doc_hash": "4253a829bb6000d836e0556ccaf704f95500558534c192bec588f3c86f4b123f", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "530660c8-5569-418f-8be0-e6e2888bb13d": {"doc_hash": "5a53bc0bb1c4b63500e4f1dde66523a6813073b35884402e71dc31453b11b854", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "2b404915-74ab-4889-84a0-8db1494685a6": {"doc_hash": "dc5bf5a2909faa755208209f55e67636aae84bc3c5eaa7647b47fe56897b7cce", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "4f7b0960-eec5-4c99-9593-95e4458c2571": {"doc_hash": "e28ecb4724af29deec0e5f7e50c1288c8ef9e54fb817b95e5b1baa66d2cb362d", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "03c655c7-e996-4dc2-a7fe-4907031f7251": {"doc_hash": "c4ad56b63581890ff5a1158d474f5cb3d402826b722e4e5f281c5bdc97555161", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "97d369c4-efdb-45ea-af36-95318954212d": {"doc_hash": "a6378653b1337eb621c63f19adb1cd2a0452a73f43db96695778aa3ada76862e", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "b906b1c7-11a5-4d11-9fb0-5a7a3aa7b548": {"doc_hash": "2d3eb0a322624fdb156b01855010a176e96752d17c7321b2d0a20f4fbd35a00f", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "6cd29bd1-1811-48e5-b899-317519a39ce4": {"doc_hash": "5e6fabf5989124f761b3defd1b94688d10b30e02e049d389ec9455590343ea83", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "e65a7921-c951-4ffd-9585-d58d2bbcba40": {"doc_hash": "68ada0f34d5b09e4bd7ee3ccfb959d2d4432b6d1551adb74028fc2ca46c624ce", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "ee1ed359-7387-4c0e-8ac1-a9410abca7b7": {"doc_hash": "a3ab4edd7d317abd3776fed81caaf142f118ee49118a6d7f4cd597b1cd8e7b3f", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "d48acfd3-d1b6-4c55-9be9-6669913d9c6d": {"doc_hash": "090e40c70033821bd342b8fd14b53ea0cdadfce7f09d5e9dc41fdb05e606f01c", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "d1c0ba64-8de4-4151-8c80-21c2256cf398": {"doc_hash": "4ef26899a6066315d58d66b44642e22ade3dd2c6914a28e130b3475780059fba", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "dc90cf59-e1ab-4bee-b70b-02205082f107": {"doc_hash": "bc5f10dce18a1ce86e67a8685b793c7d11f169288ad1a2510c2a93bc097b3eae", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "b242efd6-72de-4fd7-a8b7-3c5f987717d4": {"doc_hash": "e909f56961059bff4c63b57335a9b61610d8dfb21cd56841c2b08913fdc613c0", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "67465d60-f60b-4b41-937b-e4058353d822": {"doc_hash": "c3562a33448f44c36ab728773aa7047656ea9b2de6a205220215e240dfa959ae", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "c39c8600-7544-4dd6-a4b7-636149c3b394": {"doc_hash": "050c46d996dc2f4c80f92c373d517e98c4f6439e5bf26849cc5aa925d1240484", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "cd4d7f90-9c8f-4f03-8622-e179c3a0e470": {"doc_hash": "15131b35d7535300b108c97bd248b472868ffd0bec78b28775945471ad65269a", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "7176cd73-2572-4d55-8ff6-448ef711773e": {"doc_hash": "7c8ab209192b13fce0bab20f53bcb65de2299e2b763d0e713f98e946666f6623", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "f36d4aef-36b1-4cbc-a902-c0b2a531af73": {"doc_hash": "1ff9291c41e976ea2e97bbb00aa1b203d5b16eb8b84a260a3f81022a67429cb6", "ref_doc_id": "71df1df4-0f81-4e36-8dd2-58e02d35228f"}, "5d71d4bd-760a-47d7-a303-5d253994d5b8": {"doc_hash": "501c9f0c4598959f3fc14627b9688c6ffcf38b5b89b00fda2ca86a2a349af80d", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "65249795-f6db-480c-af00-ffbb19a13472": {"doc_hash": "b67856daf69145cded6d04957f90091f8185cb6890ec6ca4fb82f3852375b27a", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "106d56e1-d7dc-41cb-a3a8-80459617f901": {"doc_hash": "88cd04e1e9f05504e98b0b430f8bf5b6a11542c9fddba2626896ec1308499b3d", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "2f272b6c-2310-4273-81c8-e85308b333e1": {"doc_hash": "669c1f7f6f11539542e1dafa7d17a3088f2f9222445530a2e07cac76cf935f23", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "8d793bf5-70a8-42a9-81e0-a48a98f45eaf": {"doc_hash": "7476e098c2f71c24151a07df73f09be30f26c1cb35756914a2a6b6b375b932e9", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "bcb88488-d179-4c20-a7eb-f1a09d2fc76d": {"doc_hash": "5cec693cbbd23ad1cb45f6258fa4fd57361922b65a8ffcd83a92d3e6c292a7ad", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "32c789bd-dd4c-4755-90af-c2fc3a0dd67e": {"doc_hash": "280fb2ddf01de2bacfde0f3dde7ebb9899d9118b179d22f68d618cb2272fc0cc", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "9e82ce1e-5b39-40ff-bf7a-e6a905472a8d": {"doc_hash": "5aac8e9c7bdd7afaa229cf3bf08858e743c959d5e83dca870a01eb934e06513d", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "736ba005-0d65-4fea-a9f8-b05e6d2fa71d": {"doc_hash": "58991b6ae85f8103a940d10e4a020373bf3f672f9ca920f2e34a22c63ce8979f", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "cdaf8d9e-5b44-4d5a-930f-425542220d10": {"doc_hash": "b55187bca4127227193eea4d4fbacae3494f8db9a52ebf9940e4f78fcefc6b0d", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "2210c980-3a8c-4f85-98eb-1cc5524413ca": {"doc_hash": "f9429bc42351e1384fc4f8bdb2502f7d60fae44a7899a67828430a32b785c633", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "cb3d594d-ea2b-401c-934f-a93d68a2c168": {"doc_hash": "0f641ff3663f9ec4db4f412270e42d5ad89a27c0ab5100735c0dc09980933b9a", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "c445187d-a6f1-48ee-ac78-c611656d76a9": {"doc_hash": "7be837fdfd885472216aca7bdee25b0dbb6955e82be0f7e5eeac1c98c8adfa15", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "f4532ac5-83f9-4d50-a9be-526c53e1e961": {"doc_hash": "4e7913b0bbeb477a09fddf8916153d208e29d58a2b89f9da27b278f8ff856478", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "008bd8e3-9937-4fc3-9653-88f03780a8f3": {"doc_hash": "ef0cb2a77a7a38fec6cfd529ca869a2df9883dab47a772d9d3bd4c47e58a8140", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "28fd884d-62eb-4c64-963a-65406bc55702": {"doc_hash": "144826600f348d705201d7b26836df1cba72d2b7d2a9016a23c214d1cafe94b7", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "e3b11c1a-875a-4056-8422-e2c597c1d407": {"doc_hash": "60cf378ac022a13b6ad88c23b6197cb9c6c8dc683ee7768c84935d9c5413a99c", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "802ab5a9-c3ed-4c93-9312-a549f8cce853": {"doc_hash": "85117361646c005891a23655da70d6f3cdf79c17eab3f44f2c08b28cb0e1e205", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "e14e1345-00be-4abf-98a3-02f6ccc0c1c5": {"doc_hash": "ce72dba97128bac282ae8bd464d9e1d87a1b760be2cefcc645dab0a0af84891e", "ref_doc_id": "e2b04763-7209-440a-81fe-2271126d7243"}, "e0006a17-5e64-4924-b1a3-267f92071ab1": {"doc_hash": "d3d7a87d2b7be3f4a8a0660e23b56ddfc6af34d02b78c4032d7c975f28e94022", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "2e7a7a13-72c7-4e84-9c87-30c182fb2e70": {"doc_hash": "f41f676979b1d7784f75df53badc7c5a8b7ec2b8da17d7c0b96db18151f992b4", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "4e235e13-4723-4953-8de9-3f939b64a775": {"doc_hash": "cb816ca056aeadfc62a45f4eb0d600d0a7cf19841ac75d93189a2aaffb27a2a7", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "6f62febf-2573-4544-b6b6-b10f3e43ba4e": {"doc_hash": "bd65670522296798a2f35b66a792786c13012b1bdab595a5711844876c51352b", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "c61f8c65-f278-44b1-a699-df9d6a14fd09": {"doc_hash": "8bf45ba4315840578b14e1f7e1ccebb7606cc00a54fa5ed19835d8f84e1cbd8c", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "853087ed-1a62-4ba9-b10b-d0967ce68258": {"doc_hash": "c501d3465e5b80f7e9e1f757eadb45f8788b69b34e7e05c146e710ea1754ccb5", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "fcea30d0-32fa-414f-9404-08a95fa79b2e": {"doc_hash": "71574e2af8689fe4d6cce4bb9f6932395c1d8af76a45a373484a082af26d1c82", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "862d76c3-05ed-406b-bb92-7a657ef232d1": {"doc_hash": "9d7ccea04803cb5f43f437640ded893b3d07eb27949e950e0ebf33321e32858c", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "8349c93f-ffef-4c66-b6f7-4d933a7df87d": {"doc_hash": "49c0955d4bb6af8dff8ea6f284f3fec981da7ff0debc593f6fb03afd67b37490", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "1c85f7f7-da51-4056-a640-cdd2dda68851": {"doc_hash": "a1976c70bbb3c9a10e7f65480214e9c1328ddfb42a7ddc83abcd7371b65b4ca8", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "dac093a6-3498-4cfa-b2ec-16a8933673af": {"doc_hash": "a24a5359c7be216d716410e76c4c40617343db9eb165643f57527d1df8519d91", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "fb0e9a82-13b3-4ed7-acd6-e8215dfd0bae": {"doc_hash": "6ca1ab8fdd191910d15b442cabd1cc3f659814d61356a9af2cf8f68b7a8fa58c", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "f79329e2-eb8c-4962-9a04-00e44f7b4fd8": {"doc_hash": "c9f331930a0cb369f15d5bf1f5602e2adc7740eed4ec516e00ebd6030476b021", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "3703d69c-f842-4711-8724-5d831da6d6e0": {"doc_hash": "8f390fffd77870f2c882deaea52a5a17552296748b739d2e1091213bb81341d4", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "71718816-4600-442a-b2b2-9387d39ce464": {"doc_hash": "0fcb718e2ff21d605a31247474a5f36dd9c50869c4c25c2b80695dd2af4c5ff8", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "b4765183-d2d1-46f0-995a-26e7f1f1fc30": {"doc_hash": "841b19789ac18ac0f9d6b08dd143b92c7d026ac64dbe85532ffb867c135379be", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "8607371d-9010-4ddf-a736-d47c51569fb0": {"doc_hash": "6ab40a324a052e2a2093009495c81be12c04ab51d088d808ff8c683de3c3ac7c", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "651c3af4-e637-4ef6-8d8e-d41de41f0d7f": {"doc_hash": "de364df5508556fa7035f78f346ed2d5387f3ab8f15d4271a737268c1abf939a", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "ec0bbc61-9b29-4187-84ac-f8a16dfebb1f": {"doc_hash": "3724bf0af47d8d516732686c8248ebcd8040923d2620d45ec836a5cb14738e3c", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "440a777e-c664-49eb-afd9-1924042df52b": {"doc_hash": "88ee8e1f5147f54439517a5313b43c9531ca23d89f88ad1500d385b4ba43f414", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "95151d2a-de23-476b-9861-65680feaa7f9": {"doc_hash": "e2689064377b5a95dc8124c895387b11218dfaa7ef9bea8e7cf055d043489500", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "6e991af1-e722-4f0d-8c05-ca463e391acf": {"doc_hash": "fefded9df0123d483d55218385da61ea350de63ee034a7f840c70fdf5148c427", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "ee28d2da-ff73-4bc8-8419-c04eff582e23": {"doc_hash": "71941fadfda4da33daa75e08fe39ae5332d88f4e248710164506aa49c8ffa665", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "d4a903d5-bc2b-4024-a1dd-65b026655966": {"doc_hash": "4316ac9ce36736652de9ee5c850bdcc8916d4bae3128361ff78a4592f397c010", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "2183ad8e-27f8-4ece-80a8-ea528c8bdf26": {"doc_hash": "1a4aa137ee2e9a3302a6859293f76638751469f6a5382dc020f35fdb5beb9dae", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "fe418c13-0da1-4d25-8c79-2be95d4e4e28": {"doc_hash": "7c79d2cd05c9540b447c81455cdb60a33357572c0f7632d7be950b74c40afbe5", "ref_doc_id": "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7"}, "3e4ee8e3-209f-4f12-9f63-cd567aee03aa": {"doc_hash": "4ef9cfa6d4616bb4b8371f29fbc577fcc1a07ea46b1c954e7deb83d358c18e15", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "d3afa40c-abc0-4582-b705-e707b3f045f9": {"doc_hash": "4225c98e2e427c9a012886ee2eb690981d0a52961299a5c000cb9c237bb34a8c", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "476d4a0e-69cd-4e28-9094-00d90a2023e2": {"doc_hash": "fc5ed02f73788acc2006235c69816157fc020b29f13a471cc27c411e4ca80cb4", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "5626723f-0507-46a6-9350-1cba8865b80f": {"doc_hash": "8588f70206adb265555e0935933bcf017e83e074c04be511740b53a433139ac3", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "8554ff92-a7f8-412d-83e4-81216d31664e": {"doc_hash": "a498e5d12a06974eba2eb781ac6bc1683eb2ad6e26df6bbff26c9f08626abe90", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "f5d37080-976e-46fe-9649-1cacc4f3407b": {"doc_hash": "930f607990d703b850b0dc96f7878fde8a2882087ef68a321c2108181a90f8b7", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "646feb55-22f3-40cc-b1f6-293f27c7bded": {"doc_hash": "085ab49fbf66f8e64c3b671bb91584785932bccd5d5811d05d99d55306e98a3c", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "e805ea42-3077-442d-8a04-9710b3f06c2d": {"doc_hash": "431ecf43bf767f9923d22ceb573fbb752cf702024f16e4a6ffc88bc8a7784933", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "34af672f-fcd4-44c3-aaae-97e43d68880a": {"doc_hash": "5e4cb457f88782e7d9635907e916ccca1392a3a3fe35a708778489a6cc2c6c06", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "f1682cc8-f37c-4245-a87f-75aa20abf557": {"doc_hash": "9ddba9f2d71df2223cbda1557cbb4ccfb749ea2c2d68c828c95aa0074ff456ec", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "3a8ee8f6-50a0-4d55-a095-bec3b7757973": {"doc_hash": "7b695fab8c1bb5de0360560a770f2ec004482727bba7be137a624e541a5b6009", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "367c8837-7271-4af7-9f97-c8c1ecc54607": {"doc_hash": "277a2bfe1156f0f9a1c3594ddf52a81b8d325378f36f37210f857c3521c7a275", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "3faf8d91-87fc-4392-a026-d5194fce73b8": {"doc_hash": "27009cafad37559aec66a952889aedabc378bb8eded74d313e3bf850f7d3e0b5", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "ca6e771a-b583-4a19-a161-0ce7aa649008": {"doc_hash": "c1a16d775d79d9931f92bca719bc53798741ce77d0e898e915239244bd1b540a", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "cc51ee90-dcd9-4be8-be3d-e4d328d7e04b": {"doc_hash": "5e4fdf3fe9a8fb8acf6d63a0e05a89ef3cc5dec0e7046e2bdc15350e0b4f86a2", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "33d2dca6-d3cc-4cb6-ba69-345a46005396": {"doc_hash": "409c4b5d0ca68959b98655ca164469f2d2224402620ba91212926c51a2b7d6e2", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "cade10ac-0cfc-42c6-b4c0-e94e66024366": {"doc_hash": "9896566bf851de0d0e632a73e5edae3673199c460ed2d9bc6150edad89364a00", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "cb1e8c15-8c8d-405e-9719-f1345f19bfd7": {"doc_hash": "dd9aa4e61652bfb23cf2e023c1aab7ee49fab0f0750c82ed3e16ed8b27e413be", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "ebe62b77-1dbb-49ee-8359-f02a11f91a2b": {"doc_hash": "3c3b94373d1762d5f2caeb80c942ac4d9de3b7f6bf161d2d9099f4be14accb27", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "74ba9c67-177c-4e16-a2ec-9176acc7a670": {"doc_hash": "2565ef685835824deae383992102e8d8e6ce5992b19f2b8c4624d74d37ff7cc7", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "74a4e738-fd84-4207-9c37-d6362c69e3a7": {"doc_hash": "dbfdd0a166ebde79f56501cdb09ae9d551222e44e97aaf84efae1b30e5b61791", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "ff610da7-3d46-4044-95f3-ff6bd6d234a0": {"doc_hash": "aecf15a3d9b0a50dab8c74039b9001e5af65be0250ace9b7935e9317ec784101", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "77830810-92d0-4d00-a14c-299bdc7ed1d8": {"doc_hash": "2796c53512acd371a93f6cc4768d0216c8db56e4beb1fdc551a0edd1541ec60c", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "5a2d49e9-f361-4002-b72f-cb3336077e19": {"doc_hash": "4a586794f09eec009731855b7ea34b8cd457b5b8f02c7c2c78a0319fea465293", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "e069f5a7-a9f0-4ef4-b5cf-ca5d46161725": {"doc_hash": "7b8268c10b560b0d13fea1902bcc3bac16697c940ed6ae7eab5580b3e4eec613", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "60d30000-6677-4407-910b-fbe3173886ec": {"doc_hash": "eb1e29fc7c3a8df912770efcbf496ff651eafb4288b181e3cded49e38d871402", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "4ddcf847-cdcf-4aee-a502-3d780023ae61": {"doc_hash": "1caffeb87ca129e2945b79310d640ae4f9dc7fb6f5ddc6caba21e5dce1026898", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "68d48f0c-fa74-49fa-9a07-ee7905290629": {"doc_hash": "2c87ef8209196ee94ee3251cba9d8bdfd6ac683d8dfdfd6596bbce633aa7488c", "ref_doc_id": "40832261-ef49-453b-9285-febb5c4ed003"}, "d8a58821-b376-4a79-adff-d52f64c45987": {"doc_hash": "770fca2d2055e855bcf69f14b75851c39ef7a5819c698d9c8174ace5196fd736", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "b3355088-b9b1-4625-b46f-22b018242a38": {"doc_hash": "2ff9534ff545f1e1a8334dd8aab6c91d96c7ff20949f1c71dabd5626fa22519f", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "bf58b6fd-cb8f-4542-ab1f-92d62408bb35": {"doc_hash": "aa9da9f879f4948bb259fd053e4722b6bfe0c2b20ce8b7f12cc3da9a3351185f", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "71e90ea6-8b33-4d22-97a3-4187875f6dca": {"doc_hash": "cde381768d230969d37cb8c7a5dedf59571086c853313fefa6bf8c154d34d36e", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "078c991d-8e3c-4333-aa27-ccff3bc58d22": {"doc_hash": "630b5bc927eabcb99ff1e59768aec8275a46295220fdf67a25292153a2cf8b9b", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "18171c3e-763a-403e-8bed-5c5a13030af4": {"doc_hash": "902b299b47a774707668e80f25dc020f929e020dca9acd250a5e6d22a4b19f89", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "8013649d-d6b7-4416-b0b7-921a95a72c78": {"doc_hash": "495f1db0103883f5d93ceeb005672f6eabfec4ebdfde36f452a8c4814100234c", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "01d4f833-a017-43a2-ba58-a80bae53d6e5": {"doc_hash": "b9071ea9b38d2d6767a55fd10c24c726cfe1c91b981657028bfa48a24179692d", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "b50109fc-3ecf-4cc0-b360-d3dc524a6923": {"doc_hash": "f35d6ebb560557e932ffac10279351ffdc10a503e68870e5d93a0d7abf01fc54", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "5e63f3de-af33-48dc-a0a1-37e38698e2da": {"doc_hash": "b86664beea43bb1358d67cea5904b50df06427242d9af504f8efe77ce7c69137", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "ae365e17-0063-4cec-b588-f6a4306c5921": {"doc_hash": "149a767e57c393760024e6f69d9bb58589fcc1cbdf24f9a0654ad6ffd52c2616", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "6e138e13-d591-4559-af3c-f74f0945ba8f": {"doc_hash": "e2da2abf205d63ddc11bc9449eb726fff21b5fd3715fe2d407b122729df5e443", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "650448db-0406-43b2-88e7-348db0833488": {"doc_hash": "c4cb8d10ca1ef123143982876291e213d9bd5b6e752d9823f39a1090df16fd47", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "78713d44-e577-4941-bacc-9cbbf6aed611": {"doc_hash": "787b1f7e61dfb13b116e2bcffe0330d9c59984bbde8914e0fa0296986a844657", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "217258a4-679a-4bbd-9ab5-c55b7228a0e1": {"doc_hash": "64a14397c373b740bb922487731a99b28f069e6b7944b62a2a575b356e228f8a", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "0166089b-7a14-4800-8526-5a811dee11f4": {"doc_hash": "29298dd96ebbe1bdd71df65deaf40d4521b3cb09ae55fc4b16ae871306f7a57e", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "80c556d3-695a-475e-a4f1-4711e41ae663": {"doc_hash": "483ff460c5e388a6403f0e25a0fb44738f6c71db828f230d9e57dce36a3ce37a", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "7bf1ead5-c37e-45e7-a49a-1618d87882f7": {"doc_hash": "e388b31b779b52d8aa6fd9c366e977a22779ba376ecc8387c66490c32fabe037", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "db23293a-9394-4155-93e4-45cf595973ce": {"doc_hash": "1db02682c0a7271293b8acc293999d453457fe26d32addb10fc901bf607e2585", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "3db48716-d93b-4318-b01d-c5b0293e5562": {"doc_hash": "f9f80ab2344210fda1030bf1e52b8d557018e4257d77d8c8bbed78fbea69583d", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "cb67fbaf-e0b9-4b1b-8d4c-ffe664d00e83": {"doc_hash": "f33ba8bd8c6208f491c475e0fcec6b16e96573284a77b8971442bf2037e009fc", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "5e344ba0-2d13-47c0-8aba-a230472e19a2": {"doc_hash": "4566340fd2abbebd2a379d3c1bed9dd50d6b0c91487f8a27e5c5280e5cbb8d74", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "6b7ef5cf-869d-4d0b-aa97-c9976739c9e8": {"doc_hash": "acd1580c3bd81beb66afe3aa613daaa24c7670541156a3efd471f665a5a7ce01", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "6d087842-f64e-47f8-895c-6e16be6c9892": {"doc_hash": "eb1e5841d5ee10bec2a5969655a2b1e9f01174d945d9ec621a9d44b6524f43d1", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "b78858b2-1ce1-4ee3-9c61-f6bbc54e5e8a": {"doc_hash": "3b66fb76238184c1cd6666af20ff3d15db4043689a28eed24ac5264a8dccd8c9", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "0759844b-05bc-451e-87eb-dbd9880a33a8": {"doc_hash": "d9faf8ea6aebc45be7a330684559de39ac0fc32aa8378b1ffe8290e443bf1777", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "f12b87e9-9376-4719-ad72-3a7acea2886c": {"doc_hash": "a52889ef5b9effcf52e48e192174a342cf54cbcc24acd4ce03af8f00633079a3", "ref_doc_id": "ac962e2a-e515-4ce0-8d36-d6fbed7f6452"}, "7bb13c14-106b-49a8-b26a-5f3294358d8b": {"doc_hash": "efe62b79138e6cbfe6678814a0e461a3fd29ea4f886698dc4d750ab7a77564b2", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "3e828a7a-4359-4272-a0de-2c4526224613": {"doc_hash": "327d1069044a28fe9b1a235275639c399519d8c0797d5d1d1af55c652d4ed818", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "f449e9d5-2680-48eb-9a22-7545f20c23ab": {"doc_hash": "862c0dd7d112aae5cda5b91963a8b19835be6565e323dc795c5187c4244884c9", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "cc5f993b-a600-412a-a762-6586a6628130": {"doc_hash": "e7bd9a5c9f43be15bff64b958f8ab8385cadb347286603370894792f8f240cea", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "983ed34e-1e32-4ca6-b5ec-7cb5739ce916": {"doc_hash": "ba26a555e022b811798e2e4a4dd282e2f7479ddd81e646ac8fce994ca98a2c8b", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "d1a99c45-1286-4e54-bd2d-8a7501edd5d9": {"doc_hash": "bafcb2d7804c015e64c21a1f82aa1cda57157aad7c02ee9535b51bf0ea13a589", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "5e1dc4fc-a8be-447c-aba8-bd31ee5d3774": {"doc_hash": "d5fba0feb7a50c8d0409d493801bba22d67361cf04a765c4890aa566caab72f1", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "fd8df5ac-876f-408a-b3cf-acda29c036fa": {"doc_hash": "629861d6ac1f9af265f8850fd09172ab41a6f1326a3a343b5a7b7ebdecbf9045", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "5583d1d3-19e4-4c9e-a9cd-67d60a2fd4ec": {"doc_hash": "55cb8e08354b03d01f2ae7ef1293f52dab3d2601f0a9d7d2bf8b806654f52f1b", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "b4d68945-6500-4833-9688-76b1a193ed5e": {"doc_hash": "50de43ccf5329fafa73b991a56c342236e4804f3f4ee40cf5f9b943568fcc642", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "fec005ef-241e-4854-a081-91ca96f25da1": {"doc_hash": "b7c851a0c8a2028a6dfdc28a1262185177931ec31be01e7b28809aa9412c0d9a", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "e20a84ad-c979-4d89-8425-d16e9198feaa": {"doc_hash": "e34db5f400a890e3aba4dfbb97184c56e89ac8f0948a7a1d992d27bf0730e47c", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "45bf2742-8ad8-4a5a-a86e-29dd9261a92c": {"doc_hash": "85ebbcfd225ff7e26e77c9b43733f3f77ec100b6cb092d86bfb7c113b4310bf5", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "06259041-cce0-4f47-8768-619c5ab075c9": {"doc_hash": "59ed8065e57ccf320609612b55c437779d6f47c89239741d3f98f7b2a5bf2ebe", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "9e44589c-c42e-42f6-ab0e-a9f029c89efe": {"doc_hash": "2291b3368e2ee7bacb558f98100eb154f592732cc589956e7c28ab6d9b783236", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "639b3ea0-269f-46bb-b4a6-53f9deb77da6": {"doc_hash": "00f6c8c1031dd2fe220aa4b493cfbebf63e30ec34b551e5c8753841a02f3188c", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "57087c94-2f63-4c3a-812a-2b44ab9bbccb": {"doc_hash": "16c21faa7f63a30b69a3dc978be52e6681de152f316862755ef748f05f8cfa02", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "b1253432-51bd-409c-b3c1-78de87ec998e": {"doc_hash": "2652ef36d824dbd8795c1a6a03de606bdd3593895d19368034caef9bc8def2cf", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "8417452f-586c-4c9a-a048-fb73e277b09c": {"doc_hash": "d05c100b297b8ccf9918781bfc7b0b807512059adcb24aae0cce629e4bf921c3", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "b1a75981-6a1c-4b95-8a84-a4be28fe8acc": {"doc_hash": "775d7a79bea896bf41dd2cc13d8518cf7e744c9b072cc39ab012e00c76e39ee6", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "2852b7ba-8a3a-4d6d-97a0-daa31246ed89": {"doc_hash": "cd891d0168e57ab4f133a428ecd408d5cf385e8b154cb6aeedff602d484f2c14", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "5a0a1fd9-62d8-4b0c-b3f1-3c418fc0423c": {"doc_hash": "329fecf5842e993a7673fb85825f42551ab802afc0c25f2823dda805dda8e4e1", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "2424b627-5321-41cb-833b-348cdc39fde0": {"doc_hash": "ee5d4468f7c25acf3c3ea162d5d5b5a62c84b93888c838f1257ff164c690a060", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "b633d9d6-299b-4781-8f49-9343bcb2609d": {"doc_hash": "e08b26efa5751fe7b2755c304144a9d901e7429991642241543076628cda7668", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "25ec641f-2318-4982-b470-2ef9047621ce": {"doc_hash": "514f66a80464a12cbb33e0587e66c5ef75e59f7e4fb99a9e68045b74cb63f528", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "7bffa589-bc38-4c83-8e4a-e48214a54036": {"doc_hash": "394aa81e6ae2bdda5cb9df93c5f588940ca3dea80f1529ebf7b581c12e7ea724", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "e5e99e2e-6b5e-4d76-960b-c1d4a0ced4e8": {"doc_hash": "721d61b8a0120f0b92c9dd844a6c3509115cb4fd14185048a4ce16a4a0346297", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "e74ca2c0-c751-49f6-a4a2-cc9c3a6e7c2d": {"doc_hash": "9c255691aaae6e915af5b8a0f4fd37fc00feffee790beccf965987a1d9c6e9fe", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "eec4193d-f52e-4333-8089-8a136316074a": {"doc_hash": "d1a885a52dfc5597f34e8f897b23a0228e82e8493b806d8e0e00ddfcc0a6b468", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "81eacb08-620d-4e56-ba64-5cda584949ca": {"doc_hash": "a673625b4513ffc3b0e85ad3bc618d09ae4a1d866d9dff1b3c66df9b83aba785", "ref_doc_id": "e6ce7973-9853-4b98-938e-358edd69e3e3"}, "3e9e6cfd-8311-4c15-a539-9d9ab0e03329": {"doc_hash": "a21a5f453a7c644b956ddc5d8ff466549de7418d21e76fb23680a4e319731026", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "3b7414ea-62ec-4491-9da8-2dd398151a95": {"doc_hash": "7139161c69deabe48d7db5b0e98f688da652c7f59253665986e286714d6d6c4c", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "1e99081d-d082-4437-8861-3b1a680a8a2a": {"doc_hash": "0706b6e94434e472a0ff6695026dc2396f1a13241b114bf13e4c7e6c2e779047", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "976834b0-5036-4a1e-bb26-4ea70d5c93ac": {"doc_hash": "76c1cc2975989b82286442b596a95f55ff1dc9686602e38d2572faecb9ceae74", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "84694601-1a3a-44ab-984e-e6320ca968db": {"doc_hash": "0aad5a85ecb76e802f9f2065af743033bcfd45a81674b0cfe8562b4553d7f8b8", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "4bc3f217-0761-408d-b701-e8da5317118c": {"doc_hash": "31ffc1e34a7587911e75814a547085211fd8a81323cfc433bfc3a57bac74d883", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "5c1262f5-755d-491e-b639-df0ad2966d40": {"doc_hash": "2f65da22d63ede331e1e01497d3985a940fb192e37bf973dc94d9043f4a293e4", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "43a8508b-bc8c-4298-893d-b23f27c7e155": {"doc_hash": "265419c34ebb42f175e56a4f923d210e54ce8c2aaacc26ea13e1b5d175914f6e", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "03eab41f-3f30-45ca-9cac-46b1e7a486e2": {"doc_hash": "f877530329bb37886906684cae0765b9946e07747bbb45a1700f0111c14b0af1", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "6f87f680-61a9-46f4-824e-42df1d6df50b": {"doc_hash": "f098c92d1fbccd7288f2166b70a2dbc29be3649cc5a3ea720e40a53fda057358", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "c67d36e1-8dd9-4332-bec7-fc208892acc7": {"doc_hash": "736c5130ff21747167e9ecf8d06743cada169df473173e820558c37b6c3e91c9", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "bde88ed6-5ec3-4f87-8945-b146f491bb3c": {"doc_hash": "40e0eca84bd138e649cd3cd9b977ae4aad8414fa5e8797d0f4ea09ca1a625dfd", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "e0896dd9-e721-4c47-9238-0c19f6d3284b": {"doc_hash": "5149cf137ef0c9cecf509c5ef6c799948da1ba7352248f9d11bf1448cca142fd", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "b634e5b9-0648-4952-88c1-b51f189046bf": {"doc_hash": "1eeb1fad808a3b95c208466e8935d49d11eafa3ebccdd19ad2f4a4fb5e9cc83f", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "2d650c1c-849a-49d2-8f3b-2a71ce9927fe": {"doc_hash": "b553076e295e8e29c80ff49f5a669cf3028313f783650a4f009ace1426df8a47", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "de70e9e1-1aab-497c-815c-42c33653de53": {"doc_hash": "f7400df7e60a14af5b9a665ddcfafbce18c4818e1489b6385e59a0a912f92ff3", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "80ae8165-1fb8-4bdb-8f65-cf72a5e4fca0": {"doc_hash": "18121f76da45bebcaa8106657ca7efb7b5ab914ae8eb022fcb875646e14d5f9b", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "d85816db-0669-41ac-9632-ed67630be329": {"doc_hash": "6bc18d9e9f11eeca9a5dd198b9748465308aa5f9da670cd66ced35818f896f88", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "94a7b6c9-e477-4473-adcc-57fa80c63877": {"doc_hash": "f0f52f9e5c744d7063444084b8d2de16693dac4379cb551f527d99f8ee3ecdf4", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "42f1cd31-6b0b-49ee-90a2-4a161d7e66a3": {"doc_hash": "bfe50a587eb8ace4d95335322ccf9eb4592ba4aef9c15aed2b467b6a3628c368", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "9a1e181b-5b1c-44ec-b565-f5d2b385c5e4": {"doc_hash": "c8e90c90b809b47cc4e39a9b76609aa13afe572749928adb31b214b25e12349b", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "81c4e016-8598-4db0-bce5-5766c004465e": {"doc_hash": "edfdf095a95974e2c173fd63e151f872cb1060d034821e7bcf330534f3875596", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "99a48401-0475-43a0-87ea-07fc2748ca8f": {"doc_hash": "91387bffaa7fe6b76151c797c900b453042fd0f2930fad3eb775b9f5dd847b69", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "c9adfeab-35a0-4b5a-8a90-4e61301db7bd": {"doc_hash": "8ea31e9390b941086c7c604d0c695a0969cc695d747bd2b5f24da380b1514bb7", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "eb9e23a8-433e-4fc6-a54a-3160ed6e1095": {"doc_hash": "d21e1b1cfbe64ea534985397329a46697797dc2aa6947221489cb3d3467bb080", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "6826c272-4830-4053-ab5e-80d7fb6d9201": {"doc_hash": "ced8e79568f65670541d53a8391b1a587b3d8b5959edcbe52c07837565d25204", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "79c76ca8-712a-43d3-9ebc-63a7838dcebc": {"doc_hash": "b84af6b3a495ada0670919d50be377526457bdd979554aca055e2766360e78c0", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "87552d09-624b-4962-8b50-1d24f3b018ce": {"doc_hash": "b225170e6074e36f7e73b6799acece3ad60bd7fe3d530f7043a1e79f7d3b46a3", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "de8827f6-f906-4687-88d1-ca562adfd3b0": {"doc_hash": "a62d38c45dad2f26892c121eda777d8d36cdfcd6eaa10a3239accaba24cf9c58", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "7d1b4896-2319-490e-ac38-b7c1878a12b0": {"doc_hash": "afc545217e7b21678cf7888701a1c938a58eea74fe9e1d926beda49f0657b013", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "58645828-3146-4c6a-9b7e-5e9c72c39053": {"doc_hash": "f73c510cd943f49431df58a4e98a9ea42c3589753f88bdcfa37a55b75bcf75eb", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "8d2107d4-8257-41b0-8dce-f1b3e58dbe01": {"doc_hash": "c2d00a3ead7f2d606879d572ccaa19ceaf1e78e2ab19e6649efa6d7d27b5abe4", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "488d2fdc-6a76-4dd2-9cc5-4a118caf8e0a": {"doc_hash": "e4f308af5db170ef9dc9fc25cc15e03c8803caf0bfd6820cb3d0313e8f13b96a", "ref_doc_id": "edfa9425-2aee-487f-958d-c03b51919faa"}, "d6f38ff4-cf60-4a5a-b3b2-1b51f2e360ee": {"doc_hash": "e995945f10104456ddd1d453f28a1b7504666e4a7db8c51cf203d0509d9c74e9", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "e264f6b1-dc46-4ebe-9417-778c3798ecc9": {"doc_hash": "efd47743d663714d5ff920516eaeff2fe126fc8269a32c15f9b1e1f11e2039bd", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "e32e4dcd-b6d5-422f-b64e-cd2650959e65": {"doc_hash": "ae389aa547e4df43b342182a883880390e14f62c263b3cc955bfe73c05260f9e", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "138c6e8e-13f3-406b-8dd9-9dfbbb65c814": {"doc_hash": "527383c727299d99ad2839dfd0585658b55fc4ee638523c40540e67de50cf01e", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "bccaad9f-5fee-43bf-8786-b2a4091995aa": {"doc_hash": "c7623fcdd618c3fcf7cd7cacbe818bbbb2085cd000a5c0887572a68c3b781d0b", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "a13b8701-a2f5-40f5-afce-5a1266380f21": {"doc_hash": "c92a0360e605b88d9f09194d558cf1b3de42e17e34a119388a5d1b694a656bc9", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "d705a4f8-5837-4cdd-80d0-62a2aae34c61": {"doc_hash": "7401cb695828c1929da99e93f8fca371213d2c0c45747a11cfeb9de9220b8032", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "b3c538ff-11fe-4b80-baae-4aedfcb15bff": {"doc_hash": "5d66cd291b66736dd923b1728c348dc035b3afb32c427ee4b8306115e89c1623", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "c2a73b60-1c4c-40df-9ed9-a499b5f7a3b7": {"doc_hash": "17a0a587a107eee0834ecc6559ffff94e2c71491a73b319cb7215fc5256f33fd", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "02d0b9a9-c8fe-414b-9a4b-ef12e9ecb010": {"doc_hash": "16f5e40cf18398e9155607271ea7269c724b7e3122d8e409df08c6016dff797e", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "644fd851-3482-4056-b628-db3fb6e16805": {"doc_hash": "fc598884bca9dfa4d089db57738241c80f0bfde5de4c05d0a73340a935f50e6e", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "d46858f1-5f9a-4aba-b37a-ffe36a6ea742": {"doc_hash": "fd8d435e7d5d63ea713bd1573995863334c637a5dc81db3e0354406f57d62186", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "80b43d39-42dc-4e1f-8998-b4fd653cb5fc": {"doc_hash": "c9fec8b9d10d3cddf063568073206a7d4107d28474e7354959a32d21731628ac", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "43665b06-91d1-477a-8cd1-2dbe62a52f28": {"doc_hash": "bc404c61dc4b32c4bb7ab9bf774754e3a5f00125575381a7f6cb68e9229fa540", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "84d60b68-85e8-4fb0-851a-76bb251f4c5f": {"doc_hash": "36e23ac9e28e705c068eead43d3c5e054e852253b50b3361eaadf9f43e979f91", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "7702a4da-7f91-4bd1-94e6-2c4fd9ddb3cd": {"doc_hash": "6e1bf1552c02946af033a26a61cea051e4afd3f146006f14bdbc348933050da5", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "395c1813-476c-4b7f-9351-552f258f35d6": {"doc_hash": "cff077eafd8e3c2fa8c50c12c73564a1ff92fa2eef1ff1ae6ab73200099e2cc8", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "c70a7641-0ecf-4027-be30-fa1e2a2b1c37": {"doc_hash": "ea256850220544f391fcdbcb35219eaefc7a568b6c9584280ae99102cdb4c1fe", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "af437074-5df7-486c-af37-88017691c4eb": {"doc_hash": "37db451ada270f8a00a57d5286b2449aa82057236ac7e5a21406a916f5d26603", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "87612999-ece1-42ae-846d-16726d4c2a75": {"doc_hash": "598eadf7ec9ac97ddf1207c87ddda4e1473f59944893eccb5c648b3804d82f1c", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "503209c8-7a32-4ab7-8212-4ae8ad21f8ae": {"doc_hash": "cb6da52e41b6e16b4dcd7a0c5b524ef2b673ee36261850820287dd93033da884", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "efb746b1-cbab-4c09-9ef1-de7d49cc618e": {"doc_hash": "c1aa1de810328da64d1f740dfaf09d8958c1df8f23cc5c0d0a20c1f4f05b943a", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "2b36c795-7f2a-4d0b-bb9e-de47d1561cd5": {"doc_hash": "d17560d46ec1fff8bb3bee0d52279f393bbc58297f0498751479b8619f4c8d8a", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "ad8eedd4-17a5-4a70-b485-5c77c350394b": {"doc_hash": "f2f6a3d369f272adbb8de380be61c128818ff30408598f0416e83f95e8e6bc2d", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "3d01675a-6247-4e5b-93d0-f7f86271aa21": {"doc_hash": "765b10b02a6600b6b25328af112c0296484d54935bfbc9c8a9685a1ffeec4357", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "d1fdccdc-8924-4518-b686-9c3a7cb2f103": {"doc_hash": "31641a4eba470acaa601b6b2c622d2c0e9a827e326bf83c7c5bfffd638a9c29e", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "e777fbfd-bbb0-45c5-99e1-405b83ff2185": {"doc_hash": "f88bc5b960e0e4586b9f46f802e7e29cd7fde5c98495a2e43a4ea0b16f51174d", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "09d86c9a-0ff8-4ea0-b503-e7bfc44bdfd9": {"doc_hash": "1bd0fe0ca6cced422a2e1682d08916b21c6697d6ca642d575b0ea1d560f1c90d", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "4e034b24-7fc0-44ff-87d6-b1b2e08ae4cd": {"doc_hash": "80a4f760c6effd458958a2dfc0012eeba9a3b5aed1e6989a9e477e1f71a09c29", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "8cc6e394-663e-4da3-b15e-c635ba67e05e": {"doc_hash": "96203d63b8567ffe3657b5fb48a1050ef1d98ec882e86b2e23faef071596acbc", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "52c6e7b8-b914-40d1-8e92-49b6ff39f027": {"doc_hash": "1dc5a387bac9ee316834fba6bc4be1746823c9aac441c202a90a22c6f89c5c71", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "7708729b-ad37-4cd6-b7b3-fd67aedae6db": {"doc_hash": "31e11531844de492e64bb4ecf1b1d243acd44c9d81f39e07a0500ae38813f281", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "d6b75e3e-5f93-400f-a17b-0421a43c1d46": {"doc_hash": "4c8cf1a64a7cd036f60cab791983aa183b7eb95b83ba7fb24a1c86beb145d027", "ref_doc_id": "ddcb704f-7f37-4b51-a61e-fdee1d49bff0"}, "939cc6b2-073a-42a8-9de6-ca88e711b4b6": {"doc_hash": "f0423a07f02315124458913d463a8a6e6c070b831bb61917f2321938d89a0a5a", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "a9316232-53e5-4c7d-8c8f-9659f838898b": {"doc_hash": "7da8d5472dd6698771f91bada712d9cf7e8f7e438cb068678f7bfa72defcbfa1", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "69cd5e5c-8cf9-42f9-ab43-67a33e578a06": {"doc_hash": "2021c82c85402c1eecca1a0385ebfffb672c4722de5249fcb6fc2949ee51ae76", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "7e8c18ae-9df5-48ed-af84-df01a216bcb1": {"doc_hash": "8185cb788e545bed7edb10189423fea1449a917d25ae370260ef5a7a597eaef6", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "d0ad1adb-ab7a-413c-b60a-a18e8be1e43b": {"doc_hash": "e4b81e93fdabf9edc0999b4ea756bafd9dd1f913f7e26934969a72b4cda1667a", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "016e63bf-3cd8-484e-bf46-ca01a0677ae6": {"doc_hash": "9329905f668743a00a5e6384b7485fb50853bcbec8b5344bd1127cad6e5178e3", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "c59335e9-fad3-4ee5-8770-5ccb93f45e5f": {"doc_hash": "adf483124024c51af70e1285c42937cd6d3cae0770d437d690a83e66608152c5", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "11241e03-24fe-4375-b2c5-eca66f14922d": {"doc_hash": "0be7d5a5bd302cff6480190a04ef175a093d4928dbe024e634f6f4e06056c611", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "f2a621d0-b0d1-48cb-9e26-f88ac341fc69": {"doc_hash": "ca6535ba2097239d4ddcaf5fc7940ace970c6efc395ccb24eb6cc6eb9966e9aa", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "30dc2ca8-db52-4ccd-88f9-6168ff24b0f8": {"doc_hash": "acb149a1cedc6062acd4bd654c2a12072aa9b92e5a18f6d71074dea30ea48c37", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "92bf1974-bd24-404e-802c-1bc461f9c442": {"doc_hash": "b2ae1496f65f4d437683e91f9d8106b8eab809a83489ffc4e89c73687e2fc2de", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "5ae82133-8ae7-4f71-9aa1-155e6446a39c": {"doc_hash": "44646854dd49b3fe51e0ce878f4c5bf5394d28e63f6a5dcc6bd6211f31c86015", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "63d1df18-9522-413a-8b13-3e8679207b33": {"doc_hash": "dea435907161c751da7bc0b1255a25ba6eb08d05bbe967fd2f651c951ee0430e", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "c415461e-528e-4eba-999f-ca3847a6608c": {"doc_hash": "f39dd87edcf6f2698ecd8bd9e73d6e4c2cc3d4ba2c161b71b5432ef4948026fc", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "b0c8b9b5-c651-4fad-b069-d9b354bf2abb": {"doc_hash": "dbbc108941122ed32f222a2e85366591b37ac3b248db174947ec4f2242e77287", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "a579ff11-8272-4039-8319-29cfd3e9f01e": {"doc_hash": "5280b8a25c6076a979bfd993e6f6023b038942f536789bd2656b4890c139b656", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "dfaa2fed-46e6-41b8-81a4-7ff22e1ae193": {"doc_hash": "d5098f8c228fbb5185ac4ac869ef5073fc03e6123c7cb0bd55c09ddb268ec218", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "18f5283b-f8b8-41dc-bbd5-8d34b94e52a0": {"doc_hash": "5f550e3f82f61b6ec38f6796023a1f834a97308cc60ea088cc3f5946dde5e1fe", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "30abf15d-78ac-4af7-b5ae-b1c44de431f4": {"doc_hash": "334d51daa1d7b2d252b17cf3adff148f91d5a45ffa10cabceadc21df1286ea05", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "184439a9-24cb-427d-a3c0-038121719e59": {"doc_hash": "cc3c5967430285a133f451ba12d41e6968f4570283eedacc9a120aa25b5f35f9", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "0b64daaf-f1ac-484a-8a47-c8a59b7218d8": {"doc_hash": "2a54cba71da5bff078d6f230448e61422be57322e09ae8211abe3ba1937ef6b0", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "9c1343b3-8203-4a36-96c4-1a557f2e734a": {"doc_hash": "970877c260f00491ba65d85767f8e47bad089caced9f8eed45e0f8a872810fe5", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "c0ea2e97-ac20-4bb5-a2dc-663243f68066": {"doc_hash": "f5e8e4d713bb8fc5e8e6cece399aef1835566fcdcc225ba2b5f0b942eb3426e0", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "a8c88cb2-64cf-435a-93f3-7d6cbb4b4d29": {"doc_hash": "a6ec81fb42923bfb784aa4e24c1dc8ca646f518da17869eee6a0759593701a87", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "2b2eb280-ff0b-4e9d-aafe-0cb4779d0e8b": {"doc_hash": "4d10096fc3afe0feed58370b48b5b5c8f2055761afdd989972a4dfb46264f32f", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "682560b9-c269-41e2-ab07-22e391a11edf": {"doc_hash": "8ace264ad5e1d2aaba914e29b20879580d5cc89a1bcb47e049f60280353436a6", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "bd2beeab-4318-495b-8d47-a10b355035b5": {"doc_hash": "db75415a20336e269dfb424da051abaa73555527efd426027b32b0416c462696", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "38c183a0-6ae6-4089-9b32-85d4850edd96": {"doc_hash": "3707628ac8e71cc1369ba64635bc6e71b5ddcbad58c1a3851416ae8c92d43be8", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "d3161b90-25f9-4483-96ff-9aeda7abd865": {"doc_hash": "bfe52164c67c55c487680288cd66580f23a564d4ae6beb1af55e7a45c53aa425", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "942583d2-185d-45c4-809c-baa72f84268f": {"doc_hash": "21bc69d4d97658c0b42e111a63ff85ecd2c060de252cc1aac35eab16a1f486af", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "9fac79b6-f991-416d-9ffc-b25a4afe8426": {"doc_hash": "02d889f66852b0a8230601b933a95f0e3a4b3a8bf24837384a55be2e8bed6b58", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "41dc5d34-e6b1-4aa2-baf9-7d3ff0dd3755": {"doc_hash": "ff48ea416212a75a5b7c64b5766afc5921b408c2fc7e0ceb1189eeb1cf360b62", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "245fde81-8036-4ea1-a6e4-360c0dae83d4": {"doc_hash": "4f4769d9530c082f61a9586da7b45cc103d54abb36b11b65f8dc36fbb3e61535", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "f5742528-678d-4fa7-af09-1333c4abb696": {"doc_hash": "aa8b9a701fe50202d8c806443a800ae65ee4a91c0539176ec787161fface6427", "ref_doc_id": "4ef9ef20-4886-457b-8c84-a1b008c32c9f"}, "c4744cde-bfea-4f21-8643-ed39d469b1a7": {"doc_hash": "91e4445021d54c07b7cabbee9a15ed2417469af26976411f2a5e38370ba22a71", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "bb0c48c0-6d46-44d5-ae87-c5cbe4d02a7d": {"doc_hash": "e603787098230345fa7008f3b3df801df96648f63a94badfd145647e498b6242", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "8a07af77-c58a-43b7-9d6e-11fa4b12d9a9": {"doc_hash": "68b721baf9c3a7f2a26a3d25bdc2efbd6caefb2eb2c48738660f64153d64b8cf", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "115f51a0-eeb8-470a-9756-8be997faff8f": {"doc_hash": "eb9b1f7c4101fe3e2fccc6d095c636055694c6b1a6212800d28d03bc7fcd6be5", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "dba3de62-4e36-404b-b507-7403a5fedb75": {"doc_hash": "e9fb53e3d989b534650032edbd00f9aa620613372a5ad1ee8f57ffd5b5473421", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "0dd65b08-d006-4e2f-8c56-49d69e1e4f44": {"doc_hash": "a99e5fde78dd83da80e065bac8d3007ea804c9187b3583cbd5bdd4edb8b1ec81", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "984201fa-3e0f-415d-852a-6f8b61c039b1": {"doc_hash": "33cac20558a20b4d0caf5026e6850bd0ab6fe3d9ee40d13644d3d217de393855", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "be7c162e-8228-4357-a065-0f73da381f61": {"doc_hash": "0946e08d5bba5f451cfe05e4589064dc7a6808916e362428d3f25278579de130", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "f64fb6eb-7160-492a-ace8-85615791a07b": {"doc_hash": "ec35f50fbfd48480e70386e8ad2b75e71660a635a89c8c26be57064f24cafc36", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "9d3ef225-6de7-4c62-8f37-0dfd9564a8ad": {"doc_hash": "576d1fa47b294272c5676d8fd758e4f380ee7f0afa1fe1b4d2f31b6194f935ad", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "e35b2ec8-9983-445c-b28f-5dcbbe37a1d8": {"doc_hash": "ffcb370611240a7d83699e81dde69cdf3a30ac3b80e249b0831cdeb4393aad02", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "f217a758-c1e9-4750-8e5d-6d906578cc01": {"doc_hash": "4e73cc2333f83b9fcfeecb44c05e4799da98a831b1486c5e23f358ba232fdb71", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "1335f309-c1c4-4827-8921-14dd29b98ab1": {"doc_hash": "c004a0f663c43794187747903a119be24a5f352deb8d515b83eb89f47bbb2a93", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "f22ecf2f-704c-459a-8d54-d840ffed4f53": {"doc_hash": "1aaefdee6cb69035706665d214be185fb104404c667ee738e5c0b95da4cbe54b", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "5fcf37e7-44a5-4e96-aa82-0ee476c7f7ed": {"doc_hash": "c6835d285041195ab56debf568c92af2df05fea80f88a296197b2e929e5207af", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "51cba07e-63ed-4079-aef4-3068854f5449": {"doc_hash": "7e8e26f743c2590435385809a595951e40f2dd2be93a3dd6c1b36c34531dc638", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "35e05103-4ac2-44c3-8437-d4dbb6dbcc1b": {"doc_hash": "e7738214333b390f1e88d659b9202e36d7b075cc124f1bb370e674777e230a98", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "e65e9898-064f-45ed-940e-814dcc3b412e": {"doc_hash": "8e9fbb43a73d0187ad1be0aa86e0529a6c6fa3ea3793eace7804cb03621b04e7", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "7ac507cd-8906-4fe3-bd51-bf06924db27f": {"doc_hash": "eb1f399aeaf8b1e03f999a58fd16136c043ebb25a2717b37fa8be6bae37e6f3e", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "f9718400-e164-4845-9fff-1ef632bdb386": {"doc_hash": "54e17d313da4f6abb42694aa746f493d15957577543b2c554a1af55b8450cb40", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "45cee48e-a4b3-45b9-a9c5-efc0b41573d6": {"doc_hash": "44dd48a573a846ed7f0081f28b9562304c3a41e8b075e9455e1ece695b98e793", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "e76d6005-55df-4edf-b080-ea39484900e9": {"doc_hash": "c579aedb41478ca39ef0a85a35469cdef513e2040de638f948c6f052a79c91d3", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "96a36c16-eb7b-4521-951b-4036efbfedc2": {"doc_hash": "1e472950fd1d9bf4233d6d29866d6503e5a2ba9e29786d3eadbdf1aa281d7ae3", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "b9150b70-1314-4d1d-ac4a-7718328b773f": {"doc_hash": "3040fe3d74166c230d7b8ab560395b49bcf487bb96c0648aabdd6198e95b6333", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "8873bae8-17fb-4a62-a238-8eeb788b0bc4": {"doc_hash": "8aabf96efb5fbf17854f55fab60239477ea492892b2db3051fc9c5767942a8f0", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "45580cb6-b8cd-4b2b-b92f-e0bcc8378c9c": {"doc_hash": "d6c3a4618220b492df81583d837c7987e41e5b3caa857d1a0250800c8a21cb01", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "845d9639-6cdc-4b4d-803e-d25d90fb1b91": {"doc_hash": "4365456fef96d4e4016002c269c21ebae37c48570c1d1969c2d294db653f7306", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "b9235aed-3c87-4b45-a384-6d2c9fc92826": {"doc_hash": "eefbe279e812471b40eda6c02a72c457e0e391aebb9bb6200bea19ae6b7e359b", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "87482f32-db25-4685-97ba-8c3ce39d3951": {"doc_hash": "3db824a92a90f6c82a21936a3987b2f274577912e2de0b266b10f2a7c70faabc", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "cf860181-b991-42ad-8139-6d3924711d2f": {"doc_hash": "07eb4140d383ab9d1c00be63aff45b06b0fb8fdb7be077f977c6eff266bdf995", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "538567be-0010-4241-b5c1-50605cf897dc": {"doc_hash": "82935f7bd6b2347a0dc48d7aee8a472c765532c7341e700de5cc86584131f277", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "3f181b1b-e080-4ca7-b3a7-923ebb39a8c9": {"doc_hash": "7cc3451f281eb19ca2a92078b9b5243481816072e74e0b3d72cc52d246c2e284", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "bfd4a658-256b-41dd-ba5b-31ae45e14034": {"doc_hash": "136abc41e20effaf97a55ccfeab183fcb89656854fadf9862844b650272cd08d", "ref_doc_id": "f3b21ffe-3391-4a34-9707-c3eb7b9c157f"}, "d7a516f0-10eb-4b2a-b957-179fdcf03f33": {"doc_hash": "440041aecb996728355d4fc1cdaf6e6f712e5236bfeb6b750d15faaca481db36", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "6f2f0c7a-c2c9-417f-8d86-5860ae35a44b": {"doc_hash": "3688e6ef938d6f3900a1bcf3bda78a1ce5135bda92e358a98e62b8b67455376a", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "b7c2aa1d-fe3d-40ec-a898-379976e561ee": {"doc_hash": "f1b7de391d3979489b7cf0b199b829985bdf1ae953803df0c3919e7797532809", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "0bc818f8-3fff-4e2f-bef6-22339d9447f1": {"doc_hash": "df22e13a48c81abe29c3a0d7002a92495c2ed8d631fc11e169dd6cd892085f09", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "85a333e6-1eed-4ae4-a932-09b03d58e180": {"doc_hash": "17bdd2bbf97767b8bfc17211765c883a609ff37a84674b450ce143df589be2d6", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "f4d3bcb0-1500-475d-bf68-316165f34a42": {"doc_hash": "dfd2a9dc3fe85b0276d09c3c3baf02792fbb1e226fe5d6d03004409a6eca8274", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "606fde0a-ef53-459f-8481-3c276a88c89e": {"doc_hash": "946e6c1674679d9f6a3238cd4974e9aba24789cbe878ad5d929896e0c1d35c2d", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "b0d315ce-0598-4950-a21b-b71441d1c22d": {"doc_hash": "35a5e5a7790ae726c76b1f14f227d3eac16d563653a904b10e1c17df4218cd73", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "6a107b99-186e-4fd1-a9a6-65188cb69aa1": {"doc_hash": "b440684fa7bdca80b4c33b86b569355d2826ac5f0d38449c9464ff7e30204118", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "47920934-9c55-4b79-b8fd-bce27428e71c": {"doc_hash": "c8c056d85c46d4e7bd47d63cf19a43522c52250ee2541b6f6c160ae0790ba651", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "85ad8abe-3af4-435d-9d74-43a966e5b99a": {"doc_hash": "40b12be99f76cc9c982d0c4865363cb8decb2a0e61ec308626fc2521c5911f56", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "1648fe0b-94f0-4021-abb0-805908cea60e": {"doc_hash": "2a225ad8eab69fe3c983c49b80b515ab93856d0b506cd9a4d68c41d0fe6cc261", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "84d92655-2f4e-4a8e-aa1b-f454bb8ce721": {"doc_hash": "d1f0528fd95aba4fcc2c8530bdd1f5ff073fe58bb0b7c9bd2f49bf920204825b", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "62e6612a-a112-4b85-8ac2-f4dde018a919": {"doc_hash": "e3f57d69f34f73f0e1b612d4598c727044ea470675352ea71e2348e918976c3f", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "e2956441-b01d-4cf7-a420-c08d9199453a": {"doc_hash": "6eb499e45050d6d75e3be74d509c3e122d516edaf3e2eb5049e77e4c68c7696c", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "986aa329-e126-4d7b-b7c8-8e117dc74402": {"doc_hash": "1dddd35e04682336be934f5f42b23ccea48ae533e4043c8efc3f84dfe9565f09", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "623b473b-bd76-455c-a032-2c250688e504": {"doc_hash": "f6eb39c5da78d2dd68272a1b36a9e49dc051136a823bc8d8b3b6de5402554edb", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "36f80ce9-4c5f-4b93-a6e9-499840629056": {"doc_hash": "10264dadb699d0e6dcd1828a072297e26f00f88619cd86291e191d23cef421b2", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "4a310f70-e162-4942-b620-ae70095580dc": {"doc_hash": "feee6ea93e7a3db71f0c157dbf0d1f445d3ec09a2b5687b082afbd2bd9cec54f", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "eae26ce9-4f15-4374-ae50-8c34b74ab955": {"doc_hash": "7a4d5313c434bf05deea7fc86fce4d8be727af251fe87a0dace365420ba0b2f9", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "9642904c-d1b1-426b-a3e9-fd53e389f78a": {"doc_hash": "97b5de444a96f445f5054f31e5dbe14feaee790014f15f0affc2c7fab4edfda5", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "1e6f584e-e8dc-43e1-8d20-b93027151441": {"doc_hash": "d0d053be51650f8e576edc6fa518e224fad08edb8064d766b71d481a40f2936f", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "1debfc02-c90c-495d-a86f-327283ac34c1": {"doc_hash": "4de7e87d41d5ee3964c75cfd445f27136fdb59dddab46ce4c6e0a5aac9b7478f", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "914ec3cc-ee49-4afb-bb48-7adcb4209ff4": {"doc_hash": "8b4e97c8c604838b260d27c46837044f9c59d438cb34ed17587b0a9dd25e23a7", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "061376ca-db2c-4a9d-9c2f-ab27ba4e786f": {"doc_hash": "6d61987decc2bd6c99ae982a26a0704d9205a9b8000d962d26042e283924aadf", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "53096818-c6d9-4d9c-9fe9-f8728ef5be2a": {"doc_hash": "6904dda4c5e56169b3db6c751295c02627ea4081208510c1843194015eb2a616", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "875bfa49-3199-4c5a-b969-ae447d744ac1": {"doc_hash": "933e861038c59189fb67cab3af57dff5f7095367e91dd612a86292501a398969", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "4a3834c4-cd50-4e05-a2bc-815ba41302c1": {"doc_hash": "27fe25e78da00c997a9a922ca8cb0f135df419e34f18f5119e5fb7223183f29c", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "62fa8959-8242-48a3-ba24-855eef515840": {"doc_hash": "f9b95bbc5eaaf681ab7cc3beb690912c0d07e012b3f751e10cd879cfb01f9337", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "502ec097-5874-4f60-b187-5295babe8d81": {"doc_hash": "a95c399002657d5b2da5d00c3a461fbc0ff85bbaa501b2d6841213d2f3b62717", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "8d19f299-3b68-4093-9ce5-f1b9169636c0": {"doc_hash": "31d993ca9322409b1dfcc3fd204fd0f4cd06374d09ee0528491e278e41168ab3", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "e0fd6692-d25b-4ad8-84cc-bdb0a5bec585": {"doc_hash": "cd514d44a0cd0583c70c77d5a1968154288ae026e6ca6d152a87adf7558ba854", "ref_doc_id": "655ff34e-0463-4636-b472-ebdfd130922f"}, "8dd2083e-5103-4590-81f1-3833e234b3fb": {"doc_hash": "30356019f3c727cc2a404927d8e7496eda2503c2c61a31fbf88b08fced8ac554", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "234894fa-bcd9-4f39-87ca-14f793cc9cd7": {"doc_hash": "bd911146a38f0d35b0eb693782c5f301f66d276ae4f7e51c672de625fb780662", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "64c1a63f-2e39-4c45-be3e-a4d0a77aca59": {"doc_hash": "ba9acfaa8d298f12c22831dffb3bf72c6b47a9027b6df2257071f372050096ad", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "da9053f3-2d07-4256-8f45-5dd93a4412b6": {"doc_hash": "47edd580d4925133e42787348a5b64cc86ce86f5b2559df36148be207c7d4963", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "d4ec92a3-d28b-4d37-a34a-d871f0dbb1c6": {"doc_hash": "c5c0ab7d25b5aa25ce634282066381672124ff57de205dada262fb9c3711e684", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "c5565ee3-094e-49a7-9900-8bc4139457a5": {"doc_hash": "f367f71b8b1803550294ccc2f8a2e8007d84a54158b56f02bfdbc6171df205ee", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "f49c33b6-4fb2-41c2-af55-c7a5c9f6a957": {"doc_hash": "f679acb848b13aa286277ddacdba2ddebb42b9b15ec8613dc151b21e68cf5a5d", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "d17605cf-f4b5-4b7d-84ef-6cf4bccea578": {"doc_hash": "ca85223edc8a1f9be331db8b275e1ae118ac99e91d04f5e6124010a33caa8300", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "9cbd1918-37d1-4822-ada8-98b51c9b9a23": {"doc_hash": "d6bb3fa46864e774a2f89411f9e40995e14251474a7c491a58689e9e5f0ae43f", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "fbd194c6-0bd9-43b0-b9cf-1131fb20b70b": {"doc_hash": "e8ad8b678852e3ad0d0a10075f478f91b3907ac23506488b3c1d3d3d1624c760", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "0af2bae0-63ed-4c8a-b04f-4b84f2b9f747": {"doc_hash": "a137f47e959b76eec27147f7cf3c78fbcdeb9725b7f660bc80b5e6f059def532", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "fa847e2a-124e-4ffa-a288-89c463beea90": {"doc_hash": "8b721bf8ca1589ae4b9be5534b99964ebd7d07f8886645e5637a5d16e59a21ad", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "60fc3f34-ec44-4b05-977e-457e58ae0784": {"doc_hash": "1ae9756cb784bd38ea5c4d85563df3506841dfdea1d4ef0f4dd8a6940fe6c3a6", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "a93a4f98-ebd9-413f-a3f5-195adc191704": {"doc_hash": "9dc74449c4e8c3cd6dd460c534f6c50ca32476b1f63b75e847310af156fcb768", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "ee580603-ea2c-4456-a7a9-d0b155d4cf77": {"doc_hash": "746ec6a1a8db0bc560c317e18e9c27e543a142d9502564c6ae75a203df7ecb39", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "4dce5764-bb24-4a04-8195-d29e4551ced2": {"doc_hash": "b99bf2a4d85fa22607116475a7ea675b32e949658780af4de1ba92fc0e370b37", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "73da0e7d-4dbb-47b9-9766-f9ca2f28c69e": {"doc_hash": "b16c732829d81e816f3d0eeb744d61968ab1740a3f68f7c605aea98cedde1f9d", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "d6220d9a-2045-4cf9-8571-bc95731864e4": {"doc_hash": "dbe628319afdc804053136b045d28c05e1845dbe3885bd38801661049f79cad9", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "896b70ca-5110-4758-95df-5b588781b401": {"doc_hash": "b8f667ee470cb1a59ec6622baa44cd3ee29dbf36003d5c9bdd5957c163b6ee01", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "8f133897-f203-466b-b589-a93214e3e9a6": {"doc_hash": "fd47aa383913da79b09564649ea0a366b9f515e5a297276278b5a0789b07f790", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "97780a22-77a7-4a65-96e1-380f5c3e37a0": {"doc_hash": "8ad889f45f5651d7e99ceeed7e69728112d06e738df83a4f11bb9ed5e6b2d579", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "0f2a2b35-cbda-43b9-8172-e4c820b0cc22": {"doc_hash": "20aeeed7980f6b71ce2e16053f6b4185d72b9d83d75662864a557736a2aed3c0", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "19efd9f4-ce4c-4e49-9577-0878f116a110": {"doc_hash": "e565818a436dcfd389232a835d748b7d5dd103458431af69c9909843f5e4b93b", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "2cb5c591-c725-4975-b797-062e988b9c9e": {"doc_hash": "3d2c80478cc276ee51a6aa8dc2ae5951156374e235ce8b3cf5d0ca3f66a97c16", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "51a2a5d2-3b6f-45fb-a60a-8c0bf65a1c7f": {"doc_hash": "de3401206536b7fb24aacfc78e062004c65015b0e829075edf329107beb3528d", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "727b75f1-829c-482d-ba85-e2fa8831c53f": {"doc_hash": "bb641125303a0682e7267b52f87f646d1405614d08a3b046bace70ab230a8a97", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "357ba806-d4f1-437c-8d44-700e12490def": {"doc_hash": "1ec6c17ff305c8aa83998176cd246d69da3ebbe41ee53baf7faa1b823b51fcd7", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "3a7173d8-24f8-4ce2-9d7a-3c456cba7646": {"doc_hash": "963194ccb4ef3ef34e8567286c6d2a4a3c35548926712f2493da15b13f251219", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "a40bca46-555d-4fae-841e-671d6158a0e6": {"doc_hash": "e77c595c4279230285ea83683d1274110c84d8b4913c1a379ec3a990c9f220fe", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "bc89b49e-82fd-4edf-9214-6047a51d2bf3": {"doc_hash": "8841e6cc53821d2bf9773514f9f42d81ce71523069d0d700d274d1760ec344e0", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "6d700012-1a5b-4944-a2d0-233de6c8835a": {"doc_hash": "51390a529566ba97a8dcb38e08572861a9ec4eacfdcfdbe170bcc1c7739c48d8", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "f312b0fa-7682-43f1-9792-d88f58ecc691": {"doc_hash": "0de1e70f688f0a8a4630a4a14fffd225265d4eb904b7436af5a533d899d149ce", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "88f4fb6d-5446-47fe-9343-784b9fd5e689": {"doc_hash": "889172e00dd535bebec53f6cd7de3c6ead951aedbc33a9631b2fccf9fd140ec1", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "e5ad82b5-21a2-40c9-99f0-a98e43a5f64b": {"doc_hash": "04cfaa9414148e2a1cbce6fbac5ae397d5fe277080d79116b7c714ca72e6b03a", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "db85cca0-3fc9-4780-b136-5a762fcea997": {"doc_hash": "7dfaab8d50f80352df3246b89a612cdf3e453b6009d2df00ab81488a245164f0", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "04547cdd-d535-4606-9093-ff54bd6fc7c2": {"doc_hash": "9d1bc73aade8b119178383db23b58eed11fa052df213d47e5a79898e16d996be", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "618e71ba-26dd-48f4-a858-796d4ae92ca8": {"doc_hash": "696962526c4f1d059e1a18c2659636b5d08e58edd3cda76409834f207a969d7a", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "aeb77279-12d2-4635-9e53-1eeeaf3353ca": {"doc_hash": "f4ee656aa557d773988a353f3cf2f1f9404b31d21a668114256a900adbba4b8c", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "6430abf5-15db-40aa-a305-684c39157693": {"doc_hash": "2fcaec809144b77b3574eaa54581a0046e0ee493abe8d32f2090a4f0c5de1973", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "55987d1a-75c6-4224-9ff5-13ce761b24aa": {"doc_hash": "567a4f965fd57bf381e890bcbc91d29087ba5160f449987513d38b842e653e4d", "ref_doc_id": "6247e35f-f81c-4115-8d23-335886009651"}, "2a60aa63-719d-49a7-8227-0a6e5bd0c9d1": {"doc_hash": "71f474f64c920b610e9b0c9b7a5cb98659ea6ede2cb4cdfc907a3cf4e9eab527", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "5225cf70-6e42-482c-b5c7-e52771f04610": {"doc_hash": "5a7bcbc62f7976541b8c5efea93b2168622c42f68d63bf2802502f3f3121dd66", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "1d6ba0bc-0f9a-4fa7-a9e2-2a3a07479de9": {"doc_hash": "269b61439bba49b718596226024bb17ba0cf86721e6180ee59d80f86948b62dc", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "c46680ad-3bde-4a17-af87-458c45f06dd2": {"doc_hash": "e3d84188b98016d3f912ce845cf93f591e7009d79d60ac952eab4fe00028c51a", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "df68edef-101d-4132-aa66-0e1d76a347c5": {"doc_hash": "226d9325c3db00eca58de9e49f6b9eaad1da1aba9698a42ac3a8a0ec7feca81e", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "7e4385b2-fd7d-433c-b4ad-7d237fe711d3": {"doc_hash": "5b119450c41db6b068bf216b099ead1c1520acec6e4da1b0a468dea31b6fec54", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "d2ebf41f-e32e-45ba-a6a5-4892e1bffba9": {"doc_hash": "1e51bd2e12776f6f73f931cc1ca854c9d57cd6078537d1032c337735a6e5c5cd", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "15d500f0-8012-4b08-98c6-217b2f882773": {"doc_hash": "606e185c0f5484380b7f46fc653230a64c7b62a513983fd07d49b3593b26c9b1", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "ea34f2a8-a046-441f-ae3b-09eb4551ae14": {"doc_hash": "7ebf3d448bcc21fca4272bd8cc4ea872a31fb38d1d88b897c386ee58129358f8", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "406905ad-f1a5-4331-ac61-f5fe8144720f": {"doc_hash": "67460a0f18e8c2b4409e5b2caf2867b44a780bf0b93c1e80ae313907cd547b2b", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "68af0010-9111-4b07-a721-ff65d0860da6": {"doc_hash": "5c8cb5538788e0c906d96eb8a6b94609adab3cc37649b2d05fd685df6c2039f4", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "ef273240-8888-4d73-ab17-f8c4fe7ea3da": {"doc_hash": "e97f6bf993fa21cd8e561581c8c4a469e9ade165b967e2dd688af89a2b36e6b3", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "7e3fd54c-1c50-42e2-a3cf-139de5dffb6b": {"doc_hash": "af348e259ce695089d989beb2327bced645192df37d0b72689ff4a1e5d600fb4", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "69d4e717-b0a3-4cb2-8287-4490e849434f": {"doc_hash": "2573012987c2f3fa187973cc878674c285a414b46bc76c31ec3887230bfbf1a3", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "0313c664-4a4a-43e2-9b61-ccc4bea8e13e": {"doc_hash": "79eb7f3e137a47460d78d59b4dbab18f6dacabcc7fc8122dbe9b98245620b259", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "1e59953f-f72f-4ede-a4ad-21c00db4f53f": {"doc_hash": "dd634d33eb292540130248b74776a0ded3f4174f6138ca49c57d200d28270a6f", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "1012ef1a-302c-466c-93db-9e03614b623e": {"doc_hash": "b48ff308ed6b195281a01ab264b1a040f074b058772f015a830f4f694a01c699", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "d8c10209-cd60-4e3d-8a29-f13060bc258e": {"doc_hash": "8662de69d64d54620fd627af7cb65b485fa7ce792eeb625dd7ffcead1c36f479", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "9a5b8cc9-26d0-45e3-aa7f-302204df4e23": {"doc_hash": "23ded255940310e8ff8ce26a3838a29d72c9eba8016b24d5770272f492f2a874", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "1e510806-dd46-4c48-84e4-29545daf0dcc": {"doc_hash": "9a94d1a7b6a32127e916ae5c65d957d74d90e74df0222f5066669173c8e9f990", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "f80dcca5-4324-4037-9c49-9ebf2ceb878f": {"doc_hash": "0aab2ab090b5664778faa66708d6a737be57bf792c718387d4dabea86d61a476", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "1c9c650f-ab61-4976-ad37-e4ac260216d0": {"doc_hash": "a6773776d62e7738612abe2f23ba7271298e949acc5d3953c1640cbbb2207c3e", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "5ce54727-3195-476e-b8b8-36d92515b5d8": {"doc_hash": "da7ba10f80237c7982d712dbaf4379d720248c5723d1f1876663df26fda7392d", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "a5930807-32dc-47ff-babf-b109e21eb5d8": {"doc_hash": "796bfe243a022b45d1e984af387a2e3b6dad182d5c7e1fe5dd42df3947dbfb5a", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "4c682205-53e6-403b-8cba-7a6a7db27190": {"doc_hash": "a3c3337c3a3af53e1b9b5050ee79dfd1b23b917d707605cf35e964289031ebda", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "74fe8ee8-4d9f-459e-8dcf-babbd1b794e1": {"doc_hash": "98c2845e9f88befcbf722a866b4bd98ad43b9220cd8c2352a19ff0df4285e159", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "bd63911e-19f0-4622-b478-eb2c51b6a98f": {"doc_hash": "6a19dce9465c5ef7e920ef9078400da507b4ff080ac383712779e9f47a2fb6c3", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "5977c4a5-9087-469e-af14-534c2a88d999": {"doc_hash": "2acfe0567f8f2ca34f9a925c57d8e26eb4f9a6761cdc5b7ed092e3682a8dac67", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "0158b870-fbc9-497d-b229-b1ad1169bfd0": {"doc_hash": "99d214a30e9a9e5ac1e5dc3616d9172d92ff49cc39e61e2765aef3155d2c4a15", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "3567e8a3-4d0a-4a79-836c-7c6a9569bfa7": {"doc_hash": "983242b4f3b3e4d3fde993dd95931ca7708cf9066baadf93d477d5d39e77d7d4", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "73128d29-12e0-4ad2-b369-b162eabbbbd8": {"doc_hash": "60e795c4aae3a44d9bab662cf3e9bd5d5ef9033d9d498fc765fbbbd0353cef54", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "4144de29-703b-4181-8f07-cd37decacff3": {"doc_hash": "b512c3d15e0428567c35809ae14e851ee1bf600c63aee25161d2615b43d890f4", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "591f9180-6466-4300-ba60-6f50c6e861f5": {"doc_hash": "db8676485d5915381e83bcbf90c86a256c99b9d9f605ff8af0c312080fbc1994", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "906a761f-2716-43d1-ba7a-99ce0aad890d": {"doc_hash": "ae48971a2eb3c50d32766691a1329ef2bdb46a295a0ccc9a70e4300ebe4e160b", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "abeace1f-abba-4d80-9828-db2f7f955e0d": {"doc_hash": "cb656c42c44f43e008b16ac9854426f042c253dfe0733c1b305c7e0b8b46cbd9", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "ea745388-8e00-4d9b-8d34-cbf8bc3b2f06": {"doc_hash": "18bf07df8a94230f066ce2c54622781a81be58b5a9b15b03d4dee9609c1a096b", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "2df43c6d-7463-40a1-a18d-9f0a72a634d0": {"doc_hash": "1082c5b97844939cf49d1c076077b0307f485a561654304c4011ff98e65eb916", "ref_doc_id": "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43"}, "8d0be11c-eb36-4cf0-9f86-1b62a35f8dd7": {"doc_hash": "ea532adec6ecc29ec3f992c0c7dec6fd532a6eed9e5d364f4c08891c83f02502", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "66b51b19-7f75-4c80-955b-367636bab612": {"doc_hash": "f7ab5e347de51cfac402f3c7e9fe0cb4ed6446ff1e1502424b40175c2bbbbb31", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "00565591-5f86-4aed-8754-ddf1842591a7": {"doc_hash": "4758bb552429ac8f18af6a9cc822e460029066ee2bd65a91bea883af5ddcd202", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "408812da-1763-4eec-971f-504f5af430be": {"doc_hash": "72a8a7aba360ade541f5d3e286332db3b8c1eb0fbfcdcf30c7050964a70fc163", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "74d3793f-15db-491f-8f6f-7ca7d8f64c95": {"doc_hash": "d483522d1d2e003db571eaa5164f3e6c16935dd073eb311dea2e49f9d87cf771", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "57972ccb-89c3-436d-a566-887c8bc27e28": {"doc_hash": "6a798c3f8aff65bdaa4c9ae0f28bec29d5446df0a464747491cb329e71e3b69d", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "f02335ef-5a82-47fc-86ec-a9246770e50c": {"doc_hash": "317d82ecb79581619c888e09505f833e8659216f29f4ae4288e485d4ec33544e", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "66b5c1e4-c197-498a-a43d-cf2f2d4768aa": {"doc_hash": "796ed788ea3f7c94c44f8ab3de23cdc1c1001ec806ff56dff76f5ab83e994566", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "59f18800-59b1-4237-9f10-f13f2c571680": {"doc_hash": "b6745d8c124f1cbff409974d9e90b99ff4df50f5acabd5b772a1e61471984dac", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "69f37a61-8de9-4409-ae20-877c2539aa65": {"doc_hash": "6019fdf92b4cbda008fda5d12e8d529e8a9dd94652f58c37d2e6c1353b339a97", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "2b3396db-e32a-4dc2-b7d3-071f81adf666": {"doc_hash": "b37ab674c9765110cf45655c8e9989f8178aa0053671d2757815eff3934f68c9", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "84e9070f-4405-4a6b-8c37-0ae0c31a99fb": {"doc_hash": "585ba2ff3221e6096248f0ed9ea29638e7dfd46f9b7149c7818cf9bfd69a0695", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "bb9cf891-5a7d-4385-bd39-e2c60b2c0aaf": {"doc_hash": "0e7f834bb1650505151afbbabdd411dba7f6f9abf999f57729cbd13ca9b2daa1", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "ac3baa9e-b6bf-4b9f-adf6-4c73e6e324cf": {"doc_hash": "05650123b78033f8c11cc7678a0e55cf94023964208edacc85ef0ec35792c631", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "f9d42c5d-cb58-4b61-847a-185a771e58db": {"doc_hash": "4b95d2c357fdfb607e13f059ba06bb2f97f445db45b50eb8280030adf39007af", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "f5003a0a-16d9-4463-8df5-4b0e057356b7": {"doc_hash": "917e419e14bd4fcb6ee246fa0ed14e145f100bcc053f6880a8a8b47c4ae4df5b", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "ecbfaff4-b6fe-4204-a9bd-270b06f9b405": {"doc_hash": "fa5778b12bd9e1b4387ceda26dd34ce90af66afece3e533316312a621518b5d3", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "62e81f52-27a3-4d23-9542-a8d10a0cf1fd": {"doc_hash": "5fcdba8e1f856652dba17dc5a1f837b174203ff71132ef86b148b4532555ecf7", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "a9ccf27d-a4c8-402a-b19f-af0964003722": {"doc_hash": "1f01a7eac3f7dfe26839549f0c0460dfd851a80d00f9273ec7f65b2aa8b74153", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "2016aa0d-5385-483a-9e33-51a6c277e90f": {"doc_hash": "c9476af6d6ababc7fab46e316d5eb8f8a3c11e1f93270e2cbe2e26c6aca937d0", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "87f25a5e-1e48-4879-8485-04d4c482b439": {"doc_hash": "655b7eb235cb8a6fb927038084846c3048b846a316280ae622d4346dcbef7ba3", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "6fa7861b-f399-44e3-95ec-9d7d56f528e4": {"doc_hash": "675f680154a5bb0845c62a869379376e1e9e14d313c982f0d9982bad6ed70b77", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "abfcfdf8-3b10-4f5d-9f74-f8d4ebae662b": {"doc_hash": "1ae95e3f4fed981cc2af29d8b6c1c8f8dafac379b8055d8fb8f975c7a19f94ee", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "350f6442-a8bb-496b-9ca9-d41b510f3aba": {"doc_hash": "c11f92c6e6825b8f048eb6127fc58fb7fbd2b8c2537be4103f55941495be89ae", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "b3fba988-d68d-4420-8477-839f91f6d1c4": {"doc_hash": "e0741f0f42dbef52355ab42777b3bd709f1af0e322a01fa93e18bea5d9b71c4a", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "f523c176-3674-4595-bac9-d1961773372a": {"doc_hash": "90593e2e420082b7203c31c42f403831441a6d8391099d92a7c01f3677b10e62", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "1c4a1136-ca9e-4068-b989-9286f1e5cd3d": {"doc_hash": "56e5378a5995a3e4ace226314b40a938e1be932449a2d184289d07eeeaa3567f", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "07dff9fb-e4f6-4b18-85dd-0e88d6eb57cc": {"doc_hash": "6d6ae00eab269ca4949b486d5f95955eaac367eb99f127242ab09ce5b68bba60", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "8915deb1-908c-47f9-b49d-4699d6e18e44": {"doc_hash": "ab592ceabfbc14324f188ef430969e4bca6ff25508f675b806eec2c65d7ce977", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "aa645cd8-bb98-4fa7-a914-71d5d975f514": {"doc_hash": "f31ed4c4a66ce07dd917a3715dcf14e823640d3467b37ddaa895df14ded979cf", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "61db32e0-f1ad-4775-9098-dd77512ec265": {"doc_hash": "3625097c9984e0dd0317913f53b752d4b8a0800efd63b7bb8066bbd3cb7fd12b", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "f328cb18-683e-4719-be8a-f9c855cd1bb7": {"doc_hash": "8cc3090c96fd31a7843754d63b9cc34d0a5784ac597a89454f7879bc88958460", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "a1d5b40c-cfc5-431f-861c-39d7d7ceb4a3": {"doc_hash": "1f5c62ad88ac8ee3672997f8694868d04918df065c4d6ab81709a69c72e1c9b6", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "4888bbfe-7bcb-47cc-85c8-f57f6066a66c": {"doc_hash": "c86695644114f952532050a3453be04bd08f92468e55fc8fcc57f3fb53178b91", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "19cfd5f2-37a6-4ec8-8d5c-d540c259cfd7": {"doc_hash": "2dd8e206e9f3b33b83ae5162ff545d79bca47400ca0a00a2bd2d1ddd664e9ca8", "ref_doc_id": "0b883460-44e9-45b1-9944-de806ba8d4c5"}, "5cd71961-48b3-46c9-9df2-a2d478be6df9": {"doc_hash": "5f3be71c69a31cf62c6a26225cee96316b62a7c38e5864010c0229110c7bb440", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "c96a602b-f06b-4a3a-8c1b-8ad51364421c": {"doc_hash": "008015034286c530a39f12605d64096c0a62c3c0b8164051711253b9f18f0e81", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "a0b7bf56-57f1-4e67-8bdc-76e8a363552f": {"doc_hash": "9455eeaca8cf4a73796f0cb6c36f30fad75c41422913eaf2b1bf3bad24dd3bb9", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "34f731ba-8873-4faa-9741-6047ea22acfa": {"doc_hash": "0e288f42d64af567780331cc210b992c9d9cb232110db15cb961ef51ccb186ba", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "2fac7a08-8f03-4975-97f4-0d9966534f8c": {"doc_hash": "c146112d6ca37733f16dd619565cf4ed8dbc2f944c08a6659d0fc5a2569dd4b3", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "87415a1b-ff71-41a4-8e5e-15eaf44b6293": {"doc_hash": "967e51843808cce3ceb4e9662ddeb085d613d2cb64a8264f9214d1e8b683a589", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "0645bc80-2db2-4256-a51c-ac00444e8e2d": {"doc_hash": "b7d8ae67df6f333dbe6ea1ddcf258f80716a6c6845d096e90e392cbcd0233705", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "c67c0156-d738-404d-a933-e69ec060c594": {"doc_hash": "3ede4b1bf4e902d073273b48cb264ef2aba1b62627b69a10fa6c073d86756061", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "4b7ed09c-9801-4dd3-ae70-82cff38dc9be": {"doc_hash": "1e7d6a5d11afae0314732cb81ca3941854ac049a19059b876a0bbc5fe811a089", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "91d89b0d-81de-48d9-bec5-addc486e7433": {"doc_hash": "a0035d7d588ef5da0d6f339c89903c8988dcffb13fc6be94fca96b46c6fbc40b", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "72fe6bfc-67a0-4402-a0e0-f5d6e2f18971": {"doc_hash": "3bfbe3198eeb6ddaaae5b2378c1282f43e90a568889ad1dd32be113a665db044", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "b0aa2e7e-395a-415f-8e08-c92998724da6": {"doc_hash": "1f11f14d84ee9751d7c77d196973813d33166439216728ac033864f5c30590b8", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "dcf32fc4-b9ee-47d3-a732-64d648f17a96": {"doc_hash": "28532dd06a709d1654e8e6e0940487ced5843c72159ffb9c9edc95974a14583e", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "189075fa-b38b-49ea-abb7-b73a52c54962": {"doc_hash": "395cbc849d4b01583ebb36362c3c8c2cff4e7f2ac33b6716f52358268376ce07", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "f974aa64-ee79-4bec-af6e-791716591297": {"doc_hash": "e8b93d182d53ef8738d5037b91a72a6268d407c67180e3f315a85ce201b65ac5", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "a7ddcdad-3501-4a8d-981c-d18e8f809453": {"doc_hash": "64dc13c7ce70ce8d1aafd618de3897416fe2c2098445a585fdb9b9848152bfec", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "3b50a5bb-76a2-49b9-985e-1ab64caac5bc": {"doc_hash": "61a9eab00c6b663f7e03096567b6d44aa1db658f3fc02e8b52ad9e111e1e8a60", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "b436f662-6bc5-41a5-a06b-9d1d09443708": {"doc_hash": "c58fd53613278ff88353760a648808efe5f9c6f9a66f1b7a1e0f0bc08363b343", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "fc2b6964-48fd-4a3b-a545-dff18082ca0f": {"doc_hash": "e6986dd7efada6c1edbb811af599cd42ac784a52793908436b9cc9bd7b896972", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "14c911aa-3c05-40d6-96b8-b62a7f35f8fd": {"doc_hash": "bf64130d2ae29a3f0de9240adbc14b1ea526af24e6e84b9a14dfadf2a8cdb204", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "65c0c86a-b933-43db-b875-fbbb1be9b3ae": {"doc_hash": "a9fdde7b08253f0a68cfa00544aa410003eb7306c71f7bc531f84a3f77ebc3b9", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "692d1d83-a459-4e26-903e-f91d0a04236c": {"doc_hash": "46dea3ecc7bbe90684ab7de36be511e62421461ddb8b34e5c92685c3871e5ba6", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}, "2ae71482-53d2-4ad7-9aa5-d88b8413ab87": {"doc_hash": "86e2a8d2f7379329b7b9afac2a4841a175c66569f8a767002024472bc5a02712", "ref_doc_id": "b801e091-c3d8-4737-a7f7-96155bc15a92"}}, "docstore/ref_doc_info": {"033fafe1-146e-4889-91d5-095860852b9e": {"node_ids": ["aa00e485-6a39-40ce-9cbc-92520f1f6570", "969653cc-e42c-44dd-9e5b-25b022f5d422"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Nov-2023  \nMcKesson Corp.   (MCK ) \nQ2 2024 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n01-Nov-2023  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "316a22fc-48d0-4d05-a0df-e09aa8f54684": {"node_ids": ["96af4f32-e99d-4b4b-98bc-80bd2b3c1dd6", "8a220c07-4857-4eea-8522-dd3aa408cbb3", "099e83b8-6dfb-44af-b97e-2e1319142825", "64e00170-b91d-4ad9-87dc-e3f9b8aa1d93", "aacafba1-1a00-4b56-90cb-0e3ca421e1bd", "be0832c2-7b64-4f6a-9832-be1fabddd096", "bb2df4f0-ce88-4f48-8afc-f97b6fa1f3f2", "ae85b463-057e-4d7b-b9a9-76198b013ee3", "cd5d8aa2-1c97-4d3c-990e-a8c1a783af1c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e6eed5f9-8f9a-45f6-bd97-205c2824afd3": {"node_ids": ["89607f5b-075d-4403-ace2-8c3ff01d6b67", "bec546ab-b705-47b3-bb24-4e1c9e6bd82b", "3f432ced-d0cd-4d49-852f-fd9d683ff06a", "8fe9932c-d76e-4660-9a36-a199064dcb15", "fcd4a6a1-d4ca-4eff-a32d-75d0e2d34a8c", "a5454c77-7f12-46a3-99b6-62e659afc5ee", "dfe87f8e-2059-415e-9a4c-f049f1d598b9", "ff8e79a4-1501-4f51-afc8-9773f8489b74", "f4763077-f613-44b9-88ce-d8355a607c6d", "7923f500-16fe-471c-a4b4-ac797127c5b2", "847c096e-6794-449e-bf55-f0058d047ca0", "ec6d1691-3ac4-450f-87ea-6d601e20223c", "677d71d5-b8ea-480c-9827-f328ec625dc8", "88eab0df-3c24-4cd8-a362-17e7f528365d", "5fac08a8-9767-422a-ae8e-e739307103f0", "ecb61339-b0ed-4981-83fc-8d8f24f3b1b2", "a63a54dc-7284-45a9-8108-73834e6ece33", "1e4ad327-4a0c-4c4c-9eed-9a515569b0ed", "10ac4c4d-637d-4e21-9cc3-c1de7d6a808c", "38be99dd-9d12-414b-9be3-908b763e5cff", "1382ce07-80e4-4cad-af5b-e523d92140ef", "7761c5e1-47ef-4aed-b476-5e9e85e31188", "91421e40-6fe8-445e-8eaa-e0004d0ac0fb", "0ed3365b-9098-4934-b77c-067c6c9d55e2", "d59c5b46-c33d-446b-b95c-710031414c5f", "bf5497d4-44cb-4b44-b46f-5a34b54e6fe6", "43b8b382-5630-4fc0-ae99-644fc416b3a9", "be7f7286-4504-46be-9695-cb59e6de843c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's second quarter fiscal 2024 earnings conference call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "411cbe13-77f1-4e72-9bd7-d0b91cb6aee8": {"node_ids": ["f60a01d5-896a-421a-8842-4cf1dbeca723", "049ab5e4-70bb-4bbd-86bf-8bd53b5718d6", "3937c700-7f64-49e1-b4db-f959cf6a3e3e", "6093f32d-cc09-4fee-872e-976950b20214", "a227b051-baa8-4084-b34c-7fdca65f94f8", "6d0fe18e-7f02-4d14-8f52-6fbb108f3d58", "0ff3631f-a09b-4cf5-9bf5-107d5793c8f3", "fd947ace-bf49-4d25-ae64-74b7e48bc89a", "9e4857d1-f313-42d0-af3c-a3ab00bdac53", "d80afbde-ca1a-470e-8e41-53ef92b9fc1f", "0fc11a11-64ab-4106-9964-47b069027fef", "0c6fbd94-7199-4dab-974e-46ba7d35c226", "563e362a-50ec-4b1d-86b8-18ae3c373399", "14c2d3e6-a84b-485d-a3a2-4cc53c92f3a2", "9960734f-c167-4c11-b315-e9904d5853e5", "61b8298d-e5cf-4e4f-8274-a45c0365643e", "e2b666f4-9576-4bf8-a9ea-2cc6487dedae", "16206b8a-d80c-4817-8803-6e52cc4c5e7a", "bda19614-1ccd-436c-8e1c-135ad9e85cd7", "2d887fe2-a841-43b8-959a-6d0d0ff70c6f", "1d01099f-c09f-4bca-aec4-fffb60135758", "edc9f716-693a-404c-8b6d-3afbe76ec5ab", "955271a0-d83b-4e65-a0c0-ccd5d1b25ce2", "f9e51b1f-9051-43fc-972e-fdf50ba193ee", "d0de9f81-6598-4a89-95fb-c8017b7a8dde", "b6c21810-dc96-45ef-a2f7-186ac5afb299", "5f340c04-7de7-4c66-99b3-58f027ad8744", "8f4b40e3-8688-4fc9-a8c9-b58adfec6d94", "23021893-dc40-4706-b88a-e8ed613ef8ab"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs they navigate through their reorganization process, we are working closely with them to provide continued \ndelivery of products.  We're closely monitoring developments.  But as Britt will describe in h is remarks, we \nanticipate that Rite Aid's bankruptcy filing will not materially impact fiscal 2024 adjusted earnings per diluted \nshare.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "07247e9f-caf1-43a0-b9f5-3f5ccbc1c313": {"node_ids": ["4d9a48a6-ce7d-43d4-8649-a81e859efe64", "1470b283-4a83-46d3-8542-8f43a11888f5", "ccc2af5a-182a-4782-a8c6-ec38da3e0ecc", "97e735c9-0614-47f2-a25d-38e3e508cd1d", "1a695925-ddd8-4b65-a728-6555e526ec82", "e7a5a808-47b6-43e9-ac7e-aeea1fec4955", "86d7bf56-226f-4a2d-9b2c-b75ddb75edf9", "5fc91e45-9bd7-4cfc-bd1e-739f157daa65", "c8bd62b7-d5af-4ef7-9103-26f962bb6f68", "8d66f7f4-d9b6-4cd7-9cd5-f7d47c3c20f5", "20380a8e-2054-4f83-a7aa-efd6006ecbb3", "f00bc185-3c6a-49da-9ad2-db7905d52977", "9b79369f-5a99-496e-b105-0adc2695674d", "ac8014df-c485-4948-be17-3c27ef9d39a5", "9e2d741d-bdc5-4f56-9740-87e6db1f01b8", "096940a1-316e-4a56-9f62-a7e2ba68d1ac", "e4de5c3c-a595-422f-b68a-980c7ae3741f", "20353e6c-8fb6-4be1-99d1-a9e3ce7ab875", "ce023f55-612d-438e-90be-87e6d020e042", "8ff8a047-26a7-41f8-bc0c-ff51b6c491f7", "c6f6325f-30e2-43a5-a417-608eff552b6b", "555dcf8e-535a-4c67-8d74-7e13c1cb3a86", "d1668bbc-bfe2-4085-8466-2d852e0113ef", "2363fe81-d246-4b6c-a9b2-4cd88aba6ee4", "79449d2c-1e08-4a82-b4c9-329d750d3a1d", "336599c8-478f-4ca0-a321-3857cec9d050", "c3dcff51-7b0f-489b-8996-440bfb94cfd8"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nMoving on to the next company priority of expanding our oncology and biopharma platforms.  Since the beginning \nof this calendar year, we've added four new practices and welcomed hundreds of n ew providers to the US \noncology network.  The team is working hard to ensure that the new practices are leveraging the resources of the \nnetwork, including best practices, coordinated resources, technology, and infrastructure.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "71df1df4-0f81-4e36-8dd2-58e02d35228f": {"node_ids": ["069ff281-071f-4093-83b1-f71404037b2a", "9ced5154-0f9c-416b-bcc4-db24e1b2de88", "931d355b-630b-4b09-aa6d-1b343aaa2d5f", "3eff30c9-3341-43e5-a22d-c257747f6ea4", "613a2b34-abc8-4874-b6a1-3d8a1c570030", "46433335-5df7-4bdf-a9d2-7bd68af3d746", "7e5ebcab-b21a-4263-88fd-cf1ac07f677a", "530660c8-5569-418f-8be0-e6e2888bb13d", "2b404915-74ab-4889-84a0-8db1494685a6", "4f7b0960-eec5-4c99-9593-95e4458c2571", "03c655c7-e996-4dc2-a7fe-4907031f7251", "97d369c4-efdb-45ea-af36-95318954212d", "b906b1c7-11a5-4d11-9fb0-5a7a3aa7b548", "6cd29bd1-1811-48e5-b899-317519a39ce4", "e65a7921-c951-4ffd-9585-d58d2bbcba40", "ee1ed359-7387-4c0e-8ac1-a9410abca7b7", "d48acfd3-d1b6-4c55-9be9-6669913d9c6d", "d1c0ba64-8de4-4151-8c80-21c2256cf398", "dc90cf59-e1ab-4bee-b70b-02205082f107", "b242efd6-72de-4fd7-a8b7-3c5f987717d4", "67465d60-f60b-4b41-937b-e4058353d822", "c39c8600-7544-4dd6-a4b7-636149c3b394", "cd4d7f90-9c8f-4f03-8622-e179c3a0e470", "7176cd73-2572-4d55-8ff6-448ef711773e", "f36d4aef-36b1-4cbc-a902-c0b2a531af73"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs an impact -driven organization, we're deeply committed to advancing our strategy and contributing to positive \nchanges in the communities where we live and work.  This past quarter,  we celebrated our Community Impact \nDays, which is McKesson's largest annual company -wide employee volunteer event.  \n \n Thousands of McKesson employees participated in various community impact projects that align with this year's \ntheme, cancer awareness, prev ention, and support. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e2b04763-7209-440a-81fe-2271126d7243": {"node_ids": ["5d71d4bd-760a-47d7-a303-5d253994d5b8", "65249795-f6db-480c-af00-ffbb19a13472", "106d56e1-d7dc-41cb-a3a8-80459617f901", "2f272b6c-2310-4273-81c8-e85308b333e1", "8d793bf5-70a8-42a9-81e0-a48a98f45eaf", "bcb88488-d179-4c20-a7eb-f1a09d2fc76d", "32c789bd-dd4c-4755-90af-c2fc3a0dd67e", "9e82ce1e-5b39-40ff-bf7a-e6a905472a8d", "736ba005-0d65-4fea-a9f8-b05e6d2fa71d", "cdaf8d9e-5b44-4d5a-930f-425542220d10", "2210c980-3a8c-4f85-98eb-1cc5524413ca", "cb3d594d-ea2b-401c-934f-a93d68a2c168", "c445187d-a6f1-48ee-ac78-c611656d76a9", "f4532ac5-83f9-4d50-a9be-526c53e1e961", "008bd8e3-9937-4fc3-9653-88f03780a8f3", "28fd884d-62eb-4c64-963a-65406bc55702", "e3b11c1a-875a-4056-8422-e2c597c1d407", "802ab5a9-c3ed-4c93-9312-a549f8cce853", "e14e1345-00be-4abf-98a3-02f6ccc0c1c5"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAs a result of our operating performance and outlook for the remainder of the fiscal year, we are increasing and \nnarrowing our full -year outlook for fiscal 2024 adjusted earnings per diluted share to a ra nge of $26.80 to $27.40.  \n \n Moving to our consolidated results, revenues increased 10% to $77.2 billion, led by growth in the US \nPharmaceutical segment, resulting from increased prescription volumes, including higher volumes from retail \nnational account cust omers, specialty products, and GLP -1 medications, partially offset by lower revenues in the \nInternational segment resulting from fiscal 2023 divestitures of certain test and European businesses.  Excluding \nthe impact of our European business operations and completed divestitures, revenue increased 15%.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "01e080a2-bcdb-45b5-9b8a-8d1bd2e493e7": {"node_ids": ["e0006a17-5e64-4924-b1a3-267f92071ab1", "2e7a7a13-72c7-4e84-9c87-30c182fb2e70", "4e235e13-4723-4953-8de9-3f939b64a775", "6f62febf-2573-4544-b6b6-b10f3e43ba4e", "c61f8c65-f278-44b1-a699-df9d6a14fd09", "853087ed-1a62-4ba9-b10b-d0967ce68258", "fcea30d0-32fa-414f-9404-08a95fa79b2e", "862d76c3-05ed-406b-bb92-7a657ef232d1", "8349c93f-ffef-4c66-b6f7-4d933a7df87d", "1c85f7f7-da51-4056-a640-cdd2dda68851", "dac093a6-3498-4cfa-b2ec-16a8933673af", "fb0e9a82-13b3-4ed7-acd6-e8215dfd0bae", "f79329e2-eb8c-4962-9a04-00e44f7b4fd8", "3703d69c-f842-4711-8724-5d831da6d6e0", "71718816-4600-442a-b2b2-9387d39ce464", "b4765183-d2d1-46f0-995a-26e7f1f1fc30", "8607371d-9010-4ddf-a736-d47c51569fb0", "651c3af4-e637-4ef6-8d8e-d41de41f0d7f", "ec0bbc61-9b29-4187-84ac-f8a16dfebb1f", "440a777e-c664-49eb-afd9-1924042df52b", "95151d2a-de23-476b-9861-65680feaa7f9", "6e991af1-e722-4f0d-8c05-ca463e391acf", "ee28d2da-ff73-4bc8-8419-c04eff582e23", "d4a903d5-bc2b-4024-a1dd-65b026655966", "2183ad8e-27f8-4ece-80a8-ea528c8bdf26", "fe418c13-0da1-4d25-8c79-2be95d4e4e28"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nSecond quarter revenues were $69.8 billion, an increase of 16% year over year.  Revenue growth reflects an \nincrease in prescription volumes, including higher volumes from retail national account  customers, specialty \nproducts, and GLP -1 medications.  These increases were partially offset by branded -to-generic conversions. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "40832261-ef49-453b-9285-febb5c4ed003": {"node_ids": ["3e4ee8e3-209f-4f12-9f63-cd567aee03aa", "d3afa40c-abc0-4582-b705-e707b3f045f9", "476d4a0e-69cd-4e28-9094-00d90a2023e2", "5626723f-0507-46a6-9350-1cba8865b80f", "8554ff92-a7f8-412d-83e4-81216d31664e", "f5d37080-976e-46fe-9649-1cacc4f3407b", "646feb55-22f3-40cc-b1f6-293f27c7bded", "e805ea42-3077-442d-8a04-9710b3f06c2d", "34af672f-fcd4-44c3-aaae-97e43d68880a", "f1682cc8-f37c-4245-a87f-75aa20abf557", "3a8ee8f6-50a0-4d55-a095-bec3b7757973", "367c8837-7271-4af7-9f97-c8c1ecc54607", "3faf8d91-87fc-4392-a026-d5194fce73b8", "ca6e771a-b583-4a19-a161-0ce7aa649008", "cc51ee90-dcd9-4be8-be3d-e4d328d7e04b", "33d2dca6-d3cc-4cb6-ba69-345a46005396", "cade10ac-0cfc-42c6-b4c0-e94e66024366", "cb1e8c15-8c8d-405e-9719-f1345f19bfd7", "ebe62b77-1dbb-49ee-8359-f02a11f91a2b", "74ba9c67-177c-4e16-a2ec-9176acc7a670", "74a4e738-fd84-4207-9c37-d6362c69e3a7", "ff610da7-3d46-4044-95f3-ff6bd6d234a0", "77830810-92d0-4d00-a14c-299bdc7ed1d8", "5a2d49e9-f361-4002-b72f-cb3336077e19", "e069f5a7-a9f0-4ef4-b5cf-ca5d46161725", "60d30000-6677-4407-910b-fbe3173886ec", "4ddcf847-cdcf-4aee-a502-3d780023ae61", "68d48f0c-fa74-49fa-9a07-ee7905290629"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nthe McKesson Ventures portfolio compared to losses of approximately $3 million in the second  quarter of fiscal \n2023.  \n \n As a reminder, McKesson Ventures portfolio holds equity investments in several growth stage digital health and \nservices companies.  We're pleased with the insights and results that we are obtaining through this portfolio. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ac962e2a-e515-4ce0-8d36-d6fbed7f6452": {"node_ids": ["d8a58821-b376-4a79-adff-d52f64c45987", "b3355088-b9b1-4625-b46f-22b018242a38", "bf58b6fd-cb8f-4542-ab1f-92d62408bb35", "71e90ea6-8b33-4d22-97a3-4187875f6dca", "078c991d-8e3c-4333-aa27-ccff3bc58d22", "18171c3e-763a-403e-8bed-5c5a13030af4", "8013649d-d6b7-4416-b0b7-921a95a72c78", "01d4f833-a017-43a2-ba58-a80bae53d6e5", "b50109fc-3ecf-4cc0-b360-d3dc524a6923", "5e63f3de-af33-48dc-a0a1-37e38698e2da", "ae365e17-0063-4cec-b588-f6a4306c5921", "6e138e13-d591-4559-af3c-f74f0945ba8f", "650448db-0406-43b2-88e7-348db0833488", "78713d44-e577-4941-bacc-9cbbf6aed611", "217258a4-679a-4bbd-9ab5-c55b7228a0e1", "0166089b-7a14-4800-8526-5a811dee11f4", "80c556d3-695a-475e-a4f1-4711e41ae663", "7bf1ead5-c37e-45e7-a49a-1618d87882f7", "db23293a-9394-4155-93e4-45cf595973ce", "3db48716-d93b-4318-b01d-c5b0293e5562", "cb67fbaf-e0b9-4b1b-8d4c-ffe664d00e83", "5e344ba0-2d13-47c0-8aba-a230472e19a2", "6b7ef5cf-869d-4d0b-aa97-c9976739c9e8", "6d087842-f64e-47f8-895c-6e16be6c9892", "b78858b2-1ce1-4ee3-9c61-f6bbc54e5e8a", "0759844b-05bc-451e-87eb-dbd9880a33a8", "f12b87e9-9376-4719-ad72-3a7acea2886c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nOur Medical -Surgical Solutions segment remains well positioned across all alternate site channels, with \nunmatched scale, p roduct assortment and capabilities.  In the Medical -Surgical Solutions segment, we anticipate \nrevenues to be approximately a 2% decline to 2% growth and operating profit to decrease 12% to 16%.  \n \n For the full year, we anticipate volumes of COVID -19 tests to continue to decline compared to fiscal 2023. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e6ce7973-9853-4b98-938e-358edd69e3e3": {"node_ids": ["7bb13c14-106b-49a8-b26a-5f3294358d8b", "3e828a7a-4359-4272-a0de-2c4526224613", "f449e9d5-2680-48eb-9a22-7545f20c23ab", "cc5f993b-a600-412a-a762-6586a6628130", "983ed34e-1e32-4ca6-b5ec-7cb5739ce916", "d1a99c45-1286-4e54-bd2d-8a7501edd5d9", "5e1dc4fc-a8be-447c-aba8-bd31ee5d3774", "fd8df5ac-876f-408a-b3cf-acda29c036fa", "5583d1d3-19e4-4c9e-a9cd-67d60a2fd4ec", "b4d68945-6500-4833-9688-76b1a193ed5e", "fec005ef-241e-4854-a081-91ca96f25da1", "e20a84ad-c979-4d89-8425-d16e9198feaa", "45bf2742-8ad8-4a5a-a86e-29dd9261a92c", "06259041-cce0-4f47-8768-619c5ab075c9", "9e44589c-c42e-42f6-ab0e-a9f029c89efe", "639b3ea0-269f-46bb-b4a6-53f9deb77da6", "57087c94-2f63-4c3a-812a-2b44ab9bbccb", "b1253432-51bd-409c-b3c1-78de87ec998e", "8417452f-586c-4c9a-a048-fb73e277b09c", "b1a75981-6a1c-4b95-8a84-a4be28fe8acc", "2852b7ba-8a3a-4d6d-97a0-daa31246ed89", "5a0a1fd9-62d8-4b0c-b3f1-3c418fc0423c", "2424b627-5321-41cb-833b-348cdc39fde0", "b633d9d6-299b-4781-8f49-9343bcb2609d", "25ec641f-2318-4982-b470-2ef9047621ce", "7bffa589-bc38-4c83-8e4a-e48214a54036", "e5e99e2e-6b5e-4d76-960b-c1d4a0ced4e8", "e74ca2c0-c751-49f6-a4a2-cc9c3a6e7c2d", "eec4193d-f52e-4333-8089-8a136316074a", "81eacb08-620d-4e56-ba64-5cda584949ca"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nPharmaceutical and Medical -Surgical segments in fiscal 2023.  We anticipate the impact of COVID -19-related \nitems will be immaterial to fiscal 2024 when comparing fiscal 2023.  \n \n The increase to our outlook for adjusted earnings per earnings per diluted share indicates earnings per diluted \nshare growth of 14% to 17% when e xcluding these certain items. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "edfa9425-2aee-487f-958d-c03b51919faa": {"node_ids": ["3e9e6cfd-8311-4c15-a539-9d9ab0e03329", "3b7414ea-62ec-4491-9da8-2dd398151a95", "1e99081d-d082-4437-8861-3b1a680a8a2a", "976834b0-5036-4a1e-bb26-4ea70d5c93ac", "84694601-1a3a-44ab-984e-e6320ca968db", "4bc3f217-0761-408d-b701-e8da5317118c", "5c1262f5-755d-491e-b639-df0ad2966d40", "43a8508b-bc8c-4298-893d-b23f27c7e155", "03eab41f-3f30-45ca-9cac-46b1e7a486e2", "6f87f680-61a9-46f4-824e-42df1d6df50b", "c67d36e1-8dd9-4332-bec7-fc208892acc7", "bde88ed6-5ec3-4f87-8945-b146f491bb3c", "e0896dd9-e721-4c47-9238-0c19f6d3284b", "b634e5b9-0648-4952-88c1-b51f189046bf", "2d650c1c-849a-49d2-8f3b-2a71ce9927fe", "de70e9e1-1aab-497c-815c-42c33653de53", "80ae8165-1fb8-4bdb-8f65-cf72a5e4fca0", "d85816db-0669-41ac-9632-ed67630be329", "94a7b6c9-e477-4473-adcc-57fa80c63877", "42f1cd31-6b0b-49ee-90a2-4a161d7e66a3", "9a1e181b-5b1c-44ec-b565-f5d2b385c5e4", "81c4e016-8598-4db0-bce5-5766c004465e", "99a48401-0475-43a0-87ea-07fc2748ca8f", "c9adfeab-35a0-4b5a-8a90-4e61301db7bd", "eb9e23a8-433e-4fc6-a54a-3160ed6e1095", "6826c272-4830-4053-ab5e-80d7fb6d9201", "79c76ca8-712a-43d3-9ebc-63a7838dcebc", "87552d09-624b-4962-8b50-1d24f3b018ce", "de8827f6-f906-4687-88d1-ca562adfd3b0", "7d1b4896-2319-490e-ac38-b7c1878a12b0", "58645828-3146-4c6a-9b7e-5e9c72c39053", "8d2107d4-8257-41b0-8dce-f1b3e58dbe01", "488d2fdc-6a76-4dd2-9cc5-4a118caf8e0a"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nSo we've seen good stable util ization trends.  We've seen new drug launches like categories like GLP -1 \nmedications that utilize the successful prior authorization programs that we have.  And we've certainly seen \nrevenue and operating profit trend in a similar manner to that.  \n ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ddcb704f-7f37-4b51-a61e-fdee1d49bff0": {"node_ids": ["d6f38ff4-cf60-4a5a-b3b2-1b51f2e360ee", "e264f6b1-dc46-4ebe-9417-778c3798ecc9", "e32e4dcd-b6d5-422f-b64e-cd2650959e65", "138c6e8e-13f3-406b-8dd9-9dfbbb65c814", "bccaad9f-5fee-43bf-8786-b2a4091995aa", "a13b8701-a2f5-40f5-afce-5a1266380f21", "d705a4f8-5837-4cdd-80d0-62a2aae34c61", "b3c538ff-11fe-4b80-baae-4aedfcb15bff", "c2a73b60-1c4c-40df-9ed9-a499b5f7a3b7", "02d0b9a9-c8fe-414b-9a4b-ef12e9ecb010", "644fd851-3482-4056-b628-db3fb6e16805", "d46858f1-5f9a-4aba-b37a-ffe36a6ea742", "80b43d39-42dc-4e1f-8998-b4fd653cb5fc", "43665b06-91d1-477a-8cd1-2dbe62a52f28", "84d60b68-85e8-4fb0-851a-76bb251f4c5f", "7702a4da-7f91-4bd1-94e6-2c4fd9ddb3cd", "395c1813-476c-4b7f-9351-552f258f35d6", "c70a7641-0ecf-4027-be30-fa1e2a2b1c37", "af437074-5df7-486c-af37-88017691c4eb", "87612999-ece1-42ae-846d-16726d4c2a75", "503209c8-7a32-4ab7-8212-4ae8ad21f8ae", "efb746b1-cbab-4c09-9ef1-de7d49cc618e", "2b36c795-7f2a-4d0b-bb9e-de47d1561cd5", "ad8eedd4-17a5-4a70-b485-5c77c350394b", "3d01675a-6247-4e5b-93d0-f7f86271aa21", "d1fdccdc-8924-4518-b686-9c3a7cb2f103", "e777fbfd-bbb0-45c5-99e1-405b83ff2185", "09d86c9a-0ff8-4ea0-b503-e7bfc44bdfd9", "4e034b24-7fc0-44ff-87d6-b1b2e08ae4cd", "8cc6e394-663e-4da3-b15e-c635ba67e05e", "52c6e7b8-b914-40d1-8e92-49b6ff39f027", "7708729b-ad37-4cd6-b7b3-fd67aedae6db", "d6b75e3e-5f93-400f-a17b-0421a43c1d46"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \ncontinue to invest into this segment to protect future growth as well.  And all those investments are  reflected in our \nFY 2024 outlook.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4ef9ef20-4886-457b-8c84-a1b008c32c9f": {"node_ids": ["939cc6b2-073a-42a8-9de6-ca88e711b4b6", "a9316232-53e5-4c7d-8c8f-9659f838898b", "69cd5e5c-8cf9-42f9-ab43-67a33e578a06", "7e8c18ae-9df5-48ed-af84-df01a216bcb1", "d0ad1adb-ab7a-413c-b60a-a18e8be1e43b", "016e63bf-3cd8-484e-bf46-ca01a0677ae6", "c59335e9-fad3-4ee5-8770-5ccb93f45e5f", "11241e03-24fe-4375-b2c5-eca66f14922d", "f2a621d0-b0d1-48cb-9e26-f88ac341fc69", "30dc2ca8-db52-4ccd-88f9-6168ff24b0f8", "92bf1974-bd24-404e-802c-1bc461f9c442", "5ae82133-8ae7-4f71-9aa1-155e6446a39c", "63d1df18-9522-413a-8b13-3e8679207b33", "c415461e-528e-4eba-999f-ca3847a6608c", "b0c8b9b5-c651-4fad-b069-d9b354bf2abb", "a579ff11-8272-4039-8319-29cfd3e9f01e", "dfaa2fed-46e6-41b8-81a4-7ff22e1ae193", "18f5283b-f8b8-41dc-bbd5-8d34b94e52a0", "30abf15d-78ac-4af7-b5ae-b1c44de431f4", "184439a9-24cb-427d-a3c0-038121719e59", "0b64daaf-f1ac-484a-8a47-c8a59b7218d8", "9c1343b3-8203-4a36-96c4-1a557f2e734a", "c0ea2e97-ac20-4bb5-a2dc-663243f68066", "a8c88cb2-64cf-435a-93f3-7d6cbb4b4d29", "2b2eb280-ff0b-4e9d-aafe-0cb4779d0e8b", "682560b9-c269-41e2-ab07-22e391a11edf", "bd2beeab-4318-495b-8d47-a10b355035b5", "38c183a0-6ae6-4089-9b32-85d4850edd96", "d3161b90-25f9-4483-96ff-9aeda7abd865", "942583d2-185d-45c4-809c-baa72f84268f", "9fac79b6-f991-416d-9ffc-b25a4afe8426", "41dc5d34-e6b1-4aa2-baf9-7d3ff0dd3755", "245fde81-8036-4ea1-a6e4-360c0dae83d4", "f5742528-678d-4fa7-af09-1333c4abb696"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Brian, but I'm not sure what you're referring to when you use the word gain s. As we think \nabout our operating expenses, we have great operating expense discipline.  And the efficiency of our operations \nallows us to drive operating margin leverage. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f3b21ffe-3391-4a34-9707-c3eb7b9c157f": {"node_ids": ["c4744cde-bfea-4f21-8643-ed39d469b1a7", "bb0c48c0-6d46-44d5-ae87-c5cbe4d02a7d", "8a07af77-c58a-43b7-9d6e-11fa4b12d9a9", "115f51a0-eeb8-470a-9756-8be997faff8f", "dba3de62-4e36-404b-b507-7403a5fedb75", "0dd65b08-d006-4e2f-8c56-49d69e1e4f44", "984201fa-3e0f-415d-852a-6f8b61c039b1", "be7c162e-8228-4357-a065-0f73da381f61", "f64fb6eb-7160-492a-ace8-85615791a07b", "9d3ef225-6de7-4c62-8f37-0dfd9564a8ad", "e35b2ec8-9983-445c-b28f-5dcbbe37a1d8", "f217a758-c1e9-4750-8e5d-6d906578cc01", "1335f309-c1c4-4827-8921-14dd29b98ab1", "f22ecf2f-704c-459a-8d54-d840ffed4f53", "5fcf37e7-44a5-4e96-aa82-0ee476c7f7ed", "51cba07e-63ed-4079-aef4-3068854f5449", "35e05103-4ac2-44c3-8437-d4dbb6dbcc1b", "e65e9898-064f-45ed-940e-814dcc3b412e", "7ac507cd-8906-4fe3-bd51-bf06924db27f", "f9718400-e164-4845-9fff-1ef632bdb386", "45cee48e-a4b3-45b9-a9c5-efc0b41573d6", "e76d6005-55df-4edf-b080-ea39484900e9", "96a36c16-eb7b-4521-951b-4036efbfedc2", "b9150b70-1314-4d1d-ac4a-7718328b773f", "8873bae8-17fb-4a62-a238-8eeb788b0bc4", "45580cb6-b8cd-4b2b-b92f-e0bcc8378c9c", "845d9639-6cdc-4b4d-803e-d25d90fb1b91", "b9235aed-3c87-4b45-a384-6d2c9fc92826", "87482f32-db25-4685-97ba-8c3ce39d3951", "cf860181-b991-42ad-8139-6d3924711d2f", "538567be-0010-4241-b5c1-50605cf897dc", "3f181b1b-e080-4ca7-b3a7-923ebb39a8c9", "bfd4a658-256b-41dd-ba5b-31ae45e14034"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nI've heard heavy travel season from some companies.  I've heard others talk about vacation schedules, just the \ntiming of the calendar, if you will.  But I'm curious if you have any more details or thoughts you could add on the \nprimary  care trend. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "655ff34e-0463-4636-b472-ebdfd130922f": {"node_ids": ["d7a516f0-10eb-4b2a-b957-179fdcf03f33", "6f2f0c7a-c2c9-417f-8d86-5860ae35a44b", "b7c2aa1d-fe3d-40ec-a898-379976e561ee", "0bc818f8-3fff-4e2f-bef6-22339d9447f1", "85a333e6-1eed-4ae4-a932-09b03d58e180", "f4d3bcb0-1500-475d-bf68-316165f34a42", "606fde0a-ef53-459f-8481-3c276a88c89e", "b0d315ce-0598-4950-a21b-b71441d1c22d", "6a107b99-186e-4fd1-a9a6-65188cb69aa1", "47920934-9c55-4b79-b8fd-bce27428e71c", "85ad8abe-3af4-435d-9d74-43a966e5b99a", "1648fe0b-94f0-4021-abb0-805908cea60e", "84d92655-2f4e-4a8e-aa1b-f454bb8ce721", "62e6612a-a112-4b85-8ac2-f4dde018a919", "e2956441-b01d-4cf7-a420-c08d9199453a", "986aa329-e126-4d7b-b7c8-8e117dc74402", "623b473b-bd76-455c-a032-2c250688e504", "36f80ce9-4c5f-4b93-a6e9-499840629056", "4a310f70-e162-4942-b620-ae70095580dc", "eae26ce9-4f15-4374-ae50-8c34b74ab955", "9642904c-d1b1-426b-a3e9-fd53e389f78a", "1e6f584e-e8dc-43e1-8d20-b93027151441", "1debfc02-c90c-495d-a86f-327283ac34c1", "914ec3cc-ee49-4afb-bb48-7adcb4209ff4", "061376ca-db2c-4a9d-9c2f-ab27ba4e786f", "53096818-c6d9-4d9c-9fe9-f8728ef5be2a", "875bfa49-3199-4c5a-b969-ae447d744ac1", "4a3834c4-cd50-4e05-a2bc-815ba41302c1", "62fa8959-8242-48a3-ba24-855eef515840", "502ec097-5874-4f60-b187-5295babe8d81", "8d19f299-3b68-4093-9ce5-f1b9169636c0", "e0fd6692-d25b-4ad8-84cc-bdb0a5bec585"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question.  Certainly, we have a broad portf olio, and it's much broader than it was a few years ago. \n", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "6247e35f-f81c-4115-8d23-335886009651": {"node_ids": ["8dd2083e-5103-4590-81f1-3833e234b3fb", "234894fa-bcd9-4f39-87ca-14f793cc9cd7", "64c1a63f-2e39-4c45-be3e-a4d0a77aca59", "da9053f3-2d07-4256-8f45-5dd93a4412b6", "d4ec92a3-d28b-4d37-a34a-d871f0dbb1c6", "c5565ee3-094e-49a7-9900-8bc4139457a5", "f49c33b6-4fb2-41c2-af55-c7a5c9f6a957", "d17605cf-f4b5-4b7d-84ef-6cf4bccea578", "9cbd1918-37d1-4822-ada8-98b51c9b9a23", "fbd194c6-0bd9-43b0-b9cf-1131fb20b70b", "0af2bae0-63ed-4c8a-b04f-4b84f2b9f747", "fa847e2a-124e-4ffa-a288-89c463beea90", "60fc3f34-ec44-4b05-977e-457e58ae0784", "a93a4f98-ebd9-413f-a3f5-195adc191704", "ee580603-ea2c-4456-a7a9-d0b155d4cf77", "4dce5764-bb24-4a04-8195-d29e4551ced2", "73da0e7d-4dbb-47b9-9766-f9ca2f28c69e", "d6220d9a-2045-4cf9-8571-bc95731864e4", "896b70ca-5110-4758-95df-5b588781b401", "8f133897-f203-466b-b589-a93214e3e9a6", "97780a22-77a7-4a65-96e1-380f5c3e37a0", "0f2a2b35-cbda-43b9-8172-e4c820b0cc22", "19efd9f4-ce4c-4e49-9577-0878f116a110", "2cb5c591-c725-4975-b797-062e988b9c9e", "51a2a5d2-3b6f-45fb-a60a-8c0bf65a1c7f", "727b75f1-829c-482d-ba85-e2fa8831c53f", "357ba806-d4f1-437c-8d44-700e12490def", "3a7173d8-24f8-4ce2-9d7a-3c456cba7646", "a40bca46-555d-4fae-841e-671d6158a0e6", "bc89b49e-82fd-4edf-9214-6047a51d2bf3", "6d700012-1a5b-4944-a2d0-233de6c8835a", "f312b0fa-7682-43f1-9792-d88f58ecc691", "88f4fb6d-5446-47fe-9343-784b9fd5e689", "e5ad82b5-21a2-40c9-99f0-a98e43a5f64b", "db85cca0-3fc9-4780-b136-5a762fcea997", "04547cdd-d535-4606-9093-ff54bd6fc7c2", "618e71ba-26dd-48f4-a858-796d4ae92ca8", "aeb77279-12d2-4635-9e53-1eeeaf3353ca", "6430abf5-15db-40aa-a305-684c39157693", "55987d1a-75c6-4224-9ff5-13ce761b24aa"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \n \nAnd then one for Britt.  Within the RxTS segment, you guys did a large restructuring in March.  Have those OpEx \nsavin gs completely flowed through the model at this point, or should we expect more over time? ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4fd69cf0-8251-4f78-87d7-e0b34eb3ad43": {"node_ids": ["2a60aa63-719d-49a7-8227-0a6e5bd0c9d1", "5225cf70-6e42-482c-b5c7-e52771f04610", "1d6ba0bc-0f9a-4fa7-a9e2-2a3a07479de9", "c46680ad-3bde-4a17-af87-458c45f06dd2", "df68edef-101d-4132-aa66-0e1d76a347c5", "7e4385b2-fd7d-433c-b4ad-7d237fe711d3", "d2ebf41f-e32e-45ba-a6a5-4892e1bffba9", "15d500f0-8012-4b08-98c6-217b2f882773", "ea34f2a8-a046-441f-ae3b-09eb4551ae14", "406905ad-f1a5-4331-ac61-f5fe8144720f", "68af0010-9111-4b07-a721-ff65d0860da6", "ef273240-8888-4d73-ab17-f8c4fe7ea3da", "7e3fd54c-1c50-42e2-a3cf-139de5dffb6b", "69d4e717-b0a3-4cb2-8287-4490e849434f", "0313c664-4a4a-43e2-9b61-ccc4bea8e13e", "1e59953f-f72f-4ede-a4ad-21c00db4f53f", "1012ef1a-302c-466c-93db-9e03614b623e", "d8c10209-cd60-4e3d-8a29-f13060bc258e", "9a5b8cc9-26d0-45e3-aa7f-302204df4e23", "1e510806-dd46-4c48-84e4-29545daf0dcc", "f80dcca5-4324-4037-9c49-9ebf2ceb878f", "1c9c650f-ab61-4976-ad37-e4ac260216d0", "5ce54727-3195-476e-b8b8-36d92515b5d8", "a5930807-32dc-47ff-babf-b109e21eb5d8", "4c682205-53e6-403b-8cba-7a6a7db27190", "74fe8ee8-4d9f-459e-8dcf-babbd1b794e1", "bd63911e-19f0-4622-b478-eb2c51b6a98f", "5977c4a5-9087-469e-af14-534c2a88d999", "0158b870-fbc9-497d-b229-b1ad1169bfd0", "3567e8a3-4d0a-4a79-836c-7c6a9569bfa7", "73128d29-12e0-4ad2-b369-b162eabbbbd8", "4144de29-703b-4181-8f07-cd37decacff3", "591f9180-6466-4300-ba60-6f50c6e861f5", "906a761f-2716-43d1-ba7a-99ce0aad890d", "abeace1f-abba-4d80-9828-db2f7f955e0d", "ea745388-8e00-4d9b-8d34-cbf8bc3b2f06", "2df43c6d-7463-40a1-a18d-9f0a72a634d0"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nWe're able to procure generics very competitively on behalf of our customers, and we focus on stability of supply \nat the same time.  So from a generics perspective, our programs are running very well.  We feel very well \npositioned to continue to procure at a low cost and stable supply for our customers, and the environment is \nconducive to us being able do that.  \n ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0b883460-44e9-45b1-9944-de806ba8d4c5": {"node_ids": ["8d0be11c-eb36-4cf0-9f86-1b62a35f8dd7", "66b51b19-7f75-4c80-955b-367636bab612", "00565591-5f86-4aed-8754-ddf1842591a7", "408812da-1763-4eec-971f-504f5af430be", "74d3793f-15db-491f-8f6f-7ca7d8f64c95", "57972ccb-89c3-436d-a566-887c8bc27e28", "f02335ef-5a82-47fc-86ec-a9246770e50c", "66b5c1e4-c197-498a-a43d-cf2f2d4768aa", "59f18800-59b1-4237-9f10-f13f2c571680", "69f37a61-8de9-4409-ae20-877c2539aa65", "2b3396db-e32a-4dc2-b7d3-071f81adf666", "84e9070f-4405-4a6b-8c37-0ae0c31a99fb", "bb9cf891-5a7d-4385-bd39-e2c60b2c0aaf", "ac3baa9e-b6bf-4b9f-adf6-4c73e6e324cf", "f9d42c5d-cb58-4b61-847a-185a771e58db", "f5003a0a-16d9-4463-8df5-4b0e057356b7", "ecbfaff4-b6fe-4204-a9bd-270b06f9b405", "62e81f52-27a3-4d23-9542-a8d10a0cf1fd", "a9ccf27d-a4c8-402a-b19f-af0964003722", "2016aa0d-5385-483a-9e33-51a6c277e90f", "87f25a5e-1e48-4879-8485-04d4c482b439", "6fa7861b-f399-44e3-95ec-9d7d56f528e4", "abfcfdf8-3b10-4f5d-9f74-f8d4ebae662b", "350f6442-a8bb-496b-9ca9-d41b510f3aba", "b3fba988-d68d-4420-8477-839f91f6d1c4", "f523c176-3674-4595-bac9-d1961773372a", "1c4a1136-ca9e-4068-b989-9286f1e5cd3d", "07dff9fb-e4f6-4b18-85dd-0e88d6eb57cc", "8915deb1-908c-47f9-b49d-4699d6e18e44", "aa645cd8-bb98-4fa7-a914-71d5d975f514", "61db32e0-f1ad-4775-9098-dd77512ec265", "f328cb18-683e-4719-be8a-f9c855cd1bb7", "a1d5b40c-cfc5-431f-861c-39d7d7ceb4a3", "4888bbfe-7bcb-47cc-85c8-f57f6066a66c", "19cfd5f2-37a6-4ec8-8d5c-d540c259cfd7"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nRachel Rodriguez  \nVice President -Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "b801e091-c3d8-4737-a7f7-96155bc15a92": {"node_ids": ["5cd71961-48b3-46c9-9df2-a2d478be6df9", "c96a602b-f06b-4a3a-8c1b-8ad51364421c", "a0b7bf56-57f1-4e67-8bdc-76e8a363552f", "34f731ba-8873-4faa-9741-6047ea22acfa", "2fac7a08-8f03-4975-97f4-0d9966534f8c", "87415a1b-ff71-41a4-8e5e-15eaf44b6293", "0645bc80-2db2-4256-a51c-ac00444e8e2d", "c67c0156-d738-404d-a933-e69ec060c594", "4b7ed09c-9801-4dd3-ae70-82cff38dc9be", "91d89b0d-81de-48d9-bec5-addc486e7433", "72fe6bfc-67a0-4402-a0e0-f5d6e2f18971", "b0aa2e7e-395a-415f-8e08-c92998724da6", "dcf32fc4-b9ee-47d3-a732-64d648f17a96", "189075fa-b38b-49ea-abb7-b73a52c54962", "f974aa64-ee79-4bec-af6e-791716591297", "a7ddcdad-3501-4a8d-981c-d18e8f809453", "3b50a5bb-76a2-49b9-985e-1ab64caac5bc", "b436f662-6bc5-41a5-a06b-9d1d09443708", "fc2b6964-48fd-4a3b-a545-dff18082ca0f", "14c911aa-3c05-40d6-96b8-b62a7f35f8fd", "65c0c86a-b933-43db-b875-fbbb1be9b3ae", "692d1d83-a459-4e26-903e-f91d0a04236c", "2ae71482-53d2-4ad7-9aa5-d88b8413ab87"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ2 2024 Earnings Call  Corrected Transcript  \n01-Nov-2023   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2023  FactSet  CallStreet, LLC  \n \nreiterating McKesson delivered solid second quarter results.  We saw continued momentum across the business, \nand we're confident in our ability to deliver  sustained long -term growth.  \n \n As a diversified healthcare services company, we've made significant progress advancing our company priorities. \n", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q2-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 312683, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}